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Hypothesis:  Pelvic  perfusion  is  the  pivotal  factor  for  the  outcome  of  in  vitro 
fertilisation (IVF) treatment once clinical and embryological variables are controlled 
for their effect.
Demonstration of Hypothesis:  In a series of three studies, the clinical aspects of 
embryo implantation were examined from the perspective of tissue perfusion.
Epidemiological Study: Clinical and embryological data were evaluated to predict 
multiplicity of  implantation  and  ongoing  pregnancy  in  IVF  treatment.  Oocyte  and 
embryo  quality  were  appraised  and  the  impact  of  the  number  of  embryos 
transferred was assessed.
Study  on  In-vivo  Vascular  Physiology:  The  prognostic  role  of  utero-ovarian 
perfusion  and  its  pharmacological  manipulation  with  low  dose  aspirin  was 
evaluated  in  the  outcome  of  IVF  treatment.  Serum,  follicular  fluid  vascular 
endothelial  growth  factor (VEGF) and vascular endothelial  growth factor receptor 
(VEGFR) concentrations were correlated with Doppler indices.
Study on  In-vivo  Endometrial  Physiology:  Endometrial  receptivity  (in  terms  of 
endometrial  thickness  and  echo-pattern)  and  VEGF-VEGFR  concentrations were 
evaluated  with  regards  to  the  outcome  of  frozen-thawed  embryo  replacement 
(FTER) during natural and hormone replacement cycles.
Results: The epidemiological study showed that the outcome of IVF treatment was 
closely associated with the severity of subfertility. Ovarian reserve and response to 
stimulation were the key factors. The probability of pregnancy was affected by the 
number and quality of oocytes and by their fertilisation rate and the cleavage rate 
of the resulting embryos. The potential to provide mature oocytes and high quality 
embryos  was  an  inherent  characteristic  of  the  ovaries  and  independent  of
2stimulation  protocols.  When  embryo  quality  was  taken  into  consideration,  the 
number of embryos transferred no longer affected the chance of pregnancy.
The  clinical  study showed  that the  chance  of pregnancy was  directly dependant 
upon tissue perfusion. Pregnancy rates were very low with uterine artery pulsatility 
index  >3  (PI)  and  peri-follicular  PI  >1.  Better  ovarian  reserve,  response  to 
stimulation,  endometrial  development,  implantation  and  pregnancy  rates  were 
associated  with  low  follicular  fluid  VEGF-VEGFR  levels  and  this  was  also 
associated with good uterine and endometrial perfusion. Aspirin (150 mg/day) had 
no  beneficial  effect  on  Doppler  indices,  ovarian  response  to  stimulation, 
implantation or pregnancy rates.
Pregnancy rates were similar with naturally and hormonally prepared endometrium 
in  frozen-thawed  embryo  replacement  cycles.  Higher  serum  VEGF  and  lower 
VEGFR  levels  were  observed  in  pregnant  cycles,  but  the  differences  were  not 
significant. Endometrial echo-pattern and thickness did not affect conception.
Conclusions: Tissue perfusion plays a key role in the physiological steps leading 
to  conception  and  implantation.  Aspirin  (150  mg/day)  improved  neither  tissue 
perfusion  nor  the  outcome  of  fresh  embryo  transfer.  The  type  of  endometrial 
preparation  did  not  affect  the  outcome  of  frozen-thawed  embryo  replacement 
cycles.
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201  Background
1.1  Definition of Subfertility
Fertility  is  defined  by  the  duration  of  exposure  to  the  chance  of  conceiving. 
Epidemiological data indicate that the cumulative conception  rate in women aged 
25  years  or  younger  is  60%  at  six  months,  85%  at  one  year  and  91%  at  two 
years1'2’3.
By convention, couples at the lower end of the normal distribution of fecundity who 
do not conceive within one year will be included in the subfertile group, although as 
a random  event conception  may be delayed  by chance alone4,5'6. Therefore,  it is 
important to recognize that any epidemiological  demarcation  between fertility and 
subfertility  is  arbitrary.  However,  as  the  duration  of  exposure  to  the  chance  of 
conception increases,  it becomes less likely that couples will remain subfertile due 
only to chance factors with no underlying pathology, since self-selection lowers the 
natural fertility of the residual non-pregnant population7.
1.1.1  Prognostic Factors in Assisted Conception
Female  age  is  the  most  important  determinant  of  live  birth  rates  following  IVF 
treatment.  After  adjustment for female  age  there  is  a  significant fall  in  live  birth 
rates  with  increasing  duration  of  subfertility  and  repeated  failed  IVF  cycles. 
Previous pregnancy (especially  IVF  pregnancy) and  childbirth  enhance treatment 
success. The cause of subfertility has minimal effect on the outcome8.
However, assessment of specific prognostic factors that might affect the treatment 
outcome should  not be performed  in  isolation and the overall  success rate of the 
treating clinics should  also be evaluated.  Mostly these variations are attributed to 
the expertise of the individual clinics.  It is reported that even within a single clinic 
the success rate may vary from one physician to the next9’10.  It is recognized that, 
with a higher number of treatment cycles, larger clinics generally will perform better 
than  smaller  clinics11.  This  is  possibly  due  to  economies  of  scale  allowing
21opportunities for better quality control,  and economies of scope where clinics can 
provide a wider selection of treatment options to tailor the fertility management of 
individual  couples.  However,  the  importance  of  size  to  explain  the  inter-clinic 
variance  has  been  challenged12.  The other widely accepted  argument to  explain 
such persistent differences between clinics is the dissimilarity in the proportion of 
good and poor prognostic couples in their treatment populations13.
1.1.1.1  Female Age
Several  authors  have  constructed  statistical  models  to  predict  the  probability  of 
pregnancy  after  embryo  transfer  (ET)  using  multivariate  analysis  of  prognostic 
factors. The consistent conclusion is that the age of the female partner is the single 
most important factor determining spontaneous fertility and the outcome of fertility 
treatment8’14-15-16-17-18.
Commenges-Ducos  et.  al.1 9  studied  923  IVF  cycles  and found  that women  aged 
>38  years  had  less  success  in  IVF  because  they  have  a  lower  probability  of 
producing oocytes and of implantation of embryos.  In spite of increased dosage of 
human  menopausal  gonadotrophin  (hMG) stimulation  older women  yielded fewer 
oocytes and had a higher cancellation rate20. The striking finding is that female age 
does not influence the probability of fertilization, which is in agreement with Padilla 
and Garcia21.
Using  logistic  regression  on  a  national  database  established  by  the  Human 
Fertilisation  and  Embryology Authority in  the  United  Kingdom,  Templeton  et.  al.8  
demonstrated that live birth rates were highest in the group aged 25-30 years with 
a sharp decline  in  older women. Templeton  et.  al.  model  the effect of age with  a 
nonlinear  continuous  curve  showing  only  a  slight  decrease  in  the  probability  of 
success until aged 35 years, followed by a sharp decrease after aged 35 years8.  A 
steeper  decline  after  the  age  of  37  years  was  reported  by  Van  Kooij  et.  al.22. 
Stolwijk et.  al.23 found a simple linear effect. This agrees with the results of other 
national database reports from the United States and France11-24’25,26’27.
22It is generally accepted that decline in fecundity with increasing age is due to the 
decreased fertility potential  of oocytes28,29,30  rather than  a  specific uterine factor. 
The aging uterus is shown to respond adequately to the circulating oestrogen and 
progesterone31.  Navot et.  al.32  found  no difference  in  implantation  rates  between 
younger  and  older  donor  oocyte  recipients  undergoing  identical  hormone 
replacement protocols.
It  is  proposed  that  decline  in  the  overall  quality  of oocytes  with  advancing  age 
occurs due to the development of chromosomal defects.  It is now well established 
that  reduction  in  the  number  of  follicles  occurs  simultaneously  with  the 
development of meiotic spindle  abnormalities  in  oocytes from  older women33,  as 
with the aneuploidy of embryos34 and accelerated granulosa cell apoptosis35.
This chromosomal defect can be congenital. As female age advances the follicular 
pool in the ovaries decreases as a result of ovulation and physiological atresia30,36. 
During  this  process  oocytes  with  congenitally  defective  chromosomes  are  not 
recruited until the healthy oocytes are utilised.  Hence, the defective oocytes start 
dominating the pool in the later reproductive years37,38,39. Alternatively, as a part of 
the general physiological aging of the body, chromosomal defects can be acquired 
secondary to  prolonged  exposure to the  risks  of accidental  damage40.  Whatever 
the mechanism, the available oocytes are poorer in quality with advancing age41.
1.1.1.2  Duration of Subfertility
Increased  duration  of  fertility  delay  is  associated  with  a  reduced  possibility  of 
spontaneous  conception  in  untreated  subfertile  couples.  Similarly,  duration  of 
subfertility  is  prognostic  for  treatment-related  conception  rates.  A  logistic 
regression  model  constructed  from  the  Human  Fertilisation  and  Embryology 
Authority  (HFEA)  database  of  36,961  registered  cycles  shows  a  significant 
reduction  in  the  live  birth  rate  with  increasing  duration  of  subfertility  even  after 
adjustment for female age. While three years of subfertility is associated with a live
23birth  rate of  15.3%  after  IVF,  10 years of subfertility drops the  live  birth  rate per 
treatment cycle to 12.4%8.
1.1.1.3  Previous Pregnancy History
Analyses  of  the  HFEA  database  highlight  that  any  pregnancy  will  increase  the 
chances of live birth after IVF treatment even after adjusting for female age. This 
effect  is  stronger  with  a  history  of  previous  live  births  than  for  a  history  of 
pregnancies  not  ending  in  live  birth,  especially  when  the  previous  pregnancy 
resulted from IVF treatment8.
An  analysis  by  the  French  National  Register  on  IVF  (FIVNAT)  of  all  oocyte 
collections between  1989 and  1995 also reveals that women with no previous IVF 
pregnancy had  lower success in  response to ovarian  stimulation,  fertilization  and 
pregnancy rates, when compared with women with a previous failed IVF pregnancy 
(spontaneous abortion or ectopic pregnancy) or ongoing IVF pregnancy42.
Other investigators report similar findings20,43. A database review of 5073 first and 
2396 subsequent IVF cycles shows that even  a prior biochemical  pregnancy is a 
good prognostic indicator20. In this series, a similar clinical pregnancy rate of 36.4% 
in  second  treatment  cycles  is  reported  following  both  a  biochemical  and  clinical 
pregnancy in the first cycle.  Human chorionic gonadotrophin (hCG) rises, although 
transient,  are  claimed  to  indicate  the  presence  of  an  embryo  sufficiently  well 
developed for implantation44.
1.1.1.4  Previous T  reatment Cycles
In a study using the HFEA IVF database, it is demonstrated that the live birth rate 
per treatment  cycle  is  highest  in  the  first  cycle  and  decreases  significantly with 
increasing  numbers of previous treatment cycles,  after adjusting for female age8. 
The  same  finding  is  reported  by  the  French  Registry  of  IVF,  which  has  built  a 
cohort  of  35,714  couples  since  1986.  The  clinical  pregnancy  rate  per  oocyte 
collection decreased from 20.2% in the first attempt to 17.4% in the second, and to
24<13%  after the sixth. This trend  persisted whatever the female age or subfertility 
diagnosis27. However, there appears to be no consensus in the literature.
Croucher et. al 20 shows that the 26% chance of pregnancy after a single IVF cycle 
remains constant for the first three attempts and only subsequently does this begin 
to decline. Cumulative pregnancy rates continue to rise, albeit at slower rates; 54% 
after three cycles and  72% after six.  Some studies indicate a constant rise in the 
cumulative  pregnancy  rate  up  to  six  cycles,  where  it  reaches  a  plateau  of 
56%45,46,47, and even up to eight cycles48.
This  indicates  a  self-selection  process  occurring  throughout  repetitive  treatment 
attempts, during which the proportion of couples with a good prognosis is declining. 
This  leads  to  a  progressive  fall  in  overall  success  rates  in  the  residual  non­
pregnant  population  undergoing  IVF  treatment.  The  speed  of  this  decline  is  a 
function of the characteristics of the initial cohort, which is different in each study.
1.1.1.5  Cause of Subfertility
In contrast to the prediction  models of untreated couples where spontaneous live 
birth  rates  are  strongly  affected  by  seminal  defects,  tubal  disease,  and 
endometriosis, the HFEA database demonstrates no association between different 
causes of subfertility and the outcome of IVF treatment in terms of live birth  rate 
per treatment  cycle8.  A  similar  outcome  is  reported  by  Croucher  et.  al.20,  who 
report that even when  multiple factors are involved, the cause of subfertility does 
not affect IVF outcome.
However, the national  HFEA register database analysis reveals a different picture 
when  the  live  birth  rates  are  calculated  per  ET  rather  than  per  cycle  initiated8. 
Unexplained  subfertility (19.7%) achieved  a  higher success  rate than  tubal factor 
subfertility  (16.5%)  and  endometriosis  (17.9%).  This  difference  is  explained  by 
either lower fertilization but higher implantation rates in  unexplained subfertility, or 
lower implantation  rates in tubal subfertility. The presence of hydrosalpinges may
25contribute to the negative influence of tubal subfertility; nevertheless, severe tubal 
damage, regardless of hydrosalpinges, is associated with poor IVF outcome49,50.
Some  authors  find  a  reduction  in  pregnancy  rates  among  women  with 
endometriosis  due to functional  impairment at different stages  of fertility.  Altered 
folliculogenesis51,  ovulatory  dysfunction52,  hyperprolactinemia53,  luteal  phase 
defect54,  accelerated  ovum  transport55,  sperm  phagocytosis56,  impaired 
fertilization57,  poor  embryo  quality  and  embryo  toxicity58,  and  defective 
implantation59,60  are  suggested  as  possible  mechanisms  of  reduced  fertility  in 
endometriosis.
However, these observations are not universal. The presence of endometriomas in 
women  undergoing  ovum  donation  does  not  appear  to  affect  implantation61. 
Results  from  the  large  national  databases  in  the  UK  and  (JS8,11,24,25,26  do  not 
support the contention of lower pregnancy rates with endometriosis.  Despite their 
power to  overcome  the  problems  of study  population  size,  found  in  smaller  but 
better  controlled  studies,  the  inherent  problem  of  national  databases  is  their 
inability  to  collect  detailed  information  regarding  the  stage  of  endometriosis. 
Therefore,  the  pooled  summative review may miss an  association  at a  subgroup 
level.
Although  male  factor  subfertility  is  recognized  to  compromise  the  treatment 
outcome  in  earlier  reports  from  IVF  clinics14,15  or  national  databases27,  this 
apparent  disadvantage  is  no  longer  valid  due  to  the  introduction  of  the 
intracytoplasmic  sperm  injection  (ICSI)  procedure  into  routine  fertility 
management8,11,26.
1.1.1.6  Ovarian Reserve
In  terms  of fertilisation  and  subsequent  implantation,  oocyte  quality  determines 
fecundity  and  correlates  well  with  the  total  number  of  oocytes  in  the  ovary.  As 
direct oocyte assessment at clinical level is not feasible outside the context of IVF,
26follicular  characteristics  have  been  used  as  surrogate  parameters  in  ovarian 
reserve  tests.  These  tests  have  been  designed  to  reflect  the  quantity  of  the 
remaining follicular pool in the ovary and so signify the quality of the oocytes.
During  the  first  five  days  of  an  ovulatory  cycle,  basal  serum  follicle  stimulating 
hormone (FSH) levels reflect the number of antral follicles ready for recruitment62. 
Rising  levels  of early follicular phase  FSH  reveal  a  reduction  in  the  size  of this 
follicular cohort and a subsequent reduction in inhibin-mediated negative feedback 
in the pituitary30,31,36.
As  is  evident  in  clinical  practice,  while  FSH  levels  increases  with  decreasing 
ovarian  reserve the follicular response to gonadotrophin stimulation  also reduces, 
with  fewer  follicles  developing,  fewer  oocytes  produced,  and  fewer  embryos 
created63,64,65.  This observation  is valid  even when the rise  in  FSH  levels occurs 
within  the  normal  range  and  is  found  to  be  chronologically  independent  and  in 
advance of female age66,67,68. Supporting this finding,  it is reported that basal FSH 
levels  provide  a  much  better  predictive  power for  pregnancy  rates  than  female 
age69.  Faddy et.  al 4 1   conclude that the ovary measures biological time according 
to the number of oocytes remaining, rather than chronologically.
In an IVF setting, El-Toukhy et. al.70 demonstrate that treatment outcome does not 
differ in poor responders aged <30 years when compared with their older peers for 
fertilization,  implantation,  pregnancy and  live-birth  rates.  It is  proposed that these 
women,  regardless  of  age,  share  an  inherent  oocyte  problem  referred  to  as 
‘ovarian ageing’71,72. This contention is in contrast to studies suggesting that within 
poor  responder  groups,  young  women  have  a  significantly  better  outcome  than 
older women73,74.
Although there is such a decline in the numbers of oocytes recruited by exogenous 
gonadotrophin stimulation in women with high FSH levels66,75, there appears to be 
no  reduction  in  the  proportion  of these  oocytes  reaching  maturity76,  or  in  their
27fertilization, cleavage71,77, or ability to produce high quality embryos76,78.  However, 
the  implanting  ability  of  individual  embryos  declines  with  female  age  and  thus 
pregnancy  rates75,79.  It  is  argued  that  chromosomal  abnormalities  of the  oocyte 
need not affect fertilization and early embryo cleavage but can be linked to failure 
of implantation80,81,82.
Inter-cycle variation of gonadotrophin concentrations is well documented but these 
fluctuations  are  considerably  less  in  women  with  low  FSH  concentrations83,84.  It 
appears that the inter-cycle variability in basal FSH levels generally does not affect 
the  woman’s  prognostic  category85  and  a  single  raised  FSH  value,  even  if 
subsequent  levels  are  normal,  is  associated  with  decreased  ovarian 
responsiveness, fertilization and implantation rates85,86.
Post-test probabilities of elevated  basal  FSH  concentrations  enable us to  identify 
women  who  can  be  advised  not  to  undergo  IVF  treatment,  but  only  where  a 
significantly high cut-off level is chosen68,86. This is because, despite having a high 
specificity,  basal  FSH  levels  have  limited  sensitivity87.  A  substantial  group  of 
women will have normal FSH and yet respond poorly to stimulation and have poor 
pregnancy rates. This is explained by proposing that the FSH level is a late marker 
of decreased fertility potential88,89.
Immunoassays of luteinising hormone (LH) and FSH are intrinsically imprecise and 
differences  in  the antibodies  used to  measure gonadotrophin  levels contribute to 
this  imprecision.  Most  of  the  commercially  available  assays  use  polyclonal 
antibodies that bind  differently to separate haptens on  the glycoprotein  hormone. 
Consequently,  as  the  distribution  of  different  isoforms  changes  throughout  the 
menstrual  cycle,  the  ability of any single  assay to  recognize  the  gonadotrophins 
present  may differ substantially.  The  assay that  reports  a  relatively higher value 
with one set of isoforms could present a lower value when  measuring another.  In 
addition,  different  assays  may  be  calibrated  against  different  reference 
preparations, adding further variability to the reported results87.
281.1.1.7  Number of Embryos Transferred
The  number of  embryos  transferred  affects  the  chances  of a  live  birth,  but  the 
implantation  potential  of the  individual  embryo,  which  can  be  proximated  by the 
total number of embryos available for transfer, seems to be more important90.  If a 
high  number  of  embryos  is  available  for transfer this  is  shown  to  enhance  the 
likelihood of a live birth, whereas when only one or two embryos are available for 
transfer there is a reduced chance of success. However, transferring high numbers 
of  embryos  with  high  implantation  potential  carries  an  increased  probability  of 
multiple pregnancy and this is one of the major adverse effects of IVF treatment.
The  current  debate  is  on  how to  minimize  the  probability  of multiple  pregnancy 
without jeopardizing  the  likelihood  of a  healthy  singleton  birth.  An  analysis  of a 
large national database provides the answer to this90.  Guidelines were formulated 
based  on  recognition  of  the  fact  that  the  number  of  oocytes  fertilized  and  the 
number of embryos available for transfer is an  important factor in determining the 
outcome. Where more than four embryos were available for transfer, the live birth 
rate was not affected by the transfer of two or three embryos, although there was a 
significant  reduction  in  the  multiple  pregnancy  rate  when  two  embryos  were 
transferred. This is shown to be valid for all female ages up to 40 years.
This recommendation  has been criticized on the basis that no allowance is made 
for the possibility of varying embryo quality91. The ability to select suitable embryos 
remains an important determinant in the outcome of IVF treatment90,92,93. However, 
given the limitations of current embryo grading methods,  availability of more than 
four embryos  suitable for transfer may still  inherently designate  a  higher level  of 
ovarian reserve and a potential for better embryo quality.
Schieve  et.  al.94  conclude  that  the  probability  of  multiple  pregnancy  from  IVF 
treatment varies not only by the number of embryos transferred but also by female 
age. Among women aged <35 years, maximum live-birth rates were achieved with 
as  few  as  two  embryos  transferred.  However,  unlike  the  UK  study90,  this
29retrospective  cohort  analysis  indicates  a  statistically insignificant  increase  in  live- 
birth  rates  among  women  aged  >35  years  if  more  than  two  embryos  are 
transferred, but at the expense of a highly significant increase in multiple birth rates 
from 12% to 29%.
Female  age  is  a  well-documented  prognostic  factor  in  embryo  quality95  and 
treatment outcome8. Although live-birth rates drop with advancing age, the effect of 
age  on  multiple  pregnancy  rates  is  not  strong  enough  to  relax  the 
recommendations  for  the  number  of  embryos  transferred.  In  this  context,  the 
research  based  data  have  challenged  the  perceived  sense  of security regarding 
the low multiple pregnancy probability of women aged in their 40s96,97,98.
From  the  earlier  studies  by  Staessen  et.  al.92,93,99  on  the  effect  of  number  and 
quality  of  embryos  transferred  on  multiple  pregnancy,  to  the  retrospective  case 
control  study  by  Licciardi  et.  al.100,  and  the  data  analyses  of  UK  IVF  clinics  by 
Ozturk and Templeton101, the same trend has consistently emerged.  Reducing the 
number of transferred embryos from three to two largely eliminates the occurrence 
of triplet pregnancies without altering overall  pregnancy rates. The  British  Fertility 
Society  and  the  Royal  College  of  Obstetricians  and  Gynaecologists  recommend 
that UK clinics observe a limit of two embryos per transfer102.  Recently the HFEA 
have also recommended that only two embryos should be transferred. However, as 
these studies highlight, such a policy does not address the high prevalence of twin 
pregnancies,  which  are  more frequent than  higher-order  multiples  and  contribute 
substantially to perinatal morbidity. If the ultimate goal of IVF is the birth of a single 
healthy  child,  the  way  ahead  is  proposed  to  lie with  elective  single-ET  with  the 
promise of subsequent transfer of frozen-thawed embryos103.
1.1.1.8  Embryo Quality
Embryo quality is a term used in clinical practice to describe an attempt to quantify 
the development potential of embryos in vitro.  Estimation of embryo quality is used 
so  that the  best  embryos  can  be  selected  for transfer  after  culture  in  vitro.  The
30pregnancy rate,  implantation  rate,  and  incidence of multiple pregnancies increase 
significantly  with  the  number  of  good  quality  embryos  transferred92.  Embryo 
morphology is important in predicting the likelihood of embryonic progression.  It is 
apparent that severe fragmentation is a poor prognostic sign.  Blastomere size that 
is inappropriate for a particular stage of cleavage may indicate partial  or incipient 
cleavage arrest. The multinucleation and timing of the earliest stages of cleavage 
are  among the  many methods  promising  more sensitive assessment,  but to date 
there  is  no  reliable  method  of  predicting  developmental  competence  or 
implantation potential with any degree of accuracy104,105,106.
1.1.1.8.1  Embryo Selection Methods
The functional potency of human oocytes and embryos is a continuum that can be 
traced  from  prior to  ovulation.  As  direct assessment of the  developing  oocyte  in 
vivo  is  not  possible,  biochemical  analysis  of  follicular  fluid  and  sonographic 
evaluation  of  ovarian  stromal  and  perifollicular  blood  flow  have  been  utilised  to 
inspect oocyte quality for fertilisation  and  implantation  potential107. The grading of 
cumulus-coronal  morphology is proposed as a useful  predictor of success108. The 
presence of the first polar body in the perivitelline space was  looked  at to ensure 
the  timely  process  of  meiotic  divisions  and  so  the  nuclear  maturity  of  the 
oocyte109,110. The cytoplasmic polarity in human oocytes may also be linked to the 
potency of future development111.
Early  assessment  of  embryo  morphology  at  the  pronuclear  stage  provides  the 
opportunity to evaluate the transient markers of embryo development that possess 
prognostic significance112,113. However, to date the embryo morphology on day 2 or 
3  after insemination  is the  most frequently  used  parameter to  assess the growth 
potential of individual  embryos.  The number of blastomeres is used to identify the 
stage of development of embryos, and relative size and shape of blastomeres and 
evidence of fragmentation are used to grade the embryos92,96,114,115,116,117,118,119.  In 
addition  to  cross-sectional  morphological  evaluation,  kinetic  parameters  of 
embryonic growth are utilised in relation to the timing of the first cell division12 0  and
31cleavage  rate 48  hours  after oocyte  collection92,121.  Estimation  of embryo quality 
after three days of in vitro culture122 or at the morula or blastocyst stage123 takes 
advantage of the natural self-selection process for survival.
1.1.1.8.2  Cleavage Rate
The rate of embryo development is proposed as prognostic for future viability and 
more  likely to  be  influenced  by factors  intrinsic to the  oocyte  and  embryo  rather 
than  culturing  protocols,  female  age,  stimulation  protocol  and  semen 
characteristics114,124.  Early  cleavage  to  the  two-cell  stage  within  25  hours  post­
insemination is associated with significantly more clinical pregnancies120.
Number of blastomeres at the time of transfer also acts as a proxy measure of the 
developmental  potential  of the  embryo,  linking  closely to the  embryonic  genome 
activation  that  occurs  between  the  four-cell  and  eight-cell  stages  of  pre­
implantation development125.
Two studies that employed transfer of homogeneous quality embryos116,126 report 
that no delivery was  achieved  using  one-cell  embryos or embryos obtained  after 
delayed  fertilization.  Higher  pregnancy  rates  were  obtained  with  embryos 
displaying no irregular cells and embryos displaying no fragmentation. The four-cell 
embryos implanted twice as often as embryos with less or more cells116,126. Hsu et. 
al.1 22  establish  that  despite  embryo  cleavage  and  morphology  being  strongly 
correlated, embryo cleavage is a superior indicator of implantation when compared 
with embryo morphology.
Van  Royen et.  al.105 characterise a top quality embryo as four or five blastomeres 
on  day 2  following fertilisation  and  at least seven  on  day 3,  <20% fragmentation 
and  no  multinucleated  blastomeres  at  any  stage.  In  this  series,  82%  of  all 
documented implantations were attributable to such top quality embryos. However, 
embryos  with  two  blastomeres  and  initial  slow  development  on  day  2  following 
fertilisation have a high ongoing implantation rate if they later show an accelerated
32growth rate with at least seven blastomeres on day 3, <10% fragmentation and no 
multinucleated  blastomeres.  Embryos with  the  same  cleavage  rate  but with  10- 
20% fragmentation do much worse106.
1.1.1.8.3  Cellular Fragmentation
Fragmentation  is  one  of  the  most  common  morphological  features  used  in  the 
assessment  of embryo  quality.  It  is  the  extrusion  of the  plasma  membrane  and 
cytoplasm  of  an  embryo  into  the  extracellular  space.  Complete  or  partial 
fragmentation  of blastomeres  is a  common  occurrence during the early cleavage 
stages  of  human  embryonic  development,  both  in  vivo  and  in  vitro127.  It  is 
speculated that the process may be due to lethal defects in arrested embryos with 
a  deleterious  outcome92,104,116.  However,  fragmentation  may  also  be  associated 
with  self-protecting  events128 and  the embryo maintains  its viability by eliminating 
affected  blastomeres  through  apoptosis,  which  leads  to  cellular 
fragmentation129,130.
Staessen  et.  al.99,  Giorgetti  et.  al.116,  and  Ziebe  et.  al.126  report  low  implantation 
rates  after  transfer  of  embryos  with  10-50%  fragmentation  on  day  2.  However, 
these reports do not consider the size and distribution of the fragments. Alikani et. 
al.1 3 0   have  addressed  this  concern  and  their  findings  indicate  that  not  all 
fragmentation,  even  at high  levels,  is detrimental to the embryo.  Small,  scattered 
fragments did  not appear to  negatively affect cell  numbers  and  posed  no serious 
threat  to  further  development,  as  opposed  to  larger  fragments.  Ebner  et.  al.1 3 1  
detected  significantly  more  congenital  malformations  in  embryos  with  >25% 
fragmentation.
1.1.1.8.4  Multinucleation
Multinucleation  of human  pre-implantation  blastomeres  is  caused  by  changes  in 
cleavage  patterns  that  can  arise  from  karyokinesis  (nuclear  division)  in  the 
absence of cytokinesis  (cellular division).  Multinucleation  can  also arise by partial 
fragmentation  of nuclei,  or by defective  migration  at  mitotic  anaphase132,133,134.  A
33possible role of exuberant response to ovulation induction135, or suboptimal culture 
conditions  with  a  detrimental  effect  on  cytoskeleton  function  is  proposed  in  the 
development of multinucleation132,134,136.
Van  Royen  shows  that  of 213  embryos  with  documented  ongoing  implantation, 
there was  only one  embryo with  multinucleated  blastomeres105.  Tesarik et.  al.1 3 7  
found  that  multinucleated  embryos  can  cleave  beyond  the  eight-cell  stage  but 
these  cells  have  defective  transcription  of  genes  that  eventually  leads  to 
developmental arrest. If this happens after implantation it results in early pregnancy 
loss. Several authors advise against transfer of multinucleated embryos because of 
their  poor  developmental  potential  and  high  rates  of  chromosomal
abnormalities132,138,139.
1.2  Aspirin
Aspirin  is a  product of the late  19th century but medical  historians have traced  its 
origins  to  3,500  years  ago.  The  Ebers  papyrus,  a  collection  of  877  medicinal 
recipes from  the  second  millennium  BC,  recommends  an  infusion  of dried  myrtle 
leaves for rheumatic and back pain. One thousand years later, Hippocrates of Kos 
prescribed a juice extracted from the bark of the willow tree to relieve the pain of 
childbirth  and to reduce fever. All of these medicinal  remedies contain  salicylates 
and the name is derived from salix, the Latin word for willow.
In  Germany  in  1860,  salicyclic  acid  was  chemically  synthesized  as  an  external 
antiseptic and commonly used for the treatment of rheumatism. Subsequently, on 
10th  August 1897, the active ingredient, acetylsalicylic acid, was synthesized for the 
first time  in  a  chemically  pure  and  stable form  by  Dr  Felix  Hoffmann,  a  chemist 
working for Bayer, who was urged by his father to make a more palatable form of 
salicylate to treat his rheumatism.
341.2.1  Mode of Action
Aspirin covalently and irreversibly modifies both cyclo-oxygenase -1  and -2 (COX-1 
and COX-2) by acetylating Serine-530 in the active site140,141. Acetylation of COX-1 
creates  a  steric  block  that  prevents  the  binding  of arachidonic  acid  at the  COX 
active site (Figure 1.1). Acetylation of COX-2 retains the COX activity although the 
reaction  produces a  novel  product  15-R-HETE, which  serves as substrate for the 
formation  of  15-epi-lipoxin  A4,  a  compound  that  can  exhibit  anti-inflammatory 
properties primarily by down-regulating granulocyte activity142,143.
Figure 1.1.  Prostaglandin synthesis
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Aspirin  can  be  regarded  as a  non-selective  COX  inhibitor,  although  it possesses 
higher  potency  for  COX-1144.  Aspirin  does  not  inhibit  lipoxygenase.  On  the 
contrary,  inhibition of COX may lead to increased formation of leukotrienes,  most
35likely because of an increase in the amount of free arachidonic acid available to the 
lipoxygenase enzyme.
Acetylation  of  COX  by  oral  aspirin  is  dose-dependent,  cumulative  and  selective 
with  repeated  administration.  However,  biochemical  selectivity  is  at  best  relative 
but not absolute. Various regimens of low dose aspirin (LDA) were tried to achieve 
maximum  Thromboxane  A2  (TXA2)  suppression  while  maintaining  prostacyclin 
(Pgl2) levels in both obstetric and  non-obstetric populations. Thromboxane A2 has 
two potent actions: it stimulates both platelet aggregation and release reaction, and 
also  contracts  blood  vessels.  Prostacyclin  is  a  potent  inhibitor  of  platelet 
aggregation and vasodilator. Various effects of aspirin are summarised (Table 1.1).
Table 1.1.  Aspirin effects
Anti-aggregation
Anti-thrombin I TXA2  in platelet-COX 1
Catella-Lawson and 
Crofford1 4 5
Anti-inflammatory I  or no PGI2  in endothelium-COX 2 Patrono1 4 6
I Synthesis of coagulation factors Loew and Vinazzer1 4 7
Anti-thrombin T Fibrinolysis Bjornsson1 4 8
Alteration of fibrin porosity Fatah1 4 9
T Nitric oxide production Mahmood1 5 0
Anti-inflammatory
I Intracellular ATP 
T Extracellular adenosine
Cronstein1 5 1
Chemical trap for hydroxyl radicals
Van Jaarsveld1 5 2  
Colantoni1 5 3
Immune and inflammatory 
modulation
1 Mitogen activated protein-kinases, 
pro-inflammatory enzymes, cytokines, 
chemokines, cell adhesion molecules, 
activator protein 1   (activated by TNFa)
Abramson and 
Weissmann1 5 4  
Tegeder1 5 5
j
Anti-angiogenetic 
|  Prevents endothelial 
|  migration and tube formation
COX-2 modulate angiogenic factors in 
colon cancer cells Tsujii1 5 6
COX-1  regulates angiogenesis in 
endothelial cells
I: Lower, t: Increase, COX: Cyclo-oxygenase
1.2.2  Aspirin Regimens
Two  strategies  have  been  proposed  to  enhance  the  biochemical  selectivity  of 
aspirin for TXA2: a reduced dose and an alternate-day regimen. At low doses most 
of the aspirin  is  metabolized  on  the first pass through  the  liver.  Thus,  little or no
36aspirin  reaches  the  systemic  circulation  to  impair  vascular  endothelial  PGI2 
production while repeated daily doses assure that virtually all platelets are exposed 
to aspirin at perihepatic circulation.  Dosing with aspirin on alternate days is based 
on  the  premise  that,  unlike  platelets,  endothelial  cells  retain  the  capacity  to 
generate  new  enzyme  despite  the  irreversible  inhibition  of  prostaglandin  G/H 
synthase.  Although  the  enzyme  remains  inhibited  for  the  lifetime  of  exposed 
platelets, enzyme turnover permits functional recovery in the vascular endothelium 
in vitro.  In  addition,  platelet COX may be more sensitive to aspirin  inhibition than 
the vascular enzyme.
With a single daily administration the aspirin dose for near-complete suppression of 
serum  thromboxane  formation  with  best  differential  sparing  of  prostacyclin  has 
been  titrated  downward  to  approximately  0.5-2  mg/kg157.  Urinary  excretion  of  a 
stable hydrolysis product of prostacyclin still fell by 20% during the first four days of 
the treatment (0.5 mg/kg) but this failed to attain statistical significance158. The fall 
in PGI-metabolite excretion attained significance at doses in excess of aspirin  160 
mg/day159.
The antiplatelet effects of the daily dose of aspirin  depend  on the time pattern  of 
administration160.  Intermittent  pulsed  rather than  split  administration  of the  same 
cumulative  dose  of  aspirin  favour  both  better  inhibition  of  platelet  function  and 
preservation of prostacyclin formation. Serum thromboxane B2  concentrations were 
nearly identical during treatment with aspirin 325 mg every third day or aspirin 81 
mg every day161.
Tulppala  et.  al.1 62  evaluated  the  effect  of  low-dose  aspirin  on  PGI2  and  TXA2  
production  and  on  pregnancy outcome in  recurrent miscarriages with and without 
anticardiolipin  antibodies  (ACA).  Treatment  with  aspirin  inhibited  platelet  TXA2  
production similarly in women with and without ACA and with ongoing pregnancies 
or  miscarrying  pregnancies.  The  administration  of  aspirin  50  mg  during  early 
pregnancy significantly reduced TXA2  production  but left  PGI2 output unchanged.
37However,  it  did  not  improve  pregnancy  outcome  in  women  with  or  without 
detectable ACA.
1.2.3  Safety Issues During Pregnancy
Aspirin is the most frequently ingested drug in pregnancy163.  Studies investigating 
the  effect  of  aspirin  on  hypertension  in  pregnancy  and  intrauterine  growth 
retardation  did  not  observe  aspirin-induced  fetal  or  neonatal  toxicity  after  the 
chronic use of low-dose aspirin at 40 to 150 mg/day.
The  possible  relationship  between  aspirin  in  early  pregnancy  and  congenital 
defects remains controversial. A Food and Drug Administration (FDA) surveillance 
study involving  1,709 newborns exposed to aspirin during the first trimester does 
not  support  an  association  between  the  drug  and  congenital  defects163.  The 
Collaborative  Perinatal  Project  of  14,864  mother-child  pairs,  who  used  aspirin 
during the first trimester, found no evidence of a teratogenic effect in pregnancy164. 
A meta-analysis has shown that the probability of congenital  malformations in the 
offspring of women exposed to aspirin in early pregnancy is not significantly higher 
than that in control subjects (odds ratio,  1.33; 95% Confidence  Interval  (Cl), 0.94- 
1.89)165.  However, a significantly increased probability of gastroschisis (odds ratio, 
2.37;  95%  Cl,  1.44-3.88)  has  been  reported  in  women  who  have  taken  a 
nonsteroidal  anti-inflammatory  drug  (NSAID)  including  aspirin  and  paracetamol 
during the first trimester of pregnancy165,166.
A Danish population based case-control study of 1462 pregnant women prescribed 
NSAIDs at doses equivalent to 400 mg or 600 mg of ibuprofen  shows that use of 
NSAIDs  during  pregnancy  does  not  increase  the  probability  of  adverse  birth 
outcome in terms of congenital abnormality,  low birth weight,  or preterm  birth,  but 
is associated with increased probability of miscarriage (odds ratios range from  1.3 
for NSAID  use  10-12  weeks  before miscarriage  to  7.0 for  NSAID  use  one  week 
before  miscarriage)167.  The  study  was  criticised  on  the  basis  of  incomplete 
evaluation of both the NSAID use during pregnancy and the miscarriages, and lack
38of information on  important confounders such as the reason for NSAID use.  Li et. 
al.168 also evaluate the prenatal use of NSAIDs in a population based prospective 
cohort  study,  revealing  an  increased  probability  of  miscarriage  associated  with 
prenatal  use  of  NSAIDs  or  aspirin.  The  associated  probability was  higher when 
NSAIDs were used around the time of conception and when used for longer than a 
week,  indicating a dose-response relationship, though no precise dose information 
was available. In contrast to Nielsen et. al.167, Li et. al.168 identify the indications for 
use of the drugs, control the data for confounding factors and evaluate the effect of 
timing  and  duration  of  drug  use.  They  conclude  that  the  association  between 
NSAID  use and  miscarriage is  unlikely to be due to the underlying  indications for 
use of NSAIDs or aspirin.  Potential for biased recall and a confidence interval that 
includes 1.0 suggest that their results are on the borderline of statistical.
1.2.4  Safety Issues Relating to Bleeding Complications
Although  bleeding  time  is  prolonged  during  low-dose  aspirin  therapy,  the clinical 
implications  of this for the  hemorrhagic  complications  of concomitant  surgery do 
not seem to be universally accepted. Bleeding time does not correlate well with the 
occurrence  of  post-operative  bleeding169.  However,  published  clinical  studies 
present  conflicting  data.  An  increased  frequency  of  bleeding  is  reported  after 
abdominal  surgery  in  patients  treated  with  indomethacin170  and  after  prostate 
surgery  in  patients  who  received  preoperative  aspirin  or  other  NSAIDs171.  No 
significant  increase  in  blood  loss  was  found  in  patients  receiving  diclofenac 
concurrent  with  hip  replacement,  transurethral  resection  of  the  prostate,  or 
gynaecologic  laparotomies172,173,174.  In  a  review  of  haemorrhage  and  transfusion 
requirements  in  patients  undergoing  coronary  artery  bypass  grafting,  it  was 
concluded  that  aspirin  does  not  predispose  to  significant  hemorrhagic 
complications175.
The  risk  of  gastrointestinal  haemorrhage  from  long-term  treatment  with  sub­
analgesic  doses  of  aspirin  is  well  acknowledged.  A  systematic  review  of 
randomised  trials  shows  that  the  probability  is  1.68  times  higher  based  on  an
39average  of 28  months’  therapy.  There was  no  evidence  of dose  responsiveness 
over a wide range (50 to 1500 mg/day) for the occurrence of this complication176. A 
multi-centre  study  concluded  that  451  women  who  received  low-dose  aspirin 
(60mg) from  13 to  27  weeks  of pregnancy onwards  did  not  have  any  increased 
maternal bleeding complications or adverse effects related to epidural anaesthesia 
despite having increased bleeding time177.
1.3  Antiphospholipid Antibody Syndrome
Antiphospholipid  antibody  (APA)  syndrome  presents  with  the  clinical  features  of 
venous  or  arterial  thrombosis,  recurrent  pregnancy  loss,  or  thrombocytopenia. 
Diagnosis requires one clinical feature and at least one laboratory finding of either 
positive  IgG  or  IgM  anticardiolipin  antibodies  (ACA)  >20  GPL  units,  or  positive 
lupus anticoagulant (LA) test.
Defective embryo implantation  is the unifying feature of all obstetric complications 
associated  with  APA178,179,180,181.  The  pathogenesis  was  initially  believed  to  be 
associated  with  spiral  artery  thrombosis182,183,184  and  widespread  placental 
infarction.  However, later studies suggest that this is not a universal finding1 85 and 
the focus has been more on the adverse effects of APA on embryonic implantation 
and trophoblast invasion.
Several  possible  mechanisms  have  been  promoted.  APA  can  modify  the 
prostaglandin  metabolism  leading  to  a  drop  in  prostacyclin  levels  or  increase  in 
thromboxane synthesis186,187. This synthesis might be normalized  by aspirin162,188. 
Binding  of APA promotes  aggregation  of platelets  leading  to thrombus formation 
and  thrombocytopenia.  APA  also  activates  endothelial  cells  to  express  adhesive 
molecules  and  secrete  pro-inflammatory  molecules  leading  to vascular occlusive 
disease.  Microscopically,  fibrinoid  necrosis  and  thrombosis  of  spiral  arteries  is 
noted  and  associated  with  extensive  infarction  in  the  placenta  of  women  with 
recurrent pregnancy losses182,183,189.
40APA can  bind  to the surface of phospholipids resulting  in  direct cellular injury on 
the  trophoblast  and  inhibiting  the  syncytia  formation179,190,  giving  rise  to  severe 
placental  dysfunction.  It  is  proposed  that  APA  may  interfere  with  phospholipid 
dependent gonadotrophin-releasing hormone induced signal transduction, and are 
able  to  affect  human  chorionic  gonadotrophin  secretion191,192.  In  human 
miscarriages associated with APA, the level of interleukin 3 (IL-3) stays low, which 
normally  promotes  trophoblast  expansion  and  invasion193.  ACA  inhibit  prolactin 
secretion and  prostaglandin synthesis by human decidual  cells180. The favourable 
effects of aspirin are shown to directly promote decidualisation194.
A  range  of  treatments  comprising  aspirin,  heparin,  steroids  and  intravenous 
immunoglobulin  (IVIG)  has  been  advocated  to  improve the  poor live  birth  rate of 
women  with  APA  syndrome.  Women  with  a  history of recurrent  miscarriage  and 
APA-positivity had a 90% miscarriage rate when they received  no drug treatment, 
whereas a control group of APA-negative women with recurrent miscarriage had a 
34% miscarriage rate195,196.
The  treatment  of  choice  for  pregnant  women  with  APA  syndrome  is  low-dose 
aspirin with heparin. Two prospective randomized studies report that this treatment 
combination leads to a 71% live birth rate in future pregnancies and is superior to 
low dose aspirin alone (42%)196,197. There was no difference in the live birth rate in 
the  two-treatment  modality  in  pregnancies  that  went  beyond  14  weeks’ 
gestation195.
The antithrombotic effect of aspirin and  heparin  is well  known. This explains their 
mode of action  in recurrent miscarriages if one relies only on the concept of spiral 
artery thrombosis as the main factor of miscarriage in women with APA syndrome. 
However,  aspirin  may  also  increase  the  levels  of  interleukin-3,  which  promotes 
trophoblast invasion and trophoblast expansion198. Heparin also inhibits the binding 
of  APA199.  These  actions  may  protect  invading  trophoblast  phospholipids  from 
damage.  In  vitro  studies  have  reported  that  heparin  restores  placental  human
41chorionic  gonadotrophin  secretion  and  trophoblast  invasion,  both  of  which  are 
adversely affected by APA178,179.
1.3.1  Subfertility
The  hypothesis  of  APA  mediated  pregnancy  failure  has  been  proposed  to 
encompass  not  only  clinically  recognized  failure  of  post-implantation  pregnancy, 
but  also  failure  of  fertilization  and  implantation,  and  hence  subfertility200.  In 
otherwise clinically asymptomatic women,  Gleicher and  el-Roeiy2 0 1   define this as 
‘reproductive autoimmune failure syndrome’. A general polyclonal B cell activation, 
possibly  secondary  to  pelvic  tissue  damage  of  endometriosis  or  pelvic 
inflammatory disease202, is claimed to be responsible for the clinical picture.
Information  associating  immune dysfunction  with  subfertility is  largely confined to 
observational  studies linking the  prevalence of APA to clinical  situations such  as 
endometriosis, unexplained subfertility, pelvic disease and IVF failure.
Initially,  the  association  between APA and  subfertility  is  reported  by Gleicher et.
al.203,  Gleicher and  El-Roeiy201,  and Taylor et.  al.204.  Subsequently,  several  other
studies report a high prevalence, in the range of 15% to 59%, of APA in subfertile 
women undergoing  IVF treatment 202.205.206.207.208.209.210.211.212,213.214  R s c h   e t  a|  2 i5>
conclude  that  increased  APA concentration  in  women  undergoing  IVF  treatment 
reflects the subfertile state and  is not secondary to the IVF treatment. Chilcott et. 
al.2 16 report that the prevalence of APA is independent of the cause of subfertility 
(tubal, anovulatory, male factor, unexplained). Other studies report the incidence of 
APA  in  different  patient  populations:  normal  obstetric  patients  5.3%  (1.3-9.8), 
women  with  recurrent  pregnancy  loss  20%  (8-37),  women  with  systemic  lupus 
erythematosus  37%  (17-86).  The  prevalence of P 2GPI  (Anti-beta2-glycoprotein  I) 
antibody,  co-factor for ACA binding, was  16%  in the  recurrent miscarriage group 
and 9% in the IVF implantation failure group, compared with 0% in a control group 
of fertile women.
42Although there are theoretical reasons to believe that autoimmunity may play a role 
in  subfertility  in  some  women,  the  evidence  for  association  of  abnormal 
autoimmune  function  with  subfertility  remains  circumstantial.  Any  conclusion 
inferred from the published studies is fraught with inconsistencies among the study 
populations, different sets of autoantibodies used to establish diagnosis, absence 
of  standardized  autoantibody  assays,  and  various  definitions  of  ‘normal’  with 
regard to the autoantibody assays217.
Hence, among women undergoing IVF for treatment of subfertility, the relevance of 
the presence of APA has been questioned. Although these women  have a higher 
prevalence of APA,  none of the studies assessing IVF parameters have identified 
decreased  rates  of  oocyte  collection,  fertilization  and  embryo  development  and 
quality.
In order to evaluate whether among women undergoing  IVF the presence of APA 
affects the likelihood of IVF success, Hornstein et. al.218 published a meta-analysis 
of data collected from  seven  different  IVF  studies.  This  includes data on women 
with (n = 703) and without (n =  1350) elevated APA who underwent IVF treatment 
and, if APA-positive, received no therapy for abnormal levels of APA. Three studies 
were prospective207,209,210 and four retrospective202,219,220,221.
The aggregate clinical  pregnancy and  live birth  rates are respectively 57.0% and 
49.2%  in  the  APA-positive  women  and  46.0%  and  42.9%  in  the  APA-negative 
women. The odds ratio describing an association between APA and  IVF outcome 
ranged from 0.26 to 1.65 for clinical pregnancy and 0.19 to 1.64 for live births. No 
study  reveals  a  statistically  significant  effect,  although  studies  evaluating  more 
antibody types are more likely to find a non-significant reduction in the likelihood of 
IVF  success202,209,210,219,220.  As  estimated  by the  clinical  pregnancy  and  the  live 
birth rates, the presence of APA was not associated with reduced IVF success.
43Since  the  meta-analysis  was  published,  a  prospective  observational  study  by 
Chilcott et. al.216 evaluated the prevalence of APA and anti-(32-GPI antibodies and 
concludes that although women  referred for IVF have a  high  prevalence of APA, 
these antibodies do not affect the outcome of treatment.
However,  it  is  proposed  that the  apparent  lack of association  between  the APA 
seropositivity and the outcome of IVF treatment does not disprove the alternative 
hypothesis  of  abnormal  autoimmune  function  affecting  fertility.  The  antibodies 
could  be  epiphenomenon  and  developing  secondary  to  other  immunological 
disturbances212.  Therefore,  the  assumption  that APA alone  can  predict  poor  IVF 
outcome would be fraught because APA are only one marker amongst many of an 
activated  immune  system,  and  may  or  may  not  exist  in  the  presence  of  an 
abnormal autoimmune state.
1.3.2  Thrombo-prophylaxis in Subfertile Women with APA
Sher et. al.202 studied the effect on the implantation rate in women undergoing their 
first  IVF  treatment,  of  administering  low-dose  aspirin  (81  mg/day)  and  heparin 
(10000  International  Unit/day). A significantly higher pregnancy rate is reported in 
treated APA-positive women (49%), than in  untreated APA-positive women (16%) 
and untreated APA-negative women (27%).  In a report 222 on the selective use of 
aspirin  and  heparin  in combination with  intravenous  IgG,  in the  IVF cycles where 
aspirin  and  heparin were  administered  the  live  birth  rate was  significantly higher 
(45%) than when no aspirin and heparin was administered (17%). Women positive 
for anti-phosphatidylserine and/or anti-phosphatidylethanolamine  had  significantly 
lower birth rates than women with any other APA,  17% versus (vs) 43%. The live 
birth  rate  in  these women was  significantly improved  when  intravenous  IgG was 
added to heparin and aspirin.
Not all investigators found aspirin and heparin treatment effective in improving the 
IVF outcome in APA-positive women. Three studies, two non-randomized210,223 and 
one  randomized,  double-blind  and  placebo-controlled224,  report  that  aspirin  and
44heparin treatment does not improve IVF outcome in infertile women who are APA- 
positive.
1.3.3  Thrombo-prophylaxis in the General Subfertile Population
High resistance to uterine blood flow is associated with poor pregnancy outcome in 
women undergoing IVF treatment225’226227’2 2 8 1 2 2 9 '230.
It is postulated that aspirin therapy may improve embryo implantation  because of 
its  effect  on  endometrial  and  ovarian  perfusion  by  inducing  a  shift  in  local 
production  of  TXA2  toward  PGI2.  This  could  result  in  preferential  delivery  of 
gonadotrophins,  other  growth  factors  and  metabolic  substrates  to  improve 
folliculogenesis and oocyte quality. Similarly, development of the endometrium and 
final  receptivity would  be enhanced228,231.  It is also argued that aspirin may block 
the  PG-stimulated  inflammatory  process  and  the  release  of  interleukins232,233, 
which may lower the implantation rate. An improved prostacyclin/thromboxane ratio 
and reduced prostaglandin production may also prevent expulsion of the blastocyst 
while preparing the endometrium for implantation234,235,236.
Before  ET,  the  urinary  excretion  of TXB2   metabolite  is  reported  to  be  lower  in 
women who achieved  pregnancy than  in those who did  not237.  Similarly,  Battaglia 
et.  al.229  observed  lower  endometrial  cell  culture  thromboxane  concentrations  in 
pregnant women than in non-pregnant women and this correlated directly with the 
Doppler flow indices  of spiral  arteries,  whereby the  PI  values of the  uterine  and 
spiral arteries were significantly lower in women who became pregnant.  Likewise, 
Hauth et. al.238 showed that women assigned to receive aspirin had markedly lower 
maternal  thromboxane  B2  concentrations  than  the  placebo  group.  It  has  been 
shown  that the  blood  flow velocity  in  the  uterine  and  ovarian  arteries  increased 
significantly after ovulation induction239.
45Rubinstein et.  al.231,  Urman et.  al.240,  Kohl-Thomas et. al.241, Tassa et. al.242, and 
Salman et.  al.243 published their findings on  aspirin co-treatment during fresh  IVF 
cycles (Table 1.2). As seen in the table, these studies showed conflicting results.
Similarly,  impaired  uterine  perfusion  may  be  a  common  factor  in  frozen-thawed 
embryo replacement (FTER) cycles. A high proportion of women (37%) were found 
to have impaired uterine perfusion and hormone therapy alone does not invariably 
lead  to  good  uterine  perfusion228.  Also,  the  published  literature  on  aspirin  co­
treatment during FTER cycles is far from consistent (Table 1.2).  In agreement with 
the findings  of Goswamy  et.  al.244,  this  study228 found  no  difference  in  age  and 
causes  of  subfertility  between  women  with  poor  and  normal  uterine  perfusion. 
When  a  long  regimen  with  low-dose  aspirin  starting  on  day  1   of  the  hormone 
replacement therapy (HRT) cycle (47%) was compared with a short regimen with 
aspirin  starting  on  day  13  (17%), Wada  et.  al.228  report a  higher pregnancy rate 
following  FTER  in  women  with  poor  uterine  perfusion  assessed  by  Doppler 
ultrasound. Although the low-dose aspirin on both the long and short regimens led 
to improved uterine blood flow, on the long regimen more women with poor uterine 
perfusion achieved improved perfusion. The advantage of the long vs short aspirin 
regimen  is  possibly due to  more time  available during  the former to  correct any 
imbalance  in  the  thromboxane/prostacyclin  equilibrium.  The  dose  of  aspirin 
selected  for  the  short  regimen  (150  vs  300  mg/day)  did  not  significantly  affect 
treatment outcome.  Other practitioners  employed  even  smaller aspirin  doses (50 
mg/day)  and  observed  improved  utero-placental  perfusion,  thus  preventing 
pregnancy-induced hypertension245.
The high pregnancy rate (47% per ET) and low miscarriage rate (11%) observed in 
women  with  poor  perfusion  following  treatment  with  the  long  aspirin-regimen, 
suggests that low-dose aspirin  may benefit implantation  and  this is argued to be 
secondary  to  improved  uterine  perfusion228.  Higher  pregnancy  rates  were 
correlated with  improved  uterine perfusion  and  no advantage was  noted  in  using 
aspirin in women with normal uterine perfusion. However, some of the women with
46poor  uterine  perfusion  failed  to  achieve  improved  perfusion,  even  when  treated 
with the long regimen aspirin. In these cases, the reasons for treatment failure are 
uncertain  and  may  be  related  to differences  in  the  underlying  cause of impaired 
perfusion.
Check  et.  al.246  note  no  positive  effect  of  low-dose  aspirin  on  pregnancy  rates 
following FTER.  In this study,  18 women were treated with aspirin 81  mg from day 
2  of  the  treatment  cycle.  In  the  aspirin  group  the  clinical  pregnancy  rate  was
11.1%,  compared  with  33.3%  in  the  control  group,  and  implantation  rates  were 
2.9%  and  10.9%,  respectively.  The  mid-cycle  mean  endometrial  thickness  and 
echo  patterns  were  similar  in  both  groups.  In  the  aspirin  group  58%  had  no 
homogeneous  hyper-echogenic  pattern  in  the  luteal  phase,  compared  with  only 
28.6% of the control group. The mean  PI was higher for the controls (3.0±0.7 vs 
2.5±0.5). However, no inferential statistics were performed due to low numbers.
It  is  argued  that  for  oocyte  donation  recipients  with  a  poorly  developed 
endometrium,  the  reduced  pregnancy  rates  are  attributable to  decreased  uterine 
perfusion.  Weckstein  et.  al.247 found  that  low-dose  aspirin  improves  implantation 
rates  in  oocyte  donation  recipients  with  a  thin  endometrium  (24%  vs  9%).  In 
women  whose  endometrium  remained  thin  (<8  mm)  in  spite  of  augmented 
oestrogen  stimulation,  low-dose  aspirin  increased  the  pregnancy  rate  at  a 
statistically significant level (83% vs 25%).
Beginning  one week before starting  oestrogen treatment,  28  recipients of oocyte 
donation who failed to develop an endometrial thickness of at least 8 mm during a 
test cycle of oral micronized oestradiol (E2  2 mg for four days, 4 mg for four days, 
and 6 mg for four days), were randomized prospectively to receive low-dose aspirin 
(81  mg/day).  Fifteen cycles were randomized to aspirin treatment, and  13 to non­
aspirin treatment.  Similar to the results of Check et.  al.246,  the mean  endometrial 
thickness in the aspirin and non-aspirin groups was not significantly different during
47the  test  cycle,  and  there  was  no  increase  in  the  endometrial  thickness  despite 
aspirin therapy.
Uterine blood flow was not measured by Weckstein et.  al.247,  but Check et.  al2 46 
documents  no  change  in  Doppler  indices following  aspirin  therapy.  In  contrast, 
Kuo  et.  al.  demonstrate  that  aspirin  may  improve  uterine  flow  in  women  with 
unexplained  subfertility  and  repeated  treatment  failures248.  Based  on  a  uterine 
artery Doppler pulsatility index of >3.0,  one-third of the  127 women  studied were 
found to have impaired uterine perfusion during their menstrual cycles. Those with 
impaired uterine blood flow were given aspirin  100 mg/day starting on day 3 of the 
next ovulatory cycle. The PI was measured in the natural and aspirin-treated cycles 
in the same group of women. A significant improvement in uterine blood perfusion 
was detected on the day LH peaked and in the mid-luteal phase (peri-implantation 
stage) of aspirin-treated cycles.
Table 1.2: Published Studies on Aspirin co-treatment in IVF
Study Design
Number of 
Treatment 
Cycles
Aspirin
Dose
(mg)
Doppler ORS IR,
PR
Rubinstein2 3 1 Randomised, 
Aspirin vs Placebo
149 vs 149 
IVF
100
MLP t t T
Waldenstrom2 4 9 Randomised,
Aspirin vs No aspirin
703 vs 667 
IVF
75
ET N/A t
..........
Urman2 4 0 Randomised,
Aspirin vs No aspirin
139 vs 139 
ICSI
80
OS N/A < -»
Salman2 4 3 Randomised,
Aspirin vs No aspirin
169
IVF, ICSI 81 N/A < -> < -»
........  .....—.....
Lok2 5 0 Randomised, 
Aspirin vs Placebo
30 vs 30 
Poor
responder
IVF
80
MLP < -> < ->
Pakilla2 5 1 Randomised, 
Aspirin vs Placebo
186 vs 189 
IVF, ICSI
81
OS N/A
ORS:  Ovarian  response  to stimulation,  IR:  Implantation  rate,  PR:  Pregnancy rate,  ART: Assisted  reproductive technology, 
FTER:  Frozen-thawed  embryo  replacement,  MLP:  Mid-luteal  protocol,  ET:  Embryo  transfer,  OD:  Oocyte  donation, 
OS: Ovarian stimulation, N/A: Not available, I: Lower, t: Increase,No effect.
48Table 1.2: Published Studies on Aspirin co-treatment in IVF (continuation)
Study Design
Number of 
Treatment 
Cycles
Aspirin
Dose
(mg)
Doppler ORS IR, PR
Kohl2 4 1 Retrospective 133 vs 92 
ART
81
MLP N/A o
Tassa2 4 2 Retrospective 72 vs 244 
IVF
80
MLP N/A <-> I
Wada2 2 8
Randomised 
Aspirin vs 
Aspirin
26 vs 11
HRT for FTER 
Poor Perfusion
150  vs 
300 
Day 13
150 
Day 
1  vs 13
t
t  in 
Poor
<-> in
Normal
perfusion
Weckstein2 4 7
Randomised, 
Aspirin vs 
No aspirin
15 vs 13 
HRT for OD 
Thin
endometrium
N/A T
Check2 4 6
Randomised, 
Aspirin vs 
No aspirin
18 vs 18 
HRT for FTER <-» 1
ORS:  Ovarian  response  to stimulation,  IR:  Implantation  rate,  PR:  Pregnancy rate,  ART:  Assisted  reproductive technology, 
FTER:  Frozen-thawed  embryo  replacement,  MLP:  Mid-luteal  protocol,  ET:  Embryo  transfer,  OD:  Oocyte  donation, 
OS: Ovarian stimulation, N/A: Not available, I: Lower, t : Increase,  No effect.
1.4  Perfusion and Subfertility
Goswamy  and  Steptoe252  were  the first to  suggest  that  abnormal  uterine  artery 
blood  flow  might  be  associated  with  subfertility.  They  related  specific  abnormal 
waveforms with  failure of implantation  in  IVF  patients  and  successfully improved 
uterine  circulation  and  implantation  with  the  use  of  oestrogen244.  Subsequently, 
other  authors  confirmed  a  relationship  of  uterine  and  ovarian  blood  flow  to 
unexplained  subfertility253,254  and  to  successful  implantation  following
|Y  p115,255,256,257,258,259,260
1.4.1  Uterine Perfusion
1.4.1.1  Relationship to Oestrogen and Progesterone
Blood flow to the uterus increases in response to oestrogen, and the variations in 
uterine impedance over the normal menstrual cycle generally reflect the variation in 
circulating  oestradiol  levels244,261.  A  significant  correlation  between  plasma
49oestradiol level and endometrial blood flow exists in the follicular phase262.  In the 
luteal phase there is no correlation between blood flow and oestradiol  levels263. A 
significant  decrease  in  impedance  to  uterine  perfusion  as  a  result  of  increasing 
progesterone  concentration  has  been  demonstrated,  especially  in  the  late  luteal 
phase264.
Oestradiol  administered to postmenopausal women  causes decreased  resistance 
in  the  systemic  circulation265  and  dilatation  of  the  uterine  arteries266.  In  some 
studies267,268  progesterone  opposes  the  effect  of  oestradiol  but  in  others  does 
not266.
Zaidi  et.  al.269  studied  circadian  rhythm  in  uterine  artery  blood  flow and  found  a 
nadir in  PI  and  a  peak  in  time  averaged  maximum  velocity  (TAMV)  at  06.00  h, 
following sleep.
1.4.1.2  Uterine Perfusion and Subfertility
Kurjak  et.  al.253  noted  absent end-diastolic flow during  both  the  proliferative  and 
luteal  phases  in  subfertile  women,  but  no  difference  in  mean  uterine  artery 
resistance  index  (Rl)  between  subfertile  and  fertile  women.  Tinkanen  et.  al.2 70 
reported that subfertility patients had high PI in both uterine and ovarian arteries in 
the  luteal  phase  more  often  than  fertile  controls.  Steer  et.  al.254  studied  uterine 
impedance on day 21  of a natural cycle and found a significantly higher resistance 
in  various  groups  of  subfertile  women  when  compared  with  fertile  women.  The 
highest day 21  PI values were found in women presenting with anovulation but at a 
single point in time PI did not discriminate between the different groups of subfertile 
women. In the study population, there was no correlation of PI with age, number of 
years of subfertility, serum oestradiol level, or serum progesterone level.
501.4.1.3 Uterine Perfusion and IVF Outcome
Utilizing  transvaginal  colour  Doppler  ultrasound  and  based  on  differences  in  the 
mean uterine artery PI  or Rl,  it is possible to distinguish  between conception and 
non-conception  cycles  before  ET.  However,  conflicting  conclusions  have  been 
reached. Some authors have reported significant correlations between  pregnancy 
rates and uterine artery Doppler flow values 115-230-244-255-256-257-271-272'273>  biit others 
have failed to show such a relationship 225-258-264- 274,275.276.277,278.279,280.,281,282,283
These conflicting results are explained by the multiple factors affecting the uterine 
artery  PI  and  Rl  and  it  has  been  shown  that  uterine  artery  impedance  may  be 
different  in  women  with  different  causes  of subfertility254'284.  Doppler  indices  are 
also  affected  by  different  ovarian  stimulation  regimens,  different  days  of 
hemodynamic evaluation, and the circulatory levels of serum E2. Guanes et. al.2 85 
and Check et.  al.286 found  no difference in the average uterine artery PI  or Rl  by 
age.  Kurjak  and  Kupesic287  conclude that the  ageing  process  affects  the  uterus 
less than the ovaries in early postmenopausal years. However, a subsequent study 
found that in comparison to natural cycles the percentage reduction in the uterine 
artery PI during IVF was correlated with age, indicating that the benefits of ovarian 
stimulation in reducing uterine vascular impedance are less apparent in the ageing 
uterus227.
Available data indicate a wide range of overlap in uterine artery PI values between 
pregnant  and  non-pregnant  cycles288,289,290.  Only  a  remarkably  high  vascular 
impedance  (PI  >3.3  and/or  absence  of  diastolic  flow)  may  predict  impaired 
implantation;  such  a  high  impedance  is  detected  in  only  9%  to  26%  of  non­
pregnant cycles256,273,288.
One  of  the  explanations  is  that  most  of the  blood  passing  through  the  uterine 
arteries  never  reaches  the  endometrium.  In  support  of this  contention,  a  poor 
correlation between PI  in the uterine and spiral arteries has been demonstrated289
51and it is suggested that a more logical approach would be to directly evaluate the 
vascularization around the endometrium to assess endometrial receptivity282,291.
1.4.2  Endometrial Perfusion and IVF Outcome
Endometrial  blood  flow  studies  have  utilised  either  conventional  colour  Doppler 
sonography292,293  or  the  newer  techniques  of  two-  or  three-dimensional  power 
Doppler sonography282,291,294.  Power  Doppler sonography  has  the  advantages of 
less  direction  dependence,  higher  sensitivity  and  better  contrast  of  vascular 
contour295,296.  In  addition  to  qualitative  studies,  computer-assisted  quantitative 
assessment  of  power  Doppler  vascular  signals  has  also  been  applied297,298,299 
(Table 1.3).
At the  myometrial-endometrial junction,  a  subendometrial  area  is  identified  as  a 
thin  hypo-echoic  layer on  ultrasound  examination300,301,302,  and  described  as the 
subendometrial or junctional zone of the myometrium with distinct histology. Blood 
supply within  3  to  10  mm  of the  echogenic  endometrial  borders was  studied  as 
subendometrial perfusion292,303.
Although  most  investigators  agree  that  a  high  degree  of  endometrial  perfusion 
shown  by  colour  or  power  Doppler  examination  indicates  a  more  receptive 
endometrium,  there  is  no  consensus  on  how to  assess  changes  in  endometrial 
perfusion  during  IVF-ET  cycles.  Those  combining  the  endometrial  and 
subendometrial  flow  parameters  show  significant  differences  between  pregnant 
and non-pregnant women291,293,294.  In contrast, where attention is focused only on 
intraendometrial  or  subendometrial  blood  flow  there  is  no  significant  difference
274,283,304
An  immunocytochemistry  study  reveals  that  the  subendometrial  myometrium 
(junctional zone) exhibits a cyclic pattern of oestrogen and  progesterone receptor 
expression  parallel  to  that  of  the  endometrium305.  Thus,  the  endometrium  and 
subendometrial  myometrium  may  form  a  functional  unit  with  various  cyclic
52reproductive  functions.  In  the  pregnant  group  the  junctional  zone  became 
significantly thicker at  ET;  in  contrast,  changes  in  the junctional  zone were  less 
pronounced  in  the non-pregnant group306.  In  spite of the  higher uterine artery PI 
and Rl values in spontaneous cycles, Basir et. al.309 detect no significant difference 
in  the  number  of  colour  signals  in  the  endometrium  between  spontaneous  and 
stimulated cycles.  It is proposed that the relationship between uterine artery blood 
flow and endometrial perfusion may not be linear. They also report that the number 
of  women  showing  endometrial  colour  signals  was  significantly  lower  in  high 
responders than in moderate responders. It is proposed that despite low uterine PI 
and  Rl  values,  endometrial  blood  flow  and  receptivity  in  high  responders  is 
impaired.
It is claimed that low vascular resistance in the ovarian arteries of high responders 
might cause shunting of blood from the uterus through the utero-ovarian collaterals 
to  the  ovaries  and  diminish  endometrial  perfusion.  Increase  in  hormone 
concentrations in the peripheral plasma leads to a decrease in peripheral vascular 
resistance  and  a  decreased  contractility  of the  uterine  muscles.  This  results  in 
relaxation and opening up of the small uterine vascular channels252,310.
The  concept  of  evaluating  uterine  receptivity  by  a  cumulative  uterine  score 
including the endometrial blood flow was first introduced by Applebaum292. Even in 
the presence of other favourable parameters, with the absence of subendometrial 
blood  flow,  no  conception  was  achieved.  By  using  a  similar approach,  Salle  et. 
al.279  calculated  a  uterine  score  in  the  secretory  phase  of  the  menstrual  cycle 
preceding  IVF.  None  of  the  individual  ultrasonographic  or  Doppler  parameters 
tested was of sufficient accuracy to predict uterine receptivity, but the uterine score 
seemed to be a useful predictor of implantation.  Baruffi et. al.3 1 1  also evaluated an 
ultrasonographic  uterine  scoring  system  on  the  day  of  hCG  administration,  that 
correlated with female age.
53Table 1.3.  Doppler Ultrasonography of Endometrium and IVF Outcome
Study Doppler Parameters Day of Pregnancy  j
Zaidi2 9 3 Sub-endometrial PSV, PI hCG administration i
Yuval2 7 4
Endometrial Colour and Power 
Doppler PI, Rl, S/D;
Absence of diastolic flow
Oocyte collection 
ET
\
No  significant  j 
difference 
between 
pregnant  and 
non-pregnant Contart3 0 4
Power Doppler Sonography of 
endometrium hCG administration
Schild2 8 3 Absence of spiral artery blood flow Oocyte collection
Zaidi2 9 3
Chien3 0 7
Salle2 7 9
Battaglia2 2 9
Presence of sub-endometrial and 
intra-endometrial vascularization
hCG administration 
ET
Oocyte collection
Battaglia2 2 9 Lower endometrial cell culture 
thromboxane and lower spiral artery PI Oocyte collection
Yang2 9 1 Larger Power Doppler area of 
endometrium £5 mm2
Day before oocyte 
collection
Schild2 8 2 3-D Power Doppler Sonography of 
sub-endometrial area
First day of ovarian 
stimulation
Higher
Pregnancy
Kupesic2 9 4
Lower Rl in sub-endometrial vessels 
by Colour Doppler ultrasonography 
and Higher flow index by 3-D power 
Doppler
ET
Jinno3 0 8
Endometrial tissue blood flow by 
hysterofiberscopical laser blood- 
flowmetry values >29 mL/min per 100 
grams of tissue
Between days 4 and 6 
of the luteal phase in 
spontaneous cycle
PSV:  Peak  systolic  velocity,  PI:  Pulsatility  index,  Rl:  Resistance  index,  S/D:  Systolic/Diastolic,  ET:  Embryo  transfer, 
Min: Minute
1.4.3  Ovarian Blood Flow
Ovarian  blood flow can  be studied  as either the ovarian  artery flows towards the 
substance of the ovary287 or by analysing the artery within the ovary itself as intra- 
ovarian stromal flow259.  For such small vessels, the angle of insonation cannot be 
determined  and  hence  the  reproducibility  of  Doppler  indices  in  intra-ovarian 
vessels has been questioned312.
1.4.3.1  Relationship to Oestrogen and Progesterone
In  cycles  stimulated  with  hMG,  the  PI  of  the  ovarian  vessels  supplying  the 
dominant follicle and  corpus luteum  is positively correlated with  serum  oestradiol
54concentrations,  but not with serum progesterone313.  It is suggested that oestradiol 
increased  stromal  blood flow,  but not corpus luteum  blood flow.  Striginc et.  al.3 1 4  
show  that  administration  of  progesterone  100  mg  intramuscular  (IM)  during  the 
luteal  phase  significantly  suppressed  uterine  artery  PI,  but  did  not  affect  intra- 
ovarian  artery  PI.  However,  Glock  and  Brumsted315  note  a  strong  negative 
correlation  between  serum  progesterone  and  intra-ovarian  vessel  Rl  during  the 
mid-luteal phase.  Engmann et.  al.278 show a significant decline in ovarian stromal 
flow velocity  after two  to  three  weeks  administration  of gonadotrophin  releasing 
hormone agonist (GnRHa), but were unable to show a similar concurrent reduction 
in the uterine blood flow.
1.4.3.2  Ovarian Blood Flow and IVF Outcome
Zaidi et. al. were the first to show a relationship between ovarian stromal blood flow 
velocity and ovarian follicular response316. The ovarian stromal PSV was measured 
in the early follicular phase, showing that poor responders have low ovarian blood 
flow even  after adjustment for age,  polycystic ovarian  syndrome  (PCOS),  serum 
FSH and the number of hMG ampoules used.  It is also reported that PSV, but not 
PI, is related to subsequent follicular response259.
Engmann et. al.278 propose that deficient intra-ovarian vascularity may serve as the 
initial marker of reduced ovarian reserve and precedes an increased FSH level and 
reduction of the ovarian volume. They speculate that the ovarian stromal blood flow 
velocity  after  pituitary  suppression  is  a  true  representative  of  baseline  ovarian 
blood flow, because the ovaries are in a quiescent state.
The main shortcoming of these studies on ovarian stromal blood flow is the use of 
PSV,  which  requires  knowledge  of the  angle of insonation  to  the  blood  vessels 
analysed. Ovarian vessels inside the ovarian stroma are thin and tortuous and it is 
impossible to  accurately determine the angle  between  the  ultrasound  beam  and 
intra-ovarian vessels.
55Assessment of follicular blood flow has been suggested as an alternative predictor 
of  ovarian  responsiveness  and  treatment  outcome317.  Barber  et.  al.318  report  a 
highly  significant  difference  in  the  Rl  values  between  patients  who  became 
pregnant  and  those  who  did  not;  no  patient  who  became  pregnant  had  an  Rl 
greater than 0.5 on day 3 after ET.
Nargund et.  al.319 report a significant correlation between follicular blood flow and 
oocyte collection,  as well  as embryo quality. The absence of follicular blood flow 
correlated strongly with failure to collect an oocyte. PSV was significantly higher in 
follicles associated  with  a good-quality pre-implantation  embryo,  when  compared 
with  follicles  yielding  oocytes  that  did  not fertilize  or  produced  inferior embryos. 
There was no relationship to PI.
Peri-follicular circulation was subjectively scored using a grading system based on 
the percentage of follicular circumference that depicted an echo signal on the day 
of oocyte collection  (Grade  1   <25%, Grade 2 <50%,  Grade 3 <75% and Grade 4 
>75%) 320,321.
Mean follicular diameter,  number of oocytes collected,  number of mature oocytes 
collected  and  fertilization  rates  were  all  significantly  higher  and  triploidy  rate 
significantly lower in the cohort of follicles with  high-grade vascularity. There was 
no  correlation  between  embryo  morphology  and  grade  of  vascularity  321.  The 
pregnancy  rate  for  cycles  where  the  embryos  transferred  were  derived  from 
follicles with uniformly high-grade vascularity (3 or 4 only) was significantly higher 
than for cycles where the embryos were derived from mixed (1 to 4) or low- (1  or 2 
only)  grade  follicles.  There  were  no  significant  differences  in  uterine  artery  or 
intraovarian  PI  values  between the pregnant and  non-pregnant treatment cycles. 
There  was  a  trend  to  a  lower  rate  of early  pregnancy  loss  in  cycles  where  the 
embryos  transferred  were  derived  from  follicles  with  higher  vascularity,  but 
differences were not significant321.
56Coulam  et.  a!.322  assess  the  role  of follicular vascularity  in  predicting  pregnancy 
after IVF.  Using transvaginal ultrasonography,  PSV was measured from the three 
largest follicles on both the right and left ovaries on the day of hCG administration. 
The quality of follicular flow was graded from  1   to 4  according  to the  amount of 
visible  colour  flow  around  the  follicle.  All  pregnancies  occurred  in  women  with 
Grade 3 and 4 follicular vascularity and 91% of pregnancies occurred with follicular 
PSV  >10  cm/s.  This  threshold  value  of  PSV  predicted  pregnancy  with  high 
sensitivity (91%) and negative predictive value (97%), but low specificity (36%) and 
positive  predictive  value  (13%),  suggesting  that  reasons  not  associated  with 
follicular flow are associated with failure to conceive in this high-risk population.
A  link  between  follicle  size  and  vascularity  is  suggested  with  the  finding  that 
perifollicular peak velocity values gradually increase with the increasing size of the 
follicles323. Highly significant elevation of the peak velocity was observed especially 
after hCG injection. Bhal et. al.3 2 1  also witnessed low vascularity grades in smaller 
follicles as opposed to high-grade perfusion in  larger follicles and this may reflect 
the  increased  maturity of high-grade vascularity follicles.  Balakier and  Stronell32 3  
postulate that low-grade follicle vascularity pre-hCG may affect the uptake of hCG 
and  result  in  impaired  maturation  of the cumulus-oocyte complex.  Also,  a  higher 
grade  of  perfusion  may  lead  to  the  increased  access  of  FSH  to  those  follicles, 
promoting  better maturation.  However,  Oyesanya  et.  al.317  note that collection  of 
oocytes is related to the presence of a detectable velocity waveform, but not to the 
size of follicles.
Previous  studies  have  involved  the  use of mean  values for the  PSV from  many 
follicles323,  the  maximum  PSV  from  serial  monitoring258  and  the  PSV  from 
individual  follicles319,324.  When  mean  values  for  follicular  PSV323  and  maximum 
PSV from  serial  monitoring258 were  evaluated,  no  differences  in  values  between 
conception  and  non-conception  cycles  was  noted.  However,  when  individual 
follicles,  oocytes,  and  preimplantation  embryos  were  studied,  a  significant 
difference in  PSV was found in conception compared with  non-conception cycles.
57The  studies  that  minimize  the  inter-follicle  differences258,323  yield  no-difference 
results and those detailing individual follicles show significant results319,324. Thus, it 
is the individual follicles, not the cohort that determines successful outcome.
1.5  Angiogenesis
During  embryo  development,  blood  vessels  differentiate  from  endothelial 
precursors  by  a  process  called  vasculogenesis.  In  adults,  further  vessel 
development  from  pre-existing  vasculature  occurs  by  angiogenesis325. 
Physiological angiogenesis is an integral part of fetal development but occurs less 
commonly in adults,  except during wound  healing and  in the female reproductive 
tract326,327.  Pathological  angiogenesis  takes  place  in  conditions  such  as  solid 
tumour  growth,  chronic  inflammatory  disorders,  endometriosis  and  diabetic 
retinopathy328.
Angiogenesis can occur by a number of mechanisms and is influenced by a wide 
range  of growth  factors,  receptors  and  inhibitors.  Proposed  mechanisms for the 
creation of new blood vessels from the existing vasculature are vascular sprouting, 
intussusception and vessel elongation.
1.5.1  VEGF and VEGFR
Vascular endothelial growth factor (VEGF) is a family of angiogenic growth factors 
characterized  by their ability to promote vascular endothelial  cell  proliferation  and 
increase vascular permeability329. VEGF has been found to induce fenestrations in 
endothelial  cells  of  small  venules  and  capillaries330  as  a  crucial  step  in 
angiogenesis. This allows fibrinogen and other serum proteins to exit the capillary 
space and form an extravascular fibrin gel. This matrix then supports the ingrowth 
of  endothelial  cells  and  other  elements  to  generate  new  vascularized  stroma. 
VEGF also stimulates nitric oxide release from endothelial cells3 3 1  and induces the 
release  of  prostacyclin  by  activating  cytosolic  phospholipase  A2,  causing  the 
release of arachidonic acid332. Both of these actions would be expected to promote 
vasodilatation.
58Six members of the VEGF family have been described: VEGF-A through to VEGF- 
E  and  placental  growth  factor  (PLGF).  VEGF-A/vascular  permeability  factor 
(VEGFA/PF)  is  a  basic,  heparin-binding,  homodimeric  glycoprotein  of 45  KD.  Its 
gene has been localized to chromosome 6p21.3, composed of eight exons. VEGF- 
A  through  to  VEGF-D  can  occur  in  a  number  of  different  isoforms  due  to 
alternative splicing. Five molecular forms of VEGF-A are produced in humans as a 
result of such alternative splicing of the gene transcript.  Three of these, VEGF121, 
VEGF145 and VEGF165, are soluble isoforms, but the two larger forms, VEGF189 
and  VEGF206,  are  generally  membrane-bound.  These  longer  splice  variants  of 
VEGF-A  also  bind  heparin  strongly  and  are  not  as  freely  available  within  the 
tissues as the shorter splice variant.
VEGF165 is the predominant molecular form produced by a variety of normal and 
transformed  cells.  Transcripts encoding VEGF121  and VEGF189  are detected  in 
the majority of cells and tissues expressing the VEGF gene. In contrast, VEGF206 
is a rare form, and has been described only in the human fetal liver333.
VEGF  proteins  exert their functions  through  a  family  of closely  related  receptor 
tyrosine  kinases,  called:  VEGFR-1  /  Fit  1   / fms-like-tyrosine  kinase;  VEGFR-2  / 
KDR / Flk-1 / kinase domain region; and VEGFR-3 / Flt-4334.
Each  member  of  the  VEGF  family  has  specificities  for  different  receptors  with 
different  angiogenic  activities  (Figure  1.2).  VEGF-A  mediates  most  of  its 
angiogenic activities via VEGF-R2 but also binds to VEGF-R1. VEGF-B and PLGF 
only bind to VEGF-R1  and do not have strong angiogenic activity. VEGF-C and -D 
bind  to  VEGF-R2  and  VEGF-R3  and  have  major  roles  in  regulating  lymphatic 
angiogenesis.  VEGF-E  is a  protein encoded  by a strain of the parapox virus and 
only binds to VEGF-R2. VEGF-A can also bind selectively to two neuropilins, NRP- 
1  (VEGF165) and NRP-2 (VEGF165 and VEGF145)335.
It  is  proposed  that VEGF-R1  and  -R2  mediate  different VEGF-A  activities.  The 
VEGF-R2  system  is  involved  in  endothelial  cell  formation,  migration,  and
59proliferation.  In  contrast,  the VEGF-R1  system  is  important for endothelial  cell-to- 
cell interaction and vessel formation. Also described is a soluble form of VEGFR-1, 
which lacks the transmembrane and tyrosine-kinase domains essential to influence 
endothelial cell function. This soluble form of VEGFR-1  (sVEGFR) binds VEGF and 
prevents its action  on VEGFR-1  and  -2.  It has been  demonstrated  in  a rat model 
that  sVEGFR-1  can  cause  corpus  luteum  failure,  with  secondary  failure  of 
endometrial decidualization336.
Angiogenesis  is tightly  down-regulated  in  the  normal  state.  Several  proteins  that 
inhibit  angiogenesis,  including  thrombospondins337,338,  endostatin339,  angiostatin, 
endostatin,  platelet  factor  4  and  transforming  growth  factor  (B 340  have  been 
discovered.
Figure 1.2.  VEGF and VEGR
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1.5.1.1  VEGF-VEGFR and Fertility
Van  Blerkom3 4 1   demonstrates  that  both  genetic  and  epigenetic  factors  are 
associated  with  the  developmental  competence  of  human  oocytes  and  embryos 
created  by  IVF.  The  degree  of  perifollicular vascular  expansion  associated  with 
increased  rates of blood flow is developmentally important for the generation of a
60normal follicle and competent oocyte. The findings from >1000 samples of follicular 
fluid  show  that  oocytes  from  severely  hypoxic  follicles  are  associated  with  high 
frequencies  of  abnormalities  in  the  organization  of  the  chromosomes  on  the 
metaphase  spindle  that  could  lead  to  segregation  disorders  and  catastrophic 
mosaicisms  in the early embryo.  Oocytes with  cytoplasmic defects and cleavage 
stage  embryos  with  multinucleated  blastomeres  are  derived  predominantly from 
severely hypoxic follicles107. The degree of vascular development was found to be 
follicle specific and differences between follicles might reflect their unique abilities 
to regulate angiogenic growth factor production by the follicle cells in  response to 
hypoxia.
Doppler indices, which are markers of downstream impedance to blood flow, have 
a significant and negative correlation with the cleavage status of day 3 embryos342. 
Moreover,  these  indices  of  follicle-specific  vascularity  also  correlated  with 
measures  of metabolic activity,  such  as  intra-follicular partial  pressure of oxygen 
(PO2)  and  carbon  dioxide  (pC02).  However,  no  direct  relationship  was  evident 
between follicular metabolic analysis (p02, pC02, or pH) and oocyte fertilization or 
embryo  quality342.  Barroso  et.  al.3 43  demonstrate  no  significant  association 
between  blood  flow  indices  and  follicular  levels  of VEGF,  or  nitric  oxide  (NO), 
unlike Van  Blerkom  et.  al.1 0 7   who  observed  higher VEGF  levels  in  follicles with 
higher  dissolved  oxygen  contents  and  Doppler  findings  indicative  of  increased 
blood flow.
Luo  et.  al.34 4   examined  the  effect  of  human  recombinant  VEGF165  on  the 
maturation  of  bovine  oocytes  and  the  fertilization  rate  improved  from  63.0%  to 
82.3%  with  VEGF.  Cleavage,  the  development  to  the  4-  to  8-cell  stage  and 
blastocyst rates were also significantly higher in the VEGF group than the control 
group.
Follicular fluid  VEGF  concentrations were  more than  10-fold  greater than  serum 
concentrations  at  the  time  of  oocyte  collection,  thus  implying  that  the  peri-
61ovulatory, luteinising follicle produces significant amounts of VEGF345’346,347.  Doldi 
et.  al.348  found  strikingly  higher  progesterone  levels  in  the  follicles  of  low 
responders compared with  normal responders.  Likewise, VEGF was higher in the 
mature  follicles  of  low  responders,  consistent with  more  advanced  luteinisation. 
The  observation  of  positive  correlation  between  follicular  fluid  VEGF  and  both 
follicular  fluid  and  serum  progesterone  concentration  was  considered  as  an 
argument favouring the hypoxia hypothesis345 because premature luteinisation may 
be an  early manifestation  of limited ovarian  reserve or ovarian  ageing349,350.  This 
also  gives  credence  to  the  hypothesis  that  elevated  VEGF  concentrations  may 
reflect  simply  exuberant  and/or  early  luteinisation  near  the  time  of  hCG 
administration. Recent publications also report similarly diverging outcomes (Table 
1.4).
The  reconciliation  of  these  diverging  outcomes  may  be  reached  with  the 
observation  that VEGF  levels are determined  by multiple factors.  If VEGF  levels 
are induced by hypoxia then the corresponding oxygen levels would be lower than 
when  VEGF  is  induced  by  non-hypoxic  stimuli,  such  as  inherent  superiority  to 
produce higher levels of VEGF at a given oxygen level.
Poor ovarian  response  to  gonadotrophin  stimulation  is  also  proposed  to  be  the 
result of inhibited VEGF bio-availability. Hypoxemia enhances VEGF expression360 
in  maturing  follicles  and  augments  VEGFR-1  production  in  corresponding 
endothelial  cells359.  Alternative  splicing  of  the  VEGFR-1  mRNA  to  produce 
sVEGFR-1  significantly  contributes  to  the  regulation  of VEGF  activity365.  Rising 
sVEGFR-1  production  and  secretion  in  the  vicinity  of  maturing  follicles  is 
detrimental  to further development.  Thereby,  excessive  sVEGFR-1  production  in 
ovarian blood vessels results in poor ovarian response due to diminished bio-active 
VEGF  supply.  High  follicular  VEGF  production  cannot  overcome  the  blocking 
effects  of sVEGFR-1.  Concentrations of VEGF  in  follicles from women  with  poor 
ovarian  response to stimulation  may be consequently higher than  in women with 
pronounced ovarian response to gonadotrophin stimuli.
62Neulen  et.  al.366  defined  a  surrogate  indicator for biological  activity of VEGF  by 
VEGF:sVEGFR-1  ratio.  Higher  values  of  this  ratio  revealed  an  increasing 
availability  of  VEGF  and  this  was  associated  with  higher  ovarian  response  to 
gonadotrophin therapy. A significant negative correlation between soluble VEGFR- 
1  concentrations and the number of collected oocytes was also detected.
Table 1.4. Studies on Serum and Follicular Fluid VEGF and Assisted Conception
Serum VEGF FF VEGF
Manau3 4 7
Lee3 4 5
<-> Ovarian response T Female age 
t  Total gonadotrophin dose
IVF outcome <-» IVF outcome
«-> FF oestradiol,  progesterone
Christenson and Stouffer3 5 1 t  Duration of stimulation 
T Total gonadotrophin dose
Artini3 5 2
Enskog3 5 3
Licht
T Ovarian response 
t  Luteal progesterone
T Duration of stimulation 
T Total gonadotrophin dose
Anasti3 5 5 t  FF progesterone 
t  Serum LH
Doldi3 5 6 ’3 4 8  
Van Blerkom1 0 7  
Van Blerkom3 5 7  
Puchner3 5 8
f  Ovarian response 
t   Follicles  with  high  vascularization 
and oxygenation, 
t  Fertilization, pregnancy rates
Shweiki3 5 9
Gerber3 6 0 T Follicular hypoxia
Friedman49'3 6 1
Barrosso3 4 3
Battaglia3 6 2
i  Ovarian reserve 
I Ovarian response 
I Serum oestradiol 
I Embryo quality 
I Pregnancy rate
Quintana3 6 3 I Ovarian response 
I Apoptotic granulosa cells
Benifla3 6 4
<-» IVF outcome
<-» Causes of subfertility
o  Female age
t: Positive association, I: negative association,  < -> : no association, FF: Follicular fluid
631.6  Endometrial Receptivity
In  humans,  implantation  is  a  process  of  initial  apposition  of  maternal  and 
embryonic  epithelium,  intrusion  of embryonic  cells  between  the  maternal  luminal 
epithelial  cells,  and  invasion  of  placental  cells  deep  into  the  endometrium.  The 
process of implantation is inefficient and demands that minimum requirements be 
met. These depend on the synchronization of maternal and embryonic clocks. The 
maternal clock begins at ovulation when  steroid  production  in the ovary switches 
from oestrogen to progesterone plus oestrogen, which causes the endometrium to 
differentiate such that it reaches a state of readiness for implantation approximately 
seven days after the LH peak, or 5.5 days after ovulation367. Implantation occurs in 
the  mid-secretory  phase  of  the  menstrual  cycle  when  the  stroma  is 
undifferentiated, but decidualization has occurred within three days of implantation
368,369
In  some  cases,  this  sequential  maturation  of the  endometrium  and  the  related 
implantation  process  can  be  delayed,  allowing  some  of  the  slowly  developing 
embryos  to  implant  and  produce  pregnancies370.  However,  the  endometrium 
cannot  retain  its  receptivity for an  indefinite  period371.  Lenton  et.  al.372,  studying 
patterns  of  hCG  secretion  in  natural  pregnancies,  suggest  that  the  window  of 
implantation  in  humans extends to post-ovulatory day  10, which  is between days 
19 and 24 of natural cycles.  It is suggested that it might be preferential to perform 
ET when embryos are at a more advanced stage than uterine maturation, as noted 
in animal studies.
Pinopodes are smooth  membrane projections from the luminal  cell  surface of the 
endometrium at the time of implantation373,374. In humans they have been observed 
at around day 20 of a natural cycle. Their entire life span does not exceed 48 hours 
and expression of fully developed pinopodes is limited to only one day.  Pregnancy 
rates have been shown to improve with adjustment of the day of transfer so that a 
6-day embryo would encounter an endometrium with fully developed pinopodes375.
64The  standard  assessment  of  endometrial  maturation  has  been  the  histological 
dating  of  an  endometrial  biopsy376.  Delayed  endometrial  maturation  was  more 
frequent in the non-pregnant group than the pregnant group377. However, there are 
major disadvantages in  endometrial  biopsies,  such  as their invasiveness and the 
negative impact on the implantation  process. The timing and  number of biopsies, 
methods  used  for  chronological  standardization  and  the  extent  of  discrepancy 
required  to  define  an  endometrial  biopsy  as  being  ‘out  of  phase’  remain  in 
contention368.  Furthermore, assessments performed in a natural cycle may not be 
predictive of the quality of the endometrium in a subsequent stimulated cycle.
Serum  oestradiol  concentrations  or  oestradiol:progesterone  ratios  are  also 
reported  to  be  inaccurate  in  predicting  the  histological  state  of  endometrial 
development, which can occur over a wide range of serum concentrations378,379.
As an alternative, high-resolution transvaginal ultrasonography makes it possible to 
monitor histological changes in the endometrium indirectly through the analysis of 
endometrial growth and echogenicity.  In general, sonographic parameters provide 
a  high  negative  predictive  value  and  sensitivity,  but  a  limited  positive  predictive 
value and low specificity288. The reported low specificity in various studies, ranging 
between  9  and  35%,  indicates  that  uterine  receptivity  is  one  among  several 
different factors contributing to implantation.
1.6.1  Endometrial Thickness and Echo-pattern
Endometrial thickness is defined as the maximum distance between the echogenic 
interfaces  of  the  myometrium  measured  in  the  central  longitudinal  axis  of  the 
uterine body.  Endometrial pattern is defined as the type of relative echogenicity of 
the endometrium and adjacent myometrium. Endometrial pattern varies during the 
menstrual cycle380. Smith et. al.3 8 1  describes four different patterns and Gonen and 
Casper382 describe  a  simplified version with  three types; Type A representing an 
entirely  homogeneous,  hyperechogenic  pattern  without  a  central  echogenic  line; 
Type  B  an  intermediate  iso-echogenic  pattern  with  the  same  reflectivity  as  the
65surrounding  myometrium  and  a  non-prominent  or absent  central  echogenic  line; 
and Type C a multilayered ‘triple-line’ endometrium consisting of a prominent outer 
and central hyperechogenic line and inner hypo-echogenic or black region. Sher et. 
al.3 83  propose  a  more  concise classification with  two grades:  a  non-multilayered, 
homogeneous,  hyperechogenic or iso-echogenic endometrium compared with the 
myometrium, and a multilayered triple-line pattern with an outer peripheral layer of 
denser  echogenicity with  a  central  sonolucent  area.  The  central  echogenic  line 
represents the uterine cavity and the outer lines the basal layer of the endometrium 
or  the  interface  between  the  endometrium  and  the  myometrium.  The  hypo- 
echogenic regions between the two outer lines and the central  line represent the 
functional layer of the endometrium384.
During  the  follicular  phase  in  natural  cycles,  the  endometrium  is  hypo-  or  iso- 
echogenic compared with the surrounding myometrium, while the endometrium to 
myometrium  interface  and  the  uterine  cavity  appear  hyperechogenic382,385  as  a 
reflection of the glandular straightness,  reduced glandular secretion,  and reduced 
stromal oedema. After ovulation, endometrial echogenicity increases progressively, 
with hyperechogenic changes developing from the base toward the surface of the 
endometrium386, parallel with the rising progesterone levels387. It is reported that in 
ovarian  stimulation  cycles,  premature  exposure  of  the  endometrium  to 
progesterone  during  the  follicular  phase  leads  to  a  faster  progression  of 
endometrial  echogenicity  during  the  early  luteal  phase387.  Stromal  oedema, 
glandular coiling  and  secretion  are thought to  be the  key events  responsible for 
hyperechogenic signals386.
1.6.1.1  Endometrial Thickness
Endometrial thickness as a predictor of IVF-ET outcome has been investigated by 
numerous  studies  with  variable  results.  While  some  study  groups  found  a 
significant  correlation  between  thickness  of  the  endometrium  and  pregnancy
rate383-388-389-390-391-392-393-394, others reported no such relationship256,257,277,281,395,396, 
397,398.399.400.401,402.403,404.405  js rep0rted that there  is an  extensive overlap  in the
66ranges of endometrial thickness present in pregnant and non-pregnant cycles406. A 
pooled  comparison  of the  published  data on  2665  cycles  reports  that  ranges  of 
mean endometrial thickness for conception and non-conception cycles are almost 
the same (8.6 to 11.8 and 8.6 to 11.9 respectively)288.
These opposing conclusions may in part be due to the different techniques used, 
such  as  vaginal  vs  abdominal  ultrasonography,  different  ovarian  stimulation 
protocols293,  measurement  errors  in  obtaining  a  standard  sagittal  view  of  the 
uterus, or marked ovarian enlargement distorting the endometrial outline407.
On the basis of the strong correlation between uterine dimension and endometrial 
thickness,  Strohmer et.  al.408 suggests that endometrium thickness  is determined 
by  individual  uterine  architecture  and  so  is  not  predictive  of  the  likelihood  of 
implantation.  Similarly,  no  correlation  was  found  between  implantation  and  the 
mean  cross-sectional  area  of  the  endometrium407.  Endometrial  thickness,  as  a 
proxy measure of endometrial  growth,  is reported to be unrelated  to endometrial 
pattern on the day of hCG injection389,390,395.
The  published  results  on  natural  cycle  FTER  report  no  differences  in  the 
endometrial thickness between the pregnant and non-pregnant groups256,409,410.  In 
hormone  replacement  cycles  for  FTER  and  oocyte  donation,  results  are  more 
variable. While some published non-significant differences in endometrial thickness 
between  the  pregnant  and  non-pregnant  groups256,277,409,  Abdalla  et.  al.3 9 1  
(10.2±2.63  vs  8.6±3.49mm),  Shapiro  et.  al.412,  and  Alam  et.  al.4 1 1   (10.5±3.5  vs 
9.6±4.2mm) report significant differences.
Schild et. al.2 8 1  found that mean values for endometrial volume assessed by three- 
dimensional  ultrasonography,  are  non-significantly  higher  in  conception  vs  non­
conception cycles. No conception was observed below an endometrial thickness of 
6.9 mm and volume of 1.59 ml on the day of oocyte collection. Raga et. al.413 also 
found that a minimum volume of 2 ml is a prerequisite for a receptive endometrium
67and that no pregnancy was achieved when endometrial volume measured <1.2 ml. 
Beyond  an endometrial volume of 2 ml,  no relationship was apparent in terms of 
endometrial receptivity.
Various  values  of  endometrial  thickness  between  6  and  10  mm  have  been 
proposed as discriminatory between conception and non-conception cycles, albeit 
with a low specificity and low positive predictive value.  However,  recent evidence 
indicates that embryonic implantation is possible even when endometrial thickness 
is  <4  mm394,399.  The  main  advantage  of  ultrasonographic  assessment  of  the 
endometrial thickness is given as its high negative predictive value in cases where 
minimal endometrial thickness was not reached.
1.6.1.2  Endometrial pattern
Some  investigators  have  ascertained  that endometrial  echogenic  patterns  in  the 
late  follicular  phase  predict  IVF-ET  outcome256'257'277'382'383'390’392'393’396’404'405’ 
414,415,416,417,418,419  ^  triple-line  pattern  appears to  be the  sonographic  parameter
that mostly reflects endometrial receptivity as it is associated more frequently,  but 
not exclusively, with conception cycles. On the contrary, others have failed to find a 
relation between endometrial echogenicity and implantation rates397,417,420,421.
The  method  of endometrial  preparation  was found  to  have  no  specific  influence 
upon  the  endometrial  pattern  because  no  significant  differences  were  noted 
between conceptional and non-conceptional cycles of natural and HRT cycles409 or 
between  natural  IVF  and  stimulated  IVF  cycles404,422.  However,  among  natural 
cycles  for  FTER,  ovarian  stimulation  cycles  with  fresh  ET  and  HRT  cycles  for 
oocyte donation, it was only in HRT cycles for oocyte donation that a better positive 
predictive (47.8%) and specificity (42.8%) values were observed412.
It  is  proposed  that  more  advanced  hyperechogenic  transformation  of  the 
endometrium  at  the  time  of  hCG  administration  is  associated  with  lower 
implantation  and  pregnancy  rates  in  |\/F397,423.  The  mechanism  to  explain  this
68inverse relation is proposed to be an alteration of the endometrial receptivity, which 
results  from  accelerated  secretory  transformation  of  the  endometrium.  Reports 
have  shown  that  echogenicity  status  reflects  the  degree  of  histological 
development of the endometrium385,386,424.
Sher et. al.383 observed a higher prevalence of poor endometrial grade in women 
aged >40 years, as well as in women with  uterine pathology.  No relationship was 
demonstrated between the mid-luteal phase serum progesterone values and type 
of echo pattern425. Check et. al 425 also report that in FTER cycles pre-ovulatory LH 
concentrations were highest in the group with the homogeneous hyperechogenic 
pattern, which  has the best pregnancy prognosis. Ohno and  Fujimoto426 found no 
relationships between endometrial appearance, endometrial  steroid receptors and 
steroid hormone concentrations in serum.
Positive correlation  detected  between  increasing  maturity of the ultrasonographic 
endometrial  pattern  and  serum  oestradiol  concentrations  was  not  supported  by 
later studies390. No correlation was noted between serum oestradiol concentrations 
and  endometrial  thickness or pattern  during  both  natural  and  ovarian  stimulation 
cycles382,388,397. Time-dependent rather than concentration-dependent thickening of 
the  endometrium  is  reported  throughout  the  follicular  phase  of  the  menstrual 
cycle427,428.  It is hypothesized that supraphysiological E2 levels induced by ovarian 
stimulation  accelerate  neither  the  pace  nor  the  magnitude  of  endometrial 
development  beyond  values  triggered  by  physiologic  concentrations  of 
oestrogens427.  In contrast,  Ueno et. al.404 shows that mean endometrial thickness 
is significantly thinner in natural cycles compared with cycles of ovarian stimulation 
on the day of the LH surge, (8.9±8.0 vs 10.6±2.5 respectively).
1.7  Frozen-Thawed Embryo Replacement
Ovarian  stimulation  protocols  using  GnRH  analogues  and  gonadotrophins  yield 
large  numbers  of  oocytes.  With  improved  culture  methods,  a  higher  number  of 
good-quality embryos have become available for transfer. Attempts to reduce the
69incidence  of  multifetal  pregnancies  by  transferring  no  more  than  two  or  three 
embryos,  has  further  resulted  in  an  increased  number of embryos  not  used  for 
immediate  transfer  after  oocyte  collection.  Cryopreservation  of  supernumerary 
embryos  at  the  pronuclear,  multicellular  (four-eight  blastomeres)  or  blastocyst 
stage  and  transfer  after thawing,  increases  the  overall  pregnancy  rate  in  single 
oocyte collection procedures.
Since the first report429 of successful  FTER, the cryopreservation of embryos has 
been  an  important  supplementary  procedure  in  the  treatment  of subfertility.  For 
those couples who  have  embryos cryopreserved,  frozen-thawed  ET  provides  an 
additional chance of pregnancy 430 431. Embryo cryopreservation has also provided 
additional  clinical  safety  in  the  presence  of  ovarian  hyper-stimulation  and 
contributed to lowering the probability of multiple conception by reducing the need 
to  transfer  multiple  fresh  embryos432.  However,  FTER  is  not  free  from  the 
probability of multiple conception, although the implantation rate of frozen-thawed 
embryos is usually lower than that of fresh embryos. The multiple conception rate 
following  FTER  is  reported  by  the  Australian  and  New  Zealand  registry  to  be 
13%433; 15 times higher than in spontaneous conceptions.
The  overall  implantation  rate  following  FTER  ranges  from  8— 11 %409- 434-435  but 
higher  figures  are  also  published  (18%)  for  frozen-thawed  embryos  following 
ICSI436.  After FTER the reported pregnancy rate is 7.7-27%437,438.
A  crucial  factor  for  implantation  in  FTER  is  the  synchronization  of  endometrial 
maturation and embryo development.  For women who menstruate regularly, such 
synchronization  may  be  achieved  successfully  after  spontaneous 
ovulation439,440,441.  For  women  with  functioning  ovaries  but  with  anovulatory  or 
irregular  cycles,  FTER  should  take  place  only  after  adequate  endometrial 
preparation, which can be achieved  by ovulation induction with either clomiphene 
citrate  or gonadotropins442,443.  Navot et.  al.444  reports  that adequate  endometrial 
maturation can be achieved by exogenous hormone administration to women with
70ovarian  failure.  Subsequently it  is reported  that women  with functioning  ovaries 
can also have an artificially prepared endometrium using exogenous steroids after 
pituitary  suppression  by  GnRH-a  440, 445, 446. 447,448  A  receptjve  endometrium  is 
reported  after priming with  oestradiol for two weeks  (or more)  and  progesterone 
added to the regimen 3-4 days prior to ET 449.
For  simplicity,  these  regimens  can  be  subdivided  into  two  main  subcategories: 
those  with  GnRH  analogue447,448  and  those  without450,451 > 452'453-454  |n  both 
subcategories  hormones  can  be  administered  either  in  a  fixed  dose  regimen 
throughout  the  prot0col412,455,456,457,458,459,460  or  in  a  sequential  dose  regimen  to 
mimic the natural menstrual cycle277,456,459- 461-462* 463-464,
17(3-estradiol can be given either orally (in valerate or micronized form), vaginally, 
transdermally,  or  by  subcutaneous  implant465,466  in  order  to  bypass  the 
gastrointestinal  tract,  thus  avoiding  first  pass  metabolism.  Progesterone  can  be 
administered  by  intramuscular  injections,  vaginally  or  sublingually467.  Oral 
micronized  progesterone is only effective at higher doses;  it is absorbed variably 
and metabolized by the liver (first pass effect). Due to unphysiological metabolites 
this  route  has  a  high  rate  of  unwanted  side  effects.  The  IM  injection  of 
progesterone  is  safe  and  effective,  but  painful  and  inconvenient for the  patient, 
since  involvement  of  another  party  is  necessary.  Vaginal  suppositories  with 
progesterone  are  effective  in  ET  cycles  but whether the vaginal  route  results  in 
better secretory endometrial transformation remains controversial. This stems from 
the  fact  that  vaginally  administered  progesterone  results  in  adequate  secretory 
endometrial  transformation,  despite serum  progesterone values  lower than  those 
observed after IM administration, even if they are lower than those observed during 
the  luteal  phase  of the  natural  cycle.  This  discrepancy  is  indicative  of  the  first 
uterine-pass effect and of better bioavailability of progesterone in the uterus468.
711.7.1  HRT Cycles with and without Down-regulation
Although  traditionally the  use of GnRH-a  suppression  is considered  essential for 
adequate  endometrial  hormonal  modulation448,  several  studies  question  its 
necessity for controlled endometrial preparation in both FTER cycles450,451 - 453-354- 469 
and  for recipients  of oocyte donation  who  have functioning  ovaries465,470.  These 
studies suggest that avoiding GnRH agonist makes the procedure simpler, quicker 
and  cheaper.  It is also emphasised that when the  pituitary  is  not suppressed  by 
using a GnRH agonist, oestradiol treatment should be initiated in the early follicular 
phase (on days  1   or 2). Although initial follicular activity may be present, with this 
approach  spontaneous  ovulation  is  successfully  inhibited.  Starting  oestradiol 
treatment after cycle day 3 might lead to an increased incidence of LH surge and 
luteinisation of the endometrium471. The starting dose of oestradiol does not seem 
to  be  as  important.  Simon  et.  al451,452  chose  a  high  fixed  dose  of  micronized 
oestradiol  (6  mg/d).  Pattinson  et.  al 454  used  a  lower  fixed  dose  of  micronized 
oestradiol (2 mg/d) starting from cycle days 2 to 5, and report a cancellation rate of 
7.4%.  A  step-up  protocol  using  100  pg  to 400  pg  of oestradiol  administered  by 
transdermal patches has been adequate for inhibition of ovulation and endometrial 
preparation450,453.
Krasnow et. al.472 compared the effects of oral  micronized  E2  with transdermal  E2  
on  endometrial  receptivity in women  having  oocyte donation.  It is concluded that 
supraphysiological serum E2  levels associated with oral micronized E2  may have a 
deleterious  impact  on  endometrial  receptivity.  The  development  of  more 
physiologic hormone  replacement protocols is  proposed,  to  enhance endometrial 
receptivity and lead to improved clinical pregnancy rates.
1.7.1.1  Duration of HRT
The  sole  use  of  exogenous  oestrogen  and  progesterone  was  shown  to  prime 
optimal endometrial  receptivity in women with failed or absent ovaries.  Luteal  E2  
levels do not impact on endometrial morphology. After sufficient priming by E2  only, 
progesterone  alone  appears  instrumental  in  triggering  the  proper  sequence  of
72secretory  transformation  in  glands  and  stroma  with  no  clinical  role  for  the  E2: 
progesterone  ratio.  Secretory  changes  in  endometrial  glands  are  best  seen 
between  the  day  4  and  day  6  of  progesterone  administration  and  predecidual 
changes  of  the  endometrial  stroma  are  apparent  from  day  10  of  progesterone 
exposure.
In  192  oocyte donation  cycles,  Prapas  et.  al.473  show that the window for  ET  is 
dependent on duration of treatment with progesterone, beginning approximately 48 
hours after starting progesterone administration and lasting for approximately four 
days. The optimum phase for transferring embryos at the four- to eight-cell stage 
corresponds to cycle days  18 and  19.  Navot et.  al 474 studied the flexibility of E2  
priming  by  analyzing  the  consequences  of  varying  the  duration  of  the  E2-only 
phase in the HRT cycles of donor oocyte recipients.  It is reported that the E2-only 
phase  could  last  from  five  days  to  six  weeks  without  altering  the  quality  of 
progesterone induced endometrial receptivity to the embryo.
Younis et.  al.475 investigated the limits of a prolonged  endometrial  preparation on 
women with ovarian failure. Three study groups were treated with oral oestradiol 
and  oestriol  4  mg/day for  21,  28,  and  35  days  respectively  then  intramuscular 
progesterone  50  mg/day was  added  for a further seven  days.  All  late follicular 
biopsies  showed  a  normal  proliferative  endometrium.  The  mid-luteal  biopsy 
showed a secretory endometrium with no significant glandular-stromal disparity.  It 
is concluded that an artificial prolonged follicular phase does not seem to adversely 
affect the endometrial developmental capacity.
Younis  et.  al 460  further  investigated  whether  such  manipulations  of endometrial 
stimulation could  influence the pregnancy rate.  It seems that for optimal results in 
an oocyte donation  programme, oestrogen stimulation should be kept at between 
12  and  19  days.  Likewise,  Michalas  et.  al470  observes  that transfer of embryos 
between days 17 and  19 of the recipient's cycle provided the best possible clinical 
outcome.
73However,  Yaron  et.  al.476  show  that  the  endometrium  is  tolerant  to  varying 
durations  of  E2   stimulation  with  regard  to  pregnancy  rates  in  oocyte  donation 
cycles.  Similarly,  successful  implantation  was  observed  even  after  100  days  of 
unopposed  oestradiol  valerate  administration448.  However,  because  of  the  high 
incidence (>44%) of break-through bleeding after nine weeks, it is advised to stop 
oestrogen treatment at this point.  In contrast, a proliferative phase of <10 days is 
found to be related to a higher miscarriage rate474,477.
1.7.2  HRT Cycle vs Natural Cycle
Although FTER in a natural cycle is less expensive and may be more acceptable, 
as it does not require exogenous hormones, ET in a hormone replacement cycle is 
more flexible  and  better controlled.  The timing  of  ET  in  a  natural  cycle  requires 
accurate determination of ovulation but daily hormone tests and  ultrasonographic 
monitoring  can  be  inconvenient  for  the  patient.  On  the  other  hand,  hormone 
replacement cycles,  do not require intense monitoring.  They give the flexibility of 
timing  the  transfer  date  with  lower  cancellation  rates  when  compared  with  the 
commonly cited  6%  cancellation  rate  in  natural  cycles478.  The  disadvantages  of 
HRT regimens include the need to continue the exogenous hormones throughout 
the first trimester.
Some authors report higher pregnancy rates in hormonally controlled cycles than in 
natural cycles, but mostly in small groups of cases440,445, while others using large 
semi-randomized or retrospective studies report similar outcome  in  both types of 
cycles478,479. The available data from these studies suffers from the methodological 
problem  of  comparing  two  unidentical  groups  in  their  response  to  two  different 
therapeutic regimens (Table 1.5).
Dor et. al 480 compared three different methods of cycle preparation prior to FTER. 
In  natural  cycles  the  pregnancy  rate  was  16.1%,  in  cycles  with  an  ovarian 
stimulation  protocol  11.4%  and  in  cycles  with  oestrogen  and  progesterone 
substitutional  therapy  9.5%.  The  differences  were  not  significant.  In  the  natural
74cycles the implantation rate was 29.2% when the endometrium was synchronized 
with embryo development or advanced 32 hours beyond embryo development.
In  a  comparative study  Imthurn  et.  al.4 8 1   investigated  31  natural  cycles and  nine 
cycles programmed with a short-term stimulation protocol as preparation for FTER. 
In  the  natural  cycle  group  the  cancellation  rate  was  48%  and  two  clinical 
pregnancies were established  (13% per replacement).  In the stimulated group no 
cycles were cancelled and eight replacements were performed,  resulting  in three 
clinical pregnancies (38% per replacement) and one biochemical pregnancy.
In 236 women undergoing 381 consecutive FTER cycles, Tanos et. al 482 compared 
the  efficacy  of  three  protocols  of  endometrial  preparation:  spontaneous  cycles, 
HRT  preparation,  and  ovarian  stimulation.  No  statistically  significant  difference 
was found in implantation rates per ET (5.6%, 5.6%, 4.6% respectively) and clinical 
pregnancy rates per cycle (16.9%, 16.5%, 15.6% respectively).
1.7.3  Factors  Affecting  the  Treatment  Outcome  of  Frozen-Thawed  Embryo 
Replacement Cycles
High-quality embryos are known to sustain less cryoinjury during cryopreservation 
when compared with those of moderate and poor quality.  When cryopreservation 
was  performed  at the  one-,  two-,  and  three-day stages  of embryo  development, 
pregnancies were similarly achieved  with  most of the embryos  at all  cell  stages. 
Asynchronism of endometrial growth to the cell  stage does not appear to reduce 
pregnancy  rates.  Kondo  et.  al.483  concludes  that  embryo  quality  evaluated 
morphologically is the most important clinical factor for successful  implantation of 
frozen-thawed embryos.
In  a  retrospective  study  Wang  et.  al.484  analysed  3570  FTER  cycles  in  1438 
couples,  to  evaluate  the  clinical  circumstances  that  influence  the  potential  for 
embryo  implantation.  The  characteristics  associated  with  a  more  favourable 
implantation rate were the success of the previous fresh ET cycle, female age <40
75years  and  non-tubal  factor  aetiology  of  subfertility.  For  women  in  the  poor 
prognosis group with  a single embryo transferred the pregnancy rate was <10%. 
In the good prognosis group, with two embryos transferred the pregnancy rate was 
>20%  and  the  probability  of  multiple  pregnancy  15-29%.  In  the  majority  of the 
women, with three embryos transferred the probability of pregnancy was no higher 
than for two-ET but the probability of multiple conception was increased.
To  determine  the  outcome  of  FTER,  Loh  and  Leong485  studied  endometrial 
preparation,  number of embryos transferred,  female  age at embryo freezing  and 
endometrial thickness, with the most important clinical factor appearing to be the 
type  of  endometrial  preparation.  The  natural  cycle  pregnancy  rate  was  almost 
twice that of the hormone replacement cycles.  Other factors that were suggestive 
of success were younger female age at embryo freezing, transfer of at least two 
embryos and endometrial thickness >11  mm.
76Table 1.5.  Frozen-Thawed Embryo Replacement Cycles: HRT vs NC
Study Number of 
Cases
HRT Protocol
Cycle
Monitor
Outcome in HRT 
cycle
Outcome in 
Natural Cycle
Cancellation Rate Sig.
Cameron4 86 |  PR: 24% PR: 14% No
Schmidt445
Prospective
12 women 
with HRT 
26 women 
with NC
GnRHa
Transdermal E2  
Sequential dose 
PV P4
TVS
Urinary LH 
Serum LH, 
P4
PR: 17% PR: 8% 7/33 in NC
;
Yes
de Ziegler487
65 cycles with 
GnRHa +
HRT
18 cycles with 
HRT
53 cycles with 
NC
Without GnRHa 
PR of embryos 
originating from 
donated oocytes: 
33%
With GnRHa PR: 
6%
PR: 11%
Dor4 80  | PR: 9.5% PR: 16.1% No
Muasher4 40
Retrospective
22 cycles with 
HRT
144 cycles 
with NC
GnRHa
Transdermal E2  
Sequential dose 
IM P4
CPR: 36% 
IR: 18%
CPR: 21% 
IR: 10% Yes
Sathanandan4 7 8
Retrospective
84 patients 
with HRT 
78 patients 
with NC
GnRHa 
E2  valerate 
Sequential dose 
IM P4
TVS
Serum LH, 
P a ,  E2
CPR: 20% CPR: 20%
No cancellation in 
HRT
4/78 in NC
No
Pattinson4 5 4
Prospective
54 cycles with 
HRT
165 cycles 
with NC
No GnRHa 
Micronized E2  
Fixed dose of 
2mg/day
from day 2-5 start 
PV P4
TVS
Serum LH, 
P4
PR: 20% 
OPR: 12%
PR: 14.4% 
OPR: 12.2%
:
15.8% in NC 
7.4% in HRT No
Schalkoff48 8
Prospective
185 cycles 
with NC
TVS  | 
Urinary LH PR: 27.6%  I
77Study Number of 
Cases HRT Protocol
Cycle
Monitor
Outcome in HRT 
cycle
Outcome in 
Natural Cycle
Cancellation Rate  |  Sig.
....................i.......................
Al-Shawaf4 0 9
Prospective
77 cycles with 
NC
75 cycles with 
HRT
GnRHa 
E2  valerate 
Fixed dose of 
4-6mg/day 
PVP4
TVS
Urinary LH
PR:  25% 
IR: 10.6
PR: 26% 
IR: 10.3%
i
!
|  No
I ......I  .................
Queenan4 7 9
Prospective
230 with HRT 
398 cycle with 
NC
GnRHa
Transdermal E2  
Sequential dose 
IM P4
TVS
Serum LH,
P4, e2
PR: 30% 
IR: 10.3%
PR: 28% 
IR: 11.9% I  No
|  Tanos4 8 2 PR: 16.5% 
IR: 5.6%
PR: 16.9% 
IR: 5.6%
|  No \
|  Loh and Leong485 PR: Half of NC PR: 17.7%  i  |
Sig: Significance, PR: Pregnancy rate, CPR: Clinical pregnancy rate,  IR: Implantation rate, OPR: Ongoing pregnancy rate, NC:  Natural cycle for frozen-thawed embryo replacement, HRT:  Hormone 
replacement therapy for frozen-thawed embryo replacement, P4: Progesterone, E2 : Oestradiol, TVS: Transvaginal ultrasonography, PV: Intravaginal, IM: Intramuscular
782  Material and Methods
2.1  Factors Affecting the Outcome of IVF Treatment
From the computerised database of the Lister Hospital, Assisted  Reproduction 
Unit,  clinical  and  embryologic  data  on  fresh  IVF  treatment  cycles  between 
January  1994  and  July  2001  were  identified.  Overall  success  of  the  IVF 
treatment showed noticeable improvement during this long period. However, as 
distribution  of  the  prognostic  characteristics  was  an  intrinsic  feature  of  the 
patient  population,  it  was  not  anticipated  that  improvement  in  the  outcome 
would  affect  the  analysis.  Treatment  cycles  involving  oocyte  or  embryo 
donation,  and  FTER  were  excluded.  Raw  data  on  the  demographic 
characteristics of the couples, diagnostic characteristics of subfertility, response 
parameters  to  ovarian  stimulation,  features  of  oocyte  maturity  and  embryo 
development,  as  well  as  details  of the  ET  procedure  and  treatment  outcome 
had  been  logged  into  a  FoxPro  database  in  the  form  of  separate  files.  To 
establish  a  more flexible  data-management  platform,  each  file was  converted 
into SPSS format and scrutinised for reliability. Separate files were then merged 
into  a  master file  using  the  cycle  code  of each  treatment  as  the  unique  key 
variable.  Consequently,  clinical  and  embryologic variables of the  12,332 fresh 
IVF cycles were combined, making it possible to perform multiple analyses.
The aim was to identify the prognostic significance of variables in the outcome 
of assisted conception  in terms of ongoing  pregnancy and  multiple pregnancy; 
and  using  these  variables,  to  define  the  characteristics  of  good  prognostic 
couples  whose  pregnancy  chances  were  independent  of  the  number  of 
embryos transferred.
In  this  analysis,  it  was  acknowledged  that  direct  assessment  of  the  factors 
immediately  engaged  in  the  complex  biological  processes  of  gamete 
production,  fertilisation,  and  implantation  may not always  have  been  possible; 
because  either which  factors  to  measure  or  how  to  measure  them  were  not 
known.  Instead,  it  was  proposed  that  surrogate  clinical  markers,  which  are 
easier to observe, measure and compare be identified to reflect the summative 
effect of the decisive factors of the outcome.  It was also proposed that clinical
79variables  presenting  the  highest  level  of  association  with  the  outcome  must 
have  surrogated  the  most  critical  steps  of  the  actual  biological  processes 
leading  to  the  observed  outcome.  Despite  having  statistical  significance  in 
univariate analysis,  some clinical variables surrogating the less critical  aspects 
of the biological processes may lose their prognostic power when assessed with 
the other variables in multivariate analysis.
For this  reason,  firstly  a  univariate  analysis  was  performed  using  clinical  and 
embryological  parameters  as  independent  variables  for  ongoing  pregnancy. 
Variables  found  to  be  significant  were  further  evaluated  in  the  multivariate 
analyses to  identify the  independent  predictors of the treatment outcome with 
the highest level of impact. The analysis is based on  12,332 treatment cycles; 
however,  the  whole  data  were  not available for each  variable.  A  case with  a 
missing value for either the dependent or the independent variable for a given 
analysis was not used in that analysis.  Hence the number of cases included in 
the univariate and multivariate analyses may be different for each variable.
Secondly,  prognostic  significance  of the  number  of  embryos  transferred  was 
evaluated  for  the  prediction  of  ongoing  pregnancy  with  consideration  of  the 
quality of the embryos transferred, quality of the un-transferred sister embryos, 
and quality of the embryo cohort as a whole.
For practical  reasons,  embryo quality may not always  have  been  available for 
decision  making.  Hence,  thirdly,  a  series  of  receiver  operating  characteristic 
(ROC) curve analyses were employed for the ‘short listed’  prognostic markers 
for the  implantation  potential  of embryos  (female  age,  duration  of subfertility, 
and the number of cleavage stage embryos created). The cut-off points of these 
prognostic variables obtained from the ROC curve analyses were then applied 
into  the  whole  study  population  to  divide  it  into  subgroups.  The  aim  was  to 
achieve  different  subgroups  that  were  individually  homogenous  for  their 
prognostic characteristics.
80Finally, in each of these subgroups defined by ROC curve analyses, prognostic 
significance  of  the  number  of  embryos  transferred  was  evaluated  for  the 
prediction of ongoing pregnancy.
Results were presented in the sequential order of events experienced during a 
typical  IVF  cycle:  history taking for the demographic variables of the  patients, 
ovarian  stimulation  (section  3.1);  oocyte  collection  (section  3.2);  fertilisation, 
development of the individual sister embryos and  developmental  quality of the 
embryo cohort as a whole (section 3.3, 3.4); quality of the transferred embryos 
and ET procedure (section 3.5, 3.6). The prognostic significance of the number 
of embryos transferred was presented in section 3.7 and 3.8. A similar analytic 
approach was employed for the assessment of the multiplicity of implantation in 
section 3.9. Clinical variables affecting the oocyte and embryo quality were also 
appraised.  Oestradiol  and  FSH  concentrations  in  serum  were  expressed  in 
nanomole / litre (nmol/l) and international unit / litre (IU/I) respectively.
2.2  Low-Dose  Aspirin  Co-Treatment  in  Patients  Undergoing  IVF 
Treatment
A  prospective,  randomised,  placebo-controlled,  and  double-blind  clinical  trial 
was conducted to evaluate the  prognostic significance of tissue  perfusion  and 
its  pharmacological  manipulation  with  low-dose  aspirin  in  the  outcome  of 
assisted  conception.  Utero-ovarian  perfusion  was  assessed  by  Doppler 
ultrasonography.  VEGF-VEGFR  concentrations  in  serum  and  follicular  fluid 
were also studied.
2.2.1  Patient Selection, Randomisation Process and Study Design
In the subfertile couples, female partners who were younger than 40 years and 
undergoing  IVF  treatment  in  the  Aberdeen  Fertility  Centre,  were  invited  to 
participate  in  the  study.  No  limitations  were  applied  on  the  grounds  of type 
(primary or secondary),  duration  or aetiology of subfertility,  or on  the  number 
and  outcome  of  previous  fertility  treatments.  Excluded  from  the  study  were 
women  with  contraindications  to  the  use  of  non-steroidal  anti-inflammatory 
drugs, or any current or previous significant systemic disease with the possibility 
of recurrence or sequelae.
81Randomization  was  performed  at the  initial  visit  by drawing  a  sealed  opaque 
envelope  containing  instructions  on  the  individual  patient  treatment for  either 
tablet ‘A’ or ‘B’. Treatments were randomly assigned to the envelopes by using 
a  random  number  generator  in  the  Research  Pharmacy  Department.  The 
bottling of the aspirin and matching placebo tablets was also performed  by the 
Research Pharmacy Department.  All patients and clinical staff were blinded to 
the  type  of  treatment.  The  randomisation  code  was  made  available  to  the 
researchers only after the last recruited couple had completed their treatment.
A 10 ml blood sample was taken for VEGF and VEGFR concentrations as well 
as full blood count and baseline hormonal profile at the early follicular phase of 
the natural cycle.  In those women with regular ovarian cycle, controlled ovarian 
stimulation  was  initiated  with  GnRH  analogue  in  the  mid-luteal  phase  of the 
previous cycle.  Down-regulation  was  confirmed  by serum  oestradiol  level  and 
ultrasonography.  Gonadotrophin was given in the form of recombinant FSH  as 
per unit protocol. Once target follicular growth was achieved,  10,000 IU of hCG 
was  administered  intramuscularly.  Luteal  support  was  given  as  vaginal 
progesterone. At the mid-luteal phase when the GnRH analogue treatment was 
initiated, aspirin tablets at a dose of 75 mg twice daily and placebo tablets at a 
dose of one tablet twice daily were commenced  and continued throughout the 
treatment.  In  the  case  of established  pregnancy,  aspirin  and  placebo  tablets 
were continued  until the  end  of the first trimester.  Doppler assessments were 
performed on day 1   and on the last day of the ovarian stimulation  before hCG 
injection. On the day of oocyte collection blood and follicular fluid samples were 
obtained for VEGF-VEGFR assessment.
Demographic  characteristics  of  the  couples  and  clinical  and  embryological 
variables  of the  in  vitro fertilisation  cycles were  recorded.  Clinical  pregnancy, 
diagnosed  by  serum  beta-hCG  levels  on  day  15  after  ET  and  confirmed  by 
ultrasonography  at  the  seventh  week  of  pregnancy,  was  documented  as  the 
primary  outcome  measure.  Ongoing  pregnancy  was  defined  as  pregnancy 
beyond the first trimester.  Biochemical  pregnancy was defined  as a significant 
but transient increase in  (3hCG levels (>10 mll/mL). The implantation rate was 
defined  as  a  gestational  sac  per embryo transferred,  visualised  by  ultrasound
82three weeks  after ET.  ‘No-ET’  refers to the treatment cycles  cancelled  before 
the embryo transfer. ‘No-ongoing pregnancy’ refers to the treatment  cycles with 
the outcome  of no  pregnancy,  biochemical  pregnancy,  miscarriage during the 
first trimester, and ectopic pregnancy.
The clinical  study was  powered to evaluate the  null  hypothesis that ‘low-dose 
aspirin  co-treatment  does  not  alter  the  clinical  pregnancy  rates  in  IVF 
treatment’. The inclusion of 310 patients in each arm of the study gave an 80% 
chance of detecting  an  improvement in the clinical  pregnancy rates from  20% 
with  no  aspirin  treatment  to  30%  with  aspirin  treatment  at  a  5%  level  of 
statistical significance. With an anticipated 10% dropout rate, recruitment of 680 
couples  was  planned.  For  uterine  artery  Doppler  analysis,  32  patients  would 
provide  95%  power  at  the  5%  level  of  significance  to  detect  a  minimum 
difference of 0.71  (standard deviation: 0.54) in the mean uterine artery PI values 
between clinical pregnancy and no clinical pregnancy.
2.2.2  Protocol for Ovarian Stimulation
The  Day 21-long  protocol  was  the  most  commonly  used  regimen  for ovarian 
stimulation  in  our  department.  Either  buserelin  acetate  (Suprecur®;  Hoechst 
Marion  Roussel  Ltd,  Uxbridge,  UK)  500  pg  administered  once  daily  as  S.C. 
injections or nafarelin  acetate  (Synarel®;  Searle,  High Wycombe,  UK) 400  jag 
administered  twice  daily  as  nasal  spray  was  utilised  for  pituitary  down- 
regulation.
The first  ultrasound  scan  was  scheduled  usually  at  around  14  days  after the 
initiation  of  the  GnRH  analogue  treatment.  This  scan  was  to  exclude  the 
development of follicular cysts  under the  effect of GnRH  analogue.  Following 
the  sonographic  and  biochemical  confirmation  of  pituitary  down-regulation 
(serum  oestradiol  concentrations  of  <0.1  nanomole/litre  and  the  absence  of 
follicular  activity),  ovarian  stimulation  was  initiated  with  recombinant  follicle 
stimulating  hormone,  follitropin  beta  (Puregon®;  N.V.  Organon,  Postbus,  the 
Netherlands;  Gonal  F,  Serono,  Italy),  once  a  day as  S.C  injections.  Follicular 
cycts >10mm were aspirated through tansvaginal  route under ultrasonographic 
guidance before the initiation of ovarian stimulation.
83On day 8 of the ovarian stimulation, the oestradiol concentration was measured. 
If the level was £0.1  nanomole/litre (nmol/l), the gonadotrophin dose (Puregon 
or Gonal  F) was  increased.  If the level was £3  nmol/l the gonadotrophin dose 
was  reduced  and  follicular  growth  was  assessed  by  scan  on  day  9.  If  the 
oestradiol  concentration was  between 0.1  and  3  nmol/l  the  starting  dose was 
maintained  and the second  pelvic ultrasound was scheduled for day  10 of the 
ovarian  stimulation  to  assess  the  follicular  response.  Further  scans  were 
arranged  accordingly. When the final  scan  revealed  at least three follicles £17 
mm,  human chorionic gonadotrophin (hCG,  Profasi®;  Serono Pharmaceuticals 
Ltd, Middlesex, UK) 10,000 units was administered.
2.2.3  Oocyte Collection
Transvaginal oocyte collection under ultrasound guidance was performed as an 
outpatient  procedure,  36  hours  after  hCG  injection,  using  a  double  lumen 
oocyte harvesting needle.  If no oocyte was obtained in the original aspirate the 
follicles were flushed  up to three times. All  patients  received  a  preliminary I.V. 
loading  dose  of  4  mg  midazolam  (Hypnovel;  Roche  Products  Ltd.,  Welwyn 
Garden  City,  UK)  and  25  mg  fentanyl  (Sublimaze;  Janssen-Cilag  Ltd.,  High 
Wycombe,  Bucks,  UK).  Maintenance  bolus  doses  were  then  administered  by 
the  clinician  performing  the  oocyte  collection.  Monitoring  included  a  non- 
invasive blood pressure device,  Dinamap (Criticicon Ltd., Bracknell, Berks, UK) 
and  a  pulse-oximeter.  Blood  pressure,  heart  rate  and  oxygen  saturation were 
recorded  at 5 min  intervals during the  procedure.  The system  used for oocyte 
grading is given below (Table 2.1).
Table 2.1: Oocyte Maturity
Oocyte Corona ceils Cumulus Germinal vesicle Polar body
Immature Tightly apposed Tightly packed Seen Not extruded
Borderline mature Radiating Expanding No longer seen Extruded
Mature Fully radiating Expanded No longer seen Extruded
Post-mature Little, dissociating Dispersed No longer seen Extruded
842.2.4  Embryo Grading and Transfer
The system  used for embryo grading  is given  below (Table 2.2).  To complete 
the grading, the number of cells present was included as the ‘stage’.
Table 2.2: Embryo Grading
Grade 1 !  Equal size of cells No or few fragments  j
Grade 2 |  Unequal size of cells No fragments  |
Grade 3 Equal size of cells Lots of fragments  I
Grade 4 Unequal size of cells Few fragments  j
Grade 5 |  Unequal size of cells Lots of fragments  |
Grade 6 |  Undivided embryo I I
A  maximum  of  two  embryos  were  transferred  on  day  2  after  fertilisation. 
Because  of the  risk  of ovarian  hyperstimulation  syndrome,  fresh  ET was  not 
performed  if  serum  E2  concentration  was  £15  nmol/l  on  the  day  of  hCG 
administration,  if >30 follicles were aspirated, or if >20 oocytes were collected. 
For these patients all embryos were electively cryopreserved and transferred in 
subsequent cycles.
For the  ET  procedure,  patients  were  in  lithotomy  position  with  a  slight  head 
down tilt. The cervix was exposed with  a  bivalve speculum.  The vaginal walls 
and  cervix  were  cleaned  with  warmed  normal  saline  solution  and  finally with 
embryo culture  medium. Any cervical  mucus was  removed gently with a  moist 
swab.  Grasping of the cervix was performed only when difficulty in  introducing 
the catheter was encountered.
K-Jets-6019-SIVF  catheters  (Cook  IVF,  Queensland,  Australia) were  used  for 
ET.  The  outer catheter  has  a  pre-shaped  curve  to  accommodate  the  natural 
flexion of the cervical canal and the uterus. The rounded bulb tip is designed to 
tract through  the  cervical  canal.  The  catheter  has  two  depth  markers  on  the 
shaft at 4  and  5  cm  from  the tip.  The  mark  at the external  cervical  os would 
correspond to the length of the cervical  canal. The inner transfer catheter is a 
soft  small  diameter  catheter with  a  rounded  bullet  tip.  The  proximal  shaft  is 
stiffened with an external cannula.
85Drawing up of the embryos into the inner catheter was done with the three-drop 
procedure in which the embryos were separated  by a 20  pi  bubble of air. The 
total volume of medium was about 3 x 0.02 ml. Once the embryos were loaded, 
the inner transfer catheter was assembled into the outer catheter so that its tip 
would  be  1cm  inside  the  tip  of  the  outer  catheter.  The  catheter  was  then 
introduced  into the cervical  canal.  When the  internal  os was just  passed  the 
inner catheter was advanced 2 cm into the uterine cavity. The transfer volume 
was then  gently expelled by pushing the  plunger of the  attached  syringe.  The 
catheter was  left  in the cavity for  10  second  (sec)  and withdrawn  slowly as  a 
single  unit.  The  two  instruments  were  flushed  with  medium  under  a 
stereomicroscope to ensure that the embryos had been released into the uterine 
cavity.
Details  of the transfer  procedure were  recorded,  including  duration,  bleeding, 
mucus  and  excessive  manipulation.  The  degree  of difficulty  of  each  transfer 
procedure was judged subjectively by the clinician on a scale of 1  to 4:  1   = very 
easy, when the catheter had passed effortlessly into the uterine cavity; 2 = easy, 
when  the  catheter  required  some  manipulation  and  then  passed  freely;  3  = 
some difficulty, when catheter manipulation plus a tenaculum were required; 4 = 
very  difficult,  when  multiple  catheter  changes  and  cervical  dilatation  plus  a 
tenaculum were required.
At the end of the procedure, patients were permitted to empty their bladder 10- 
15  min  after  ET  and  they  then  rested  for  one  hour  in  the  recovery  room. 
Thereafter,  patients  were  discharged  and  advised  to  resume  their  usual 
activities.  Following  ET,  progesterone  pessaries  (Cyclogest®;  LD  Collins&Co 
Ltd, London, UK) 400 mg once daily were given as luteal support.
2.2.5  Colour and Pulsed Doppler Measurement
Transvaginal colour and pulsed Doppler measurements were performed on the 
day  that  pituitary  suppression  was  confirmed  and  on  the  day  prior  to  hCG 
injection (day of last scan). To minimise the effect of circadian rhythm over the 
uterine blood flow269, Doppler assessments were performed at the same time of 
day for each  patient.  Before being scanned the patients rested for at least  15
86min  and  completely emptied their bladder to  minimise any external  effects on 
the pelvic blood flow489. All scans were performed  by a single operator initially 
under  supervision  using  the  C60-Toshiba  Core  Vision  with  a  6-MHz 
endovaginal  transducer.  The  thermal  index  for  B-mode  and  Doppler 
examinations  was  <0.46.  The velocity  range,  wall  filter and  colour gain  were 
standardised for all  scans. A 70  Hz filter was used to eliminate low frequency 
signals  originating  from  vessel  wall  movements.  Colour  flow  mapping  and 
pulsed  Doppler  measurements  were  performed  once  normal  pelvic  findings 
were  confirmed.  Uterine  artery,  sub-endometrial  and  peri-follicular  blood  flow 
and vascularity were studied.
The  uterus  was  visualised  in  a  central  longitudinal  section.  The  maximum 
endometrial thickness between the echogenic interfaces of the myometrium and 
endometrium  was  measured.  The  endometrial  pattern  was  graded  in 
accordance with  the  method  described  by  Gonen  and  Casper382:  Type A,  an 
entirely homogeneous, hyperechogenic pattern without a central echogenic line; 
Type B,  an  intermediate isoechogenic pattern with the same  reflectivity as the 
surrounding myometrium and a non-prominent or absent central echogenic line; 
Type  C,  a  multi-layered  triple-line  endometrium  with  a  prominent  outer  and 
central hyperechogenic line and inner hypoechogenic regions.
Colour flow  images  of the  ascending  uterine  artery  were  sampled  bilaterally 
through  the  uterine  isthmus  in  a  coronal  plane261.  When  satisfactory  colour 
signals were obtained, blood flow velocity waveforms were recorded by placing 
the  sample volume across the vessel  and entering the  pulsed  Doppler mode. 
Areas of maximum colour intensity representing the greatest Doppler frequency 
shifts  were  selected  for  pulsed  Doppler  examinations.  Only  those  samples 
avoiding wide angles of insonation  (>60°) were accepted for spectral  analysis. 
The  pulsatility  index  (Pl=  S-D/mean)  was  calculated  automatically  by  the 
machine  auto-trace  facility,  where  S  is  the  peak  systolic  Doppler  shifted 
frequency, D is the minimum diastolic Doppler shifted frequency, and the mean 
is the mean maximum Doppler shifted frequency over the cardiac cycle. The PI 
has the  advantage of reflecting  blood  flow  impedance  accurately,  even  in  the 
absence of end diastolic blood flow490. Resistance index (Rl= S-D/S), maximum
87peak  velocity  (Vmax)  and  minimum  diastolic  velocity  (Vmin)  were  also 
assessed.
Thereafter,  sub-endometrial  spiral  arteries  were  identified  by  superimposing 
colour Doppler mapping  over the 2-D  image of the  longitudinal  section  of the 
uterus at the level of maximum endometrial thickness. No correction was made 
for the angle of insonation of the Doppler beam but the presence of good colour 
signals was ensured within 1cm of endometrial-myometrial junction.
Colour flow mapping was  used to localise perifollicular blood  flow surrounding 
the selected follicle with the most extensive perifollicular vascular perfusion. The 
pulsed  Doppler gate was  placed  over the vessel  of interest and the  recorded 
velocity waveforms were used for spectral analysis. No correction was made for 
the angle of insonation  in the vessels  but the highest achievable signals were 
sought over the maximum colour intensity. Subsequently, the vascularity of the 
follicle  with  the  most  extensive  peri-follicular  vascular  perfusion  was  studied 
using power Doppler imaging unilaterally within the more responsive ovary. The 
percentage  of  the  peri-follicular  circumference  that  showed  the  contact 
vascularity with visible flow was  recorded  (Grade  1:  <25%;  Grade 2:  25-49%; 
Grade 3: 50-74%; Grade 4: 75-100%). Ovarian blood flow as either the ovarian 
artery  flows  towards  the  substance  of  the  ovary287  or  within  the  ovarian 
stroma259 was not analysed.  Beacuse for such small  and tortuous vessels, the 
angle  of  insonation  cannot  be  determined  and  hence  the  reproducibility  of 
Doppler indices was questioned312. Quantitative determination of oestradiol and 
FSH  concentrations  in  serum  was  performed  by  immunoradiometric  assay 
using the ADVIA® Centaur System™. Values were expressed in nmol/l and IU/l 
respectively.  Intra-  (2.0%  to  2.9%  for  FSH;  2.2%  to  5.5%  for oestradiol)  and 
inter-  (1.2  to  2.7%  for  FSH;  2.7  to  5.2%  for oestradiol)  assay  coefficients  of 
variations were determined.
2.2.6  VEGF-VEGFR Concentrations
2.2.6.1  Blood Collection and Serum Preparation for VEGF-VEGFR
Blood samples were collected by venipuncture into  10 ml tubes and allowed to 
clot for  30  min  before  centrifugation  at  1000g  for  15min  under temperaturecontrol.  To minimize the potential contribution of VEGF released from platelets 
during blood clotting centrifugation was not delayed491. Supernatant was divided 
into  aliquots  and  stored  at  -80°C  until  measurement of  VEGF  and  VEGFR 
concentrations.
2.2.6.2  Follicular Fluid Preparation for VEGF-VEGFR
From  each  woman,  follicular  fluid  (FF)  was  collected  from  the  first  follicle 
punctured  to  avoid  a  dilution  effect  caused  by  follicle  irrigation,  which  could 
artificially alter VEGF concentration. This follicle was selected as being the most 
regular and  the  largest.  A wide  interfollicular variation  in  intrafollicular steroid 
and cytokine concentrations  is reported as a  reflection  of follicular asynchrony 
during ovarian stimulation for |VF492,493.  Therefore, to eliminate the uncertainty 
originating  from  unquantifiable  contribution  from  all  individual  follicles,  it  was 
elected  to  evaluate  only the  largest follicle  separately.  After  identification  and 
removal of the oocyte, the clear FF from each woman was centrifuged at 1000 g 
for 15 min to separate cellular contents and debris. When blood contamination 
was  observed,  follicular  fluid was  discarded.  Follicular  fluid  supernatant  was 
transferred to sterile polypropylene tubes and cryopreserved at -80°C for further 
analysis.  All  samples  were  assayed  at  the  same  time  to  avoid  interassay 
variations.
2.2.6.3  Quantitative  Determination  of Free  Human  VEGF  Concentrations 
in Serum and Follicular Fluid
The  Quantikine  VEGF  Immunoassay  (R  &  D  System,  Inc.,  Minneapolis,  MN, 
USA)  is  a 4.5-hour solid  phase enzyme-linked  immunosorbent  assay (ELISA) 
designed  to  measure  VEGF165  levels.  This  assay  employs  the  quantitative 
sandwich enzyme immunoassay technique. A monoclonal antibody specific for 
VEGF  has  been  pre-coated  onto  a  microplate.  Standards  and  samples  were 
pipetted  into the wells  and  any VEGF  present was  bound  by the  immobilized 
antibody.  After  washing  away  any  unbound  substances,  an  enzyme-linked 
polyclonal antibody specific for VEGF was added to the wells. Following a wash 
to  remove  any  unbound  antibody-enzyme  reagent,  a  substrate  solution  was 
added to the wells and colour developed  in  proportion to the amount of VEGF
89bound in the initial step. The colour development was stopped and the intensity 
of the colour was measured.
2.2.6.3.1  Assay Procedure
100 pL of assay-diluent and  100 pL of standard or sample were added to each 
well  and  incubated  for  two  hours  at  room  temperature.  Each  well  was  then 
aspirated  and  washed  by  filling  with  400  pL  of  wash-buffer,  repeating  the 
process twice for a total  of three washes.  After the  last wash,  any  remaining 
wash-buffer was removed  by aspirating.  The plate was  inverted  and  blot dried 
against clean paper towels. 200 pL of VEGF-conjugate was added to each well 
and  incubated  for two  hours  at  room  temperature.  Three  cycles  of aspiration 
and wash were performed. 200 pL of substrate-solution was added to each well 
and incubated for 25  minutes at room temperature by protecting from  light.  50 
pL of stop-solution was added to each well and to ensure thorough mixing the 
plate was gently tapped.
The  optical  density  of each  well  was  determined  within  30  minutes,  using  a 
microplate reader set to 450  nm. The average value of the duplicate readings 
for each  standard  and  sample was  calculated  and the average zero standard 
optical  density was  subtracted.  A standard  curve  was  constructed  by  plotting 
the mean absorbance for each standard on the y-axis against the concentration 
on the x-axis. A best fit curve was drawn through the points on the graph. The 
minimum detectable dose was <9.0 pg/mL.
2.2.6.4  Quantitative  Determination  of  Human  Soluble  VEGF  Receptor
Concentrations in Serum and Follicular Fluid
The Quantikine VEGF R1  immunoassay (R & D System, Inc., Minneapolis, MN, 
USA) is a 4.5hr solid-phase ELISA designed to measure human soluble VEGF 
R1.  This  assay  employs  the  quantitative  sandwich  enzyme  immunoassay 
technique.  A  monoclonal  antibody specific for VEGF  R1  has  been  pre-coated 
onto a microplate. Standards and samples were pipetted into the wells and any 
VEGF R1  present was bound by the immobilized antibody. After washing away 
any  unbound  substances,  an  enzyme-linked  polyclonal  antibody  specific  for 
VEGF  R1  was  added  to the wells.  Following  a wash to  remove  any  unbound
90antibody-enzyme  reagent,  a  substrate  solution  was  added  to  the  wells  and 
colour developed  in  proportion to the amount of VEGF  R1  bound  in the  initial 
step. The colour development was stopped and the intensity of the colour was 
measured.
2.2.6.4.1  Assay Procedure
100 pL of assay-diluent and  100 pL of standard or sample were added to each 
well  and  incubated  for two  hours  at  room  temperature  on  a  horizontal  orbital 
microplate shaker set at 50 rpm.  Each well was then aspirated and washed by 
filling with 400 pL of wash-buffer, repeating the process three times for a total of 
four washes.  After the  last wash,  any remaining wash-buffer was  removed  by 
aspirating.  The  plate was  inverted  and  blot  dried  against  clean  paper towels. 
200 pL of VEGF  R1-conjugate was added to each well  and  incubated for two 
hours at room temperature on the shaker.  Four cycles of aspiration and wash 
were  performed.  200  pL  of  substrate-solution  was  added  to  each  well  and 
incubated for 30 minutes at room temperature by protecting from light. 50 pL of 
stop-solution was added to each well and, to ensure thorough mixing, the plate 
was gently tapped.  The optical density of each well was determined within  30 
minutes,  using  a  microplate  reader  set  to  450  nm.  The  minimum  detectable 
dose of VEGF R1  ranged from 1.63 -14.4 pg/mL.
2.3  Frozen-Thawed  Embryo  Replacement (FTER)  Treatment  in  Natural 
Cycle vs Hormonally Programmed Cycles
A  prospective,  randomised  study  with  preference  arm  was  conducted  to 
evaluate  if  a  natural  cycle  provides  better  hormonal  milieu  for  endometrial 
receptivity  than  hormonally  prepared  cycles  in  ovulatory  women  undergoing 
FTER.
2.3.1  Patient Selection, Randomisation Process and Study Design
Women  with  clinical  and  laboratory  evidence  of ovulation  (regular  menstrual 
cycle  between  26 to 35 days,  mid-luteal  progesterone levels >30  nmol/l) were 
invited  to  participate  in  the  study.  Couples  who  received  oocyte  or  embryo 
donation  or had  logistic  problems with  daily visits for blood  tests to either our 
Unit or their GP, were excluded from the study.
91Randomisation  was  performed  by  drawing  a  sealed  opaque  envelope 
containing  instructions  on  the  treatment  to  be  utilised.  Treatments  were 
randomly  assigned  to  the  envelopes  by  using  a  random  number  generator. 
Patients who were willing to participate in the study but had a strong preference 
for one particular type of treatment were allocated to the preference arm.
Demographic characteristics of the couples, clinical and embryological variables 
of the  primary fresh  IVF treatment cycles  and  subsequent  FTER  cycles were 
evaluated  for their prognostic  significance  in  the  outcome  of the  index  FTER 
cycles.  For the variables found  to  be  independent  predictors  of the treatment 
outcome of FTER in natural cycle (NC) and down-regulated  replacement cycle 
(DRRC), the groups were compared to assure like-to-like evaluation of the two 
endometrial  preparation  methods.  Clinical  pregnancy was documented  as the 
primary  outcome  measure.  Serum  VEGF-VEGFR  concentrations  and 
endometrial  thickness  and  echo-pattern  were  also  evaluated  as  prognostic 
determinants of the treatment outcome.
131  patients in each arm of the study would give an 80% chance of detecting a 
clinically significant difference in the clinical  pregnancy rates from  15% to 30% 
at 5% level of statistical significance. With the anticipation of a 10% dropout rate 
the recruitment of 300 couples was planned.
2.3.2  IVF Protocol
Routine unit protocols for GnRH  analogue down-regulated ovarian  stimulation, 
oocyte  collection,  in  vitro  fertilization,  cryopreservation  and  thawing  routines 
were employed (refer to section 2.2.2 and CD Rom 2.3.2).
2.3.3  Natural Cycle (NC)
For 28-day  menstrual  cycles,  cycle  monitoring  with  blood  tests  for oestradiol 
(E2)  and  LH  concentration  was  commenced  on  cycle  day  10.  For  longer 
menstrual  cycles,  this was  commenced  four days  before the  expected  day of 
ovulation. If E2 concentration was <0.2 nmol/l, the blood test was repeated after 
two days; if E2 was between 0.2 and 0.5 nmol/l, the test was repeated after one 
day; and if E2 was >0.5 nmol/l, tests were performed daily.
92The LH surge was diagnosed when the LH concentration was at least twice that 
of the  mean  of the two  preceding  days  with  a  concomitant drop  in  serum  E2  
levels in the next sample. If no LH surge was detected after a reasonable length 
of  time,  progesterone  (P4)  level  was  checked  to  evaluate  if  the  surge  was 
missed  or the  cycle  was  anovulatory.  ET  was  scheduled  on  day 4  from  the 
onset of LH  surge.  Patients outside the Grampian area and  not able to attend 
the  Unit  for  daily  blood  tests,  posted  their  bloods  to  the  Unit.  Mid-luteal  P4 
concentration was checked seven days after the ET.
2.3.4  Hormonally Programmed Cycle (DRRC)
Down-regulation with  GnRH  analogue was  initiated  on  day 2  of the  menstrual 
cycle  and  continued  until  day  15  of oestradiol  valerate  replacement when  P4  
was  added  to the  regimen.  On  day  18  of GnRH  analogue treatment,  serum 
oestradiol  concentration was checked to confirm down-regulation.  If oestradiol 
was <0.2 nmol/l  HRT was started.  Otherwise, GnRH  analogue was continued 
for  one  more  week  before  blood  tests  were  repeated  to  confirm  down- 
regulation.
Oestradiol  valerate  tablets  were  given  as  2mg/day  from  day  1   (after 
confirmatory blood test of down-regulation) to day 10; 4mg/day from day 11  to 
day 14; and 6mg/day from day 15.  Progesterone (Cyclogest suppositories) 400 
mg twice daily (PV or per-rectal) was added from day 15. ET was performed on 
day 18 of the HRT. Serum beta hCG was measured on day 33 and, if positive, 
ultrasonography was  performed  after three  weeks.  If the  pregnancy test was 
negative the  hormone  replacement was discontinued;  if positive, the  hormone 
replacement  was  continued  until  12  weeks  of  pregnancy  and  gradually 
discontinued thereafter.
In both study groups, endometrial thickness and echo-pattern was assessed by 
vaginal  ultrasonography  and  a  blood  sample  was  obtained  for  VEGF  and 
VEGFR concentrations on the day of ET.
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Statistical  analysis  was  performed  by  using  SPSS  software,  version  10.0 
(SPSS, Inc., Chicago, IL). Univariate analysis was performed to define the most 
probable predictors of pregnancy and multiple pregnancy. Multivariate analyses 
were  conducted  to  define  the  best  independent  predictors  of  pregnancy  and 
multiple pregnancy.
The  h2  test was  used  to  analyze  nominal  variables  in  the  form  of frequency 
tables.  Fisher’s  exact  test  was  computed  when  a  table  had  a  cell  with  an 
expected frequency < 5. Yates’ corrected chi-square was computed for all other 
2 by 2 tables.  Normally distributed  metric variables were tested with the t test. 
Ordinal variables or not-normally distributed metric variables were analyzed with 
the Mann-Whitney U test. If more than two groups had to be analyzed, normally 
distributed  metric variables with  equal variances  (Levene test) were examined 
by  means  of  one-way  ANOVA  test.  Multiple  comparisons  were  made  with 
Bonferroni  test.  For  not-normally  distributed  metric  variables  or  for  variables 
with unequal variances, the Kruskal-Wallis one-way ANOVA test for ranks was 
employed. For correlation analysis, Spearman's rank correlation coefficient was 
used. All tests were two-tailed with a confidence level of 95% (p<0.05). Logistic 
regression  analyses  were  done  by  using  forward  stepwise  and  forced  entry 
techniques.  Regression coefficient (pn ), regression constant (p0) and odds ratio 
(OR)  was  documented.  Cumulative  probability  of  the  standardized  residuals 
was plotted to assess the normal distribution. Goodness of fit of the model was 
assessed by R2 statistics.
Regression constant is the loge  transformation of the odds of an event occurring 
when all independent predictors are zero. The odds of an event can be defined 
as the ratio of the probability of an event occurring to the probability of an event 
not occurring.  The odds ratio is the change in the odds for an event when the 
value of the  independent variable  increases  by  1   unit.  The  logistic  regression 
equation for an event occurring can be written as ’Probability (event)=1 /1  + e'z 
,  where  e  is  the  base  of  the  natural  logarithms,  2.718  and  Z  is  the  linear 
combination of ‘“Z = po + pi Xi + p2 X2  +  ...  +  pn Xn‘.and Xn  is the independent 
variable.
94The predictive value of prognostically significant parameters was calculated  by 
receiver  operating  characteristics  (ROC)  curve  analysis.  Receiver-operating 
characteristic curves represent the probability of true positive results (sensitivity) 
as  a  function  of the  probability  of false  positive  results  (1  -  specificity).  The 
decision criterion  (cut-off point) was set at each different point of the decision 
axis and  sensitivity and  specificity for these  points were calculated. When the 
cut-off  points  were  varied,  the  possible  combinations  of  sensitivity  and 
specificity obtained were combined to calculate the area under the curve (AUC). 
The AUC, calculated as [sensitivity / (1  - specificity)],  is a measure that shows 
how ‘good’ (AUC close to 1) or ‘bad’ (AUC close to 0.5) a test is.
953  Factors Affecting IVF Outcome: Results
3.1  Descriptive  Statistics  of  Patient  Characteristics,  Clinical  Variables 
of IVF (Ovarian Stimulation) and Treatment Outcome
Demographic  characteristics of the couples,  diagnostic  characteristics  of their 
subfertility,  response  parameters  to  the  ovarian  stimulation  and  treatment 
outcome  were  summarized  (Table  3.1,  3.2,  3.3).  The  analysis  is  based  on 
12,332  IVF  treatment  cycles;  however,  the whole  data  were  not available for 
each variable. Couples may have more than one aetiology of subfertility, hence 
the cumulative percentage was >100% (Table 3.2).
Table 3.1: Patient Characteristics and Clinical Variables of IVF
Clinical Variables Mean ± SD N
Female Age (year) 35.2 ±4.9 10827
Duration of Subfertility (year) 5.3 ±3.6 8354
Previous Pregnancy 0.6 ±1.1 10827
Previous IVF Cycles 1.8 ± 1.4 10827
Early Follicular Phase FSH (IU/I) 6.6 ±3.6 4336
Early Follicular Phase E2  (nmol/l) 0.24 ± 0.52 2544
Total Gonadotrophin Dose (IU) 2851 ± 1351 8427
Duration of Ovarian Stimulation (day) 11.0 ± 3.1 8425
8-12 mm 3.4 ± 3.0 8488
Number of Follicles Measuring
13-16 mm 4.1 ±3.1 8488
17-19 mm 3.7 ±2.6 8488
£20 mm 1.8 ±2.2 5928
hCG Day E2  (nmol/l) 5.92 ± 4.27 4206
Number of Oocytes Collected 8.7 ±5.6 10752
Number of 2-PN Embryos 5.1  ±4.0 10752
Number of Embryos Transferred 2.3 ±1.0 10752
Number of Embryos Implanted 0.4 ± 0.7 9701
Endometrial Thickness (mm) 11.0 ± 1.8 8363
N: Number of subjects whose data were available for each variable, SD: Standard Deviation, PN: Pro-nuclear
Table 3.2: Aetiology of Subfertility
I  N Percent  |
Male Factor 4799 44.3  |
Unexplained 3125 28.9  |
Tubal Factor 3229 29.8  |
Endometriosis 1128 10.4  |
PCOS 878 8.1  |
Cervical Factor ______________ 0.7  |
96The frequency distribution of female age, duration of subfertility, gravidity,  pre­
stimulation  FSH  concentrations,  number  of  previous  IVF  attempts,  cyst 
development  after  down-regulation,  detection  of  hydrosalpinx  on 
ultrasonography  (USG),  endometrial  thickness  on  the  last  day  of  ovarian 
stimulation, and number of embryos transferred and implanted are given on the 
CD Rom (Table 3.1-3.10CD).
Table 3.3: Treatment Outcome
N Percent
No-Embryo Transfer 983 9.2
Ongoing Pregnancy 2477 23.2
No Pregnancy 6456 60.4
Miscarriage 559 5.2
Ectopic Pregnancy 69 0.6
Biochemical Pregnancy 150 1.4
Total 10694 100.0
3.1.1  Univariate Analysis
The  following  variables  differed  significantly  between  women  with  ongoing 
pregnancy  and  no-ongoing  pregnancy:  Female  age,  duration  of  subfertility, 
early follicular FSH,  previous  IVF attempts, total gonadotrophin dose, average 
daily  gonadotrophin  dose,  number  of  developing  follicles  (except  >20mm), 
number  of  oocytes  collected,  number  of  2-PN  embryos  created,  number  of 
embryos  transferred,  number  of  embryos  cryopreserved,  and  endometrial 
thickness (Table 3.4).
In the presence of an ovarian cyst following down-regulation, the probability of 
no-ET (p:  <0.01) and  no-ongoing  pregnancy (p:  0.09) was  higher but only the 
former  had  statistical  significance.  A  sonographically  visible  hydrosalpinx 
decreased  the  probability of ongoing  pregnancy (p:  0.05) without affecting the 
probability of no-ET (p: 0. 12) (Table 3.11, 3.12, 3.14, 3.15CD).
97Table 3.4: Patient Characteristics and Clinical Variables of IVF for Ongoing Pregnancy
Ongoing
Pregnancy N Mean ± SD P
............ j
No 7224 35.6 ±4.8
<0.01 remaie Mye ^year;
Yes 2474 33.6 ±4.0
No 5627 5.4 ± 3.7
<0.01 uuiauun ui  ouuieiwuy
Yes 1980 4.7 ±3.1
No 7235 0.6 ± 1.1
.............
NS rieviuus rieynanuy
Yes 2476 0.6 ± 1.0
No 5555 2911 ± 1257
<0.01 i uiai ounauuuupinn uu&e
Yes 2042 2516± 1090
No 7181 9.8 ± 5.8
<0.01 iNuinoer ui uouyies ouneuieu
Yes 2476 11.5 ±5.7
No 7235 1.9 ± 1.4
<0.01 rieviuus ivr o  yuies
Yes 2476 1.7 ± 1.1
8-12 mm
No______________ _
Yes
5580
2054
________ 3.3 ±3.0
3.8 ±3.1
<0.01
13-16 mm
No 5580 4.0 ±2.9
<0.01 Number of
Follicles
Measuring
Yes 2054 4.9 ±3.2
17-19 mm
No 5580 3.7 ±2.6
<0.01
Yes 2054 4.3 ±2.7
£ 20 mm
No_____________
Yes
3834
1478
________ 1.8 ±2.2
1.9 ±2.0
NS
Endometrial Thickness (mm)
No_______________
Yes
5495
2031
_______ 11.0 ± 1.7
11.4 ± 1.7
<0.01
No 2711 6.07 ±4.52
NS M O O   Uay  U-2  ^M IM U I/ly
Yes 1082 6.13 ±3.40
No 2850 6.6 ± 3.3
<0.01 r i c   o u iilu ic u iu i 1  ro n  V IU/I/
Yes 1038 6.2 ± 2.8
Number of 2-PN Embryos
No_______________
Yes 2476
________5.2 ± 3.7
6.7 ±3.8
<0.01
No 7181 2.5 ±0.7
<0.01 inuimuci  ui  cniuiyub  i lanaieiieu
Yes 2476 2.6 ±0.5
Number of Embryos 
Cryopreserved
No  ___________I  7181
Yes  |  2476
________ 1.0 ±2.6
1.9 ±3.3
<0.01
NS: Not significant, p: Significance value
983.1.2  Multivariate Analysis
Using  the  forward  conditional  stepwise  entry  method,  logistic  regression 
analysis  was  performed  with  the  following  independent  variables  to  predict 
ongoing pregnancy in 2109 cycles: Female age, gravidity, early follicular phase 
FSH  concentration,  aetiology of subfertility,  duration  of subfertility,  number of 
previous  IVF  attempts,  ultrasonographic  appearance  of  PCO  and  of 
hydrosalpinx,  type  of  luteal  support,  total  gonadotrophin  dose  required  for 
ovarian  stimulation,  average gonadotrophin  dose  per day,  duration  of ovarian 
stimulation,  duration  of  coasting,  E2  level  before  hCG  administration,  sperm 
concentration,  number  of  oocytes  collected,  number  of  oocytes  used  for 
fertilisation,  number of 2-PN embryos created,  number of embryos transferred, 
use of assisted hatching, and number of embryos cryopreserved.
Female  age,  duration  of  subfertility,  total  gonadotrophin  dose,  number  of 
oocytes collected,  number of 2-PN  embryos created,  and  number of embryos 
transferred were found to be significant (Table 3.5).
Table  3.5:  Patient  Characteristics  and  Clinical  Variables  of  IVF  in  the  Equation  for Ongoing 
Pregnancy
Age
Regression Coefficient J  SE  J  OR
-0.11  I  0.01  I  0.90
  P.
<0.01
Duration of Subfertility -0.04  0.02 0.96  I   <0.05
Total Gonadotrophin Dose
Oocytes Collected <0.01
umDer 0
umDer 0
Constant 24.42
SE: Standard error, ET: Number of embryos transferred, OR: Odds ratio
The  same  analyses  were  repeated  for  the  ongoing  pregnancy,  miscarriage, 
biochemical  pregnancy,  no-ET, and no-pregnancy outcomes (Table 3.13, 3.16- 
3.18CD).
993.2  Descriptive Statistics of Variables of IVF (Oocytes)
Number and  percentages of the oocytes collected  at varying levels of maturity 
were summarized (Table 3.6).
Table 3.6: Descriptive Statistics of Oocytes
Mean ± SD N
Aspirated Follicles 11.7 ± 6.4 8561  |
Collected Oocytes 9.8 ± 5.9 12332
Number of
Mature Oocytes 4.9 ±4.1 12068
Borderline Mature Oocytes 3.5 ±2.8 12068  |
Immature Oocytes_________ 0.9 ± 1.4 _______________ 12068  j
Post-mature Oocytes 0.2 ± 0.9 9454  |
Collected Oocytes 0.8 ±0.1 8567  |
Mature Oocytes 0.4 ± 0.2 12046  I
% of Borderline Mature Oocyte 0.3 ±0.2 12046
Immature Oocytes 0.1 ±0.1 12046  |
Post-mature Oocytes 0.02 ± 0.09 9432  |
% of collected oocytes  ‘number of oocytes collected:number of follicles aspirated’ ratio
% of mature oocytes  ‘number of mature oocytes number of oocytes collected’ ratio
Percentages  represented as decimal of 1.0 ± SD
3.2.1  Factors Related to Oocyte Maturity
Patients’  characteristics  and  clinical  variables  of  ovarian  stimulation,  which 
correlated  significantly with  the  number of mature,  immature  and  post-mature 
oocytes  retrieved  were  summarized  (Table  3.7).  Positive  correlation  between 
the variables was given as “t ”, negative correlation as “I ”, and no correlation as 
V»”.  Numerical  values  of  the  correlation  coefficients  and  corresponding  p 
values were detailed on the CD Rom (Table 3.19, 3.20CD).
For  the  number  of  mature  oocytes  collected,  the  correlation  coefficient  of 
follicles measuring  13-19mm was twice that of follicles measuring <13mm and 
six  times  that  of  follicles  measuring  >20mm.  For  the  number  of  immature 
oocytes  collected,  the  highest  correlation  coefficient  was  with  follicles 
measuring 8-16mm.
100Table  3.7:  Correlations  between  Patient  Characteristics,  Clinical  Variables  of  IVF  and  the 
Number and % of Oocytes Collected
|  Number of Oocytes
Mature Immature Post-mature
Female Age 4 4 t
Duration of Subfertility <-» 4 < -»
Previous Pregnancy t 4 t
Total Gonadotrophin Dose 4 4 t
Duration of Ovarian Stimulation 4 f <->
8-12mm t ..................1. t
Follicles
13-16mm t t t
17-19mm t t < -»
£ 20mm t t t
hCG Day E2 t T t
Pre-stimulation FSH 4 4 t
E2  per Follicle < -> T
Number of Oocytes Collected t t t
Number of 2-PN Embryos T t T
Number of Embryos Cryopreserved t T t
Number of Embryos Implanted t <->
% of Oocytes
Mature Immature Post-mature
Female Age 4 4 t
Number of Oocytes Collected t t t
Duration of Subfertility 4
Total Gonadotrophin Dose 4 t ..................................I j
Duration of Ovarian Stimulation <-» t <->
E2  Level on the day of hCG t t
Pre-stimulation FSH 4 <r> T
Number of 2-PN Embryos t t t
Number of Embryos Implanted t 4
_   .   __________
T : Positive correlation between the variables, 4-: Negative correlation,  : No significant correlation.
The  following  variables  differed  significantly  when  women  with  PCOS  and 
women  without  PCOS  were  respectively  compared;  %  of  oocytes  collected 
(86%  vs  88%),  %  of borderline  (34%  vs  37%),  immature  (11%  vs  9%),  post- 
mature (4% vs 2%) oocytes,  number of oocytes collected (11.5 vs 10), number 
of follicles aspirated (13.2 vs 11.5), number of mature (5.7 vs 5), borderline (3.8 
vs 3.5),  immature  (1.3 vs 0.9),  and  post-mature (0.5 vs 0.2) oocytes collected 
(Table 3.21CD).
101In women with and without endometriosis, the respective percentage of oocytes 
collected  (86% vs  88%)  and  the  percentage  (4%  vs  2%)  and  number (0.3 vs 
0.2) of post-mature oocytes collected, differed significantly. Among Grades 1, 2, 
3 and 4 endometriosis, the multiple comparison tests revealed that the following 
variables  differed  significantly  between  Grades  1   and  3  endometriosis 
respectively; % of oocyte collected (88% vs 83%), number of follicles aspirated 
(11.7  vs  10.2),  number  of  oocytes  collected  (10.5  vs  8.8),  and  number  of 
borderline oocytes collected (3.7 vs 3) (Table 3.22, 3.23CD).
The following variables differed  significantly between women with  unexplained 
subfertility and women  with  a  specific subfertility diagnosis,  respectively:  %  of 
oocytes collected  (87% vs 88%),  % of mature (48% vs  50%) and  post-mature 
(4%  vs  2%)  oocytes  collected,  number  of  oocytes  collected  (9.5  vs  10.1), 
number of follicles  aspirated  (11  vs  12),  and  number of  mature  (4.8  vs  5.2), 
borderline  (3.4 vs  3.6),  and  post-mature  (0.3 vs 0.2) oocytes  collected  (Table 
3.24CD).
The following  variables differed  significantly between  women  with  and without 
ovarian  cysts  following  down-regulation,  respectively:  %  of  oocytes  collected 
(85% vs 88%),  number of oocytes collected (9.7 vs  10.4), and  number of post- 
mature oocytes collected  (0.1  vs 0.3)  (Table 3.25CD).  The  number of follicles 
aspirated  (10.7 vs  12) insignificantly differed  between women with and without 
hydrosalpinx on USG (Table 3.26CD).
3.2.2  Univariate Analysis
The  following  variables  differed  significantly  when  women  with  ongoing 
pregnancy and no-ongoing  pregnancy were compared:  % of oocyte collected, 
%  of  mature,  borderline,  immature  oocytes  collected,  number  of  follicles 
aspirated,  number of oocytes collected,  and  number of mature and  borderline 
oocytes collected (Table 3.8).
102Table 3.8: Oocyte Maturity for Ongoing Pregnancy
Ongoing Pregnancy N Mean ± SD P
% of Oocytes from Follicular Aspirate
No 5628 0.8 ±0.1
<0.01
Yes 2068 0.9 ±0.1
% of Mature Oocytes
No 7003 0.4 ± 0.2
<0.01
Yes 2437 0.5 ±  0.2
% of Borderline Oocyte
No 7003 0.37 ±0.2
<0.01
Yes 2437 0.36 ±0.2
% of Immature oocytes
No 7003 0.1  ±0.1
<0.01
Yes 2437 0.09 ±0.12
Number of Aspirated Follicles
No 5626 11.5 ± 6.2
<0.01
Yes 2068 13.1 ±6.0
Number of Oocytes Collected
No 7182 9.8 ± 5.8
<0.01
..... Yes 2476 11.5 ±5.7
Number of Mature Oocytes
No 7005 4.9 ±4.1
<0.01
Yes 2437 6.1  ±4.3
Number of Borderline Mature No 7005 3.5 ±2.8
<0.01 Oocytes Yes 2437 4.0 ±3.0
% of Post-mature Oocytes
No 5201 0.02 ± 0.09
NS
Yes 1810 0.02 ± 0.08
Number of Immature Oocytes
No 7005 0.9 ± 1.4
NS
Yes 2437 1.0± 1.5
Number of Post-mature Oocytes
No 5203 0.2 ±1.0
NS
Yes 1810 0.2 ± 1.1
Percentages represented as decimal of 1.0 ± SD
The same analysis was performed for the pregnancy,  miscarriage, biochemical 
pregnancy,  no-ET,  and  no-pregnancy  outcomes.  Percentage  of  mature, 
borderline mature, immature, post-mature oocytes, % of oocytes collected from 
follicular  aspirate,  number of aspirated  follicles,  number of oocytes  collected, 
and  number  of  mature,  borderline  mature,  and  immature  oocytes  differed 
significantly among these different outcomes groups (Table 3.27CD).
3.2.3  Multivariate Analysis
In  7013  cycles,  logistic  regression  analysis was  performed  using  the  forward 
stepwise conditional entry method to evaluate the prognostic significance of the 
number  of  mature,  borderline,  immature,  and  post-mature  oocytes  in  the 
prediction  of  ongoing  pregnancy.  Prognostic  significance  was  found  in  the 
number of mature and borderline oocytes (Table 3.9).
103Table 3.9: Oocyte Maturity in the Equation for Ongoing Pregnancy
Regression Coefficient SE OR P
Mature oocytes 0.06 0.01 1.06 <0.01  I
Borderline Mature Oocyte 0.05 0.01 1.05 <0.01  I
Constant -1.56 0.05 0.21 <0.01  I
3.3  Descriptive  Statistics  of  Variables  of  IVF  (Fertilisation,  Individual 
Embryo Quality)
Statistical  details  of  the  fertilisation  related  variables  and  the  morphological 
development of the  individual  embryos  graded  1   to  6  (G)  and  developmental 
stages  1   to  9  (S)  (indicating  the  number  of  blastomeres)  were  summarized 
(Table 3.10, 3.11).
Table 3.10: Fertilisation Variables
Mean ± SD N  I
Number of Oocytes 9.4 ± 5.5 8090  i
Number of Fertilised Oocytes (2-PN) 6.2 ±4.2 8090  I
Number of Cleavage Stage Embryos 4.9 ±3.2 8090  !
% of Fertilisation 0.6 ±0.2 8090  i
% of Cleavage 0.8 ± 0.2 8090  I
% of Fertilisation: ratio of oocytes fertilized to oocytes used  % of Cleavage: ratio of embryos cleaved to 2-PN embryos
Table 3.11: Number of Embryos at Various Levels of Development
Embryo Stage and Grade Mean ± SD N
S2G1 0.3 ± 0.8 8090
S2G2 0.6 ± 1.1 8090
S2G3 0.2 ±0.7 8090
S2G4 0.1 ±0.4 8090
S2G5 0.02 ±0.21 8090
S3G1 0.09 ± 0.35 8090
S3G2 0.2 ±0.5 8090
S3G3 0.1  ±0.5 8090
S3G4 0.07 ± 0.34 8090
S3G5 0.01 ±0.11 8090
S4G1  ________________________ 0.5 ±1.1 8090
S4G2 0.8 ± 1.3 8090
S4G3 0.3 ± 0.8 8090
S4G4 0.1 ±0.5 8090
S4G5 0.03 ± 0.33 8090
S6G1 0.1 ±0.5 8090
S6G2 0.4 ± 0.9 8090
104Embryo Stage and Grade Mean ± SD ...............................................N.]
S6G3 0.2 ± 0.6 8090  |
S6G4 0.04 ± 0.30 8090
S6G5 0.01 ±0.16 8090  |
S8G1 0.09 ± 0.45 8090  j
S8G2 0.1 ±0.6 8090  I
S8G3 0.03 ± 0.24 8090  |
S8G4 0.01 ±0.12 8090
S8G5 0.0 ± 0.0 8090
S9G1 0.0 ± 0.0 8090
S9G2 0.01 ± 0.09 8090
S9G3 0.0 ±0.0 8090
S9G4 0.0 ±0.0 8090
S9G5 0.0 ± 0.0 8090
S: Stage of the embryo, G: Grade of the embryo. Grade 6 refers to non-cleaved embryos, and hence not included .
3.3.1  Univariate Analysis
There were significant differences when embryological variables were evaluated 
for  their  distribution  between  cycles  with  and  without  ongoing  pregnancy: 
number  of  oocytes  used  for  fertilisation,  number  of  oocytes  fertilised,  and 
number of cleavage stage embryos. Although fertilisation rates differed between 
the ongoing pregnancy and no-ongoing pregnancy groups, cleavage rates were 
similar in both groups (Table 3.12).  At almost all stages of embryo development 
(S2 to S8), there were more Grade  1   and 2 embryos in the ongoing pregnancy 
group (Table 3.28CD). The number of Grade 3 embryos had positive prognostic 
significance but mostly if cellular division was at S2 to S4. The number of Grade 
4 and 5 embryos was almost always higher in the non-pregnant group but not at 
a level of significance.
Table 3.12: Fertilisation Variables for Ongoing Pregnancy
Ongoing Pregnancy N  I Mean ± SD P
Number of Oocytes
No 5578  j 9.0 ± 5.4
<0.01
Yes 2054  | 10.7 ±5.3
Number of Fertilized Oocytes No 5578  | 5.9 ±4.1
<0.01 (2-PN) Yes 2054  | 7.5 ±4.1
Number of Cleavage Stage No 5578  | 4.7 ±3.1
<0.01 Embryos Yes 2054  i 6.1 ±3.0
% of Fertilization
No 5578  ! 0.67 ±0.2
<0.01
Yes 2054  i 0.72 ± 0.2
% of Cleavage
No 5578  | 0.85 ±0.2
NS
Yes 2054  | 0.85 ±0.1
1053.3.2  Multivariate Analysis
A  logistic  regression  analysis  using  the  forward  stepwise  conditional  entry 
method was  performed  on  3616 cycles to  predict ongoing  pregnancy with the 
following  variables  as  independent  predictors:  number  of  oocytes  used  for 
fertilisation,  number of oocytes fertilised,  number of cleavage  stage  embryos, 
fertilisation  rate,  cleavage  rate,  and  number  of  embryos  at  different 
developmental stages (S) and grades (G) (S2G1 to S9G5).
The  number  of  oocytes  used  for  fertilisation,  fertilisation  rate  and  embryo 
cleavage  rate  positively  affected  the  outcome.  The  number  of  slow  dividing 
embryos  with  either  good  or  poor  grading,  and  the  number  of fast  dividing 
embryos  with  poor  grading,  both  had  a  significant  negative  effect  on  the 
outcome.  The  number  of  four-cell  stage  embryos  with  good  morphological 
grading had the largest positive effect on the probability of ongoing  pregnancy 
(Table 3.13).
Table 3.13: Fertilisation Variables in the Equation for Ongoing Pregnancy
Regression Coefficient SE OR
Number of Oocytes
% of Fertilization <0.01
% of Cleavage
S2G1 -0.11 0.04 0.90 0.01
S3G4 -0.28 0.12 0.76 <0.05
S4G1 0.08 0.03 1.09 <0.05
S4G2 0.06 0.03 1.06 <0.05
S4G4 -0.43 0.12 0.65 <0.01
S8G3 -0.56 0.28 0.57 <0.05
Constant -3.25 0.28  I  0.04 <0.01
3.4  Univariate  Analysis  of  the  Global  Quality  of  the  Whole  Embryo
Cohort
Total  number and  % of good  (Grades  1   and 2) and  poor (Grades 3, 4 and  5) 
grade  embryos  created  in  the  whole  embryo  cohort  differed  significantly 
between  women  with  ongoing  pregnancy  and  with  no-ongoing  pregnancy 
(Table 3.14).  Number of good  grade embryos appeared to  have  more clinical 
significance  due  to  larger  differences  between  pregnant  and  non-pregnant 
women.
106Table 3.14: Good-Poor Grade Embryos for Ongoing Pregnancy
Ongoing Pregnancy N Mean ± SD P  I
Good Grade Embryos
No 5577 3.1  ±2.7
<0.01
Number of
Yes 2054 4.3 ± 2.8
Poor Grade Embryos
No 5578 1.5 ±2.0
0.01  I
Yes 2054 1.7 ± 2.1
Good Grade Embryos
No 5541 0.6 ±0.3
<0.01  I
%of
Yes 2050 0.7 ±0.2
Poor Grade Embryos
No 5542 0.3 ±0.3
<0.01
Yes 2050 0.2 ± 0.2
To assess the predictive power of the total number of good grade embryos for 
ongoing pregnancy, an ROC curve analysis under non-parametric assumptions 
was performed on 2054 cycles with ongoing pregnancy and 5577 cycles with no 
ongoing  pregnancy.  The  area  under  the  curve  0.64  signified  a  prognostic 
significance beyond a chance factor (p:>0.01). Sensitivity and specificity values 
were detailed  in the table with corresponding numbers of good grade embryos 
(Table 3.52CD).
An  arbitrary  cut-off  point  of three  good  grade  embryos  was  chosen  to  sub- 
categorise the study population.  In the group with >3 good grade embryos the 
probability of ongoing pregnancy was significantly higher than in the group with 
<3 good  embryos  (36%  vs  20%)  (Table  3.53CD).  Test sensitivity for ongoing 
pregnancy was 55-72%.
3.5  Descriptive Statistics of Variables of IVF (Quality of the Transferred 
Embryos and Embryo Transfer Procedure)
Descriptive details of the morphological development of the transferred embryos 
graded  1   to  6  and  developmental  stages  1   to  9  (indicating  the  number  of 
blastomeres)  were  given  (Table  3.15).  Descriptive  details  of  the  tip  of  the 
transfer  catheter,  tenaculum  and  stylet  use,  degree  of  discomfort  and 
procedural difficulty, and USG guidance during ET were detailed in the CD Rom 
(Table 3.29-3.34CD).
107Table 3.15: Clinical and Embryological Variables of Embryo Transfer
Mean ± SD N  |
Grade of the First Transferred Embryo 1.7 ±0.7 8013  I
Stage of the First Transferred Embryo 4.8 ±1.7 8003
Grade of the Second Transferred Embryo 1.9 ±0.8 7261
Stage of the Second Transferred Embryo 4.4 ± 1.6 7254
Grade of the Third Transferred Embryo 2.0 ± 0.8 5032  |
Stage of the Third Transferred Embryo 4.0 ± 1.6 5032  |
Number of Embryos Transferred 2.5 ± 0.6 9931  |
Embryo Transfer Time (sec) 53.6 ± 11.8 7345  |
3.5.1  Factors Related to the Quality of Transferred Embryos
Patients’  characteristics  and  clinical  variables  of  IVF,  which  correlated 
significantly  with  the  grade  and  the  stage  of  the  transferred  embryos  were 
summarized (Table 3.16). Positive correlation between the variables was given 
as “t ”, negative correlation as “i",  and no correlation as  Numerical values 
of the correlation coefficients and  corresponding  p values were detailed  in the 
CD Rom (Table 3.35-3.37CD).
Table  3.16:  Correlations  between  Patient  Characteristics,  Clinical  Variables  of  IVF  and  the 
Quality of Embryos Transferred
Female age
Duration of ovarian stimulation
1st Embryo  |  2nd Embryo  | 
____ Stagej „  Grade]__ Stagej
T  |  |  <-»  |  «->  |
_   ______« j ______ t]_ ....._.._...i.!
<->  j  i   j  <->  j  i   ]
i   f   " T i   f   ’   ’  Y i E2  level on the day of hCG administration
Number of oocytes collected
<
-
 
j
—
»
j
 
<
—
 
|
-
>
 
J
Number of 2-PN embryos created i
<
—
-
>
<
—
Number of cleavage stage embryos 1 1   t 1  11
Number of embryos cryopreserved i t   |  t
Number of embryos implanted t i   1   11
Stage of the 1st Embryo transferred T o I  t !
Stage of the 2n d  Embryo transferred 1 1   < ->  1   1
Stage of the 3rd  Embryo transferred 4 t !   1 !   1 1
Grade of the 2n d  Embryo transferred t |   o |  |  Y
Grade of the 3rd  Embryo transferred ..........1.1 ...........~ .!..........1.1 ............tl
t : Positive correlation between the variables, I : Negative correlation, <->: No significant correlation.
1083.5.2  Univariate Analysis
When  women  with  ongoing  pregnancy  and  no-ongoing  pregnancy  were 
compared,  there  were  significant  differences  in  the  following  variables 
respectively:  ET time  (52  sec vs  54),  number of embryos  transferred  (2.6  vs 
2.5),  stage  of the  first  (5  vs  4.8),  second  (4.6  vs  4.3)  and  third  (4.2  vs  3.9) 
embryos transferred, and grade of the first (1.6 vs  1.8), second  (1.8 vs 2), and 
third (1.9 vs 2.1) embryos transferred (Table 3.38CD).
The ongoing pregnancy rate was not affected by the condition of the catheter tip 
after the transfer,  degree of discomfort experienced  by the woman  during the 
transfer,  degree  of  technical  difficulty  of  the  transfer  as  assessed  by  the 
physician,  or the use of tenaculum,  stylet or ultrasound  guidance (Table 3.39- 
3.43CD).  There was  no link between the duration of the  ET and  its degree of 
technical difficulty (Table 3.44CD).
Biochemical  pregnancy,  miscarriage,  ectopic  pregnancy  and  ongoing 
pregnancy outcomes could not be differentiated by grade and stage of the best 
three embryos transferred or the total  number of good (1  and 2) and poor (3, 4 
and 5) grade embryos in the cohort (Table 3.45CD).
3.5.3  Multivariate Analysis
Logistic  regression  analysis  using  the  forward  selective  conditional  entry 
method was performed on 4953 cycles, to evaluate the individual contribution in 
the  prediction of ongoing  pregnancy rates,  of the  number,  grade and  stage of 
the embryos transferred.
The  stage  and  grade  of the first,  grade of the  second,  and  stage  of the third 
embryos  transferred  were  significant  predictors  of  ongoing  pregnancy  (Table 
3.17,  3.18).  After  correction  for  embryo  quality,  the  number  of  embryos 
transferred was no longer a significant determinant of the treatment outcome (p: 
0.69).
109Table 3.17:  Embryo Quality in the Equation for Ongoing Pregnancy
1 Regression Coefficient .......SE.1 OR  I
0.88  |
......... P.J
<0.05  | Grade of the 1st Embryo -0.12 0.05  |
I  Stage of the 1st Embryo 0.08 0.03  | 0.92  | <0.01
Grade of the 2n d  Embryo -0.16 0.05  | 0.85  j <0.01  !
I  Stage of the 3rd  Embryo 0.16 0.03  | 1.17  | <0.01  I
|  Constant -0.65 0.13  | 0.52  | <0.01  I
Table 3.18:  Variables not in the Equation for Embryo Quality and Ongoing Pregnancy
P
Number of Embryos Transferred NS  [
Stage of the 2n d  Embryo NS  |
Grade of the 3rd  Embryo ......_.......................NS
3.6  Multivariate Analysis of Patient Characteristics, Clinical Variables of 
IVF:  Ovarian  Stimulation,  Oocyte  Quality,  Fertilisation,  Individual 
Embryo  Quality,  Transferred  Embryo  Quality  for  Ongoing 
Pregnancy
Logistic  regression  analysis  using  the  forward  stepwise  conditional  entry 
method and the number of embryos transferred as the constant, was performed 
on  515  cycles  to  assess  the  prognostic  significance  of  different  clinical  and 
embryological  variables  in  the  prediction  of  ongoing  pregnancy  (Table  3.19, 
3.20).
Table 3.19: Independent Variables used in Logistic Regression Analysis
Female Age S2G1
Duration of Subfertility S2G2  |
Number of Previous IVF Attempts S3G1  |
Pre Stimulation FSH S3G2  |
Total Dose of Gonadotrophin S4G1  |
Duration of Ovarian Stimulation S4G2  |
hCG day E2 S6G1  |
Number of Aspirated Follicles S6G2  I
Number of Collected Oocytes _ Grade and Stage of the 1st Embryo  j
Number of  Mature Oocytes Grade and Stage of the 2n d  Embryo  |
Number of Borderline Oocytes Grade and Stage of the 3rd  Embryo  |
Number of 2PN Embryos Number of Cleavage Stage Embryos  |
I  Number of Cryopreserved Embryos  ]
110Table 3.20: Variables in the Equation for Ongoing Pregnancy
Regression Coefficient SE OR P  I
Female Age -0.13 0.03 0.88 <0.01  ]
Number of Aspirated Follicles 0.06 0.02 0.94 0.01  I
Grade of the 2n d  Embryo -0.32 0.15 0.73 <0.05  i
Stage of the 3rd  Embryo 0.18 0.08 1.20 <0.05  |
S2G2 0.27 0.08 1.31 <0.01  |
S4G2 0.22 0.08 1.25 <0.01
Constant 3.74 1.07 41.87 <0.01  ]
Inclusion of the % expression of the maturity of oocytes collected and fertilised 
did  not  alter the  most  prognostic  variables  found  in  the  first  analysis  (Table 
3.46-3.48CD).
3.7  Prognostic  Significance  of  Number  of  Embryos  Transferred  for 
Ongoing  Pregnancy with  Consideration of Quality of the Individual 
Embryos  and  the  Whole  Embryo  Cohort  (Number  of  Good  Grade 
Embryos)
Logistic regression  analysis was  performed to  predict ongoing  pregnancy rate 
by using female age,  number of embryos transferred,  and  number of embryos 
at different grade and stage of cell division as independent variables in couples 
who had <3 cleavage stage embryos available for transfer and  in couples who 
had  >3  cleavage  stage  embryos.  The  forward  stepwise  conditional  entry 
method was employed.
In  the  group  with  <3  cleavage  stage  embryos  available  for  ET,  number  of 
embryos transferred was  not found to be  prognostic once the effect of female 
age  and  embryo  quality  in  terms  of  number of embryos  at  different  stage  of 
development  and  morphological  grade  were  controlled.  In  the  group  with  >3 
cleavage stage  embryos  available for ET,  the  number of embryos transferred 
had a negative influence on the ongoing pregnancy rates where higher numbers 
were associated with lower pregnancy rates (Table 3.21).
I l lTable 3.21: Cleavage Stage Embryos in the Equation for Ongoing Pregnancy
Cleavage Stage 
Embryos
Regression Coefficient SE OR P
Age -0.11 0.02 0.90 <0.01
S4G1 0.59 0.16 1.80 <0.01
S4G2 0.48 0.12 1.61 <0.01
<3
S2G2 0.37 0.13 1.45 0.01
S3G1 0.72 0.37 2.05 0.05
S4G4 -1.80 1.02 0.17 NS
S9G2 1.29 0.68 3.62 NS
Constant 1.61 0.63 4.99 0.01
Age -0.09 0.01 0.92 <0.01
Number of ET -0.28 0.10 0.76 <0.01
S2G1 -0.12 0.05 0.89 0.01
>3 S3G4 -0.37 0.13 0.69 <0.01
S4G4 -0.43 0.12 0.65 <0.01
S8G3 -0.59 0.30 0.56 0.05
Constant 3.31 0.38 27.32 <0.01
Total  number of good  grade  (1  and  2) embryos  created  in the whole embryo 
cohort  and  the  number  of  embryos  transferred  differed  significantly  between 
women with ongoing pregnancy and with no-ongoing pregnancy (Table 3.22).
Table  3.22:  Number  of  Embryos  Transferred,  Good-Poor  Grade  Embryos  for  Ongoing 
Pregnancy
Ongoing Pregnancy N  Mean ± SD  j  p
Number of Embryos Transferred 
Good Grade Embryos Grade 1, 2
No
Yes
No
Yes
7181  I 
2476  | 
5577 
2054  i
1 ,5 ± 0 J J
2.6 ± 0.5  |  
3.1  ± 2.7  I  
4.3 ±2.8
<0.01
<0.01
Logistic  regression  analysis was  performed  to  predict the  ongoing  pregnancy 
rate  by using female age and  number of embryos transferred  as  independent 
variables in couples who had <3 good grade embryos available for transfer and 
in couples who had >3 good grade embryos. The forward stepwise conditional 
entry method was employed.
In  the  group  with  <3  good  grade  embryos  available  for  ET,  the  number  of 
embryos  transferred  was  found  to  be  prognostic.  In  the  group  with  >3  good 
grade  embryos  available  for  ET,  the  number  of  embryos  transferred  had  a
112negative influence on the ongoing pregnancy rates where higher numbers were 
associated with lower pregnancy rates (Table 3.23).
Table 3.23:  Number of Embryos Transferred,  Good-Poor Grade  Embryos  in the  Equation for 
Ongoing Pregnancy
Good Grade 
Embryos
|  Regression 
j  Coefficient SE OR P
Age -0.09 0.00 0.91 <0.01
<3 Number of Embryos 
Transferred 0.42 0.05 1.52 <0.01
Constant 0.87 0.31 2.40 <0.01
Age -0.07 0.00 0.92 <0.01
>3 Number of Embryos 
Transferred
-0.24 0.08 0.78 <0.01
Constant 2.68 0.33 14.67 <0.01
3.7.1  Analysis of Variables of IVF (Number of Cleavage Stage Embryos, Good 
Grade Embryos and Transferred Embryos) for Ongoing Pregnancy
If there were <3 cleavage stage embryos available for transfer but none of good 
grade,  a  higher  number  of  embryos  transferred  was  associated  with  higher 
probability  of ongoing  pregnancy.  If at  least  one  embryo  was  of good  grade 
there was no benefit in increasing the number of embryos transferred. This was 
more evident if all three embryos were of good grade. If there were >3 cleavage 
stage embryos available for transfer but none of good grade, then transferring a 
higher  number  of  embryos  was  associated  with  an  insignificantly  higher 
probability of pregnancy. If at least one of the embryos was of good grade there 
was  clearly  no  benefit  in  increasing  the  number of embryos  transferred.  This 
was more evident if three or more embryos were of good grade (Table 3.24).
113Table 3.24: Cleavage Stage and Good Grade Embryos for the Number of Embryos Transferred
(Continuous Variable)
Number of
Number of Embryos 
Transferred
Cleavage Stage 
Embryos
Good Grade 
Embryos
Ongoing
Pregnancy
N Mean SD P
0
No 537 1.8 0.8
0.01
Yes 36 2.2 0.7
1
No 811 1.6 0.7
NS
<3
Yes 119 1.7 0.7
2
No 634 2.3 0.4
NS
Yes 149 2.3 0.4
3
No 374 2.9 0.3
NS
Yes 110 2.8 0.3
0
No 220 2.8 0.3
............
NS
Yes 69 2.9 0.2
1
No 223 2.8 0.3
NS
Yes 74 2.7 0.4
>3 2
No 337 2.8 0.3
NS
Yes 121 2.8 0.3
3
No 446 2.9 0.3
<0.01
Yes 229 2.7 0.4
>3
No 1994 2.7 0.4
<0.01
Yes 1147 2.6 0.4
If there were <3 cleavage stage embryos available for transfer but none of good 
grade, transferring  all  available embryos was associated with an  insignificantly 
higher probability of pregnancy (8.9% vs 5.3%,  p:  0.08).  If at least one embryo 
was  of good  grade  there was  no  benefit  in  transferring  >2  embryos.  If there 
were >3 cleavage stage embryos available for transfer but none of good grade, 
then  3-embryo  transfer  provided  an  insignificantly  higher  probability  of 
pregnancy than <3-embryo transfer (24.6% vs 18.2%, p: 0.28). If at least one of 
the embryos was of good grade there was no benefit in transferring >2 embryos 
(Table 3.25).
114Table 3.25: Cleavage Stage and Good Grade Embryos for the Number of Embryos Transferred
(Categorical Variable)
Number of
.......
| Number of 
Embryos 
Transferred
Cleavage
Stage
Embryos
Good Grade 
Embryos
Ongoing
Pregnancy
<3 3
Pregnancy
Rate P
<3
0
No 94.7% 91.1%
6.3% NS
Yes 5.3% 8.9%
1
No 87.5% 85.9%
12.8% NS
NS
Yes 12.5% 14.1%
2
No 80.8% 81.3%
19.0%
Yes 19.2% 18.7%
3
No 71.2% 78.0%
22.7% NS
Yes 28.8% 22.0%
>3
0
No 81.8% 75.4%
23.9% NS
Yes  |  18.2% 24.6%
1
No  |  61.9% 77.3%
24.9% <0.05
Yes  38.1% 22.7%
2
No 70.4% 74.2%
26.4% NS
Yes 29.6% 25.8%
3
No 46.4% 69.4%
33.9% <0.01
............
Yes 53.6% 30.6%
>3
No  I  55.6% | 66.4%
36.5% <0.01
Yes  44.4% 33.6%
3.8  Prognostic  Significance  of  Number  of  Embryos  Transferred  for 
Ongoing  Pregnancy  with  Consideration  of  Patient  Characteristics 
and Variables of IVF (Fertilisation)
When the information for embryo quality is not available for assessment, clinical 
surrogate markers can be used to define a good prognostic subgroup where the 
number of embryos transferred is no longer an influential factor for the outcome. 
In  the  following  section,  patient  characteristics  and  variables  of  in  vitro 
fertilisation were used as surrogate markers for embryo quality.
The prognostic value for the prediction of ongoing pregnancy of different cut-off 
levels  of  female  age,  duration  of  subfertility  and  number  of  cleavage  stage 
embryos was calculated using a series of ROC curve analyses.  Female age at 
35 years  had a sensitivity of 40-51%,  at 38 years  15-21%,  and  at 40 years 5- 
9%. Duration of subfertility at four years had a sensitivity of 45-61% and at eight
115years 12-17%. Three cleavage stage embryos had a sensitivity of 85-99%, five 
55-72% and 10 a sensitivity of 6-11 % (Table 3.54-3.56CD).
These cut-off levels selected by the ROC curve analysis for female age (35, 38, 
40  years),  duration  of subfertility (4,  8  years),  and  number of cleavage  stage 
embryos (3, 5, 10) were applied to the whole study population to define the sub­
groups. Ongoing pregnancy rates differed significantly between the sub-groups 
(Table 3.57-3.64CD).  Hence, these variables were used  as surrogate markers 
with  prognostic  significance  to  evaluate  the  importance  of  the  number  of 
embryos transferred.
When  the  whole  study  population  was  evaluated,  the  number  of  embryos 
transferred was  significantly different between the  pregnant and  non-pregnant 
groups.  The  mean  number of embryos transferred  in the  pregnant group was 
2.68 and in the non-pregnant group 2.55.  In the pregnant group, 69.1% of ETs 
were 3-embryo transfers as opposed to 63.7% in the non-pregnant group (Table 
3.26, 3.27). Next, the study population was evaluated by sub-group analysis.
Table 3.26: Number of Embryos Transferred for Ongoing Pregnancy (Continuous Variable)
Number of Embryos Transferred
Ongoing
Pregnancy
N 7180
No
Median 3.0
SD 0.7
Yes
N 
Mean 
Median
2475|
2,6 |
3.0  I
<0.01
SD 0.5
Table 3.27: Number of Embryos Transferred for Ongoing Pregnancy (Categorical Variable)
Number of Embryos 
Transferred N Percent  j
1 846 11.8  |
No 2 1756 24.5  |
Ongoing 3 4578 63.7  |
Pregnancy 1 71 2.9  |
Yes 2 692 28.0  |
3 1712 69.1  |
116Number  of  embryos  transferred  was  still  significantly  higher  in  the  pregnant 
group when compared with the non-pregnant group in all sub-groups defined by 
female age (£35 or >35 years; <38 or >38 years; £40 or >40 years,  Table 3.65- 
3.67CD),  duration  of subfertility (£4 or >4 years;  £  8 or >8 years,  Table 3.68, 
3.69CD)  and  all  their combinations  (female  age  <35  years  with  a  duration  of 
subfertility <4 years; <35 years with a duration of subfertility >4 years; >35 years 
with  a duration of subfertility <4;  >35 years with  a duration of >4 years,  Table 
3.70CD). This was also true for women £38 or >38 years; £40 or >40 years with 
a duration of subfertility: £4 or >4 years; or £ 8 or >8 years (Table 3.71-3.75CD).
Therefore,  female  age  and  duration  of  subfertility,  either  alone  or  in 
combination, failed to identify a sub-population where the probability of ongoing 
pregnancy  is  independent  of  the  number  of  embryos  transferred.  Numerical 
embryological data were then incorporated into the analysis.
In couples with £3 cleavage stage embryos, a greater number of embryos were 
transferred in the pregnant group when compared with the non-pregnant group 
(2.3 vs 2.1; p: <0.001); with >3 embryos, fewer embryos were transferred in the 
pregnant group compared with the non-pregnant group (2.7 vs 2.8;  p:  <0.001, 
Table 3.76CD).
As the cut-off level increased from 3 to 12 cleavage stage embryos available for 
ET,  a similar trend  was  maintained  (Table  3.77-3.81 CD).  Furthermore,  as the 
cut-off levels increased, the probability of pregnancy improved for couples with 
a greater number of embryos created and the number of embryos required for 
pregnancy was progressively reduced (2.7 for 3 cleavage stage embryos to 2.5 
for  12  cleavage  stage  embryos)  (Table  3.76-3.81CD).  Nevertheless,  a  cut-off 
number of embryos as low as three showed significant differences between the 
pregnant and non-pregnant groups.
Although statistically significant,  small differences at decimal  level  in the mean 
number of embryos transferred is not helpful  in clinical  practice. Therefore, the 
significance  of  number  of  embryos  transferred  in  the  prediction  of  ongoing 
pregnancy  was  reanalysed  using  categorical  variables  of  <3-  or  3-embryo
117transfer.  Female age, duration of subfertility and the number of cleavage stage 
embryos were used as surrogate clinical markers of embryo quality.
In  poor  prognostic  groups  (women  with  a  lower  number  of  cleavage  stage 
embryos  available  for  transfer),  transferring  3  embryos  persistently  provided 
higher  ongoing  pregnancy  rates  than  transferring  <3  embryos.  Furthermore, 
regardless  of  whether  3  or  <3  embryos  were  transferred,  pregnancy  rates 
increased progressively with increasing availability of cleavage stage embryos. 
Although,  a  5%  difference  in  pregnancy rates was  maintained  between  3  and 
<3  embryos  transferred  with  up  to  9  cleavage  stage  embryos  available,  the 
impact of higher numbers of embryos transferred  become less obvious (Table 
3.28).
In  good  prognostic  groups  (women  with  a  higher  number of  cleavage  stage 
embryos available), transfer of <3 embryos persistently provided higher ongoing 
pregnancy rates than  3-embryo transfer.  Furthermore,  regardless  of 3- or <3- 
embryo  transfer,  pregnancy  rates  did  not  alter  appreciably  with  increasing 
availability of cleavage stage embryos. At cut-off levels up to 9 cleavage stage 
embryos  created,  with  <3-embryo  transfer,  the  ongoing  pregnancy  rate  was 
maintained at 42-43% and with 3-embryo transfer at 31-34% (Table 3.29).
Table 3.28: Number of Embryos Transferred in Sub-groups of Cleavage Stage Embryos in the 
Poor Prognostic Group for Ongoing Pregnancy
Number of Ongoing Pregnancy
P
Cleavage Stage Embryos Embryos Transferred No Yes
<12
<3 75.4% 24.6%
<0.01
3 72.1% 27.9%
£10
<3 76.0% 24.0%
<0.01
3 72.2% 27.8%
£9
<3 76.6% 23.4%
<0.01
3 72.5% 27.5%
<6
<3 80.4% 19.6%
<0.01
3 75.0% 25.0%
<3
<3 86.8% 13.2%
<0.01
3 82.2% 17.8%
118Table 3.29:  Number of Embryos Transferred  in  Sub-groups of Cleavage Stage Embryos  in the
Good Prognostic Group for Ongoing Pregnancy
Number of Ongoing Pregnancy
P
Cleavage Stage Embryos Embryos Transferred No Yes
>12
<3_____________________
3
64.6%
66.1%
35.4%
33.9%
NS
>10
<3 59.9% 40.1%
NS
3 67.9% 32.1%
>9
<3 58.5% 41.5%
<0.05
3 66.5% 33.5%
>6
<3 57.8% 42.2%
<0.01
3 66.1% 33.9%
>3
<3 56.8% 43.2%
<0.01
.  _ 3 69.0% 31.0%
3.9  Univariate Analysis  of Patient Characteristics and Variables  of IVF 
(Ovarian Stimulation) for Number of Embryos Implanted
Clinical  and  embryological  parameters  were  evaluated  for their distribution  in 
four outcome categories defined as no-implantation,  and single, two and  more 
than  two  gestational  sacs  detected  at  the  time  of  first  ultrasonographic 
assessment following positive pregnancy test (Table 3.30).
Among  the four outcome  groups,  the following  variables  differed  significantly: 
female  age,  early  follicular  phase  FSH  concentration,  gravidity,  duration  of 
subfertility, number of previous IVF cycles, total gonadotrophin dose, duration of 
ovarian  stimulation,  number  of  developing  follicles,  endometrial  thickness, 
number  of  oocytes  collected,  number  of  2-PN  embryos  created,  number  of 
embryos transferred, and number of embryos cryopreserved (Table 3.31).
There  was  a  significant  variation  in  female  age,  the  number  of  oocytes 
collected,  and  2-PN  embryos  created  when  the  no-implantation  group  was 
compared with the singleton implantation group, and the singleton implantation 
group with the multiple implantation groups. The difference between the multiple 
implantation groups was not significant (Table 3.82CD).
The  difference  between  the  number  of  embryos  transferred  was  significant 
when the no-implantation group was compared with the singleton  implantation
119group  and  the  singleton  implantation  group  with  the  multiple  implantation 
groups.  The  difference  between  the  multiple  implantation  groups  was  also 
significant (Table 3.82CD).
Table 3.30: Frequency Distribution of the Number of Embryos Implanted
Number of Embryos Implanted Frequency Percent  |
0 6658 68.6
1 2018 20.8
2 853 8.8  |
3 168 1.7  |
4 3 0.0  I
Table 3.31: Distribution of the Clinical Variables among the Number of Embryos Implanted
Embryos
Implanted
N Mean ± SD P
0 6659 35.6 ± 5.0
Female Age (year)
1 2019 34.3 ± 4.4
<0.01
2 853 33.1  ±3.8
>3 171 32.8 ± 4.0
0 6605 9.7 ± 5.8
Oocytes Collected
1 2019 10.8 ±5.8
<0.01
2 853 12.2 ±5.5
>3 171 12.2 ±5.5
0 6659 1.9 ± 1.4
Previous IVF Cycles 1 2019 1.7 ± 1.2
<0.01
2 853 1.6± 1.0
>3 171 1.8 ± 1.1
0 5203 5.4 ± 3.7
Duration of Subfertility (year)
1 1560 4.9 ± 3.3
<0.01
2 705 4.6 ±3.1
>3 142 4.9 ±2.9
0 6659 0.6 ± 1.1
Previous Pregnancies
1 2019 0.6 ± 1.0
0.04
2 _______ 853 0.7 ±1.1
>3 171 0.7± 1.2
0 5154 2925 ± 
1262
Total Gonadotrophin Dose (IU) 1 1558 2633 ± 
1537 <0.01
2 731 2425 ± 922
>3 142 2448 ± 999
0 5147 11.0 ± 3.1
Duration of Ovarian Stimulation (day)
1 1558 10.9 ±2.8
0.05
2 733 11.3 ±3.3
>3 140 11.9 ±4.4
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Implanted N Mean ± SD P
0 5173 3.3 ±2.9
8-12 mm
1 1566 3.6 ±3.0
<0.01
2 737 4.2 ± 3.2
>3 142 4.3 ±3.3
0 5173 4.0 ± 2.9
13-16 mm
1 1566 4.7 ±3.3
<0.01
2 737 5.0 ±3.1
Number of
Follicles
Measuring
>3 142 5.2 ±2.9
0 5173 3.7 ± 2.6
17-19 mm
1 1566 4.1 ±2.7
<0.01
2 737 4.5 ±2.8
>3 142 4.6 ± 2.9
0 3596 1.8 ±2.2
>20 mm J_ _ _ _ _ _ _ _
2
1089
521
1.9 ±2.3 
2.0 ±2.0
NS
------------------------- ------------------------------------ >3________
0
87
5097
1.5 ± 1.4 
11.0 ± 1.7
Endometrial Thickness (mm) 1 1544 11.3 ±1.7
<0.01
; 2 : _____728 11.4 ± 1.7
>3 141 11.5 ± 1.9
0 2548 6.09 ±4.57
1 782 5.90 ±3.41
NS IIV -/0  U d y C .2 [lUIIVI/lj
2 394 6.41  ± 3.38
>3 57 6.24 ± 3.34
0 2642 6.6 ± 3.4
1 801 6.4 ±2.9
<0.01 r re s u m u ic u io ri ron U u/lJ
2 370 6.0 ±2.5
>3 68 5.8 ±2.7
2-PN Embryos
Number of Embryos Transferred
Number of Embryos Cryopreserved
5.1 ± 3.7
6.2 ±3.8
7.4 ± 3.9
7.9 ± 3.5
2.5 ±0.7
2.6 ± 0.6
2.7 ±0.4
2.9 ±0.2
1.0 ±2.5
1.5 ± 3.1
2.4 ± 3.6
2.7 ±3.5
121Embryos
Implanted
N  | Mean ± SD P  I
0 1529  | 0.23 ± 0.36 I
Early Follicular Phase 
Pre-stimulation E2  (nmol/l)
1 470  | 0.23 ±0.52
NS
2 224  | 0.28 ± 1.21
>3 ______ ?8j 0.21  ±0.18
Both  singleton  and  twin  implantations were  reduced  in  cycles  complicated  by 
ovarian  cysts  after  down-regulation  but  the  differences  did  not  reach 
significance  (p:  0.06).  Both  singleton  and  twin  implantations  were  reduced  in 
cycles  complicated  by  sonographically  detectable  hydrosalpinx  but  the 
differences did not reach significance (p: 0.3) (Table 3.83, 3.84CD).
Of  all  singleton  deliveries,  59%  had  one,  34%  had  two  and  7%  had  three 
embryos  implanted.  Of the  twin  deliveries,  80%  had  two  and  20%  had  three 
embryos  implanted.  Of the triplet deliveries,  98%  had  three  and  2%  had  four 
embryos implanted (Table 3.85-3.87CD).
3.9.1  Univariate Analysis of Patient Characteristics and Variables of IVF
(Transferred-Embryo Quality) for Singleton vs Multiple Pregnancy
There were significant differences when the following variables were compared 
between singleton and multiple pregnancies respectively: Female age ( 34.3 vs
33.1  years), duration of subfertility (5 vs 4.6 years), number of oocytes collected 
(10.8  vs  12.2),  number  of  2-PN  embryos  created  (6.2  vs  7.5),  number  of 
embryos transferred  (2.6 vs 2.8), grade of the first (1.7 vs  1.5),  second (1.9 vs 
1.7) and third  (2 vs  1.9) embryos transferred, stage of the second  (4.5 vs 4.7) 
and  third  (4  vs  4.4)  embryos  transferred,  and  number  of  cleavage  stage 
embryos created (5.6 vs 6.7) (Table 3.88CD).
3.9.2  Univariate Analysis of Patient Characteristics and Variables of IVF
(Transferred-Embryo Quality) for Singleton vs Twin vs  High-order 
Multiple Pregnancy
The following variables differed significantly when compared between singleton, 
twin  and  high  order  pregnancies  respectively;  female  age  (34  vs  33  vs  32 
years),  number of oocytes  collected  (10.8  vs  12.2  vs  12.3),  number of 2-PN 
embryos created (6 vs 7 vs 8), number of embryos transferred (2.6 vs 2.7 vs 3), 
grade of the first (1.7 vs  1.5 vs  1.5), second (1.9 vs  1.7 vs  1.6) and third (2 vs
1221.9  vs 1.8) embryo transferred, stage of the second (4.5 vs 4.7 vs 5) and third (4 
vs  4.3  vs  4.7)  embryo  transferred,  and  number  of  cleavage  stage  embryos 
created (5.6 vs 6.7 vs 7) (Table 3.89CD).  None of the observed differences in 
these  variables  between  twin  and  high  order  pregnancies  were  significant, 
except the number of embryos transferred (p:<0.001).
3.9.3  Multivariate  Analysis  of  Patient  Characteristics  and  Variables  of
IVF  (Transferred-Embryo  Quality)  for  Singleton  vs  Multiple 
Pregnancy
After  excluding  women  with  no  pregnancy,  logistic  regression  analysis  was 
performed on 2400 cycles to predict multiple pregnancy by female age, duration 
of  subfertility,  number  of  2-PN  embryos  created  and  number  of  embryos 
transferred as independent variables (Table 3.32).
After the effect of female age and number of 2-PN embryos was corrected, the 
number of embryos  transferred  remained  the  most  influential  variable  on  the 
multiplicity  of  pregnancy,  unlike  in  the  prediction  of  pregnancy  where  the 
number  of  embryos  transferred  lost  significance  after  correction  for  other 
variables.
Table 3.32: Variables in the Equation for Multiple vs Singleton Pregnancy (1)
Regression Coefficient SE OR P  I
Age -0.08 0.01 0.92 <0.01  I
2-PN Embryos 0.07 0.01 1.07 <0.01  I
Transferred Embryos 0.64 0.08 1.90 <0.01  I
Further logistic regression analysis using the forward stepwise conditional entry 
method was performed on 1579 cycles of ongoing pregnancy to predict multiple 
pregnancy with  a  more comprehensive  range of independent variables  (Table 
3.33).
Table 3.33: Independent Variables used in Logistic Regression Analysis
|~Age_______________________________I  Transferred  embryos_______________________
Duration of Subfertility    [  Grade and Stage of the 1st ET_________
2-PN Embryos  __  _     [  Grade and Stage of the 2n d   ET
I  Cleavage Stage Embryos_____________ [  Grade and Stage of the 3rd   ET_______________
123After  the  effect  of  embryo  quality,  number  of  cleavage  stage  embryos  and 
female age were corrected the number of embryos transferred remained as the 
most significant predictor of multiple pregnancy (Table 3.34).
Table 3.34: Variables in the Equation for Multiple vs Singleton Pregnancy (2)
Regression Coefficient SE OR P
..Age................................ -0.09 0.01 0.91 <0.01
Transferred Embryos 0.99 0.18 2.70 <0.01
Grade of the 1st ET -0.28 0.10 0.75 <0.01
Grade of the 2n d   ET -0.31 0.09 0.73 <0.01
Stage of the 3rd   ET 0.09 0.03 1.09 0.01
Cleavage Stage Embryos 0.07 0.02 1.07 <0.01
1244  Factors Affecting IVF Outcome: Discussion
Using univariate analysis, clinical and embryological variables of IVF cycles with 
prognostic  significance  in  the  probability  of  ongoing  pregnancy  and  multiple 
pregnancy were  identified.  The list of variables was then  narrowed  by logistic 
regression  analysis  to  include  only  the  variables  with  the  highest  prognostic 
significance and clinical  relevance.  Different cut-off levels for these short-listed 
variables were then  tested  by ROC  curve analysis for their diagnostic  power. 
Using  these  cut-off  levels,  the  study  population  was  divided  into  sub­
populations.  The prognostic significance of the number of embryos transferred 
was  tested  by  comparing  the  number  of  embryos  transferred  in  each  sub­
population.
4.1  Analysis  of  Patient  Characteristics  and  Clinical  Variables  of  IVF 
(Ovarian Stimulation) for Ongoing Pregnancy
The treatment outcome in IVF cycles was closely associated with the response 
of the ovaries to gonadotrophin stimulation and this was evident in both the pre­
stimulation  surrogate  markers  of ovarian  reserve  and  the  variables  of actual 
stimulation.
Younger women  with  a  shorter duration  of subfertility and  fewer previous  IVF 
attempts  were  more  likely  to  achieve  ongoing  pregnancy  (Table  3.4,  Table 
3.13CD).  These  findings  are  in  close  agreement  with  those  in  the  published 
literature.
Female  age  is  cited  as  the  single  most  important  factor  determining  the 
outcome of fertility treatment8,14,15,16,19,20.  Several others also conclude that the 
chances  of  successful  live  births  after  IVF  drop  significantly  with  increased 
female age16,17,18.  Van  Kooij et.  al.22 reports a steeper decline after the age of 
37 years. Stolwijk et. al.23 reports a simple linear effect.
It is well established that increased duration of fertility delay is associated with a 
reduced  possibility  of  conception  in  both  treated  and  untreated  subfertile 
couples even after adjustment for female age8.
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treatment  cycle  is  highest  in  the  first  cycle  and  decreases  significantly  with 
increasing numbers of previous treatment cycles, after adjusting for female age. 
The  same  finding  is  reported  by  the  French  Registry  on  IVF42.  However, 
Croucher  et.  al.20  report  that  the  chance  of  pregnancy  after  a  single  IVF 
treatment  cycle  remains  constant  for  the  first  three  attempts  and  only 
subsequently begins to decline. Likewise, smaller studies report a constant rise 
in the cumulative success rate up to six cycles46,48.
Lower pre-stimulation  FSH  values were observed  in ongoing  pregnancy when 
compared with the non-pregnant and no-ET groups.  More importantly, in these 
outcome groups,  FSH  levels were well  below the traditionally accepted  upper 
limit of  10  IU/I  for good  prognosis  (Table  3.4,  Table  3.13CD).  This  implies  a 
dose  response  relationship  between  ovarian  reserve  and  the  treatment 
outcome.  This  is  valid  even  when  the  rise  in  FSH  levels  occurs  within  the 
normal  range66,67'68.  Basal  serum  FSH  levels  reflect  the  number  of  antral 
follicles  ready for  recruitment62  and  rising  levels  of early follicular phase  FSH 
reveal  a  reduction  in  the  size of this follicular cohort30,31,36,  with  fewer follicles 
developed, fewer oocytes collected, and fewer embryos created in response to 
gonadotrophin stimulation63,64,65,67,69,85,86.
Likewise, cycles with ongoing pregnancy were characterised by higher levels of 
ovarian response than non-conception cycles. This relationship also manifested 
in  a  dose  response  pattern,  whereby  the  poorest  response  was  usually 
associated  with  the  highest  probability  of  no-ET.  The  treatment  cycles  that 
produced  more  follicles  and  oocytes  with  less  intensive  gonadotrophin 
stimulation and higher E2 concentrations with thicker endometrium  before hCG 
injection,  were  more  likely  to  have  a  successful  outcome.  A  functional 
association  between  qualitative  and  quantitative  ovarian  response  became 
evident  with  the  high  E2  levels  linked  to  the  high  number  of  follicular 
development and subsequently to the collection of a greater number of oocytes 
and the creation of a greater number of embryos.  Hence the women who had a 
higher number of embryos had a higher chance of pregnancy.  In the pregnant 
group,  a thicker endometrium also reflected the presence of a responsive end
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synchrony for implantation (Table 3.4, Table 3.13CD).
In subgroup analyses, the distribution of these variables in different pregnancy 
outcomes was  evaluated  (Table  3.16CD). The women who  achieved  ongoing 
pregnancy were significantly younger than those in the no-ET, no-pregnancy, or 
miscarriage group, but not younger than women who had ectopic pregnancy or 
biochemical  pregnancy.  This  emphasised the age  effect over ovarian  reserve 
and ovarian response capacity in the genesis of pregnancy and miscarriage. To 
exemplify this contention more precisely, in cycles with ongoing  pregnancy the 
number of oocytes  collected  was  significantly  higher than  in  miscarriage,  no­
pregnancy and  no-ET  cycles,  but  not higher than  cycles  leading to ectopic or 
biochemical  pregnancy.  The  same  trend  was  maintained  for  duration  of 
subfertility,  total  gonadotrophin  dose  required  for  ovarian  stimulation,  and 
number of embryos created and cryopreserved. All of these variables complied 
with a common theme that better ovarian response leads to less miscarriages 
and better ongoing pregnancy rates. Although the pre-stimulation FSH levels of 
women who would  achieve ongoing  pregnancy was  significantly lower than  in 
the  no-ET  or  no-pregnancy  women,  there  was  no  significant  difference  in 
women  who  would  miscarry.  This  manifests  in  the  limitation  of  surrogate 
markers to  represent the full  spectrum  of the  biological  processes.  When  the 
contrast between the outcomes was distinct, as in the case of the dichotomous 
outcomes of pregnant vs  non-pregnant,  surrogate  markers  like FSH tended to 
function  better.  However, when the difference between outcomes was gradual 
over a wide transition,  as  in  the  case  of biochemical  pregnancy,  miscarriage, 
and ongoing  pregnancy, the discriminative power of FSH did  not reach a level 
of significance (Table 3.16CD).
Endometrial thickness  measured on the day of hCG  injection was significantly 
higher  in  women  with  ongoing  pregnancy than  in  miscarriage,  no-pregnancy 
and  no-ET  cycles.  However,  the  measurements  were  very  similar,  within 
fractions of a millimetre. Therefore, despite emphasising the key role of physical 
development  in  endometrial  receptivity,  the  clinical  application  of endometrial 
thickness is limited for practical reasons.  It is of note that the mean endometrial
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and  so  this  clinical  observation  alone  should  not  be  used  for  differential 
diagnosis (Table 3.16CD).
Sonographically  visible  hydrosalpinx  decreased  the  ongoing  pregnancy  rate 
without  affecting  the  prevalence  of  no-ET  cycles.  Furthermore,  hydrosalpinx 
doubled the incidence of biochemical pregnancy but did not alter the probability 
of  miscarriage  (Table  3.15,  3.18CD).  Tubal  factor  itself  did  not  affect  the 
biochemical pregnancy rate.  Hence hydrosalpinx should present a unique toxic 
effect on  implantation.  This  may  provide circumstantial  evidence that its toxic 
effect  is  dose  dependent  and  likely  to  affect  implantation  with  premature 
termination  rather  than  through  the  ovarian  response494.  Somewhat 
unexpectedly, no ectopic pregnancy was observed in this group.
The  presence  of ovarian  cysts following  down-regulation  significantly reduced 
the chances of ongoing pregnancy and was associated with a higher probability 
of no-ET. Ovarian cysts may exert this negative effect either through altering the 
paracrine  milieu  in  the  ovary,  thereby  suppressing  follicular  recruitment  and 
maturity,  or  by  exerting  a  space  occupying  effect  on  the  remaining  ovarian 
tissue  and  physically  restraining  its  response  to  stimulation  (Table  3.14, 
3.17CD).
The  number  of  embryos  transferred  had  an  influence  on  the  chances  of 
pregnancy  (this  will  be  detailed  in  the  following  sections),  but  no  prognostic 
determination was noted over the outcome of pregnancy in terms of miscarriage 
or biochemical or ectopic pregnancy (Table 3.4, Table 3.13, 3.16CD).
Following these univariate analyses, logistic regression analysis was performed 
on  2109  cycles  to  predict  the  independent  prognosticators  of  ongoing 
pregnancy.  A  wide  range  of  clinical  variables  was  studied,  including  the 
demographic  characteristics  of  couples,  details  of  ovarian  stimulation  and 
ovarian response. Female age, duration of subfertility, total gonadotrophin dose, 
number of oocytes collected, number of 2-PN embryos created, and number of
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3.5).
The  univariate  and  multivariate  analyses  revealed  the  same  finding  by 
emphasising  the  pivotal  role  of ovarian  reserve  (female  age),  severity  of the 
pathology  behind  subfertility  (duration  of subfertility)  and  the  level  of ovarian 
response, for determining pregnancy.  However, logistic regression analysis has 
shown  that  pre-stimulation  FSH  levels,  E2  concentrations  and  endometrial 
thickness before hCG  injection, aetiology of subfertility,  previous  IVF attempts, 
presence  of  hydrosalpinx  or  ovarian  cysts,  number  of  ovarian  follicles  and 
cryopreserved embryos lost their prognostic significance once their confounding 
effects  were  corrected  against  each  other.  This  is  because  different  clinical 
variables  can  surrogate  the  same  underlying  physiological  process  but  with 
varying levels of association. Regression analyses tend to select those with the 
highest level of association.
4.2  Factors Related to Oocyte Maturity
The  clinical  variables  characterising  the  demographic features  of the  patients 
and  the  response  parameters  of  the  ovarian  stimulation  were  analysed  in 
12,332  cycles  to  establish  the  most  informative  surrogate  markers  of oocyte 
quality (Table 3.6, 3.7,  Table 3.19-3.26CD).
The number of mature oocytes correlated negatively with  both female age and 
early follicular phase  FSH  concentration, confirming the clinical value of these 
two  most commonly employed  surrogate variables  in the  prediction of ovarian 
reserve. The number of mature oocytes was also positively associated with the 
number  of  previous  pregnancies.  This  observation  not  only  highlighted  the 
clinical  value  of  the  obstetric  history  as  a  surrogate  variable  for  the  current 
probability  of  pregnancy,  but  also  provided  circumstantial  evidence  for  the 
presence of a functional quality shared by the collectable oocytes in the ovary.
The  number  of  mature  oocytes  increased  with  the  total  number  of  collected 
oocytes. This was not just a simple mathematical equation but also highlighted 
the positive correlation between qualitative and quantitative ovarian response to
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correlation  of  the  number  of  mature  oocytes  to  the  number  of  developing 
follicles and  E2 level before hCG injection.  Further evidence of the association 
between  optimum  follicular  size  and  oocyte  maturity,  was  the  observed 
correlation  coefficient  of  follicles  measuring  13-19mm  being  twice  that  of 
follicles  measuring  <13mm  and  six times  that  of follicles  measuring  >20mm. 
Hence, follicular development to >20mm should not be encouraged to optimise 
oocyte  maturity.  Moreover,  a  negative  correlation  of  the  number  of  mature 
oocytes  with  immature  oocytes  probably  reflects  the  biological  tendency  of 
ovaries to support one dominant cohort of growth.
It  is  likely  that  the  potential  to  provide  mature  oocytes  on  stimulation  is  an 
intrinsic  response  capability  of  the  ovaries.  The  number  of  mature  oocytes 
correlated  negatively  with  the  total  gonadotrophin  dose  required  for  ovarian 
stimulation and with the duration of stimulation. Although quantitative response 
may  be  augmented  by  utilising  more  aggressive  stimulation  protocols  this  is 
less likely to improve the qualitative response.
The literature provides supporting evidence for this contention in reporting that a 
low number of developing follicles is associated with  poor oocyte  and  embryo 
quality495 and  reduced  embryo viability496.  In  a  study of poor  responders,  no 
improvement  is  reported  in  any  of  the  stimulation  parameters  when  six 
ampoules  of FSH  were  used  instead  of four497.  In  a  prospective  randomized 
study, van-Hooff et. al.498 report that increasing the daily gonadotrophin dose to 
>225  IU  fails  to  improve  the  ovarian  response  in  poor  responders.  Similar 
studies comparing recombinant FSH  100 IU vs 200 |(j499,500 and  150 IU vs 200 
IU5 0 1   report that pregnancy rates are not influenced by gonadotrophin doses. In 
a group of woman with a first cycle abandoned due to poor response, increased 
gonadotrophin  dosage  does  not  appear  to  improve  outcome  in  subsequent 
treatment502.  While  a  large  number of ampoules  can  marginally  increase  the 
probability of collecting  oocytes,  this  might also  be associated  with decreased 
probability  of  fertilization  and  of  implantation  of  the  resulting  embryos19.  A 
detrimental effect of high dose gonadotrophin stimulation in relation to the zona 
pellucida thickness is suggested by Bertrand et. al.503 who conclude that a small
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translated into any other quality improvement in embryological variables.
The  number  of  mature  oocytes  was  linked  to  better  treatment  outcome  and 
correlated  positively  with  the  number  of  2-PN  embryos  created,  number  of 
embryos cryopreserved and the number of embryos implanted (Table 3.7).
Because  the  number  of  mature  oocytes  is  a  function  of the  total  number of 
oocytes  collected,  the  same  analyses  were  repeated  with  the  percentage  of 
mature oocytes.  In mathematical terms, this parameter was independent of the 
total numbers.  The results revealed the same associations, with the exception 
of E2 levels on the day of hCG administration, which lost its association with the 
percentage of mature oocytes. However, serum E2  levels continued to correlate 
with  the  percentage  of  immature  follicles.  Hence,  serum  E2  level  was  not  a 
reliable surrogate marker for high oocyte quality. The positive link between the 
percentage  of  immature  oocytes  and  E2   levels  also  explains  the  positive 
association  observed  between  the  percentage  of  immature  oocytes  and  the 
endometrial thickness, which was missing in the case of mature oocytes.
The  percentage  of  immature  oocytes  correlated  positively  with  the  total 
gonadotrophin dose and the duration of ovarian stimulation, but mature oocytes 
did  not.  Hence,  this  is  a  further  verification  that  employing  aggressive 
stimulation  regimens  will  mostly  help  to  increase  the  immature  but  not  the 
mature oocyte response.
Unlike  mature  oocytes,  the  implantation  potential  of  embryos  created  by 
immature oocytes was significantly lower. This contention was supported  by a 
negative association with the number of implanted embryos and the percentage 
of immature oocytes, as opposed to a positive association with the percentage 
of mature oocytes.  Therefore,  a  negative association  between  higher levels of 
gonadotrophin  stimulation  and  the  chances  of  implantation  and  pregnancy  is 
apparent.
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and early follicular phase FSH concentration. Accelerated follicular development 
and  oocyte  maturation  occurs  in  older women,  due  to  higher  early  follicular 
phase FSH concentrations. This was not unique to spontaneous cycles but was 
also observed in stimulated cycles. Replacing the role of high endogenous FSH 
concentration,  the  intensity  of  gonadotrophin  stimulation  was  found  to  be 
associated  with  the  post-maturity  of  oocytes.  The  number  of  post-mature 
oocytes correlated positively with the number of developing follicles, particularly 
those  measuring  >20mm.  Furthermore,  despite  a  positive  correlation with the 
number of  embryos  created,  post-mature  oocytes  did  not  associate  with  the 
number  of  implanted  embryos,  indicating  a  deterioration  of  oocyte  quality  in 
terms of implantation potential with increasing follicular size and post-maturity.
In women with  PCOS, the percentage of mature oocytes was similar to that of 
non-PCOS  women  but the  percentage  of immature  and  post-mature  oocytes 
was  higher,  at the  expense  of borderline  mature  oocytes.  Hence,  in women 
with PCOS, the extremes of oocyte maturity, either delayed or accelerated, was 
likely to occur during  ovarian  stimulation.  Unlike common expectations,  only a 
clinically insignificant increase in the number of oocytes collected was observed 
in PCOS women (Table 3.21 CD).
The  systemic  endocrine  environment  during  the  later  stages  of  follicle 
development is shown to have a crucial role in coordinating follicular and oocyte 
maturation  before ovulation504.  Despite PCOS  being  associated with abnormal 
circulating  hormones,  abnormal  peri-follicular  vascularity  and  significant 
abnormalities of granulosa cell function,  after in  vitro maturation  of oocytes or 
following  ovulation  induction  for  IVF,  oocyte  and  embryo  quality  are  not 
obviously  impaired  in  PCOS504.  These  findings  are  in  agreement  with  those 
presented  in the current study.  In contrast, Cano et.  al.505 show that there is a 
particular subgroup of PCO patients with  lower fertilization  rates  and  embryos 
unable  to  implant.  These  patients  are  obese  and  non-hyperandrogenic  and 
show  derangements  of insulin  secretion.  The  presented  data  did  not  allow  a 
subgroup  analysis  for  specific  endocrine  abnormalities,  such  as
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study and others.
There was  no apparent detrimental effect of endometriosis on the quantitative 
and  qualitative  response  of  the  ovaries.  The  effect  of  different  grades  of 
endometriosis  on  these  variables  was  not  consistent  and  not  clinically 
significant,  with  the  exception  of  percentage  of  oocytes  collected.  The 
probability of finding  an  oocyte  in the follicular fluid  declined  significantly from 
88%  in  mild  endometriosis  to  83%  in  severe  endometriosis  (Table  3.22, 
3.23CD).
In contrast to the findings of the current study, poor quality of oocytes has been 
suggested  as one  possible cause of subfertility506;  higher apoptotic  incidence, 
more alterations of the cell cycle, and a higher incidence of oxidative stress are 
among  the  other  possible  mechanisms  suggested  in  endometriosis  when 
compared  with  other  subfertility  causes507.  Reliance  on  history  based  data 
collection  on  aetiology,  which  may  not  be  as  reliable  as  small  scale  but well 
controlled clinical trials, can explain the discrepancy between this study and the 
others.
In  unexplained  subfertility,  the  percentage of mature oocytes was  significantly 
lower and the percentage of post-mature oocytes  higher (Table 3.24CD).  This 
was  the  same  pattern  as  that  observed  in  the  older  women  with  high  FSH 
values.  Hence, one of the possible explanations behind unexplained subfertility 
is  likely to  be  a  subtle  ovarian  failure  with  a  tendency to  accelerated  oocyte 
maturity.
Women  who  developed  ovarian  cysts  following  down-regulation  developed  a 
similar number of follicles to those without such baseline cysts, but the number 
of  oocytes  collected  was  less,  albeit  at  a  clinically  insignificant  level.  This 
equates with lower oocyte collection rates in the presence of ovarian cysts.  No 
effect over the level of maturation was observed.  Hence, the effect could be a 
pure  space  occupying  effect,  rather  than  paracrine  suppression  of  ovarian 
response  (Table  3.25CD).  The  effect of hydrosalpinx  was  insignificant on  the
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number  of  follicles  aspirated  and  oocytes  collected  was  lower,  albeit  at  a 
clinically insignificant level. Hence, the main site of action is less likely to be the 
ovaries (Table 3.26CD).
4.2.1  Analysis of Variables of IVF (Oocytes) for Ongoing Pregnancy
We  have  seen  that  treatment  cycles  characterised  by  a  greater  number  of 
follicles  aspirated  and  oocytes  collected  were  more  likely  to  be  those  with 
conception.  However, in numerical terms the differences were small, being one 
or two oocytes at most. The maturity of the oocytes was what appeared to be 
more important.  Conception cycles had a higher percentage of mature oocytes 
and lower percentage of immature oocytes (Table 3.8).  In 7013 cycles, logistic 
regression  analysis  evaluating  the  prognostic  significance  of  the  number  of 
mature,  borderline,  immature,  and  post-mature  oocytes  in  the  prediction  of 
ongoing  pregnancy,  revealed that it was the number of mature and  borderline 
mature oocytes that possessed the prognostic significance (Table 3.9).
Degree  of  oocyte  maturity  also  influenced  the  probability  of  miscarriage, 
biochemical  pregnancy  and  ongoing  pregnancy.  The  percentage  of  mature 
oocytes  dropped  progressively  from  ongoing  pregnancy  to  miscarriage  and 
biochemical  pregnancy.  The  percentage  of  mature  oocytes  was  highest  in 
women who eventually developed ectopic pregnancy and lowest in women with 
no-ET.  On the other hand,  the  percentage of borderline mature and  immature 
oocytes  increased  from  ongoing  pregnancy  to  biochemical  pregnancy.  The 
percentage  of  post-mature  oocytes  was  higher  in  women  who  developed 
biochemical pregnancy (Table 3.27CD).
These  associations  provided  evidence  for  the  contention  that  biochemical 
pregnancy, miscarriage and ongoing pregnancy are likely to be the progressive 
stages  in  the  process  of  implantation.  In  this  section  this  argument  was 
furthered  by emphasising  the  role of oocyte  maturity  as  the  underlying  factor 
determining  the  ability  of  embryos  to  proceed  through  the  stages  of 
implantation; the greater the maturity of the oocyte, the greater the probability of 
completing  the  implantation  process  and  establishing  ongoing  pregnancy.  As
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dependant  way.  Hence,  if  maturity  is  low  the  outcome  will  likely  to  be 
miscarriage,  if lower the outcome will  be biochemical  pregnancy,  and  if lowest 
the  outcome  will  be  no  embryo  transfer.  The  observation  that  the  highest 
percentage of oocyte maturity was in the cycles resulting in ectopic pregnancy 
raises  an  interesting  hypothesis;  that  the  resulting  embryos  had  the  highest 
implantation  potential  and  so  became  less  selective  of the  receptivity  of the 
implantation site.
4.3  Analysis  of  Variables  of  IVF  (Fertilisation,  Individual  Embryo 
Quality) for Ongoing Pregnancy
Embryo  quality  is  a  term  used  in  clinical  practice  to  define  the  development 
potential of embryos in  vitro. The estimation of embryo quality is  used  so that 
the  best  embryos  can  be  selected  for transfer to  enhance  the  probability  of 
implantation19,22,23,104.  The  morphological  features  of the  dividing  embryo  are 
well  documented  prognostic  factors  in  determining  the  treatment 
outcome16,92,104,105,106,115,116,130,508,509,510
To evaluate the  prognostic value of embryo quality in the treatment outcome, 
8090 treatment  cycles  were  studied.  The  embryos  were  anatomically  graded 
from  1   for  the  best  to  6  for  the  worst.  The  blastomeres  were  counted  and 
graded as a developmental stage. The combination of these two variables was 
documented  as S()G() for all  created  embryos.  Of the collected  oocytes,  68% 
were fertilised and of these 82% reached the cleavage stage (Table 3.10, 3.11).
It was demonstrated that the number of oocytes used for fertilisation, number of 
oocytes  fertilised  and  number  of  embryos  achieving  cleavage  stage  was 
significantly  higher  in  conception  cycles.  Despite  fertilisation  rates  (2PN 
embryos/oocytes  used  for fertilisation)  being  higher  in  conception  cycles,  the 
cleavage rate of the fertilised embryos (cleavage stage embryos/2PN embryos) 
did  not differ between  conception  and  non-conception  cycles  in  the  univariate 
analysis  (Table  3.12).  To  evaluate this  unexpected  finding,  logistic  regression 
analysis was performed  in 3616 treatment cycles using the number of oocytes 
used  for fertilisation,  number  of oocytes  fertilised,  number  of cleavage  stage
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different  quality  groups  within  the  cohort  as  independent  predictors  of  the 
treatment  outcome.  This  revealed  that  the  number  of  oocytes  used  for 
fertilisation, fertilisation  rate and cleavage rate positively affected the outcome. 
Unlike  univariate  analysis,  regression  analysis  designated  the  percentage  of 
cleavage stage embryos (cleavage rate) as a significant prognosticator.  Hence 
the  percentage  of  first  mitotic  division  in  the  whole  embryo  cohort  is 
discriminative for outcome (Table 3.13).
Nevertheless,  the  fertilisation  rate  of  the  oocytes  had  the  highest  predictive 
value  among  all  qualitative  and  quantitative  variables  tested  in  this  analysis 
(Table  3.13).  This  is  in  contrast  to  the  published  literature,  in  which  the 
prognostic  importance  given  to  fertilisation  and  cleavage  rates  is  not 
high71,75,76,77,511,512. It is proposed that even those oocytes collected from women 
with  poor ovarian  reserve can  undergo fertilisation  and  cleavage and  produce 
high  quality  embryos76.  However,  the  implanting  ability  of  such  embryos 
declines with female age and thus  pregnancy rates decline75,76,79.  It is argued 
that chromosomal abnormalities of the oocyte do not need to affect fertilization 
and early embryo cleavage, but can be linked to failure of implantation80,81,82. In 
contrast to the published literature from smaller study populations, the statistical 
power of the current study allowed the detection of differences that may have 
otherwise failed to reach significance.
Higher  numbers  of  oocytes  and  embryos  favouring  a  successful  outcome 
indicated the opportunity of better selection from a larger cohort. The probability 
of  finding  good  quality  embryos  would  be  higher,  for  simple  mathematical 
reasons,  if the selection  involved  a greater number of candidates.  However,  it 
was  also  the  percentage  of fertilised  oocytes  that  affected  the  probability  of 
pregnancy.  Hence,  an  intrinsic  quality  response  linked  to  the  quantitative 
response  was  also  noticeable,  indicating  that  it  was  not  only the  size  of the 
cohort that  improved the  probability of finding  a  good  quality embryo  but also 
the inherent ability of larger cohorts to develop better quality embryos, thereby 
improving the probability of pregnancy.
136Different  expression  (%  or  numbers)  of  the  same  variable  may  selectively 
highlight the  relative  importance  of the  quantitative  and  qualitative  aspects  of 
the ovarian response for their surrogate roles in future embryonic development 
and implantation.  In this setting, numbers were regarded as surrogate markers 
for quantitative and percentages for qualitative response.
Both the size of the cohort in terms of available oocytes, and the quality in terms 
of  ability  to  achieve  higher  fertilisation  and  cleavage  rates,  independently 
affected  the  probability  of  pregnancy.  Furthermore,  irrespective  of  the 
morphological appearance of the developing blastomeres, slow cellular division 
indicated  a  severe  developmental  problem  leading  to  a  low  probability  of 
pregnancy.  On  the  other  hand,  a  rapidly dividing  embryo  did  not  necessarily 
possess  high  implantation  potential,  unless  the  developing  blastomeres  were 
morphologically  of  good  quality.  Four-cell  stage  embryos  with  good  grade 
development  had  the  best  probability  of  pregnancy.  This  highlighted  an 
optimum  developmental  stage  that  maximises  the  probability  of  further 
development in utero and the probability of implantation and  pregnancy (Table 
3.13).
The  number of blastomeres  at the time of transfer has  been  used  as a  proxy 
measure  of  the  development  potential  of  the  embryo,  linking  closely  to  the 
embryonic genome  activation  that occurs  between  the four-cell  and  eight-cell 
stages of pre-implantation development125. Erenus et. al.104 report that embryos 
of  at  least  two  mitotic  divisions  implant  better  than  two-cell  embryos  of 
comparable morphology and that heavily fragmented embryos do not implant as 
well  as  embryos with fewer or no anucleate fragments.  Giorgetti  et.  al.1 1 6  and 
Ziebe et.  al.126  report that the transfer of four-cell  embryos  results  in  a  higher 
implantation  and  pregnancy  rate  when  compared  with  two-cell  and  three-cell 
embryos.  Furthermore, the transfer of four-cell embryos results in a significantly 
higher  pregnancy  rate  compared  with  embryos  cleaved  beyond  the  four-cell 
stage.  Fast  cleavage  with  more  than  five  cells  on  day  2  is  unfavourable, 
especially  if  associated  with  >10%  fragmentation,  as  the  probability  of 
chromosomal abnormality appears to be higher513.
137The morphological development of the individual blastomeres became decisive 
for the outcome only if the embryo exhibited  good  growth  in terms of cellular 
division.  A  poor  developmental  stage  with  few  blastomeres  was  not 
compensated  by superior morphology. The association between the grading of 
the embryos and their developmental stage in terms of number of blastomeres 
was weak and likely to reflect both grading and staging operate independently 
in the probability of implantation. Good grade embryos and those with a greater 
number of blastomeres had higher implantation potential (Table 3.35-3.37CD).
After assessment of the quality of the individual embryos, the importance of the 
global quality of the whole embryo cohort in determining the treatment outcome 
was  also  appraised.  Grade  1   and  2  embryos,  classified  as  ‘good  grade’ 
regardless  of  their  developmental  stage,  dominated  the  embryo  cohort  in 
women who went on to achieve pregnancy (Table 3.14).
4.4  Analysis of Variables of IVF (Quality of the Embryos Transferred) for 
Ongoing Pregnancy
After confirming the importance of quality in the whole embryo cohort created in 
the  same  stimulation  cycle,  the  impact  of  quality  of the  best  three  embryos 
selected  for transfer was  investigated.  Univariate  analysis  revealed  that  both 
stage  and  grade  of  the  embryos  transferred  were  prognostic  for  ongoing 
pregnancy (Table 3.38CD).
The  multivariate analysis  used  patient characteristics  (female  age,  duration  of 
subfertility,  number of previous IVF attempts,  FSH  level), details of the ovarian 
stimulation  (total  dose  of gonadotrophin,  duration  of ovarian  stimulation,  hCG 
day E2), and embryological variables (number of oocytes collected, and number 
of  mature  oocytes,  borderline  oocytes,  2-PN  and  cleavage  stage  embryos, 
number of embryos cryopreserved, quality of the individual embryos transferred, 
and quality of the individual embryos in the whole embryo cohort). The number 
of embryos  transferred  was  used  as  a  constant  in  the  equations  to  maintain 
stability in its effect over the outcome.
138Female age,  number of follicles,  quality of the embryos transferred and quality 
of the individual embryos in the whole cohort were prognostic. The quality of the 
individual embryos in the whole cohort had the highest impact on the outcome 
(Table  3.20).  Therefore,  the  quality of untransferred  sibling  embryos  affected 
the  probability  of  pregnancy  independently  of  the  quality  of  the  embryos 
transferred.  This  indicated  that  a  common  characteristic  inherently  present  in 
the embryo cohort determined their growth potential.
Wheeler  et.  al.514  construct  a  similar  statistical  model  and  conclude  that  the 
probability of  pregnancy  increases  with  an  increasing  total  embryo  score  but 
decreases with  increasing female age.  Hunault et.  al.515 demonstrate that the 
best predictors of ongoing pregnancy after multivariate analyses are the number 
of  oocytes  collected,  the  development  stage  of  the  second-best  embryo 
transferred, and the morphology score of the best embryo transferred.
On the other hand,  neither the quality of the  best three embryos  nor the total 
number of good grade embryos in the cohort differentiated the outcome in terms 
of  biochemical  pregnancy,  miscarriage,  or  ectopic  pregnancy,  reflecting  the 
presence of other mechanisms operating in their pathogenesis and unrelated to 
or indefinable by these embryological variables  (Table 3.45CD).  Levy et.  al44 
also demonstrate that morphological grading of embryos is similar in an ongoing 
or biochemical pregnancy after IVF treatment.
4.4.1  Factors Linked to Embryo Quality
The quality of transferred embryos, semi-quantified  in terms of embryo grading 
and  quantified  by their blastomere  numbers,  was  strongly associated with the 
clinical  surrogate  markers  of  the  ovarian  reserve  (Table  3.16,  Table  3.35- 
3.37CD). Younger women who produced more oocytes with higher levels of E2  
in  response  to  low  intensity  ovarian  stimulation,  had  better  quality  embryos. 
Therefore,  it  was  the  inherent  ability  of  the  women,  not  the  intensity  of the 
ovarian stimulation that dictated the quality of the embryos.  While quantitative 
ovarian  response can  be augmented with  more aggressive ovarian stimulation 
regimens, within the limits of ovarian  reserve, this  is less likely to  improve the 
qualitative outcome.  It is of note that the same conclusion was reached in the
139section on oocyte quality. This association further highlighted the pivotal role of 
ovarian reserve and its response capability to stimulation in the creation of high 
quality embryos with the best probability of implantation.  In this context,  it was 
female  age  but  not  the  pre-stimulation  FSH  levels  that  correlated  with  the 
quality of transferred embryos.
In the whole  cohort,  embryo  quality varied  within  a  narrow  range  and  shared 
similar traits. The quality of the best three embryos strongly correlated with each 
other but also with the size of the cohort. As the number of 2-PN and cleavage 
stage embryos increased the quality of the embryos transferred also increased. 
Once  again,  this  was  not  simply a  reflection  of a  better selection  opportunity 
made  possible  by the  availability of a  larger cohort,  but  also  an  indication  of 
inherent quality. Women who could produce greater numbers of embryos could 
also produce better quality embryos (Table 3.37CD).
4.5  Prognostic  Significance  of  Number  of  Embryos  Transferred  for 
Ongoing Pregnancy
The number of embryos transferred was higher in the pregnant group, but once 
the quality of the individual embryos in the whole cohort, the global quality of the 
whole embryo cohort or the quality of the embryos transferred  was taken  into 
consideration,  the  number of embryos transferred  was  no  longer a  significant 
determinant  of the  treatment  outcome  (Table  3.17,  3.18,  3.21,  3.23).  In  this 
section  this  important  observation  is  further  discussed  by  using  surrogate 
clinical variables for embryo quality.
Female age, duration of subfertility, and the number of cleavage stage embryos 
created  were  prognostic  variables  of  IVF  treatment.  In  the  current  study  a 
pragmatic  selection  was  made  for  different  cut-off  levels  of  each  variable 
(female  age:  35,  38,  40  years;  duration  of subfertility:  4,  8  years;  number of 
available  embryos:  3,  5,  10)  and  their  predictive  power  was  evaluated  for 
ongoing  pregnancy.  Higher  cut  off levels  were  associated  with  progressively 
increasing specificity but at the expense of dropping sensitivity in the prediction 
of  ongoing  pregnancy  after  IVF  treatment.  This  indicates  that  higher  cut-off 
levels are good at identifying women who are less likely to achieve pregnancy,
140but not at identifying women who are more likely to achieve pregnancy. All cut­
off  levels  significantly  demarcated  the  good  and  poor  prognosis,  albeit  at 
varying levels of sensitivity and specificity. Among all three variables, depending 
upon the cut off level, the number of cleavage stage embryos had the highest 
sensitivity and specificity in the range of 92 to 99% (Table 3.56CD).
These cut-off levels were applied individually and then in combination to create 
different  sub-groups  of  the  whole  study  population  for  comparison  of  the 
number of embryos required to achieve pregnancy in each category.
Women  with  a  greater  number  of  embryos  transferred  were  more  likely  to 
achieve pregnancy, regardless of age <35 or >35 years, £38 or >38 years, £40 
or >40 years, or duration of subfertility £4 years or >4 years, or £8 or >8 years 
(Table  3.65-3.75CD).  On  the  other  hand,  the  number  of  cleavage  stage 
embryos  available  for  transfer  defined  a  subgroup  of  women  in  whom 
transferring  more  embryos  did  not  positively  affect  the  treatment  outcome 
(Table  3.76-3.81 CD).  While  women  with  £3  cleavage  stage  embryos  still 
needed a greater number of embryos transferred to improve the probability of 
pregnancy,  women  with  >3  embryos  did  not  need  to  increase the  number of 
embryos transferred to achieve pregnancy.
With increasing availability of cleavage stage embryos from 3,  pregnancy rates 
were steeply increased then began to plateau at the 9-embryo level.  However, 
with  3  cleavage  stage  embryos  available  for  transfer,  the  difference  in 
pregnancy  rates  between  3-embryo  and  <3-embryo  transfer  was  almost  the 
same as that observed  with  9  embryos available  and this  difference changed 
only marginally with increasing availability of embryos.  Hence, the difference in 
pregnancy  rates  between  3-embryo  and  <3-embryo  transfer  with  higher 
numbers  of  cleavage  stage  embryos  was  mostly  due  to  a  difference  that 
originated  from  the  group  with  3  embryos  available  and  was  then  carried 
through  to  the  higher  cut-off  levels,  which  consistently  included  that  group 
(Table  3.28,  3.29.  Table  3.76-3.81 CD).  Therefore,  it  was  concluded  that  3- 
embryo  transfer was  only  beneficial  when  only  3  embryos  were  available  for 
transfer and women with >3 embryos did not benefit from high-number ET. This
141statement can be applicable as a population based protocol where the details of 
the  individual  patients  (age,  duration of subfertility,  and  quality of individual  or 
transferred embryos) are pragmatically not used for decision making.  However, 
the  guidance  can  be  more  refined  if the  knowledge  of embryo  quality  is  also 
available. It was observed that regardless of the number of available embryos, if 
there was  at least one good  grade embryo in the whole cohort, there was  no 
benefit of transferring >2 embryos.  If none of the embryos were of good grade, 
then transferring 3 embryos may increase the probability of pregnancy albeit at 
an insignificant level (Table 3.24, 3.25).
Hence,  although  previous  guidelines  limit the  number of embryos  transferred 
solely on the  basis of the number of embryos available without accounting for 
embryo quality90 91, it was shown that such guidelines can still inherently identify 
a sub-population who will not benefit from high-number ET; and we have further 
refined  these  population  based  protocols with the  availability of embryological 
data. Literature supports the significance of this concurrent couple and embryo 
selection. It is shown that in a good prognostic group of women aged <34 years 
and  in their first  IVF treatment,  strict embryo selection  criteria are essential to 
maintain  pregnancy  rates118.  The  importance  of  embryo  selection  in  elective 
single-ET is further emphasised  by the drop in ongoing  pregnancy rates from 
36% to 13% when the embryo transferred is not of ‘top grade’516.
It was also observed that more 2-embryo transfers achieved ongoing pregnancy 
in  the  good-embryo  grade  dominant  cycles  when  compared  with  the  poor- 
embryo  grade  dominant  cycles.  However,  in  women  who  did  not  achieve 
pregnancy the  percentage  of 2-  and  3-embryo transfers was  the  same  in the 
good  and  poor prognostic groups.  Hence, there are other factors that are not 
manifested  by or operated through embryo quality,  and  increasing the  number 
of  embryos  transferred  cannot  overcome  the  underlying  pathology,  so 
pregnancy is not achieved.
1424.6  Multiple Pregnancy Following IVF Treatment
It  has  been  demonstrated  in  previous  sections  that  female  age,  duration  of 
subfertility,  and  number of cleavage stage embryos  available for transfer was 
predictive of the treatment outcome, but these variables interacted differently in 
the different combinations unique to individual women. For example, in younger 
women,  longer  durations  of  subfertility  were  more  detrimental  to  pregnancy 
chances,  and  availability  of  a  greater  number  of  embryos  for  transfer  could 
compensate for the decreased fertility chances of advanced female age.  Each 
combination  of  these  surrogate  markers  defines  different  levels  of  inherent 
fertility, reflecting the severity of the ‘disease process’ underlying the subfertility.
It is widely acknowledged that for optimum outcome, the intensity of treatment 
should  be  balanced  with  the  severity  of  the  disease;  while  less  aggressive 
treatments  may  fail  to  overcome  the  pathology,  more  aggressive  treatments 
may exert unacceptable side effects.  A common  practice  in fertility treatment 
tries  to  achieve  this  balance,  by titrating  the  number  of embryos  transferred 
against the perceived severity of the subfertility.
The  main  criticism  of  high-number  ET  is  that  it  is  an  easy  but  risky  way  of 
overcoming fertility barriers.  Embryo quality and endometrial receptivity are the 
key  elements  and  their  favourability  can  be  estimated  by  clinical  surrogate 
markers. The number of embryos to be transferred should be balanced with this 
estimation  of favourability,  rather than  employing  a  blanket  policy of multiple- 
embryo  transfer,  which  inevitably  increases  the  probability  of  multiple 
pregnancy. A study on elective single-ET concludes that the selection of a good 
prognostic  group  could  keep  an  acceptable  balance  between  reduction  in 
multiple gestation and overall pregnancy rates517.
The opponents of this policy argue that the sensitivity of the surrogate markers 
is low and so titration is not possible122. A common concern of those who argue 
against limiting the number of embryos transferred, is the iatrogenic lowering of 
pregnancy rates by the transfer of fewer embryos. They further argue that in the 
presence of poor quality embryos the number of embryos transferred needs to 
be increased to compensate for the fertility deficit.
143We  have  already  demonstrated  that  as  women  age  and  their  duration  of 
subfertility  increases  they  require  high-number  ET  to  achieve  pregnancy. 
However, women who  produced  a  high  number of embryos,  despite their age 
and  duration  of subfertility,  could  achieve  pregnancy without  high-number ET, 
particularly if at least one of the embryos was of good grade.
The  literature  details  similar  approaches  to  optimise  the  number  of embryos 
transferred. It is widely observed that the number of embryos transferred affects 
the  probability of live  birth,  but that the implantation  potential  of the  individual 
embryo approximated  by the total  number of embryos available for transfer,  is 
more  important90.  Therefore,  if  a  high  number  of  embryos  is  available  the 
probability of a live birth is greater than if only one or two embryos are available 
for transfer.  When  >4 embryos are available for transfer, the live  birth  rate  is 
not  affected  by  the  transfer  of  two  or  three  embryos,  although  there  is  a 
significant  reduction  in  the  multiple  pregnancy  rate  when  two  embryos  are 
transferred. This is shown to be valid for all female ages up to 40 years90.
In the next section the prognostic factors of multiple pregnancy were evaluated 
from the  perspective  of the  number of embryos transferred.  In  an  analysis  of 
9700 ET procedures, the mean number of embryos implanted per transfer was 
0.44 (range 0-4); 21 % were singleton 9% were twin, and 1.7% were triplet.
Higher  ovarian  reserve,  better  ovarian  response  to  stimulation  and  better 
embryo quality were associated with a higher probability of multiple pregnancy. 
Younger women with a shorter duration of subfertility were more likely to have a 
multiple pregnancy than singleton. Treatment cycles characterised by a greater 
number of 2-PN and cleavage stage embryos available for transfer were also at 
greater  risk  of  multiple  pregnancy,  correlating  with  the  quality  of  embryos 
transferred.  Embryos  with  a  lower  grade  of  quality  and  higher  stage  of 
development  were  more  likely to  establish  multiple  pregnancy  than  singleton 
and  the  probability  of  multiple  pregnancy  was  clearly  associated  with  the 
number of embryos transferred (Table 3.30, 3.31).
144A  dose  response  relationship  between  these  variables  and  the  order  of 
multiplicity  (singleton  vs  twin  vs  high  order)  was  observed  but  did  not  reach 
significance, with the exception of the number of embryos transferred, whereby 
both the probability of multiple pregnancy and the order of multiplicity increased 
with the increasing number of embryos transferred.
Both singleton and twin implantations were reduced  in cycles complicated with 
ovarian  cysts  after down-regulation  and  in  the  presence  of hydrosalpinx.  The 
former  probably  acts  by  impeding  the  ovarian  response,  as  shown  in  the 
previous section, and the latter by disturbing endometrial receptivity and embryo 
viability (Table 3.30, 3.31, Table 3.82CD).
Significant  spontaneous  fetal  resorption  following  multiple  implantation  was 
noted.  At  delivery,  only  59%  of  singleton  pregnancies  had  one-embryo 
implantation,  34%  two-embryo  and  7%  three-embryo.  Likewise,  20%  of twin 
pregnancies initially had triplet implantation, and 2% of triplet pregnancies had 
quadruplet implantation. Although the data were not available, it is unlikely that 
selective fetal  reduction  can  explain  the  discrepancy  between  the  number of 
embryos  implanted  and  the  number  of  babies  born  in  singleton  and  twin 
pregnancies.
Logistic regression analysis was performed on 2400 cycles to predict singleton 
or multiple pregnancy. The number of embryos transferred was found to affect 
the multiplicity of pregnancy, even after correction for the effect of female age, 
the  number  of  embryos  available  for  transfer  and  the  embryo  quality.  This 
differed from the prediction of pregnancy where the significance of the number 
of embryos transferred was lost after other clinical and embryological variables 
were  corrected.  Hence,  the  implantation  potential  of the  embryo  is  linked  to 
intrinsic factors unique to individual women  but not to extrinsic factors such as 
the number of embryos transferred. However, the number of embryos implanted 
was linked with the number of embryos transferred (Table 3.32-3.34).
Schieve  et.  al.94  conclude that the  probability of multiple  pregnancy from  IVF 
treatment varies,  not only with the number of embryos transferred but also with
145female age. Women aged <35 years achieved maximum live-birth rates with as 
few  as  two  embryos  transferred.  However,  unlike  the  UK  study90,  this 
retrospective  cohort  analysis  indicates  a  statistically  insignificant  increase  in 
live-birth  rates  among  women  aged  >35  years  if  more than  two  embryos  are 
transferred,  but at the expense of a highly significant increase in  multiple birth 
rates  from  12%  to  29%.  If  more  than  three  embryos  are  transferred  even  in 
women  with  a  poor  prognosis  (aged  >36  years,  previous  unsuccessful  IVF 
treatment  and  poor embryo  quality),  a  significant trend  toward  higher multiple 
pregnancy rates remains96.
It is obvious that factors that increase the probability of pregnancy also increase 
the  probability  of  multiple  pregnancy.  This  is  not  surprising  because  the 
underlying factor is the same: the implantation potential of each embryo and the 
receptivity  of  the  endometrium.  Factors  associated  with  high  embryo 
implantation rates lead to singleton pregnancy if one embryo is transferred, and 
to multiple pregnancy if more embryos are transferred.
These  findings  are  in  agreement  with  the  published  literature.  The  key 
determinants  of  success  in  IVF  treatment,  including  female  age,  duration  of 
subfertility and  numbers  of previously failed  IVF  attempts are  also  reported to 
affect the probability of multiple pregnancy8,90.  It is this association that frames 
the  current  debate  on  minimising  the  multiple  pregnancy  probability  without 
jeopardising  the  pregnancy  chances.  While  transfer  of  a  multiple  number  of 
embryos is proposed to compensate for the severity of subfertility,  reflected  by 
low implantation potential of the embryos or low endometrial receptivity, even to 
achieve singleton  implantation,  previous observations and  publications indicate 
that  this  approach  carries  an  unacceptably  high  probability  of  multiple 
pregnancy without  necessarily increasing the  pregnancy rates.  Because what 
is  being  contemplated  is  not to correct the  underlying  pathology  by improving 
embryo  quality or endometrial  receptivity,  but simply to take  advantage  of the 
statistical  probability  of  multiple  independent  events,  no  matter  how  low,  by 
transferring  multiple  embryos  in  the  hope that one will  implant.  If this  is done 
indiscriminately there is a good possibility that some of the multiple ETs will  be 
done in good  prognosis patients with otherwise high  implantation  potential and
146endometrial  receptivity,  with  the  inevitable  outcome  of  high  order  multiple 
pregnancy.
From the earlier pioneering studies by Staessen92,93,99 investigating the effect of 
quality  and  number of embryos transferred  over the  multiple  pregnancy  risks 
following  IVF  treatment,  to  the  recent  retrospective  case  control  study  by 
Licciardi  et.  al.100  and  HFEA-data  analysis  by  Ozturk  and  Templeton101,  the 
same  trend  has  persistently  emerged;  ‘reducing  the  number  of  embryos 
transferred  from  three  to  two  largely  eliminates  the  occurrence  of  triplet 
pregnancies without altering the overall pregnancy rates’.
4.7  Prognostic Significance of Embryo Transfer Procedure
In IVF treatment,  ET is the final and most crucial step.  It is estimated that poor 
ET  technique  may  account  for  as  much  as  30%  of  all  failures  in  assisted 
reproduction518.  There  is  little  scientific  evaluation  of  different  ET  protocols. 
However,  it  is  customarily  proposed  that  an  easy,  atraumatic  transfer  is 
important,  with  attention  to  factors  such  as  patient  preparation,  medication, 
mock  ET,  choice  of  catheter,  ultrasonographic  guidance,  and  transfer 
technique.
In  the  current  analysis,  clinical  variables  defining  different  aspects  of the  ET 
procedure  had  no  influence  over the  treatment  outcome  in  terms  of  ongoing 
pregnancy rates.  Despite the duration of ET being statistically shorter in women 
who  achieved  pregnancy, the difference was clinically negligible.  Furthermore, 
there was  no  link  between  the  duration  of ET  and  its  technical  difficulty.  The 
state  of  the  catheter  tip  after  the  ET  procedure,  degree  of  discomfort 
experienced  by  the  woman,  degree  of  technical  difficulty  graded  by  the 
physician, and use of tenaculum, stylet or ultrasound guidance did not affect the 
ongoing pregnancy rates (Table 3.39-3.44CD).
These findings are in  contrast with the published data.  Blood  or mucus,  which 
may attach to the end of the catheter during ET, is shown to impede the embryo 
release.  Blood  on the outside of the catheter also has  been  related to difficult 
ET  and  poorer  results519.  It  was  shown  that  technically  difficult  ETs  are
1475  Low-dose  Aspirin  Co-treatment  in  Patients  Undergoing  IVF 
Treatment: Results
5.1  Patient Characteristics of the Aspirin and Placebo Groups
The  study  recruited  100  couples.  Three  couples  randomized  to  the  aspirin 
group later decided  not to proceed with  IVF treatment.  From the remaining 97 
couples, 46 women were in the aspirin group and  51  in the placebo group. All 
97  couples  completed  their  primary  fresh  IVF  treatment  cycle  in  accordance 
with  the  study  protocol  and  routine  policies  of the  Unit where  the  study was 
based.  Patient characteristics,  clinical  and  embryological  details  of the  aspirin 
and  placebo  groups  were  given  (Table  5.1-5.3).  Details  of female  lifestyle  in 
terms  of  smoking  and  alcohol  consumption,  and  regularity  of  the  menstrual 
cycle were detailed on the CD Rom (Table 5.1-5.8CD). In the aspirin group 32% 
of  the  men  presented  with  a  sperm  count  <20  million/ml  and  14.6% 
<5million/ml.  In  the  placebo  group,  16%  of  men  had  a  sperm  count  <20 
million/ml, and 10% <5 million/ml (Table 5.9, 5.10CD).
Table 5.1: Subfertility in the Aspirin and Placebo Groups
............................_........1
Aspirin  |
Subfertility
Primary
Secondary
Female N (%)  |
____31(67.4%)  |___
15(32.6%)  |
Male N (%)
__ 30 (65.2%)
16 (34.8%)
Couple N (%)
36 (78.3%) 
10 (21.7%)
Placebo
Primary 30 (58.8%)  | 32 (62.7%) 37 (72.5%)
Secondary 21  (41.2%) 19 (37.3%) 14(27.5%)
N: Number of subjects
Table 5.2: Diagnosis of Subfertility in the Aspirin and Placebo Groups
Aetiology  1 Aspirin N (%) Placebo N (%)
Unexplained | 5(10.9%)  | 13(25.5%)
Male Factor 20 (43.5%)  I 13(25.5%)
Ovarian 2 (4.3%)  | 2 (3.9%)
Endometriosis 4 (8.7%)  |  4 (7.8%)
Tubal Factor 1
i. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..........15 (32.6%) j ...... 19(37.3%)
149Table  5.3:  Patient  Characteristics,  Clinical  and  Embryological  Variables  of  the  Aspirin  and 
Placebo Groups
Aspirin Group Placebo Group
N Mean ± SD N Mean ± SD
Female Age (year) 46 32.4 ± 4.0 51 34.0 ± 4.4
Duration of Subfertility (month) 46 51.0 ±38.2 51 53.9 ± 42.7
Gravity 46 0.7 ± 1.2 51 0.6 ± 1.0
Parity 46 0.2 ±0.5 51 0.4 ± 0.9
BMI (kg/m2) 46 24.0 ±4.2 49 25.2 ± 5.7
Baseline FSH (IU/1) 46 6.7 ±2.0 51 7.3 ±3.9
Initial Gonadotrophin Dose (IU) 46 157 ±31 51 157 ±34
Duration of Gonadotrophin Stimulation 
(day)
46 12.4 ±2.1 51 12.0 ±2.3
Total Gonadotrophin Dose (IU) 46 2046 ± 728 51 1942 ±725
E2  Level after Down-Regulation (nmol/l) 46 0.10 ±0.05 51 0.10 ±0.07
Size of Baseline Ovarian Cyst (mm) 10 30.0 ± 9.0 11 24.9 ± 8.7  !
E2  Level before hCG Injection (nmol/l) 46 5.3 ±2.7 51 6.6 ±4.4  |
< 9 mm 46 2.8 ±3.3 51 2.6 ±4.6  |
10-15 mm 46 6.0 ± 3.9 51 7.6 ± 5.9
Number of Follicles 16-17 mm 46 2.5 ± 2.4 51 3.0 ±2.1
measuring 18-20 mm 46 1.7 ± 1.3 51 2.0 ± 1.4
21-25 mm 46 0.8 ± 1.2 51 0.8 ±1.4
26-30 mm 46 0.23 ± 1.62 51 0.05 ± 0.24  |
Number of Follicles Aspirated 45 12.3 ±6.4 49 12.4 ±7.0  !
Number of Oocytes Collected 45 11.2 ± 6.5 49 11.2 ±6.5
Number of Oocytes Used 44 10.7 ±6.2 46 10.2 ±5.4
Number of 2-PN Embryo 45 6.8 ±4.6 49 6.6 ±4.7
Number of Embryos Transferred 38 1.9 ±0.2 43 1.9 ±0.3
Number of Embryos Cryopreserved 45 3.7 ± 5.0 49 3.6 ±4.7
Grade of the First Embryo 38 1.1  ±0.5 43 1.2 ±0.5
Grade of the Second Embryo 35 1.6 ±0.8 40 1.5 ±0.7
Grade of the Third Embryo 0 1 3.0
Embryo Transfer Time (sec) 38 31  ±31 43 42 ± 59
Number of Embryos Implanted per 
Pregnancy in Fresh Cycle
14 1.35 ±0.49 21 1.28 ± 0.46
Number of Embryos Implanted per 
Pregnancy in Fresh + FTER Cycle
19 1.31  ±0.47 25 1.28 ±0.45
N: Number of subjects whose data were available for each variable 
BMI: Body mass index
Percentages  represented as decimal of 1.0 ± SD
150In the aspirin group 82% had Day 21  protocol and  in the placebo groups 73%. 
The  remaining  used  Day  2  protocol.  Following  down-regulation  21%  of  the 
women in both groups experienced ovarian cysts.  ICSI was used in 41% of the 
aspirin group and  27% of the placebo group.  Donor sperm was used only in a 
small  subgroup  of  4.3%  in  the  aspirin  group  and  2%  in  the  placebo  group. 
Technical difficulty of the ET procedure was graded by the physician as easy in 
83-84%  of  both  groups,  with  only  5.3%  in  the  aspirin  group  and  2.3%  in  the 
placebo group being graded difficult (Table 5.11-5.15CD).
In  the  aspirin  group  82.6%  had  ET  and  in  the  placebo  group  84.3%.  In  the 
aspirin group,  10.9% of couples elected cryopreservation of all embryos due to 
the  high  probability of ovarian  hyper-stimulation  syndrome  (OHSS)  and  in the 
placebo group this was  9.8%.  In the aspirin group 4.3%  had failed fertilisation 
and  in  the  placebo  group  2%.  Cycle  cancellation  before  oocyte  collection 
occurred in 2.2% of the aspirin group and 3.9% of the placebo group.
In the aspirin group the ongoing  pregnancy rate was 23.9% and in the placebo 
group 33.3%. When cumulative pregnancy rates were calculated  by combining 
the  fresh  IVF  cycles  and  related  FTER  cycles,  the  ongoing  pregnancy  rates 
became 34.8% in the aspirin group and 39.2% in the placebo group (Table 5.4, 
5.5).  With  low-dose  aspirin  co-treatment,  the  mean  platelet volume  increased 
from 8.6 to 9.2 during treatment for IVF. A similar increase from 8.8 to 9.1  was 
evident in the placebo group (Table 5.16CD).
Table 5.4: Treatment Outcome
Ongoing Pregnancy after Fresh Treatments _____ __  .  N (%) j
Ongoing Pregnancy 11  (23.9%)  |
Miscarriage_________________________________________ _________m m i
Aspirin Biochemical 2 (4.3%)  |
Not Pregnant 22 (47.8%)  |
No Embryo Transfer 8(17.4%)  )
Ongoing Pregnancy 17 (33,3%)  |
Miscarriage 4 (7.8%)  |
Placebo Biochemical 1   (2.0%)  |
Not Pregnant 21  (41.2%)  |
No Embryo Transfer 8(15.7%)  |
151Table 5.5: Cumulative Treatment Outcome
Cumulative Ongoing Pregnancy 
after Fresh and Frozen Treatments N (%)  J
Ongoing Pregnancy 16 (34.80%)  |
Miscarriage 3 (6.50%)  |
Aspirin Biochemical 2 (4.30%)  |
Not Pregnant  1   21(45.70%)  |
No Embryo Transfer 4 (8.70%)  |
Ongoing Pregnancy 20 (39.20%)  |
Miscarriage 5 (9.80%)  |
Placebo Biochemical 2 (3.90%)  |
Not Pregnant 20 (39.20%)  |
No Embryo Transfer 4 (7.80%)  |
5.1.1  Comparison of Patient Characteristics of the Aspirin and Placebo Groups
Differences in female age did not reach statistical significance in the aspirin and 
placebo groups  (32 vs  34 years respectively).  Duration of subfertility,  previous 
obstetric  history,  regularity  and  duration  of  menstrual  cycle,  female  height, 
weight,  and  BMI  and  female  lifestyle  in  terms  of  smoking  and  alcohol 
consumption  were  similar  in  both  groups.  The  distribution  of  primary  and 
secondary  female,  male  and  couple  subfertility  and  aetiologies  of  subfertility 
were  similar  in  both  groups.  There  was  no  difference  in  male  weekly 
consumption  of alcohol,  sperm  concentration,  morphology,  and  motility grades 
between the aspirin and placebo groups (Table 5.17-5.25CD).
5.1.2  Comparison  of Clinical  and  Embryological  Variables  of the  Aspirin  and 
Placebo Groups
When  the  clinical  and  embryological  variables were  compared,  there were  no 
differences  between  the  aspirin  and  placebo  groups  for  early follicular  phase 
FSH values, type of the stimulation protocol (Day 21  vs Day 2), oestradiol levels 
after  down-regulation  and  on  the  day  of  hCG  administration,  initial 
gonadotrophin dose,  total  gonadotrophin dose required for ovarian  stimulation, 
duration of ovarian stimulation, follicular growth at different levels of maturation, 
total  number  of  follicles  aspirated,  oocytes  collected,  and  oocytes  used  for 
fertilisation,  number  of  2-PN  embryos  created,  number  of  embryos 
cryopreserved and transferred, and the grade of the best two embryos selected 
for transfer.
152The  duration  of the  ET  procedure,  platelet  count  and  mean  platelet  volume, 
both  before  and  after ovarian  stimulation,  were  similar  in  both  groups  (Table 
5.26CD).
IVF or ICSI and husband or donor sperm, were similarly employed in the aspirin 
and placebo groups. The occurrence of ovarian cysts following down-regulation 
was  similar  in  both  groups  and  the  technical  difficulty of  ET  procedures  was 
graded similarly (Table 5.27-5.33CD).
The  distribution  of  cycles  with  ET  and  with  no-ET  due  to  elective  embryo 
cryopreservation  for  OHSS,  failed  fertilisation,  and  cancellation  before  oocyte 
collection  was  similar.  There  was  no  difference  between  the  two  groups  in 
ongoing pregnancy, biochemical pregnancy, miscarriage, and no-ET rates after 
the  fresh  IVF  treatment  study  cycle  and  also  for the  cumulative  rates  of the 
fresh  and  the  related  FTER  cycles  (Table  5.6,  5.7).  The  number of embryos 
implanted  per pregnancy was similar in the aspirin  and  placebo groups  in the 
fresh cycle. The cumulative rate, including the related FTER cycle following the 
fresh cycle was also similar (Table 5.26CD).
There was no difference between the aspirin and placebo groups for the mean 
platelet volume before and after ovarian stimulation. The mean platelet volume 
before  and  after  ovarian  stimulation  were  similar  in  the  ongoing  pregnancy, 
miscarriage,  chemical  pregnancy,  no-pregnancy,  and  no-ET  groups  (Table 
5.34-5.36CD).
Table 5.6: Treatment Outcome in the Aspirin vs Placebo Groups
Aspirin  j Placebo P  I
Ongoing Pregnancy 11  ! 17 I
Miscarriage 3  ! 4
Biochemical Pregnancy 2  ! 1 NS
Not Pregnant 22  ! 21
No Embryo Transfer 8J 8 I
153Table 5.7: Cumulative Treatment Outcome in the Aspirin vs Placebo Groups
Fresh + FTER Aspirin Placebo P
Ongoing Pregnancy 16  | 20
Miscarriage 3  ! 5
Biochemical Pregnancy 2  I 2 NS
Not Pregnant 21  | 20
No Embryo Transfer 4  ! 4
5.2  Doppler Analysis
A total  of 34 consecutive  non-selected women  aged  24-39 years  in the same 
cohort of the  aspirin  study,  were  studied  using  colour-flow  Doppler in  34  IVF 
treatment  cycles.  Elective  cryopreservation  of  all  embryos  was  performed  in 
four cases  because  of the  imminent  risk of OHSS,  and  two  IVF  cycles  were 
cancelled  due to failed  fertilisation.  All  of the women  received  GnRH  agonist 
and recombinant FSH to achieve adequate ovarian stimulation. In 28 ET cycles, 
13 clinical pregnancies were confirmed.
The  patient  and  treatment  cycle  characteristics were  summarized  (Table  5.8- 
5.10). When women who conceived were compared with those who did not, no 
significant  differences  in  any  of the  demographic  parameters  were  observed 
except  for  the  duration  of  subfertility.  Longer  delays  in  fertility  were  more 
common in women who did not conceive.
In the pregnant group, the day  10 serum oestradiol  concentrations,  number of 
developing  follicles  measuring  13  to  16mm,  number  of  follicles  aspirated, 
oocytes collected, and 2-PN embryos created were greater, and the duration of 
stimulation shorter with smaller doses of FSH stimulation.
154Table 5.8: Patient Characteristics for Clinical Pregnancy
Mean ± SD or Incidence  |
Pregnant Non-pregnant P
Age (year) 32.7 ±4.8 33.8 ± 3.4 NS  I
Gravidity 0.9 ± 1.4 0.6 ±0.7 NS
Parity 0.2 ± 0.4 0.4 ±0.7 NS
BMI (kg/m2) 25 ±6.1 25 ±4.3 _.„......NS
Duration of subfertility (year) 3.5 ±1.6 5.9 ±3.8 <0.05
Type of the subfertility (couple) |  j
Primary 7 (53%) 11  (73%) NS
Secondary 6 (47%) 4 (27%) NS
Parity |
Parous 3  (23%) 4  (26%) NS
Nulliparous 10 (77%) 11  (73%) NS
Table 5.9: Diagnosis of Subfertility for Clinical Pregnancy
Pregnancy
Aetiology
P I Male Tubal Unexplained Ovarian
Yes 6 7 o 0  I i
No 5 5 3 2  ! NS
Total 11 12 3 2  I I
Table 5.10: IVF Cycle Characteristics for Clinical Pregnancy
Pregnant
Mean ± SD 
Non-pregnant _____P..
Number of days of stimulation 11.5 ± 1.7 13.6 ±2.5 <0.05
Total dose of FSH used (IU) 1741 ±331 2398 ±  827 <0.05
Day 10 E2  (nmol/l) 2.7 ± 1.9 1.4 ± 1.2 <0.05
Number of Day 10 follicles (13-16 mm) 5.6 ±4.6 2 ± 1.5 <0.05
Number of follicles aspirated 11.3 ±4.7 7.4 ±4.2 <0.05
Number of oocytes collected 10.1 ±4.5 6.4 ± 3.9 <0.05
Number of 2-PN embryos 5.8 ± 2.9 3.6 ±2.7 <0.05
There  were  no  statistically  significant  differences  in  Doppler  indices  (PI,  Rl, 
Vmax, Vmin) for right and left uterine artery impedance and so the mean value 
for each  woman  was  calculated  and  used  for subsequent  comparison  (Table 
5.39, 5.40CD).
Throughout the different stages of the IVF treatment (baseline and the last day 
of ovarian stimulation), there was a strong linear correlation among the different 
Doppler indices  of PI,  Rl,  S/D for uterine,  sub-endometrial  and follicular blood 
flows (Table 5.41-5.44CD).
155In  the  pregnant  and  non-pregnant  groups,  there  was  no  difference  in  mean 
baseline uterine artery impedance (PI and Rl), but in the pregnant group the last 
day  flow  before  hCG  injection  in  the  ascending  uterine  arteries  was 
characterised by significantly lower PI values (Table 5.11).
During  ovarian  stimulation,  when  compared  with  baseline values there was  a 
significant  decrease  in  the  PI  values  on  the  day  of the  last  ultrasound  scan 
before  hCG  injection  in  the  pregnant  group.  This  drop  in  vascular  resistance 
was not seen in the non-pregnant group (Table 5.11).
Table 5.11: Uterine Artery Doppler Indices for Clinical Pregnancy
Mean ± SD  I
Pregnant  |  Non-pregnant  |  p
Baseline uterine artery PI 2.9 ±1.3 2.4 ±0.9  I   NS
Baseline uterine artery Rl 0.8 ±0.1 0.8 ±0.0  j  NS
Last day uterine artery PI 2.0 ±0.5 2.8 ± 1.3 <0.05
Last day uterine artery Rl 0.7 ± 0.0 0.8 ±0.1 0.08
■
<0.05 Baseline -  Last day uterine artery PI 0.9 ±1.4 -0.2 ± 0.4
When  measured  by  S/D  ratio  rather  than  PI  and  Rl,  lower  uterine  artery 
impedance lost its significant association with the treatment outcome,  because 
of the undefined  S/D values in cases of absent end diastolic blood flow (Table 
5.45CD).
In the pregnant group, the last day peri-follicular blood flow was characterised 
by lower vascular impedance but this did not reach statistical significance. The 
follicle  with  the  most  extensive  perifollicular  vascular  perfusion  on  colour 
mapping was selected for assessment (Table 5.12).
156Table 5.12: Peri-follicular Blood Flow to the Dominant Follicle for Clinical Pregnancy
Mean ± SD  j
Pregnant Non-pregnant P
Last day follicle PI 0.7 ±0.1 1.1 ±0.6 NS
Last day follicle Rl 0.5 ±0.0 0.5 ±0.1 NS
Last day follicle S/D 2.1 ±0.3 2.5 ± 1.2  | NS
Last day peri-follicular vascularity 24% ±  8% 24% ±13%  I NS
In the pregnant and non-pregnant groups, there was no significant difference in 
mean sub-endometrial vascular impedance during ovarian stimulation, with the 
exception of baseline sub-endometrial  Rl  values, which were slightly higher in 
the pregnant group (Table 5.13).
Table 5.13: Sub-Endometrial Blood Flow for Clinical Pregnancy
Mean ± SD
Pregnant Non-pregnant P
Baseline Sub-endometrial PI 1.8 ±0.9 1.6 ± 1.4 NS
Baseline Sub-endometrial Rl 0.7 ±0.1 0.5 ±0.1 <0.05
Baseline Sub-endometrial S/D 3.9 ±3.0 3.6 ±13.9 NS
Last day Sub-endometrial PI 1.3 ±0.7 1.3 ± 1.0 NS
Last day Sub-endometrial Rl 0.6 ±0.2 0.6 ±0.1 NS
Last day Sub-endometrial S/D 2.5 ±0.9 2.9 ± 1.7 NS
No  significant  association  was  detected  between  the  uterine  artery  vascular 
impedance  values  and  corresponding  oestradiol  levels,  baseline  FSH  values 
and BMI (Table 5.14).
Table 5.14: Correlations between Uterine Artery PI and Clinical Variables
e2   I  I
Uterine Artery BMI Baseline Last day  |  FSH  j
Baseline PI
Correlation Coefficient 0.12 -0.03 0.17  |  -0.13  I
P NS NS NS|  NS  |
Last day PI
Correlation Coefficient 0.20 0.20 0.009  |  -0.25  |
P NS NS NS  |  NS  |
157During ovarian stimulation endometrial growth was comparable in the pregnant 
and  non-pregnant  groups  and  there  were  no  significant  differences  in 
endometrial thickness at the end of ovarian stimulation.  Further, there was  no 
linear correlation of endometrial thickness with E2 levels, Doppler indices of the 
uterine artery, or sub-endometrial blood flow at baseline and the day of the last 
ultrasound scan (Table 5.15, 5.16).
Table 5.15: Endometrial Thickness for Clinical Pregnancy
Mean ± SD  |  |
Pregnant Non-pregnant  | P  1
Baseline  Endometrial Thickness 2.4 ± 1.7 mm  | 2.3 ± 0.9 mm  | NS  |
Last day  Endometrial Thickness 11.4 ± 2.7 mm  | 10.7 ± 2.8 mm  | NS)
Table 5.16: Correlations between Endometrial Thickness and (E2  level,  Uterine Artery PI, Sub- 
endometrial PI)
Correlation Coefficient (p)  |
E2 level Uterine artery PI Sub-endometrial PI  |
Baseline  Endometrial Thickness -0.16 (NS) -0.20 (NS) -0.01  (NS)  |
Last day  Endometrial Thickness 0.21  (NS) 0.10 (NS) -0.10 (NS)  [
In  the  pregnant  group  the  last  day  uterine  artery  resistance  was  significantly 
lower.  An  ROC  curve was  plotted  to  identify the optimum  cut-off point for the 
last  day  uterine  artery  PI,  which  separated  the  good  and  poor  prognostic 
groups. The aim was to locate a PI cut-off level above which none of the women 
in  the  poor  prognostic  group  would  achieve  pregnancy,  so  that  the  poorest 
response group could be identified (sensitivity 0.00). When the cut-off level was 
3.00 (Area: 0.31, SE: 0.10, 95%CI: 0.1  to 0.5) ROC curve analysis revealed the 
test  sensitivity  to  be  0.00  with  specificity  0.54.  Therefore,  in  women  with  PI 
values >3.00, the probability of pregnancy is very low when predicted by the last 
day  uterine  artery  Doppler.  This  was  further tested  by  categorising  the  study 
population into two groups based on their PI values being < or > 3 (Table 5.17).
Table 5.17: Last Day Uterine Artery PI for Clinical Pregnancy
Pregnancy Last  Day Mean Uterine Artery PI |
<3 >3 P
Yes 13 0
<0.01  |
No 8 7
158There  was  no  difference  in  the  baseline  uterine  artery  vascular  resistance 
between  the  pregnant  and  non-pregnant  groups.  The  hypothetical  PI  cut-off 
level of 14.5 minimised the sensitivity of the test to 0.00 (Area: 0.52,  SE: 0.11, 
95% Cl: 0.3 to 0.7). Therefore, at the baseline investigation, the conventional PI 
cut-off level of 3 did not prognostically identify the women (Table 5.18).
Table 5.18: Baseline Uterine Artery PI for Clinical Pregnancy
Pregnancy Baseline Mean Uterine Artery PI
<3 >3
P
Yes 7 6
NS
No 8 7
The last day peri-follicular vascular resistance of the dominant follicle was lower 
in women in the pregnant group, however the difference in mean values did not 
reach a level of statistical significance. An ROC curve was plotted to identify the 
optimum cut-off point for statistical  significance (Area:  0.37,  SE:  0.12,  95% Cl: 
0.1  to 0.6).  In  determining the  prognosis, when the cut-off level  was  1.08,  the 
sensitivity  of  the  test  was  0.00  with  a  specificity  of  0.73.  Therefore,  when 
predicted  by  peri-follicular  blood  flow,  with  PI  values  >1  the  probability  of 
pregnancy  was  very  low.  This  was  further  tested  by  categorising  the  study 
population  based  on  PI  values  <  or >1,  and the  probability of pregnancy was 
significantly different between the two groups (Table 5.19).
Table 5.19: Last Day Follicular PI for Clinical Pregnancy
Pregnancy
Last  day Follicular PI
<1 >1
Yes 11 o <0.05  I
No 8 3
When the same approach was  applied to sub-endometrial  vascular resistance 
values at baseline and the day of the last scan, very high cut-off levels beyond 
the  maximum  observed  test values  were  required  to  achieve  0.00  sensitivity. 
Therefore,  there  were  no  practical  cut-off  levels  at  which  the  statistical 
significance could be tested for good or poor prognosis (Table 5.20).
159Table 5.20: Baseline and Last Day Sub-endometrial PI for Clinical Pregnancy
Pregnancy
Baseline Si 
£ 3
ib-endometrial PI  j  I
............................................>3.1........................P
Yes 8 5
NS  I
No 7  |  8
Last Day Sub-endometrial PI  |
Yes 11  |  2
NS  |
No 11  |  4
Women with a last day uterine artery PI value >3, also had poorer perifollicular 
vascularisation and sub-endometrial perfusion, and fewer maturing follicles and 
collected oocytes.  Higher alcohol consumption appeared to be associated with 
lower uterine artery resistance (Table 5.21).
Table 5.21: Variables for Last Day Uterine Artery Doppler Indices with ‘cut off = 3’
High
Resistance
Mean ± SD  [
Low  j  
Resistance
i
p !
<0.05  | Number of follicles (8-12mm) on the last scan day 2.4 ± 1.9 4.7 ±4.8  |
Number of follicles (13-16mm) on the last scan day 2.8 ±2.2 5.5 ±4.4  | <0.05
Number of aspirated oocytes 7.5 ±4.1 11 ±7.1 0.08
Peri-follicular vascularity on the last scan day (%) 0.1 ±0.0 0.2 ±0.1  | 0.01  |
Peri-follicular PI on the last scan day 1.3 ±0.8 0.7 ±0.1  | <0.01  |
Sub-endometrial PI on the last scan day 1.7 ± 1.2 1.1 ±0.5  I 0.07  j
Female alcohol intake (unit / week) 1.7 ±2.3 8.0 ± 10.4  | <0.01  j
High resistance: Vascular resistance above the cut off  Low resistance: Vascular resistance below the cut off
At the baseline scan there was a  significant linear correlation  between female 
smoking and higher sub-endometrial vascular resistance (Table 5.22).
Table 5.22: Female Smoking for Baseline Sub-endometrial PI, Rl
Baseline 
Sub-endometrial PI
Baseline 
Sub-endometrial Rl
Female smoking
Pearson Correlation 0.39 0.38
.P................. .............. <0.05 <0.05
160With the last day follicular PI  cut-off level  of 1.5 the sensitivity of the test was 
minimised  to  0.00,  as  with  the  cut-off level  1,  but with  a  higher  specificity of 
80%, thereby ensuring that the women with the lowest probability of pregnancy 
could be identified with less probability of including those with a better prognosis 
(Area: 0.37, SE: 0.12, 95% Cl: 0.1 to 0.6)
When  this  cut-off  level  was  applied  to  identify the  poorest  prognostic  group, 
women  with  a  PI  value  of  >1.5  had  lower  oestrogen  concentrations,  fewer 
mature  follicles,  fewer  follicles  aspirated,  fewer  oocytes  collected,  and  fewer 
embryos  created.  This  suggested  an  association  between  poor  follicular 
perfusion, poor ovarian response, and poor clinical outcome (Table 5.23).
Table 5.23: Variables for the Last Day Peri-follicular Doppler Indices with ‘cut off = 1.5’
High
Resistance
Mean ± SD
Low
Resistance
____   I
P
Last scan day E2  concentration (nmol/l) 1.3 ±0.0 4.9 ±2.8 <0.01  j
Number of follicles (8-12mm) on the last scan day 2.0 ±0.0 4.5 ±4.8 <0.01  I
Number of follicles (>20mm) on the last scan day 0.0 ±0.0 1.1 ± 1.1 <0.01  I
Number of follicles aspirated 4.5 ±0.7 12.3 ±7.0 <0.01  I
Number of oocytes collected 3.5 ±2.1 11.0 ± 7.0 <0.05
Number of 2-PN embryos 1.0 ±0.0 6.4 ±4.8 <0.01  |
Number of embryos cryopreserved 0.0 ±0.0 3.4 ±5.1 <0.01  I
High resistance: Vascular resistance above the cut off  Low resistance: Vascular resistance below the cut off.
When compared with the placebo group, co-treatment with aspirin  150 mg per 
day did not improve any of the Doppler Indices of the uterine, sub-endometrial, 
and follicular blood flow or the follicular vascularity and endometrial thickness at 
any  significant  level  either  soon  after  pituitary  down-regulation  or  during  the 
ovarian stimulation (Table 5.46CD).
1615.3  VEGF-VEGFR Concentrations in the Aspirin and Placebo Groups
Serum  VEGF  and  VEGFR  levels  were  measured  in  80  women  during  pre­
treatment  natural  cycles,  and  in  59  of these  on  the  day of oocyte  collection. 
Four  samples  of  follicular  fluid  were  discarded  due  to  blood  contamination. 
Follicular fluid levels were measured in 55 women from the same cohort (Table 
5.24).  In the  aspirin  and  placebo groups there was  no significant difference in 
pre- and  post-treatment serum  levels of VEGF (pg/ml) and VEGFR (pg/ml), or 
follicular fluid concentrations (Table 5.25).
Table 5.24: VEGF and VEGFR Concentrations
Pre-
Treatment
Serum
VEGF
Post-
Treatment
Serum
VEGF
Follicular
Fluid
VEGF
Pre-
Treatment
Serum
VEGFR
Post-
Treatment
Serum
VEGFR
Follicular  I 
Fluid  | 
VEGFR
N 80 59 55 80 59 55  |
Mean 
± SD
285.0 ± 
203.3
297.1  ± 
179.2
3107.5 ± 
1636.3
32.8 ± 
12.3
35.0 ± 
10.6
4470.7 ±  I 
1755.7  |
VEGF and VEGFR Concentrations: pg/ml.
Table 5.25: VEGF and VEGFR Concentrations for the Aspirin vs Placebo Groups
N Mean ± SD  p
Pre-treatment Serum VEGF
Aspirin  |  36  I______ 265.2 ± 176.6  j  N§
Placebo  |  43  |  299.4 ± 225.8  |
Post-treatment Serum VEGF
Aspirin  |  29  |  288.3 ±169.8  |  
Placebo  |  30  |  305.6 ±190.3  |
Follicular Fluid VEGF
Aspirin  [  27  {   2738.7 ± 1318.0  I   Ng 
Placebo  I  28  |  3463.2 ± 1848.0  j
Pre-treatment Serum VEGFR
Aspirin  |  36  [  34.1  ± 12.6 
Placebo  |  43  |  31.5 ±12.3  |
Post-treatment Serum VEGFR
Aspirin  I  29  [_________ 35.0 ± 7.7  j  ^
Placebo  |  30  |  35.1 ± 13.0  |
Follicular Fluid VEGFR
Aspirin  |  27  |  4062.8 ± 1736.1
Placebo  |  28
1  NO
4864.2 ± 1713.4  i
VEGF and VEGFR Concentrations: pg/ml.
1625.3.1  VEGF-VEGFR Concentrations in Different Outcome Groups
In  the  ET  and  no-ET  groups  there  was  no  difference  in  the  pre-  and  post­
treatment  serum  VEGF  and  VEGFR  levels,  and  the  FF  VEGF  levels  were 
similar.  However,  FF VEGFR levels were significantly lower in the no-ET group 
(Table 5.26,  Table 5.47CD).
Table 5.26: Comparison of VEGFR levels for ET and No-ET Groups
Embryo Transfer N Follicular Fluid VEGFR (Mean ± SD) P  I
Yes 50 4635.5 ± 1744.7
0.01  |
No 5 2823.1  ±770.8
VEGFR Concentrations: pg/ml.
There were no differences in pre- and post-treatment serum VEGF and VEGFR 
or  FF  VEGF  levels  in  the  ET,  no-ET  due  to  elective  cryopreservation  of  all 
embryos to  prevent OHSS,  no  ET due to failed fertilisation,  and  no-ET due to 
cancellation  before  oocyte  collection  groups.  However,  FF  VEGFR 
concentrations were lower in the no-ET group due to elective cryopreservation 
of  all  embryos  than  in  the  ET  group  (3038  vs  4635  pg/ml;  p:<0.05)  (Table 
5.48CD).
In the pregnant, non-pregnant and no-ET groups there was no difference in the 
levels of pre-  and  post-treatment serum VEGF  and VEGFR.  The  levels of FF 
VEGF were  also similar,  but the  levels of FF VEGFR were  significantly lower 
(Table 5.27, Table 5.49CD).
Table 5.27: Comparison of Follicular Fluid VEGFR for Clinical Pregnancy
Pregnant !   n  | Follicular Fluid VEGFR (Mean ± SD)  | P
Yes i  26  | 4529.1 ± 1800.5  |
No 24 4750.8 ± 1713.0  | <0.05
No ET J .  5 j  _  _ 2823.1  ±770.8
VEGFR Concentrations: pg/ml.
In the ongoing pregnancy, no-ongoing pregnancy and no-ET groups, there was 
no  difference  in  the  levels  of  pre-  and  post-  treatment  serum  VEGF  and 
VEGFR.  The  levels  of  follicular  fluid  VEGF  were  similar,  but  there  were 
significant differences in the levels of FF VEGFR (Table 5.28,  Table 5.50CD).
163Table 5.28: Comparison of Follicular Fluid VEGFR for Ongoing Pregnancy
Ongoing Pregnancy N Follicular Fluid VEGFR (Mean ± SD) P i
Yes 20 4525.6 ± 1924.8 |
No 30 4708.8 ± 1643.7 <0.05
No ET 5 2823.1  ±770.8 ..............I
VEGFR Concentrations: pg/ml.
In the ongoing  pregnancy,  miscarriage,  biochemical  pregnancy,  no-pregnancy 
and  no-ET  groups,  there  was  no  difference  in  the  levels  of  pre-  and  post­
treatment serum VEGF  and VEGFR,  and the levels of FF VEGF  and VEGFR 
were similar (Table 5.51CD).  In the fresh IVF treatment study cycle and related 
FTER  cycle,  the  cumulative  pregnancy  rates  were  calculated  and  the  data 
evaluated for the ongoing  pregnancy,  biochemical  pregnancy,  miscarriage,  no­
pregnancy and no-ET groups. There was no difference in the levels of pre-and 
post-treatment  serum  VEGF  and  VEGFR  or  FF  VEGF  and  VEGFR  (Table 
5.52CD).
5.3.2  VEGF-VEGFR Concentrations and Number of Embryos Implanted
In  the  fresh  IVF  treatment  cycles,  the  number of  implanted  embryos  did  not 
correlate with the levels of pre- or post-treatment serum VEGF and VEGFR or 
FF VEGF and VEGFR. Although not reaching a level of statistical significance, 
there  was  a  consistent  negative  association  between  implantation  and  the 
levels  of  pre-  and  post-treatment  serum  VEGFR  and  FF  VEGF  and  VEGFR. 
However, when the cumulative implantation rate of the fresh and  related FTER 
cycles was evaluated,  the  number of implanted  embryos  negatively correlated 
with the levels of FF VEGF (p: 0.01).
Pre-treatment  levels  of serum  VEGF  correlated  positively with  post-treatment 
levels  of  serum  VEGF  (p:  <0.001),  but  negatively  with  pre-treatment  serum 
VEGFR (p: <0.01) and post-treatment serum VEGFR (p: <0.05). However, there 
was  no correlation  with  FF VEGF or its  receptor.  The levels of post-treatment 
serum  VEGF  correlated  negatively  with  pre-  (p:  <0.01)  and  post-  (p:  <0.05) 
treatment  serum  VEGFR.  There  was  no  correlation  with  FF  VEGF  or  its 
receptor.  The  levels  of  FF  VEGF  correlated  positively  with  the  levels  of  its 
receptor  in  follicular fluid  (p:  <0.05)  and  negatively  with  pre-treatment  serum
164VEGFR (p: <0.05). Pre-treatment serum VEGFR correlated positively with post­
treatment serum VEGFR (p: 0.001) (Figure 5.1, 5.2,  Table 5.53-5.56CD).
165Figure 5.1: Correlations between VEGF-VEGFR Concentrations (1)
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166Figure 5.2: Correlations between VEGF-VEGFR Concentrations (2)
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1675.3.3  VEGF:VEGFR  Ratio  and  Difference  Between  Pre-  and  Post-treatment 
VEGF Concentrations
The  ratio  of  VEGF  to  VEGFR  and  the  change  in  VEGF  levels  during  IVF 
treatment were used as independent parameters. No differences were detected 
in  either  parameter  in  the  ongoing  pregnancy,  miscarriage,  biochemical 
pregnancy, no-pregnancy and no-ET groups (Table 5.57-5.60CD).
5.3.4  VEGF-VEGFR Concentrations and Clinical Variables
The  levels  of  pre-treatment  serum  VEGF  did  not  correlate  at  a  statistically 
significant level with female age,  duration of subfertility,  gravity,  parity,  alcohol 
consumption,  duration  of menstrual  cycle and  bleeding,  weight,  height or BMI 
(Table 61 CD). The levels of pre-treatment serum VEGFR correlated negatively 
with duration of subfertility (p: <0.01) and weight (p: 0.01).
The  levels  of post-treatment  serum  VEGF  and  VEGFR  did  not  correlate  at  a 
statistically significant level with the clinical parameters (Table 61 CD).
The levels of FF VEGF correlated positively with female age (p: <0.001), weight 
(p:  <0.01)  and  BMI  (p:  <0.001),  and  the  levels  of  FF  VEGFR  correlated 
positively with female age (p: 0.01) (Table 5.61CD).
There  was  no  significant  difference  between  primary  and  secondary  female 
subfertility (Table 5.62CD), or between regular and irregular menstrual cycles in 
the  levels  of pre-  and  post-treatment serum  or  FF  VEGF  and VEGFR  (Table 
5.65CD).  There  was  no  significant  difference  between  smoking  and  non­
smoking women or between women who do and do not consume alcohol in the 
levels of pre- and  post-treatment serum or FF VEGF and VEGFR (Table 5.66, 
67CD).
In the aetiologies of subfertility, there was no significant difference in the levels 
of  pre-  and  post-treatment  serum  or  FF  VEGF  and  VEGFR.  However,  the 
absolute  values  for  VEGF  in  serum  and  follicular  fluid  showed  a  trend  of 
endometriosis > unexplained > tubal factor = male factor > ovarian factor.  The
168absolute values for VEGFR in serum and follicular fluid showed a trend of male 
factor > tubal factor > unexplained > endometriosis > ovarian (Table 5.68CD).
5.3.5  VEGF-VEGFR Concentrations and IVF Variables
Patient  characteristics,  clinical  variables  of  ovarian  stimulation  and  IVF  that 
correlated with the VEGF and VEGFR concentrations were summarized (Table 
5.29,  5.30).  Positive  correlation  between  the  variables  was  given  as  ‘t \  
negative  correlation  as  and  no  correlation  as  Correlations  with  a  p 
value of <0.05 were marked as **’, and those with a p value of 0.05-0.09 as 
Numerical  values  of  the  correlation  coefficients  and  corresponding  p  values 
were given on the CD Rom (Table 5.69CD).
There was  no difference in the levels of pre- and  post-treatment serum VEGF 
and VEGFR or FF VEGF and VEGFR between women who developed ovarian 
cysts following down-regulation and those who did not (Table 5.70CD).
169Table 5.29:  Correlations between Clinical Variables of Ovarian Stimulation,  IVF and the VEGF,
VEGFR Concentrations
Pre-treatment
Serum
Post-treatment
Serum
Follicular Fluid
VEGF  | VEGFR VEGF VEGFR VEGF VEGFR
Baseline FSH <-» <-» < ->
Duration of Gonadotrophin 
Stimulation < -> <->
Total Gonadotrophin Dose t*
Oestrogen Level after 
Down-regulation
< |k * <-> < ->
Oestrogen Level before 
hCG Injection < -> < -> <-> < ->
< 9 mm <-> <-> <-> < ->
10-15 <-> < -> <-> <-> k **
Number of 16-17 < -> <-> > < ->
Follicles
18-20 < -> < -> <-» < ->
21-25 < -> • <-> <-> < ->
26-30 < -> < -> <-> <-> <->
Follicles Aspirated < -> 4r**
Oocytes Collected < -> <-> I I **  i
Oocytes Used <-> < -> 4*  |
2-PN Embryo < -> < -> <-> > < ->
Number of Embryos 
Transferred < -> < -> < -> < ->
Number of Embryos 
Cryopreserved I* O < -> k
O
Grade of the First 
Transferred Embryo <-> <-» <-> <-> O
Grade of the Second 
Transferred Embryo <-> < -> <-> < -> < -> < ->
Mean Platelet Volume 
Before Treatment < -> < -> <-> < ->
Mean Platelet Volume 
After T  reatment
<r> < -> *-> < ->
t:  Positive  correlation  between  the  variables, I:  negative  correlation,  <-»  :  no  correlation,  *  :  p:<0.05,  :  p:0.05-0.09.
170Table  5.  30:  Summary  of the  Significant  Correlations  between  Clinical  Variables  of Ovarian 
Stimulation, IVF, Treatment Outcome and the VEGF, VEGFR Concentrations
Pregnant
vs
Not-
pregnant
vs
no-ET
ET
vs
no-ET
Positive
Correlation
Negative
Correlation
Pre­
treatment
Serum
VEGF NS NS
FSH
Number of Embryos 
cryo-preserved
VEGFR NS NS
Subfertility duration 
Weight
Post­
treatment
Serum
VEGF NS NS E2  after
down- regulation
VEGFR NS NS  |
Follicular
Fluid
VEGF
i  in
pregnant
(NS)
1 in 
no-ET
(NS)
Age
Weight, BMI 
Stimulation 
duration 
Total FSH dose
Implantation in Fresh + 
FTER
E2  before hCG 
Number of 10-17mm 
follicles
Follicles aspirated 
Oocytes collected 
Embryos created 
Embryos cryo-preserved
VEGFR
I  in no-ET 
due to imminent 
hyperstimulation risk
Age
Stimulation
duration
Total FSH dose
Number of 10-15 mm 
follicles
Oocytes collected
NS: Not significant. Associations not reaching the level of significance are marked as NS.
5.3.6  VEGF-VEGFR Concentrations and Doppler Variables
Correlations between sub-endometrial and the uterine artery Doppler variables 
and VEGF, VEGFR concentrations during ovarian stimulation were summarized 
(Table  5.31).  Positive  correlation  between  the  variables  was  given  as  ‘t \  
negative  correlation  as  li'.  Correlations with  a  p value  of <0.05 were  marked 
with  and  those  with  a  p  value  of  0.05-0.09  with  Poor  perfusion  was 
defined by the combination of a high PI ± low drop in PI during the treatment. In 
this assessment, correlations with the PI had the priority to define the perfusion 
status  unless  the  correlations  with  the  level  of  drop  in  PI  had  a  statistically 
higher significance.  Correlations with  a  p value of >0.09 were  included  only if 
the  direction  of  their  associations  with  the  VEGF-VEGFR  concentrations 
persistently fitted a common theme of poor or good perfusion. Numerical values 
of the correlation coefficients and corresponding p values were given in the CD 
Rom (Table 5.71, 5.72CD).
171Table 5.31: Correlations between Doppler Variables and the VEGF, VEGFR Concentrations
Pre-treatment
Serum
Post-treatment
Serum Follicular Fluid
VEGF VEGFR VEGF VEGFR VEGF VEGFR  j
Uterine
Artery
Perfusion
Baseline PI Ijli* I T* t t  1
Last Day PI
Last Day -  
Baseline PI
t
f t
I
t
__ t _
4**
__ T___ t  |
Poor Uterine Artery 
Perfusion
High
VEGF
Low
VEGFR
High
VEGF
Low
VEGFR
High
VEGF
High
VEGFR
Sub-
endometrial
Perfusion
Baseline PI T I t I t
Last Day PI t ft t I "pp t
Last Day -  
Baseline PI 4 t I
Poor Sub-endometrial 
Perfusion
High
VEGF
Low
VEGFR
High
VEGF
Low
VEGFR
High
VEGF
High
VEGFR
t   Positive correlation between the variables,  negative correlation, f : p:<0.05, ** : p:0.05-0.09. 
uterine artery perfusion: Positive correlation of PI values and VEGF concentration (High resistance associated with high 
VEGF), and negative correlation of the drop in PI values during treatment and VEGF concentration (Lower levels of drop 
in  PI  values during treatment associated with  high VEGF).  Because high  PI  values and a  low drop in  PI  values during 
the treatment referred to poor perfusion, high VEGF concentrations were associated with poor uterine artery perfusion.
5.3.7  Multivariate  Analysis  of  Doppler Variables  of  Utero-ovarian  Blood  Flow 
and VEGF and VEGFR for Prediction of Pregnancy
Logistic  regression  analysis  on  53  subjects  revealed  the  late follicular phase- 
uterine  artery  Doppler  indices  during  ovarian  stimulation  and  post-treatment 
serum  VEGFR  levels  as  the  independent  prognosticators.  The  following 
independent variables were tested for prognostic significance using the forward 
stepwise conditional entry method (Table 5.32, 5.33).
172Table 5.32: Independent variables used in the Logistic Regression Analysis (1)
Female A ge_______
Duration of Subfertility
Parity
Gravity
BMI
Sperm Parameters
Aetiology
Protocol
Total Gonadotrophin Dose
Duration of Gonadotrophin Stimulation
Baseline Oestrogen Level
Day 10 Oestrogen Level
Last Day Oestrogen Level
Number of Follicles Aspirated
Number of Oocytes Aspirated
Number of Embryos Created
Grade of the First Embryo
Grade of the Second Embryo
Cryopreserved Embryos
Type of IVF
Treatment Group
Pre Treatment Serum VEGF
Post Treatment Serum VEGF
Follicular Fluid VEGF
Pre Treatment Serum VEGFR
Post Treatment Serum VEGFR
Follicular Fluid VEGF Receptor
Mean Platelet Volume Before Treatment
Mean Platelet Volume After Treatment
Differences in Platelet Count
Difference in Mean Platelet Volume
Baseline Endometrial Thickness
Last Day Endometrial Thickness 
Uterine Artery Doppler Values
Sub-endometrial Doppler Values
Peri-follicular Doppler Values
Table 5.33: Variables in the Equation for Clinical Pregnancy (1)
Regression
Coefficient
SE OR  | p R2
Uterine Artery PI 8.84 3.81 >10.00  I <0.05 0.34
Post Treatment Serum VEGFR 0.10 0.04 1.10  | <0.05
Constant -9.96 3.62 0.00  | 0.01
173A more focused logistic regression analysis was performed on 35 patients using 
the  forced  entry  method.  The  dependent  variable  was  pregnancy,  and 
independent  variables  were  assessed  for their  prognostic  significance  (Table 
5.34, 5.35).
Table 5.34: Independent Variables used in the Logistic Regression Analysis
Pre Treatment Serum VEGF______________________________________________________
Post Treatment Serum VEGF____________________________ ■ ________________________ |
Follicular Fluid VEGF____________________________________________________________j
Pre Treatment Serum VEGFR  _ _  ________________   _  _  |
Post Treatment Serum VEGFR____________________________________________________|
Follicular Fluid VEGFR__________________________________________________________ |
Uterine Artery Doppler Values________________________________    |
Peri-follicular Doppler Values_____________________________________________________ |
Table 5.35: Variables in the Equation for Clinical Pregnancy (2)
Regression Coefficient SE OR P  I
Pre Treatment Serum VEGF 0.02 0.01 1.02 0.05
Post Treatment Serum VEGF -0.02 0.01  i 0.98 0.05  |
Only pre- and post- treatment serum VEGF concentrations were significant and 
none  of the  Doppler  indices  maintained  their  univariate  discriminative  power. 
This  may further  indicate  the  primacy of VEGF  control  over tissue  perfusion, 
which  was  subsequently  assessed  sonographically  and  hence  assumed  a 
secondary role.
1746  Low-dose  Aspirin  Co-treatment  in  Patients  Undergoing  IVF 
Treatment: Discussion
The ‘aspirin group’  comprised 46 couples and the ‘placebo group’  51  couples. 
All  couples  invited  for  participation  had  consented  to  take  part;  but  three 
couples who were randomized to the aspirin group later decided not to proceed 
with IVF treatment. There were no reported or observed side effects caused by 
the  use  of  aspirin.  For  the  extent  of  the  study,  there  were  no  bleeding 
complications during oocyte collection procedures.
The  strength  of  the  study  was  its  ability  to  establish  cross-links  between 
demographic,  clinical,  embryological,  and  ultrasonographic  variables,  Doppler 
indices and VEGF-VEGFR concentrations, to build a comprehensive model.  All 
assessments were  performed  serially throughout the treatment for  IVF on the 
same  study  cohort,  allowing  real  time  evaluation  of  different  associations  as 
they  arose  and  interacted.  A  stepwise  approach  was  employed  for  different 
clinical  outcome  variables  in  a  logical  time  perspective  from  ET  to  positive 
pregnancy test,  clinical  pregnancy,  and  pregnancy  beyond  the  first  trimester. 
This was done as  both  a cross-sectional  examination of the primary fresh  IVF 
treatment  cycles  alone  and  a  cumulative  examination  of  the  related  FTER 
cycles.
The main weakness of the study was  its small  sample size,  but wherever this 
has  appeared  to  influence  the  level  of significance  of a  trend,  this  has  been 
specifically emphasized  in the text.  Because an extensive list of variables was 
analyzed  in  a  relatively  small  study  population,  some  of the  associations  and 
differences  may  be  influenced  by  a  random  chance  factor.  However,  the  aim 
was, wherever possible, to interpret the results in an overall biologically rational 
model built with the support of other statistically significant findings.
The first part of the discussion follows, with comparison between the aspirin and 
placebo  groups  in  terms  of  their  demographic,  clinical,  and  embryological 
variables and treatment outcome. The second part of the discussion covers the 
Doppler variables in terms of their association with the treatment outcome and 
the influence of aspirin on their performance. The third and final section of the
175discussion  is of VEGF  and VEGFR  interactions  in the whole study population 
and separately in the aspirin and placebo groups.
6.1  Comparison of Aspirin and Placebo Groups
The demographic characteristics of the couples and the semen  parameters of 
the male partners were similar in the aspirin and placebo groups.  Furthermore, 
the two study groups received the same stimulation protocol (Day 21  vs Day 2), 
type  of  GnRH  analogue,  gonadotrophin  and  fertilization  (conventional  IVF  or 
ICSI). The occurrence of ovarian cysts following down-regulation was similar in 
both groups (Table 5.17-5.25CD). The degree of technical difficulty and duration 
of the  ET  procedures  were  also  similar in  both  groups.  Hence,  there was  no 
confounding  factor affecting  the  comparison  of the two  groups,  that  might  be 
related  to  the  ET  procedure  (Table  5.33CD).  Therefore,  with  two  study 
populations  having  a  comparable  background  prognosis  for  assisted 
conception, any variation observed in the outcome of their treatment should be 
a  function  of that  treatment.  Consequently,  the  only  variable  with  prognostic 
potential that differed between the two groups was the aspirin co-treatment.
No  statistically  significant  differences  in  ovarian  stimulation  and  In  vitro 
fertilization  variables  were  noted  between  the  aspirin  and  placebo  groups. 
Further,  the  number  of  embryos  cryopreserved  or  transferred,  and  the 
anatomical grading of the best two embryos selected for transfer, did not differ. 
The  percentage of couples  having fresh  ET,  elective embryo cryopreservation 
due to the risk of OHSS, failed fertilization, and cycle cancellation before oocyte 
collection was also similar between the two groups (Table 5.26-5.33CD).
Therefore,  in  terms  of clinical  and  embryological  variables,  no  quantitative  or 
qualitative  improvement that  can  be  attributable  to  the  aspirin  treatment was 
evident in the ovarian response to stimulation.
The ineffectiveness of the aspirin co-treatment was also witnessed in relation to 
endometrium  and  implantation.  After fresh  ET,  the  implantation  and  ongoing 
pregnancy  rates were  similar in the aspirin  and  placebo groups.  Furthermore, 
no  benefit  of  aspirin  co-treatment  was  detected  in  minimizing  biochemical
176pregnancies or first trimester miscarriages.  However, when the absolute values 
were studied beyond their statistical comparison, a different picture emerged. In 
the  placebo  group,  the  number  of couples  who  achieved  ongoing  pregnancy 
was one third higher than that of the aspirin group (33% vs 24%). Although this 
difference was not statistically significant, a possible detrimental effect of aspirin 
on  implantation  cannot  be  ruled  out  (Table  5.6,  Table  5.26CD).  Because the 
ovarian  response  parameters  were  similar  in  both  groups,  even  in  absolute 
terms,  it could  be argued that if there is such a detrimental effect,  it should  be 
operating primarily on the endometrial aspect of the implantation process.
The same picture emerged when the cumulative outcome of the related FTER 
cycles were taken  into consideration with the outcome of the primary fresh  ET 
cycles  (Table  5.7,  Table  5.26CD).  This  cumulative  outcome  provides  the 
opportunity for broader evaluation of the whole initial embryo cohort, beyond the 
outcome of the fresh cycle. Additionally, during the subsequent FTER cycles, no 
aspirin co-treatment was given to the women. Therefore, if any differences were 
noted in the outcome, they should have been due mainly to the presence of the 
aspirin  effect on  embryological  factors or the absence of the aspirin  effect on 
endometrial  receptivity,  assuming  that the  cryopreservation  process  does  not 
eliminate  the  effect  of  aspirin  on  embryos.  A  limitation  of  this  cumulative 
assessment  is  that  it  gives  only  a  partial  view,  as  not  all  the  cryopreserved 
embryos created in the primary fresh IVF treatment study cycle were transferred 
by the time of this analysis.
The  absence  of  any  significant  differences  in  this  cumulative  outcome 
assessment  supported  the  initial  observation  from  the  primary  fresh  IVF 
treatment  cycle,  that  there  is  no  positive  effect  of  aspirin  on  the  embryo 
implantation  potential  or endometrial  receptivity.  However,  absolute values  of 
ongoing pregnancy still differed between the two groups in favour of the placebo 
group (35% vs 39%) but less strikingly than  in the primary fresh  IVF treatment 
cycle.  This  observation  also  provided  some  circumstantial  evidence that once 
the effect of aspirin is removed from the endometrial development, as in  FTER 
cycles, the presumed detrimental effect of aspirin on implantation becomes less
177obvious, possibly suggesting the endometrium as the target organ more so than 
the ovary.
Contrary to the findings of the current study, Rubinstein et. al.231, report that low 
dose aspirin co-treatment improves the utero-ovarian perfusion and that this is 
associated with a  better response to ovarian stimulation  in terms of number of 
mature follicles and  number of oocytes collected,  as well  as better fertilization, 
implantation  and  pregnancy rates.  These authors,  like  others  in  the  literature, 
propose  that  a  decrease  in  peripheral  impedance  in  the  uterine  and  ovarian 
vascular bed  improves  uterine receptivity and oocyte quality115,244,229,525.  In the 
current study, no improvement in utero-ovarian perfusion at 150mg dosage was 
observed. This must be the critical factor affecting the outcome.  In the absence 
of any perfusion effect,  aspirin  becomes ineffective in  improving the probability 
of pregnancy  and  this  is  most  likely  a  dose-dependent  phenomenon.  In  their 
prospective, double-blind study, Rubinstein et. al.2 3 1  use a similar protocol to the 
current study but with a lower-dose regimen of aspirin 100 mg/day.
Waldenstrom  et.  al.249  report  a  modest  increase  in  birth  rate  with  aspirin 
compared  with  no  treatment  (27.2%  vs  23.2%)  giving  an  odds  ratio  of  1.2. 
Patients were randomly assigned to treatment with aspirin 75 mg daily from the 
day of ET until pregnancy test or no treatment. Hence, aspirin only affected the 
implantation process, but the confidence interval includes the unity.
Not all studies agree with Rubinstein et. al.2 3 1  or with Waldenstrom et. al.249.  In 
a  prospective  randomized  study,  with  similar  findings  to  the  current  study, 
Urman  et.  al.240  report  no  differences  in  ovarian  response  but  a  lower clinical 
pregnancy  rate  in  the  aspirin  group  (39.6%)  compared  with  the  non-aspirin 
group  (43.4%).  This  provides  further  support to  the  contention  of the  current 
study that  implantation  is  hampered  by aspirin  and,  although  not  exclusively, 
this  is  more  significant  than  its  probable  influences  over  the  ovaries.  In  a 
randomized  study,  Salman  et.  al.243  report  no  difference  between  the  aspirin 
and  control  groups  in  ovarian  response  parameters  and  pregnancy  rates. 
Further,  a  prospective  randomized,  double-blind  study reports  no  benefit from
17880  mg  aspirin  supplementation  per day in  terms  of ovarian  and  uterine  blood 
flow or ovarian responsiveness in poor responders undergoing IVF treatment250.
In  their  retrospective  analysis,  Tassa  et.  al.242  also  fail  to  demonstrate  any 
improvement in  ovarian  response and  pregnancy rates  in women treated with 
low-dose aspirin (80 mg/day), and clinical  pregnancy rates in the aspirin group 
are lower than in the placebo group (45% and 54%).
Other  methods  proven  to  increase  tissue  perfusion  are  also  linked  to  better 
treatment outcome in  IVF. Sher and Fisch526 report that a NO donor (sildenafil) 
was  effective  in  improving  uterine  artery  blood  flow  and  endometrial 
development with improved pregnancy chances.  However similar interventions, 
if failing to improve tissue perfusion, were shown to be ineffective in improving 
the  treatment  outcome.  In  a  population  of women  with  a  previous  history  of 
implantation failures and having treatment for IVF, Ohl et. al.527 report that Nitro­
glycerine  (NTG)  treatment  on  the  day  before  ET  is  no  more  effective  than 
placebo  in  improving the  implantation  or pregnancy rate  and,  as  a  NO donor, 
NTG  treatment  does  not  affect  uterine  Doppler  values.  In  another  study528 
women  randomly  received  two  sublingual  spray  emissions  or  placebo  3min 
before  ET;  NTG  was  used  and  no  significant  effect  is  reported  on  any 
parameter of the transfer procedure.
Therefore, the key point in response to such adjuvant treatments might be their 
ability to improve tissue perfusion. In populations where the intervention was not 
successful  in  improving  tissue  perfusion,  the  intervention  was  also  ineffective 
and even maybe potentially detrimental to the ultimate treatment outcome. Why 
aspirin  treatment  may  have  such  diverse  effects  on  the  outcome  will  be 
discussed in the following sections.
In the current study the  platelet count and  mean  platelet volume,  both  before 
and  after  the  ovarian  stimulation,  were  similar  in  both  groups  (Table  5.34- 
5.36CD). Therefore, it could be argued that the lack of observable aspirin effect 
in the ovarian  and  endometrial  response  parameters was  because the aspirin 
dose used  in the study was  not optimized for its  maximum  anti-platelet effect.
179However, the current study argued that it was  not the antiplatelet effect of the 
aspirin that should be maximized but its vascular effect.
The  benefit  of  aspirin  is  thought  to  derive  from  the  inhibition  of  platelet 
Thromboxane^  production529.  Because Thromboxane-A2  is  a  potent  platelet 
aggregator and vasoconstrictor530, the effect would  be anti-thrombosis and this 
is thought to offset the thrombophilic tendency that leads to  decreased tissue 
perfusion  through  platelet activation  and  arterial  occlusion531.  This  antiplatelet 
effect  of  aspirin  has  found  its  successful  clinical  applications  in  cardiology, 
because the platelet-rich, intravascular thrombus is central to the pathogenesis 
of diminished coronary perfusion532,533 and, to a certain extent, antiplatelet effect 
also explains the  success  of aspirin treatment in  recurrent  miscarriage due to 
antiphospholipid  antibody  syndrome.  In  the  latter  condition,  an  exaggerated 
haemostatic  response  leading  to thrombosis of the  uteroplacental  vasculature 
has  been  suggested  as  the  underlying  pathology  along  with  the  direct 
trophoblastic  dysfunction.  In  such  women,  pregnancy  outcome  appears  to 
improve with aspirin alone196. An even greater improvement is reported with the 
concomitant  use  of  heparin196,197.  Conversely,  if  there  is  no  thrombophilic 
tendency,  aspirin  is  not  useful  in  the  prevention  of recurrent  early  pregnancy 
losses534.
However,  an  autoimmune  mediated  hyperthrombotic  state  did  not  find  much 
scientific evidence  in  the  pathogenesis  of decreased  fertility.  Despite  a  higher 
prevalence of antiphospholipid antibodies, the IVF population did not appear to 
be  affected  negatively  with  these  antibodies  contrasting  to  recurrent 
miscarriages218.  On  the  contrary,  diminished  uterine  perfusion  has  been  a 
widely  accepted  pathology  of  subfertility,  indicating  that  what  needs  to  be 
corrected is not an intravascular, but rather a vascular pathology252.
Aspirin  also  inhibits  cyclo-oxygenase  enzymes  in  the  vascular  endothelium, 
which is the source of prostacyclin, a potent inhibitor of platelet aggregation and 
a  vasodilator535  with  the  effect  then  being  thrombogenic.  Nevertheless,  the 
selective inhibition of platelets sparing the functional capacity of endothelium is 
possible  (refer to  section  1.2.2).  This  can  alter the  prostacyclin:  thromboxane
180ratio favourably and  result  in  increased  tissue  perfusion.  As  the  effect occurs 
through lowering of the vascular tone, it is independent from the state of platelet 
activation.  It  is  this  vascular  effect  of  aspirin  that  should  be  prioritized  in 
subfertility patients.
At higher doses aspirin can achieve more complete and rapid platelet inhibition, 
and at lower doses can spare more endothelial cyclooxygenase activity.  In this 
context, using higher doses of aspirin maximizes the anti-platelet effect, and this 
is only beneficial  if the tissue  perfusion  is primarily hampered  by intravascular 
micro-thrombus  formation.  On  the  contrary,  where  tissue  perfusion  is 
compromised by high vascular tone, higher doses of aspirin are detrimental and 
lower  doses  should  be  used  to  achieve  vasodilatation.  Aiming  for  a  higher 
Pgl2:TxA2 ratio with  low-dose aspirin  is a sub-optimal  compromise in  recurrent 
miscarriage  patients,  as  it  does  not  improve  tissue  perfusion  or  pregnancy 
outcome  as  much  as  high  doses  can  achieve162,536.  Aiming  for a  higher anti­
platelet  effect  in  IVF  patients  may  be  equally  detrimental  as  it will  lower the 
Pgl2:TxA2 ratio and subsequent tissue perfusion.
Further  to  its  vascular  effect,  aspirin  may  have  far  reaching  effects  on 
implantation.  Human  endometrium  secretes  a  variety  of  prostaglandins, 
including  the  stable  metabolites  of  prostacyclin  and  thromboxane  A2:  6-keto- 
prostaglandin  F,a  and  thromboxane  B2236,537.  An  unfavourably  altered 
prostacyclin .thromboxane  ratio and  prostaglandin  production  may increase the 
probability  of  expulsion  of the  blastocyst  and  hamper the  preparation  of the 
endometrium for implantation234,235,236. Embryo-endometrial communication and 
decidualisation  has  been  linked  to  prostaglandin  stimulated  inflammatory 
process  and  the  release  of  interleukins232,233.  Aspirin  inhibition  of  local 
prostaglandins may impede this process and lower the implantation rate.
High doses of salicylates are usually inhibitory to kinases. Targets include pro- 
inflammatory  enzymes,  cytokines,  chemokines,  and  cell  adhesion  molecules. 
COX-2  over-expressing  cells  produce  prostaglandins  and  proangiogenic 
factors, and stimulate both endothelial migration and tube formation. This effect 
is  inhibited  by  aspirin156.  Hence,  while  tissue  perfusion  was  improved  via
181existing vasculature either at lower doses through vascular effect or at higher 
doses through anti-platelet effect, depending on the underlying  pathology,  in a 
dose-dependent  manner  aspirin  can  actually  interfere  with  the  new  vessel 
formation,  which  is  far  more  fundamental  to  folliculogenesis,  endometrial 
development and implantation.
In  the  current  study,  the  mean  platelet  volume  after  ovarian  stimulation  was 
insignificantly higher in the non-pregnant women than the pregnant women who 
all  received  aspirin  co-treatment.  This  may  signify  a  lower  probability  of 
pregnancy in women whose biological response to aspirin was higher, in terms 
of anti-platelet effect. This provided further circumstantial evidence that aspirin 
co-treatment might be detrimental to the IVF outcome at the dose used  in this 
study.
It  can  be  concluded  that  the  optimal  dose  influencing  vascular  haemostatic 
regulation  depends  on  the  balance  between  the  anti-platelet  and  vasodilatory 
effects  of  aspirin,  and  dose  selection  should  be  based  on  the  reasons  for 
impaired perfusion.
In  summary,  no  beneficial  effect  of aspirin  at  the  current  dose  regimen  was 
found  in  the  current  study  in  the  outcome of fresh  IVF treatment.  Despite  no 
differences  in  the  ovarian  response  to  stimulation  and  subsequent  embryo 
implantation and ongoing pregnancy rates, a legitimate argument has emerged 
that  aspirin  might  act  detrimentally  on  the  endometrium  during  implantation, 
because  the  dosage  used  in  the  current  study was  probably  high  enough  to 
compromise  the  optimum  prostacyclin:thromboxane  ratio  required  for  better 
tissue  perfusion.  The  absence  of  any  significant  improvement  in  the  utero- 
ovarian tissue perfusion in the aspirin group also supports this contention.
Implantation  is  a  complex,  closely  regulated,  highly  selective  but  poorly 
understood  process.  Its  vital  role  in  the  survival  of  species  demands  this 
meticulous complexity to select the fittest and to ensure the sound foundations 
of the  best  environment for the  selected  embryo  during the forthcoming  most 
demanding  nine  months.  Therefore,  it  is  not  surprising  to  encounter
182unprecedented  and  even  conflicting  results  of  any  intervention  that  is  not 
precise  enough  to  pinpoint  specific  steps  of  this  interlinked  process  without 
disturbing  the  others.  Certainly  aspirin  is  far from  being  a  specific  modulator 
with an ever increasing list of actions, and interactions.
6.2  Doppler Assessment of Utero-ovarian Perfusion
In an unselected subgroup of women undergoing IVF treatment and taking part 
in the ‘aspirin study’, uterine artery blood flow, sub-endometrial blood flow, peri­
follicular  vascularity  and  vascular  impedance  were  assessed.  Multi-point 
assessment  in  reference  to  time  and  site  allowed  the  development  of  a 
physiological framework to understand the harmonious efforts of the ovary and 
uterus  during  assisted  conception.  The  study  was  powered  to  evaluate  the 
relation between uterine artery impedance values and ongoing pregnancy rates. 
Therefore,  some  of the  observed  trends  of association  fell  short  of statistical 
significance and should be interpreted cautiously, in view of the relatively small 
sample size for sub-endometrial and follicular perfusion.
There  were  no  differences  in  demographic  characteristics  between  pregnant 
and  non-pregnant women  in  terms  of age,  parity,  number of previous  fertility 
treatments, BMI and basal FSH values (Table 5.8-5.10). This allowed like-to-like 
comparison of the clinical and sonographic responses to IVF treatment.
The first assessment of uterine artery and  sub-endometrial  spiral  artery  blood 
flow was carried out after pituitary down-regulation, which removed the effect of 
follicular and  endometrial  angiogenesis  and  represented  the  baseline  state of 
pelvic perfusion.  Scans on the last day of stimulation were then  able to reflect 
the true response potential of the individual under ovarian stimulation.
A  single  operator  performed  the  ultrasound  scans  in  order to  eliminate  inter­
observer  variances.  Serial  assessment  of  the  peri-follicular  blood  flow  was 
achieved  with  hard  copies  of the  scan  pictures.  This was  not  possible for the 
measurement  of  the  sub-endometrial  spiral  artery  impedances.  However, 
vessels  with  the  maximum  Colour  Doppler  intensity  were  chosen  for  the 
representative  evaluation.  The calibre and  anatomic localization  of the  uterine
183arteries,  with  respect  to  sonographically  detectable  landmarks,  allowed  the 
longitudinal  assessment  of  the  uterine  artery  impedance  values.  As  no 
differences were found in mean Doppler indices of the right and left ascending 
uterine  artery,  further analysis was  carried  out with  their  mean  values  (Table 
5.39,  5.40CD).  Because  a  strong  correlation  was  found  between  pulsatility 
index (PI) and other Doppler indices (Rl, S/D), PI was used for the comparative 
analysis with the advantage of reflecting blood flow impedance accurately even 
in the absence of end-diastolic blood flow.
A  strong  correlation  was  detected  between  the  uterine,  sub-endometrial  and 
follicular  blood  flow  (Table  5.41-5.44CD).  However,  the  predictive  values 
differed  in  determining  the  treatment  outcome  and  discriminating  the  good 
prognostic group. Although  no difference was found between the pregnant and 
non-pregnant groups in the uterine artery impedance during the baseline scan, 
in the pregnant group, the difference gradually widened and  reached statistical 
significance  by the  day of the  last ultrasound  scan  (Table  5.11).  Therefore,  it 
was not only the static cross-sectional observation but also the dynamic trend of 
these parameters that presented a prognostic value.
As  the  uterine  artery  impedance  values  were  prognostically  linked  to  the 
treatment outcome, a cut-off point was selected to facilitate its clinical use in the 
selection  of good  and  poor  prognostic groups.  Because the  data  proposed  a 
high negative predictive value, the cut-off point was selected to discriminate the 
poorest  prognostic group.  A cut-off point of 3 for uterine artery  PI  indicated  a 
negligible chance of achieving pregnancy (Table 5.17).
This finding was in agreement with other trials reporting similar cut-off points of 
uterine  artery  PI  values  with  high  negative  predictive  power115,226,256,260. 
However,  the  literature  is  contradictory  as  others  report  no  significant 
differences in  uterine artery PI values between conception and  non-conception 
cycles278,280,283,290,321.  Differences  in stimulation  protocols,  study groups, timing 
of  Doppler  investigations  and  study  designs,  either  cross-sectional  or 
longitudinal,  appear  to  affect  the  outcome  and  could  be  considered  as  the 
possible explanation for these conflicting results.
184Perifollicular vascular impedance was found to be lower in the pregnant group 
on  the  last day of stimulation  (Table  5.12).  Although  this  trend  did  not  reach 
statistical significance in two-tailed hypothesis testing, a cut-off point of 1.08 for 
PI values was shown to discriminate the women with good and poor prognosis 
(Table  5.19).  The  discriminative  performance  of  the  test  reached  statistical 
significance  at one-tailed  hypothesis testing,  employed  because the  published 
data had already established the direction of the association between follicular 
perfusion and the treatment outcome319,322,324.
Perifollicular vascularity,  defined  as the  percentage  of follicular circumference 
that showed  contact vascularity with  visible flow,  was  semi-quantified  using  a 
subjective  scale321,322.  No  correlation  was  detected  between  the  degree  of 
perifollicular vascularity  and  the  vascular  impedance  expressed  as  PI.  There 
were  no  differences  in  the  peri-follicular vascularity values  between  pregnant 
and non-pregnant women (Table 5.12).
These results were contradictory to the findings of Bhal et.  al.  and  Coulam et. 
al., and may be explained  by the differences in patient population, the effect of 
different  stimulation  protocols,  and  differences  in  the  design  of  the  current 
study321,322.  In  the  current  study,  the  perfusion  of  a  single  follicle  having  the 
most extensive vascularity on power Doppler mapping was evaluated, whereas 
in  the  previously  mentioned  studies,  multiple  follicles  are  assessed. 
Furthermore,  in  the  current  study,  the  majority  of cases  remained  in  the  low 
vascularity  range  (<25%  of  contact  vascularity).  This  was  not  surprising, 
because  all  of  the  Doppler  assessments  were  performed  prior  to  the 
luteogenesis  of  hCG  administration.  The  physiology  of  limited  vascularization 
during follicular development,  as opposed to  intense  neovascularization of the 
corpus  luteum,  might  hinder  the  detection  of  significant  differences  with 
prognostic importance. Therefore, the timing of the assessment in reference to 
hCG administration, might explain the lack of association between the degree of 
vascularity and the treatment outcome.
185Nevertheless,  the  current  study  findings  suggested  that  it  was  the  vascular 
impedance  rather than  the  degree  of vascularity that  predicted  the  treatment 
outcome, and this allowed the hypothesis that the amount of blood flow within a 
given artery determined the tissue perfusion  better than the contact surface of 
the vessel to the tissue of concern. Furthermore, as vascularity depicted by the 
semi-quantitative  assessment  of  the  power  Doppler  mapping  cannot 
differentiate  arterial  and  venous  supply from  each  other,  it  makes  physiologic 
sense  to  assume  that  quantitative  Doppler  evaluation  of  the  arterial  flow 
correlates  better  with  the  perfusion  related  outcomes.  The  quantitative 
assessment was based on PI values, which took into consideration the diastolic 
as well  as systolic compartment of the flow in an  angle independent equation, 
since it has been shown that peak systolic velocity of peri-follicular blood flow is 
not prognostically significant323.
When the data were evaluated to identify the clinical characteristics associated 
with high peri-follicular vascular impedance, these cycles were distinguished by 
their  lower  oestrogen  concentrations  and  lower  number  of  mature  follicles, 
oocytes, and 2-PN embryos (Table 5.23). These findings agreed with the study 
of  Battaglia  et.  al.362  and  provided  evidence  of an  association  between  poor 
follicular perfusion, poor ovarian response and poor clinical outcome.
The pathophysiology of this clinical association can be explained from a genetic 
perspective.  Huey et.  al.  report that PI  is significantly and  negatively correlated 
with  follicular  fluid  O2  concentration  and  the  same  correlation  is  reported 
between  RI  and the fertilization rate of oocytes342. Van Blerkom et. al.1 0 7  relate 
the  developmental  potential  of  oocytes  to  the  dissolved  oxygen  content  of 
follicular fluid. The mechanism is explained by chromosome mis-segregation in 
hypoxic follicular milieu.
Vascular  impedance  of  the  sub-endometrial  spiral  arteries  showed  a 
progressive change towards lower PI values during ovarian stimulation and this 
drop in resistance was more evident in the pregnant than non-pregnant women. 
However, this trend fell short of statistical significance (Table 5.13).
186Yuval et. al.  report similar findings, where Doppler indices of endometrial blood 
flow  show  a  non-significant  trend  towards  lower  impedance  values  in  the 
pregnant  group274.  Zaidi  et.  al.293  report  no  significant  difference  between 
pregnant and non-pregnant groups with regard to sub-endometrial peak systolic 
blood  flow  velocity  or  sub-endometrial  PI,  except  for  the  absence  of  flow 
predicting  poor probability of pregnancy.  Likewise,  endometrial  vascularization 
with  power Doppler assessment is reported to have no prognostic value in an 
ICSI  programme304.  However,  Schild  et.  al.282  who  used  three-dimensional 
power Doppler sonography and Yang et. al.2 9 1  who evaluated intra-endometrial 
power Doppler area,  report significantly higher pregnancy rates in women with 
better endometrial perfusion. Battaglia et. al.229 also report that PI values on the 
day  of  oocyte  collection  are  significantly  lower  in  patients  who  become 
pregnant.
Differences in the published literature can be attributed to relatively small-sized 
study  groups,  which  failed  to  demonstrate  an  existent  relationship  between 
(sub)endometrial  blood  flow  and  endometrial  receptivity.  In  the  current  study, 
the  high  coefficient  of variance  leading to  extensive  overlap  between the two 
outcome groups supported this power problem. Despite the physiological role of 
local  tissue  perfusion  in  the  functional  capacity  of organ  systems,  variability 
between the  published  studies  indicates a current  inability to  identify the  right 
method  of assessment  of low velocity  blood  flow  in  the  endometrium.  Three- 
dimensional power Doppler ultrasonography may provide more accurate means 
of evaluating such vascularization.
Neither endometrial  thickness  nor its echo-pattern  had  prognostic value in the 
prediction  of treatment outcome. Although endometrial thickness  progressively 
increased  during ovarian stimulation this was comparable in  both the pregnant 
and  non-pregnant group. This growth was also found to be independent of the 
level of uterine and sub-endometrial vascular impedance and serum oestradiol 
levels.  Similarly,  regardless  of their treatment outcome,  all  women  presented 
with a multi-layered triple-line endometrium (Table 5.15, 5.16).
187Related  data from  the  literature  are  conflicting.  While an  association  between 
endometrial thickness and E2 levels is reported428,538 other studies dispute such 
correlation388,389'404.  Differences  can  be  explained  on  the  basis  of  timing  of 
assessment during the ovulation induction397.
It  is  possible  that  supraphysiological  concentrations  of oestradiol  achieved  in 
fresh  IVF  treatments  were  well  above  the  required  stimulation  levels  for 
endometrial growth, so that differences above this level make no change in the 
growth pattern of endometrium.  In such hormonal milieu for anatomic growth, it 
may be the  paracrine control that determines the functional  differentiation and 
receptivity.
The  published  literature  is  also  inconclusive  with  regard  to  the  value  of 
endometrial thickness and echo-pattern. While the current study on endometrial 
echo-pattern  agreed  with  some256,397,398,403,420,421;  others  report  significant 
association  between  endometrial  echo  pattern  and  the  outcome  of  IVF
traafmonf257'382'383'392'393'396'390'404'405'418-539
Similarly, the  prognostic value of endometrial thickness  in terms of pregnancy 
rates  is  not  universally  accepted.  Whilst  a  lack  of association  is  reported  by 
some143,256,257,283,395,396,397,398,402,403,408,420,421,540,541,  others  report  a  significant 
association  between  endometrial  thickness  and  treatment 
outcome382'388'390393'423'542.  To  the  contrary,  Weissman  et.  al.  report  that 
implantation  and  pregnancy  rates  are  significantly  reduced  in  patients  with 
endometrial thickness of >14 mm on the day of hCG administration543.
Because of the differences in stimulation protocols, and timing and  methods of 
sonographic  assessment  of  the  endometrium,  a  definitive  conclusion  is  not 
possible  but,  as  the  endometrial  thickness  and  echo-pattern  reflects  the 
supraphysiological  hormonal milieu of ovarian stimulation, threshold stimulation 
is  likely to  be  achieved  even with  a  poorly receptive endometrium  in terms  of 
anatomical growth.  Nevertheless, the available data suggest that at present the 
sonographic  and  Doppler  assessment  of  endometrium  in  terms  of functional 
capacity and fertility potential is not optimized for routine clinical use.
188The current study found no correlation between the vascular impedance values 
of  the  uterine  arteries  and  corresponding  oestradiol,  FSH  and  BMI  values 
(Table 5.14). This finding confirmed previously published data425. Although both 
PI and oestradiol values showed progressive and opposite directional changes 
during  ovarian  stimulation,  their  lack of correlation  proposed  a  non-hormonal 
modulation of the uterine perfusion. Although basal FSH and BMI values had a 
wide range of 30.30 IU/l and 19 kg/m2  respectively, their mid-central distribution 
was narrow with an inter-quarter range of 3.4 and 5 respectively. Therefore, as 
both basal  FSH and BMI values were predominantly within the normal range, it 
was unlikely that they could have explained the overall variation of the vascular 
impedance values, which had a wider distribution on  either side of the chosen 
cut-off point.
In  summary,  the  current study  provided  evidence for the  association  between 
utero-ovarian  perfusion  and  reproductive outcome following  IVF treatment.  In 
women with PI values >3, the probability of achieving pregnancy was negligible 
when  predicted  by the last day uterine artery Doppler measurement.  Likewise, 
in women with perifollicular PI values >1, the probability of achieving pregnancy 
was  insignificant.  Therefore,  if Doppler assessment reveals  impedance values 
above  these  cut-off  points,  the  created  embryos  could  be  cryopreserved  for 
subsequent  FTER  cycles.  However,  this  approach  is  unlikely  to  overcome 
intrinsic  embryo  related  problems.  Furthermore,  it  may  actually  reduce  the 
probability  of  pregnancy  due  to  detrimental  effects  of  cryopreservation. 
Measures  to  decrease  uterine  and  ovarian  vascular  impedance  reflected  by 
lower  PI  values  might  enhance  pregnancy  rates  by  improving  embryo  quality 
and uterine receptivity for implantation. As vascular indices were not associated 
with  higher  E2  levels,  non-hormonal  methods  such  as  omega-3  fatty  acid 
supplementation, NO donors, or future angiogenetic agents with regional/topical 
application could provide alternatives.
6.2.1  Comparison of Doppler Indices of the Aspirin and Placebo Groups
At  a  daily  dose  of  150mg,  aspirin  did  not  improve  uterine  artery,  sub- 
endometrial,  and  peri-follicular  blood  flow,  or the  perifollicular vascularity  and 
endometrial  thickness.  This  observation  was  valid  after  both  pituitary  down-
189regulation when  hormonal  effect over vascular tonus was  minimal,  and  during 
ovarian stimulation with increasing oestradiol concentrations (Table 5.46CD).
This  lack of effectiveness  over tissue  perfusion  was  most  likely to  be  a  dose 
dependent phenomenon secondary to the loss of selective inhibition of platelet 
cyclooxygenase,  while sparing the functional  capacity of endothelium,  thereby 
altering the prostacyclin:thromboxane ratio unfavourably and resulting in loss of 
beneficial effect on vascular tonicity and tissue perfusion.
With  repeated  administration,  acetylation  of cyclooxygenase  by oral  aspirin  is 
dose-dependent,  cumulative and  selective.  However,  biochemical  selectivity is 
at  best  relative,  not  absolute,  and  partial  inhibition  of  prostacyclin  formation 
seems  to  be  an  unavoidable  consequence  of  inhibition  of  platelet  cyclo­
oxygenase by aspirin. With single daily administration, the aspirin dose for near- 
complete  suppression  of  serum  thromboxane  formation  with  best  differential 
sparing  of  prostacyclin,  has  been  titrated  downward  to  approximately  0.5-2 
mg/kg157. It appears that a mean >40 mg/day of aspirin is necessary for plateau 
inhibition  of  platelet  aggregation,  although  suppression  of  prostacyclin  will 
inevitably  be  more  pronounced.  Fitzgerald  et.  al.159  report that  depression  of 
Thromboxane-metabolite attained statistical significance at doses of aspirin >80 
mg/day, with the fall  in PGI-metabolite excretion attaining significance at doses 
of  aspirin  >160  mg/d.  Therefore,  at  150mg/day  the  current  study  may 
iatrogenically  have  diminished  the  theoretical  benefit  aspired  to  by  low  dose 
aspirin in tissue perfusion.
6.3  VEGF-VEGFR Concentrations
Pre-treatment serum samples were studied for VEGF and VEGFR levels in 80 
women during  natural  cycles prior to the IVF treatment.  On the day of oocyte 
collection  59  post-treatment  serum  and  55  follicular fluid  samples  were  also 
available.  Thirty-six  pre-treatment  serum  samples,  29  post-treatment  serum 
samples  and  27  follicular  fluid  samples  were  from  the  aspirin  group  (Table 
5.24).
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serum  VEGF  levels  and  this  was  also  valid  for serum  VEGFR  levels.  VEGF 
exhibited  a  negative  correlation  with  its  receptor  both  before  and  after  the 
treatment.  Contrary  to  this,  follicular fluid  VEGF  correlated  positively  with  its 
receptor.  No  correlation  was  found  between  serum  and  follicular fluid  VEGF 
levels  (Table  5.54CD).  In terms of angiogenetic  response,  positive  correlation 
between  pre-  and  post-treatment  serum  samples  reflected  the  importance  of 
baseline characteristics that determined the boundaries of personal response to 
ovarian  stimulation.  In  other words,  women  who  presented  with  a  favourable 
angiogenetic  steady  state  were  able  to  provide  even  more  favourable 
angiogenetic  support  to  folliculogenesis  and  endometrial  development  during 
IVF  treatment.  Women  with  a  less favourable  angiogenetic  background  were 
limited in their angiogenetic response by their disadvantageous starting point.
The negative correlation between VEGF and VEGFR levels in serum suggested 
a  dynamic  equilibrium  between  these  two  systems,  probably  working  in 
opposite directions.  In support of this contention is the report of He et. al.365 that 
alternative  splicing  of the VEGFR-1  mRNA  produces  soluble VEGFR-1  which 
significantly  contributes  to  the  regulation  of VEGF  activity.  Rising  sVEGFR-1 
production  is  reported  to  be  detrimental  to  follicular  development  due  to 
diminished bio-active VEGF supply544.
However,  the  direction  of association  between  VEGF  and  VEGFR  levels was 
the  same  in  follicular  fluid,  possibly  indicating  that  different  mechanisms 
determined the levels of these two factors in systemic circulation and follicular 
fluid. Supporting this contention, the current study found no link between serum 
and follicular fluid concentrations.
The  following  is  a  set  of  proposals  for  biologically  plausible  VEGF-VEGFR 
interactions  on  the  premise  that  hypoxemia  enhances  VEGF  expression  in 
maturing  follicles  and  in  the  endometrium360,545;  while  VEGFR  diminish  bio- 
active VEGF supply544.
191VEGF  response can  be described  as  ‘U-shaped’.  High  levels could  indicate a 
state of optimum  stimulus for angiogenesis  resulting  in  better tissue  perfusion 
and  consequently  higher oxygen tensions,  but at the same time  higher levels 
could  also  indicate a  physiological  response to a  hypoxic state.  Therefore,  an 
isolated  high  VEGF  measurement  could  have  been  associated  with  either 
hypoxia or normoxia. Lower VEGF levels could indicate a state of normal tissue 
oxygen tension or, to the contrary, the absence of angiogenetic response to a 
hypoxic stimulus. Therefore, an isolated low VEGF concentration could indicate 
either good  tissue  perfusion  or inability of tissue to  generate  its  angiogenetic 
stimulus to hypoxia.
To demonstrate this dichotomy, some reports suggest that VEGF is associated 
with  high  vascularization  and  oxygenation,  resulting  in  oocytes  with  superior 
pregnancy  potential107,348,356,357,358,  while  others  demonstrate  that  an  elevated 
level  of  VEGF  implies  follicular  hypoxia359,360,  thus  considered  a  marker  of 
diminished pregnancy potential349.
Concomitant  measurement  of  VEGF  and  VEGFR  levels  may  be  helpful  to 
differentiate both states.  If both VEGF and VEGFR levels are low, the absence 
of  stimulation  could  be  argued  as  both  hypoxia  and  VEGF  itself  positively 
regulate  VEGFR  expression,  which  in  turn  controls  VEGF-driven 
angiogenesis546. The absence of stimulation could be due to the presence of an 
optimum  physiological  state and  in this  situation  outcome  of the  physiological 
state  should  be  desirable,  such  as  in  higher ovarian  response  or  successful 
implantation.  Alternatively,  the  absence  of  stimulation  could  be  due  to  the 
inability of the tissue to respond to an unfavourable situation  and the outcome 
would be undesirable, such as in poor ovarian response or implantation failure. 
If VEGF  and  VEGFR  levels  are  both  high  then  the  presence  of a  stimulated 
state and a counter regulatory response of VEGFR to prevent over stimulation 
by  increasing  VEGF  levels  could  be  argued.  It  is  already  discussed  in  the 
literature that the soluble form of VEGFR, which is free in circulation or follicular 
fluid, acts as a deterrent factor against VEGF activity by blocking it to stimulate 
the  membrane  bond  physiologically active  receptors.  If VEGF  levels  are  high 
and  VEGFR  levels  are  low  this  logically  indicates  a  state  of  maximum
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steady state.  Alternatively if VEGF  levels are low and VEGFR  levels are high 
the possible conclusion is over-correction of angiogenetic stimulation or indeed 
a state of inappropriate suppression that may eventually lead to hypoxia.
The current study investigated the physiological  role of VEGF  and VEGFR by 
associating  their  concentrations  to  different  treatment  outcomes.  The  first 
outcome measure was the ET.
Pre-  and  post-treatment  serum  VEGF  and  VEGFR  concentrations  were 
statistically similar in women who had ET and those who did not.  Follicular fluid 
VEGF  concentrations were also  similar in these two groups  but follicular fluid 
VEGFR  concentrations  were  significantly  lower  in  women  with  no-ET.  In  the 
current  study  the  most  common  reason  for  no-ET  was  the  imminent  risk  of 
OHSS and so the lower follicular fluid VEGFR concentration was likely to reflect 
a high responsive state in ovarian stimulation (Table 5.47-5.52CD).
Unlike the follicular fluid  measurements, the absence of statistically significant 
differences  in  serum  samples  indicated  the  importance  of obtaining  samples 
from  the  target  environment  as,  despite  having  persistently  low  VEGF  and 
VEGFR levels in all serum samples from the no-ET group when compared with 
the ET group, the differences became insignificant once they were diluted in the 
systemic circulation. Although there was no such dilution effect on follicular fluid 
VEGF  concentrations,  the  lower  values  in  the  no-ET  group  did  not  reach 
statistical  significance.  This  may  have  been  due to  small  sample  size  limiting 
the differences from attaining significance beyond a chance factor.
Because on this occasion, the outcome of ovarian stimulation was favourable, 
lower levels of VEGF and VEGFR could not have been due to under-stimulation 
but  rather  indicated  a  state  of  favourable  oxygenation  not  requiring  VEGF 
stimulation  and  subsequent  compensatory  VEGFR  elevation.  In  this  setting, 
higher VEGF and VEGFR levels probably indicated poor oxygenation.
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follicular  fluid  VEGFR  levels,  the  no-ET  group  was  analysed.  Follicular  fluid 
VEGFR  concentrations  were  particularly  lower  in  women  with  elective  no-ET 
due to the  imminent  risk of OHSS, when  compared  with the  ET  group.  Once 
again,  no  significant differences were found  in  pre-  and  post-treatment serum 
VEGF  and  VEGFR  levels  in  all  outcome  groups:  ET,  no-ET  due  to  elective 
cryopreservation of all embryos, failed fertilization or cancellation before oocyte 
collection.  Follicular fluid VEGF levels were also similar in these groups (Table 
5.47-5.52CD).
The  second  set  of outcome  measures  compared  was  clinical  pregnancy,  no­
pregnancy and no-ET.  Follicular fluid VEGFR concentrations were significantly 
lower  in  the  no-ET  group,  as  already  observed  in  the  previous  analysis. 
However,  when  compared  with  the  non-pregnant  group,  insignificantly  lower 
follicular fluid  VEGFR  concentrations were evident  in  the  pregnant group and 
the same was  noted for ongoing  pregnancy.  Follicular fluid VEGF  levels were 
also lower in the no-ET and the pregnant group but at a statistically insignificant 
level.  No differences were detected between the pregnancy,  no-pregnancy and 
no-ET  groups  in  terms  of  pre-  and  post-treatment  serum  VEGF  and  VEGFR 
concentrations (Table 5.47-5.52CD). Therefore, the argument detailed in the ET 
analysis  also  applied  in  this  analysis,  where  insignificantly  low  follicular fluid 
VEGF  and  significantly  low  VEGFR  concentrations  in  the  good  prognostic 
group,  indicated  a  state of good tissue perfusion  and  oxygenation  rather than 
inability to provide a physiological stimulation against hypoxia.
Failure of low follicular fluid VEGF levels to reach significance was due either to 
the inability of the good perfusion group (pregnancy) to lower their VEGF levels 
or,  more  possibly,  the  inability of the  poor perfusion  group  (no  pregnancy) to 
increase their VEGF levels against hypoxia, so that in either case the difference 
was not large enough to attain significance. Alternatively,  in the poor perfusion 
group,  significantly  high  follicular  fluid  VEGFR  concentrations  arguably 
sequestrated  the  already  high  levels  of VEGF  initially  stimulated  by  hypoxia, 
and  subsequently made lesser amounts of free VEGF  molecules available for 
ELISA test detection; thereby, the difference failed to reach significance at the
194time  of sampling.  In  this  scenario,  follicular fluid  VEGFR  concentrations  were 
inappropriately  but  significantly  high  for  the  level  of  hypoxia  leading  to  an 
unfavourable outcome.
The  data  were  further  evaluated  to  investigate  whether  any  of  the  VEGF- 
VEGFR  variables  could  differentiate  ongoing  pregnancy  from  miscarriage  or 
biochemical  pregnancy, following the fresh  IVF treatment cycle.  No differences 
were found  between  these groups  in  terms  of pre-  and  post-treatment serum 
VEGF and VEGFR levels or their follicular fluid concentrations. Although lower 
follicular fluid VEGFR levels indicated a state of higher ovarian response and a 
trend  of  better  probability  of  pregnancy,  it  appeared  that  its  prognostic  role 
regarding  the  outcome  of  implantation  (chemical  pregnancy,  miscarriage,  or 
ongoing pregnancy) was not as significant (Table 5.51 CD).
No significant correlation was found between the number of implanted embryos 
following fresh treatment and any of the serum or follicular fluid VEGF-VEGFR 
levels.  To  provide  a  wider  assessment  of the  whole  embryo  cohort  created 
during  the  fresh  treatment,  the  cumulative  implantation  figures  including  both 
the  fresh  and  related  FTER  cycle  were  evaluated.  In  this  assessment,  the 
number of embryos  implanted  correlated  negatively with  follicular fluid  VEGF 
levels at a significant level (Table 5.53-5.56CD).
To clarify whether follicular fluid VEGF levels differ on  a continuous scale with 
the  increasing  number  of  implantations,  a  comparison  was  made  of 
concentrations  between  the  no-implantation,  singleton  implantation,  and  twin 
implantation groups.  Follicular fluid VEGF concentrations showed a noticeable 
variance  only  between  the  no-implantation  group  and  the  rest  of the  cohort, 
indicating that higher levels are associated with poor outcome but levels do not 
progressively drop with increasing numbers of implantations.
Neulen  et.  al.366  define  an  index  of  biological  activity  of  VEGF  by 
VEGF:sVEGFR-1  ratio and show an increasing availability of VEGF with higher 
ovarian response to gonadotrophin therapy.  However, in the current study, the 
VEGF:VEGFR  ratio,  level  of  change  in  VEGF  concentrations  during  IVF
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of this change (decreased or increased) showed  no difference in the outcome 
variables (Table 5.57, 5.60CD).
6.3.1  Factors Linked to VEGF-VEGFR Levels
After  realizing  the  positive  association  between  low  follicular fluid  VEGF  and 
VEGFR  levels  and  the  desirable  treatment  outcome  in  terms  of  ovarian 
response,  and  possibly  implantation  and  pregnancy,  in  order  to  propose  a 
model  by  which  VEGF-VEGFR  may  affect  the  treatment  outcome,  the 
demographic,  clinical  and  embryological  variables  persistently  linked  to  the 
lower or higher VEGF-VEGFR levels were investigated. In this assessment pre­
treatment  serum  concentrations  reflected  the  baseline  characteristics  of  the 
women  and  post-treatment  serum  concentrations  reflected  their  response  to 
ovarian stimulation built on the pre-treatment background of steady state values 
(Table 5.61 -5.70CD).
Pre-  and  post-treatment  serum  VEGF  and  VEGFR  levels  did  not  show  a 
common theme where the associations with demographic variables revealed a 
good or poor ovarian reserve. However, higher follicular fluid VEGF and VEGFR 
levels  indicated  a  lower  ovarian  reserve,  as  they  positively  correlated  with 
female age;  follicular fluid  VEGF  also correlated  positively with  female weight 
and  BMI. Therefore,  any future studies or clinical applications of follicular fluid 
VEGF should use a BMI-correction in comparative analysis (Table 5.61 CD). No 
significant  association  was  noted  between  VEGF-VEGFR  concentrations  in 
serum and follicular fluid, or menstrual cycle regularity, female smoking, alcohol 
consumption, and type and aetiology of the subfertility.
It was  not  possible to  make  inferences for the  pre-  and  post-treatment serum 
VEGF  concentrations  in  terms  of  ovarian  response  because  the  level  of 
associations  either  did  not  reach  significance  or  did  not  reveal  a  biologically 
plausible  pattern  (Table  5.69CD).  However,  it was  of note that  post-treatment 
serum  VEGF  concentrations  still  showed  similar  associations  as  revealed  by 
pre-treatment levels,  once again  reflecting the dominant and  persistent nature 
of the  baseline  predilections throughout the  ovarian  stimulation.  Similarly pre-
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embryological  variables  tested  at  a  significant  level  but  the  direction  of  the 
associations  appeared  to  be the  opposite  of that of the  corresponding  VEGF 
levels. These also provided evidence of the initial contention that VEGF-VEGFR 
systems possessed opposing and probably balancing effects.
High follicular fluid VEGF  and VEGFR concentrations  once  again  portrayed  a 
picture  of  poor  ovarian  reserve  characterized  by  the  need  for  more  intense 
ovarian  stimulation  and  subsequently  poor  response  to  this  stimulation.  They 
not  only  correlated  positively  with  female  age,  but  also  with  the  initial 
gonadotrophin  dose,  duration  of ovarian  stimulation,  total  gonadotrophin  dose 
required for ovarian stimulation,  and negatively with the oestradiol  level  before 
hCG administration, the number of follicles measuring  10-15mm and  16-17mm, 
number  of  follicles  aspirated,  number  of  oocytes  collected  and  used  for 
fertilization,  number of 1-PN,  2-PN and 3-PN embryos created,  and  number of 
embryos cryopreserved. There was a tendency of an association between high 
follicular fluid VEGFR concentrations and high FSH levels (p: 0.09).
It was  of major  interest that  no  correlation  was  detected  with  embryo  quality. 
Previous studies by Van Blerkom et. al.107,357 report a link between follicular fluid 
VEGF  levels  and  subsequent  embryo  quality,  based  on  the  argument  that 
hypoxic  follicular  environment  leads  to  chromosomal  abnormalities  of  the 
dividing oocytes and consequently poor fertilization and embryo growth.
In the current study, there had been a consistent and significant association of 
high  follicular  fluid  concentrations  of  VEGF  and  VEGFR  and  poor  ovarian 
reserve, poor ovarian response to stimulation and poor treatment outcome, that 
in turn were associated with older female age and higher BMI.
6.3.2  Associations between VEGF- VEGFR Levels and Doppler Indices
The  association  between  VEGF  and  VEGFR  concentrations  and  pelvic 
perfusion assessed  by Doppler ultrasonography was investigated  (Table 5.31). 
In the whole study population, a tendency was noted to an association between 
poor uterine artery and sub-endometrial perfusion during IVF treatment (high PI
197values  ±  low  drop  in  PI  values  during  treatment)  and  higher  pre-  and  post­
treatment serum VEGF, lower pre- and post-treatment serum VEGFR level, and 
higher  follicular  fluid  VEGF  and  VEGFR  levels.  These  observations  provided 
further evidence that high VEGF levels are the hypoxic response of the system, 
as they are likely to be associated with poor perfusion. This hypoxic response in 
women  with  poor  uterine  perfusion  was  a  personal  prognostic  characteristic 
evident  at  the  baseline  investigation  but  this  also  persisted  throughout  the 
treatment  for  IVF  and  was  consequently  observed  at  the  end  of the  ovarian 
stimulation,  both  systemically  in  the  serum  and  locally  in  the  follicular  fluid. 
Serum VEGFR levels also responded to this hypoxic state and were maintained 
at a  lower concentration to  maximize the availability of the free VEGF form to 
bind the membrane receptors.  However,  in follicular fluid  higher VEGFR levels 
were found  as a  reflection of poor uterine-endometrial  perfusion  indicating that 
either there was an effort to control  biological activity of the rising VEGF  levels 
during hypoxia or inappropriately high follicular fluid VEGFR levels were actually 
preventing the available VEGF from  improving the tissue  perfusion  at the time 
of sampling and leading to hypoxia.
As  already  documented,  good  uterine  perfusion  detected  by  Doppler analysis 
was  associated  with  better sub-endometrial  and  follicular  perfusion  and  better 
ovarian  response to stimulation  and  higher pregnancy  rates  (Table  5.17,  5.21, 
Table  5.41-5.44CD).  It was  also  shown that good  uterine  and  sub-endometrial 
perfusion was associated with low follicular fluid VEGF and VEGFR, which were 
also  associated  with  good  ovarian  reserve,  better  ovarian  response  to 
stimulation and possibly better implantation and pregnancy rates.
The  initial  model  of the current study stated that low VEGF  and VEGFR levels 
have  indicated  optimum  oxygenation  and  desirable outcome,  and  low VEGFR 
levels in the presence of high VEGF levels have suggested a hypoxic response. 
The observations of the current study fitted this simple model.
Lee et.  al.345 show that follicular fluid  VEGF  concentrations  are  more than  10- 
fold greater than serum concentrations at the time of oocyte collection.  Manau
198et.  al.347 also detect significantly higher follicular fluid  concentrations of VEGF 
than the corresponding circulating concentrations.
A positive correlation is reported between blood VEGF levels and the number of 
follicles detected  by vaginal  sonography  prior to oocyte  collection352,353,354.  In 
contrast,  Manau  et.  al.347  observe  no  relationship  between  circulating 
concentrations of VEGF and parameters of ovarian  response to gonadotrophin 
stimulation on the day of oocyte aspiration.
Although  some  reports  suggest  that  high  follicular  fluid  VEGF  levels  are 
associated  with  high  follicular  vascularization  and  oxygenation,  resulting  in 
oocytes with  superior  pregnancy  potential107,348,356,357,  other studies  show that 
an  elevated  level  of follicular fluid  VEGF  implies  follicular  hypoxia345,347,359,360. 
Thus, the increased follicular fluid VEGF concentration  is considered a marker 
of diminished  pregnancy potential349,361  and  correlates  negatively with  embryo 
quality  in  IVF  patients547.  Likewise,  Battaglia  et.  al.362  report  that  poor 
responders  experience over-production  of follicular fluid VEGF  consistent with 
ovarian ageing and decreased ovarian reserve. Quintana et. al.363 observe that 
follicular  fluid  VEGF  concentration  is  elevated  in  patients  with  decreased 
ovarian  response  to  controlled  ovarian  hyperstimulation.  Tokuyama  et.  al.548 
report  that  regardless  of  the  stimulation  protocol,  women  with  the  highest 
number of oocytes collected  have the lowest VEGF concentrations in follicular 
fluid.
Barroso et. al.547 describe no significant association between blood flow indices 
and follicular levels of VEGF, unlike Van Blerkom et. al.107,357 who show higher 
VEGF levels in follicles with higher dissolved oxygen contents and with Doppler 
findings indicative of increased blood flow.
All  of these  findings  give  credence  to  our  contention  that  in  the  absence  of 
simultaneous  VEGF-VEGFR  measurements,  isolated  assessment  of  VEGF 
levels  could  lead  to  conflicting  results  and  conclusions.  The  observations  and 
interpretation  of VEGF  levels  in  the  current  study,  extended  by  the  combine 
VEGFR interactions could provide a physiologically plausible model.
1996.3.3  Aspirin and VEGF-VEGFR Levels
In the following  section the aspirin-VEGF-VEGFR interaction will  be discussed 
(Table  5.25).  Differences  in  pre-  and  post-treatment  serum  and  follicular fluid 
levels  of  VEGF  and  VEGFR  were  not  statistically  significant.  However,  a 
biologically plausible model  may be inferred by the tendencies observed in the 
absolute values of VEGF-VEGFR levels.
Serum  and  follicular  fluid  VEGF  levels  were  persistently  lower  in  the  aspirin 
group  when  compared  with  the  placebo  group  both  before  and  after  IVF 
treatment.  Serum VEGFR  levels,  although  higher in  the  aspirin  group  prior to 
treatment,  was  level  with  that  of  the  placebo  group  in  the  post-treatment 
samples.  In  the  aspirin  group,  much  lower follicular fluid  VEGFR  levels were 
found than in the placebo group.
Therefore,  with  the  limitation  of  a  significant  chance  factor  in  mind,  such  a 
distribution of differences in aspirin and placebo groups might have indicated a 
subtle  tendency  towards  better  perfusion  in  the  aspirin  group.  Doppler 
assessment differences between the aspirin and placebo groups were mostly in 
favour of the aspirin group with lower vascular resistance, but once again were 
not  statistically  significant.  Hence,  these  two  separate  assessments 
(biochemical  and  physical)  of the  same condition  (tissue  perfusion)  agreed  in 
broad  terms  but  were  not  strong  enough  to  reach  a  level  of  statistical 
significance beyond the pre-set level of an acceptable chance factor.
In this context, it is of interest to refer to the observations of Tsuji et. al.1 56 which 
provide  an  alternative  scenario;  where  aspirin  can  slow  down  the  endothelial 
migration and tube formation stages of neovascularization via inhibition of COX- 
2 and subsequent proangiogenic factor production. Hence, lower concentrations 
of VEGF  both  in follicular fluid and  in  peripheral  circulation could  be the direct 
result of aspirin.  VEGF  stimulates  nitric oxide  release from  endothelial  cells3 3 1  
and  induces  the  release  of prostacyclin  by activating  cytosolic  phospholipase 
A2,  causing the  release of arachidonic acid332.  Both of these actions would  be 
expected to promote vasodilatation. Aspirin can irreversibly block this process.
2006.3.4  Prognostic Significance of Doppler Variables of Utero-ovarian Blood Flow 
and  VEGF  and  VEGFR  in  Serum  and  Follicular  Fluid  in  Prediction  of 
Pregnancy
On  an  extensive  list  of  demographic,  clinical,  embryological,  Doppler, 
ultrasonographic  and  VEGF-VEGFR  variables,  logistic  regression  analysis 
highlighted  the  uterine  artery  Doppler  indices  in  the  late  follicular  phase  of 
ovarian  stimulation  and  post-treatment  serum  VEGFR  levels  as  the  only 
independent  prognosticators.  This  finding  indicated  the  fundamental  role  of 
tissue perfusion whether expressed in physical terms by Doppler assessment or 
in  biochemical  terms  by  VEGF-VEGFR  levels  in  the  fertility  potential  of  the 
women, leaving the demographical and clinical variables as surrogate markers. 
Furthermore,  it was of note that both qualitative and quantitative embryological 
variables  lost  their  prognostic  significance  once  the  effect  was  corrected  for 
perfusion  variables.  This  association  also  emphasized  the  primacy  of uterine 
over  ovarian  perfusion  and  the  final  assessment  of  these  parameters  after 
ovarian stimulation over their initial baseline values. The latter limits the clinical 
application  of these  parameters  in  pretreatment evaluation  of the  patients for 
their  prognostic  potential  to  tailor  their  ovarian  stimulation  but  can  still  be 
valuable  in  management  of  ET  in  terms  of number of embryos  (Table  5.32- 
5.35).
Using  a  more  focused  list  of independent variables  including  only VEGF  and 
VEGFR  concentrations  and  Doppler  indices,  logistic  regression  analyses 
showed  that only  pre-  and  post-treatment serum VEGF were the  independent 
prognosticators of pregnancy. This may reflect the foremost role of angiogenetic 
stimulation  and  tissue  perfusion  in  the  overall  down-stream  process  of 
conception.
2017  Frozen-Thawed Embryo Replacement Cycles: Results
7.1  Clinical  and  Embryological  Variables  of  the  FTER  and  their  Primary
Fresh IVF Treatment Cycles
From  the  total  study  population,  21.9%  of  the  couples  were  randomised  to 
either the NC or DRRC groups.  The remaining 78.1% of the couples expressed 
a strong preference for one mode of treatment and were allocated to either the 
NC or DRRC groups according to their preference.  In the NC FTER group 18% 
of  cycles  were  randomised  and  in  the  DRRC  FTER  group  26.5%  were 
randomised. Of all the FTER cycles, 53% were in the NC group and 47% in the 
DRRC group.
Demographic characteristics of the couples and details of the primary fresh IVF 
treatment  cycles  relating  to  the  index  FTER  cycles  were  summarized  (Table 
7.1,  7.2,  Table  7.1-7.16CD).  For  all  FTER  cycles,  the  average  number  of 
embryos implanted  per cycle was 0.3, the pregnancy rate 26.7% and on-going 
pregnancy 21% (Table 7.17CD).
202Table 7.1:  Patient Characteristics,  Clinical and  Embryological Variables of the NC and  DRRC 
Groups in their Primary Fresh IVF Treatment Cycle
Natural Cycle DRRC  |
N Mean ± SD N Mean ± SD
Female Age (year) 56 34.6 ± 5.0 49 33.4 ± 4.3  |
Duration of Subfertility (month) 56 49.0 ±30.3 49 59.5 ± 38.8  i
Gravity 56 0.8 ± 1.1 49 0.7 ± 1.6  |
Parity 55 0.3 ± 0.6 47 0.3 ±0.5  |
Duration of Menstrual Cycle (day) 56 28.5 ±4.1 49 30.1 ±2.6  I
Duration of Menstrual Bleeding (day) 56 4.9 ±1.1 49 5.1 ± 1.1  !
BMI (kg/m2) 55 24.1  ±4.3 47 23.1 ±3.3  [
Baseline FSH (IU/I) 51 7.5 ±3.9 48 6.1 ± 1.8  |
Initial Gonadotrophin Dose (III) 56 170 ±45.3 49 155 ±36.5  |
Duration of Gonadotrophin Stimulation (day) 56 12.0 ±2.7 49 11.5 ± 2.5  |
Total Gonadotrophin Dose (IU) 56 2067 ± 800 49 1748 ±618  |
E2  Level after Down-Regulation (nmol/l) 56 0.08 ± 0.02 49 0.08 ± 0.0  |
E2  Level before hCG Injection (nmol/l) 56 6.6 ±3.6 49 8.4 ±2.6  |
< 9 mm 56 4.0 ± 6.6 49 5.8 ±7.1  |
10-15 mm 56 7.2 ± 4.8 49 8.8 ±4.4  |
Number of Follicles 16-17 mm 56 2.8 ± 1.6 49 3.2 ± 1.6
measuring 18-20 mm 56 2.3 ±1.2 49 2.8 ± 1.8  |
21-25 mm 56 0.4 ± 0.7 49 0.5 ±0.8  |
26-30 mm 56 0.0 ±0.0 49 0.04 ± 0.29  !
Number of Follicles Aspirated 56 15.4 ±5.8 49 18.8 ±5.7  |
Number of Oocytes Collected 56 14.1 ± 5.8 49 17.7 ±6.1
Number of Oocytes Used 53 13.3 ±5.5 49 17.3 ±5.6
Number of 2-PN Embryo 55 9.9 ± 3.9 49 12.7 ±4.0
Number of Embryos Transferred 56 1.7 ±0.7 49 1.2 ±0.9
Number of Embryos Cryopreserved 56 8.2 ±7.6 49 9.9 ±4.7
Number of Frozen after Cell Division 48 5.4 ±2.6 44  |  6.9 ±3.1
Number of Frozen at Pronuclear Stage 14 8.5 ±4.3 21 8.8 ±3.2
Grade of the First Embryo Transferred 48 1.1  ±0.4 32 1.1 ±0.4
Grade of the Second Embryo Transferred 48 1.3 ±0.6 31 1.2 ±0.5
Grade of the Third Embryo Transferred 4 1.5 ±0.5 o  I
Embryo Transfer Time (sec) 48 46.8 ±46.6 32 53.5 ± 64.8
Number of Embryos Implanted in Fresh 
Cycle
53 0.3 ±0.5 45 0.1 ±0.3
Number of Embryos Implanted in FTER 
Cycle
55 0.3 ±0.6 47 0.3 ±0.5
N: Number of subjects whose data were available for each variable 
Percentages represented as decimal of 1.0 ± SD
203Table 7.2: Outcome of the Fresh IVF Cycle in the NC and DRRC Groups
Natural Cycle
Outcome of Fresh Cycle
Pregnant Ongoing
N
13
Percent
Pregnant Miscarriage 5 1 8.9
Pregnant Biochemical _____ i___________J j __________5AJ
Not pregnant 35  ] 62.5
Pregnant Ongoing 5 10.2
Pregnant Miscarriage 2  I 4.1
DRRC
’regnant Biochemical 
Not pregnant
Al
38 77.6  I
In the  NC  FTER group, the median day of LH  surge was cycle day 14 (9-23). 
On the day that onset of the surge was first detected, the average LH level was
35.1  IU/I (7.8 -100) with E2 concentration of 1   nmol/l (0.29-1.88). After detection 
of the  onset  of the  surge,  LH  levels  continued  to  increase to  a  peak  of 45.2 
nmol/l (13.8-124.4). ET was scheduled for day 4 following detection of the onset 
of  LH  surge  (cycle  days  3-6).  A  median  of 3  embryos  were  thawed  (1-7),  2 
survived  (1-5),  and  2  were transferred  (1-3).  The three  embryos  selected for 
transfer  were  Grade  1,  2,  and  3  respectively.  After  the  index  study  cycle  a 
median  of  2  embryos  remained  for future  transfer  (0-16).  The  average  mid- 
luteal P4 concentration was 44 nmol/l. Of the NC, 71% graded the ET procedure 
‘easy’  and  1.8%  ‘difficult’.  The  pregnancy and  ongoing  pregnancy  rates  were 
25% and 19.6% respectively. (Table 7.18,  7.20, 7.21 CD).
In the DRRC  FTER group, the average E2 and  P4 levels after down-regulation 
were 0.1  nmol/l (0.07-0.76) and 1.6 nmol/l (0.06-6.6) respectively. A median of 3 
embryos  were thawed  (2-13),  2  survived  (1-11),  and  2 were transferred  (1-3). 
The three  embryos  selected  for transfer were Grade  1,  2,  and  3  respectively. 
Following  the  index  study  cycle  a  median  of  5  embryos  remained  for future 
transfer (0-16).  Of the DRRC, 67% graded the ET procedure ‘easy’ and  10.2% 
‘difficult. The pregnancy and ongoing  pregnancy rates were 28.6% and 22.4% 
respectively.’ (Table 7.19CD).
2047.1.1  Correlation Between Clinical and Embryological Variables of the NC
Correlations  observed  among  the  clinical  and  embryological  variables  of the 
NCs were  summarized  (Table  7.3).  Positive correlation  between the variables 
was  given  as  ‘t \   negative  correlation  as  ‘I ’,  and  no  correlation  as 
Correlations with  a  p value of <0.05 were  marked  with  ‘*’t  and those with  a  p 
value of 0.05-0.09 with ***’.  Numerical values of the correlation coefficients and 
corresponding p values were given on the CD Rom (Table 7.22-7.24CD).
Table 7.3: Correlations between Clinical and Embryological Variables in the NC
LH Surge Number of Embr\ros
Day
e2
Level
LH
Level
Maximum 
LH Level
Thawed Survived Left Transferred
Day of LH 
Surge
<-> <-> <-> <-> <-> t*
E2  Level at 
LH Surge <-> <-» <-> <-> <->
LH Level at <-> <->
Maximum 
LH Level <-> 'jV* <-> <-> <-»
ET Day > 1 ** <-> I* <-» <-> <-> <-> ........tt.........
Embryos
Thawed <r> < -> <->
Embryos
Survived
<-> <->
Embryos
Left <-» < -> <-> <->
Embryos
Transferred <-» 'I'** < -> <-> "I'* o
Grade of
the 1st I* <-> •fi <-> <-»
Embryo
Grade of
the 2n d <-> <-> ^11 <-> <-> <->
Grade of
the 3rd  
Embryo
4* <-> **
Luteal
Phase P4 <-> <-» < -> <-> <-> <-» <->
Level
t: Positive correlation between the variables,  negative correlation,  : no correlation, * : p:<0.05, ** : p:0.05-0.09.
2057.2  Clinical and Embryological Variables of the Primary Fresh IVF Treatment 
Cycle in Predicting the outcome of Subsequent FTER in the Whole Study 
Population
The  data  were  evaluated  to  assess the  prognostic  significance  of the  clinical 
and embryological variables of the primary fresh IVF treatment cycle, to predict 
the  outcome  of the  FTER  cycle  in  terms  of ongoing  pregnancy  (Table  7.25- 
7.38CD).
In  the  primary  fresh  IVF  treatment  cycle,  the  parameters  that  showed 
significantly  different  distribution  between  the  pregnant  (ongoing)  and  non­
pregnant  groups  of the  subsequent  FETR  cycles  respectively  (p:<0.05)  were 
female  height  (1 . 6 6   vs  1.62cm),  number  of  developing  follicles  particularly 
between  10-15mm  (10.5  vs  7.2),  number  of follicles  aspirated  (20.8  vs  16), 
number of oocytes collected (19 vs 14), number of oocytes used for fertilisation 
(18  vs  14),  number  of  2-PN  embryos  (12.9  vs  10.8),  number  of  embryos 
transferred (0.8 vs 1.7) and number of embryos cryopreserved (11  vs  8 ). Being 
randomised or allocated on personal choice to the NC or DRRC groups did not 
affect the outcome of FETR.
The pregnant and non-pregnant groups in the FTER cycle showed no difference 
when the following variables were compared in the primary fresh  IVF treatment 
cycle:  female  age,  duration  of  subfertility,  past  obstetric  history,  duration  of 
menstrual cycle, female weight and BMI, early follicular phase FSH, initial daily 
gonadotrophin  dose  and  total  gonadotrophin  dose,  duration  of  ovarian 
stimulation,  E2  levels  after  down-regulation  and  before  hCG  injection,  sperm 
concentrations  before  and  after  preparation  and  grade  of  the  embryos 
transferred.  Primary and secondary male or couple subfertility did not affect the 
outcome  of  the  FTER  cycle.  However,  in  contrast  to  general  expectation, 
women  with  secondary  subfertility  were  less  likely  to  achieve  ongoing 
pregnancy  in  an  FTER  cycle  (p:  0.01).  The  aetiology  of  subfertility  and  the 
female life-style in terms of smoking and alcohol consumption did not affect the 
treatment outcome of FTER.  When the  pregnant and  non-pregnant groups  in 
the FTER cycles were compared, there were no differences  in the use of mid- 
luteal or early follicular protocols, type of GnRHa, type of gonadotrophin, type of
206fertilization (IVF vs ICSI) and the use of husband or donor sperm in the primary 
fresh IVF treatment cycles. The outcome of the FTER cycles was not influenced 
by the  degree  of technical  difficulty of the  ET  in  either the  primary fresh  IVF 
treatment cycle or FTER cycles for both NCs and DRRCs (Table 7.26-7.38CD). 
The  probability  of  pregnancy  in  FTER  was  higher  with  pronuclear  stage 
cryopreservation when compared with cleavage stage (p: 0.05).
The  outcome  of  the  fresh  IVF  treatment  in  terms  of  ongoing  pregnancy, 
biochemical  pregnancy,  miscarriage,  or  no-pregnancy  did  not  affect  the 
outcome  of  the  subsequent  FTER  cycle.  However,  it  is  of  note  that  of  the 
women  with  biochemical  pregnancy or miscarriage  in  the fresh  IVF treatment 
cycle,  none  achieved  ongoing  pregnancy in  the  FTER  cycle  (Table  7.4).  The 
outcome  of the  primary  fresh  IVF  treatment  cycle  did  not  affect  the  type  of 
FTER  cycles  to  be  used  for  the  subsequent  index  study  cycle  and  had  no 
influence  on  whether  couples  agreed  to  randomisation  or  had  a  strong 
preference for a particular type of FTER (NC or DRRC) (Table 7.5).
Table 7.4: Association between the Outcome of Fresh IVF Cycle and FTER in the Whole Study 
Population
Pregnant
Ongoing
Not
Pregnant
Miscarriage Biochemical
Yes
Pregnant NS
No Outcome 
of FTER Yes
No
Ongoing
Pregnant
NS
Table  7.5:  Association  between  the  Outcome  of  Fresh  Cycle  and  Type  of  FTER  and 
Randomization Status in the Whole Study Population
Outcome of Fresh Treatment Cycle |
Pregnant
Ongoing
Miscarriage Biochemical Not pregnant P I
Natural Cycle 13 5 3 35 f
NS  |
DRRC 5 2 4 38
Randomized 3 1 19 i
Non-
Randomized
15 6 7 54
NS
2077.3  Clinical and Embryological Variables of the NC in Predicting the Outcome 
of FTER
When clinical and embryological variables of the NC were evaluated for clinical 
pregnancy  between  the  pregnant  and  non-pregnant  groups  respectively,  the 
number of remaining cryopreserved embryos after FTER (5.7 vs 2.1) and mid- 
luteal  P4  levels  (52  vs  40)  were  found  to  be  significantly  different  (p:<0.05) 
(Table 7.39,  7.40CD).
Clinical  and  embryological  variables  were  evaluated  for  their  prognostic 
significance  to  predict  ongoing  pregnancy  after  NC  FTER.  Between  the  two 
outcome groups  respectively, there was no difference for the day of LH  surge 
(15 vs  14),  LH  (33 vs 35 IU/I) and E2 (1  vs 1   nmol/l) concentrations on the day 
of LH  surge,  maximum  LH  concentration (peak level of surge) (47 vs 44  IU/I), 
day  of  ET  after  LH  surge  (4  vs  5),  number of embryos  thawed  (3.7  vs  3.1), 
number  of embryos  that  survived  thawing  (2.5  vs  2.3),  number  of  remaining 
cryopreserved  embryos  (6.5 vs  2.1),  number of embryos transferred  (2  vs  2), 
grade of the first (1  vs  1.44), second and third embryos transferred, duration of 
ET, technical difficulty of ET and mid-luteal  P4 level (47.7 vs 43.3 nmol/l) (Table 
7.41,  7.42CD).
7.4  Clinical  and  Embryological  Variables  of  the  DRRC  in  Predicting  the 
Outcome of FTER
When clinical  and  embryological variables  in the  DRRC group were evaluated 
for clinical  pregnancy,  the grades of the first (1  vs  1.4) and  second  (1.5 vs 2) 
embryos selected for transfer and duration of the ET procedure (92 vs 34 sec) 
were  found  to  be  significantly different  (p:<0.05)  between  the  pregnancy  and 
non-pregnancy outcomes (Table 7.43,  7.44CD).
Clinical  and  embryological  parameters  were  evaluated  for  their  prognostic 
significance  to  predict  ongoing  pregnancy  after  DRRC  FTER.  There  was  no 
difference between the two outcome groups for E2 (0.12 vs 0.15 nmol/l) and P4 
(1.98 vs  1.49  nmol/l) concentration  after down-regulation,  number of embryos 
thawed  (3.2  vs  3.6),  number  of embryos  that  survived  thawing  (2.6  vs  2.6), 
number of remaining cryopreserved embryos (7.3 vs 5), grade of the first (1  vs
2081.36),  second  (1.6  vs  2),  and  third  embryos  transferred,  number  of embryos 
transferred  (2 vs  2),  and  duration  and technical  difficulty of the  ET procedure 
(Table 7.45,  7.46CD).
7.5  Comparison  of the  Clinical  and  Embryological  Variables  in  the  Primary 
Fresh IVF Treatment Cycles of the NC vs DRRC Groups
Clinical  and  embryological  variables of the  primary fresh  IVF treatment cycles 
were  compared,  to assess whether they differed  between  the  related  NC  and 
DRRC groups (Table 7.47CD).
The  following  variables  of  the  fresh  treatment  cycle  differed  significantly 
between  the  NC  and  DRRC  groups,  respectively  (p:<0.05):  early  follicular 
phase FSH levels (7.5 vs 6.1  IU/I), initial daily gonadotrophin dose (170 vs 155 
IU) and total gonadotrophin dose (2067 vs 1748 IU), E2 level on the day of hCG 
injection (6.6 vs 8.4 nmol/l), number of developing follicles measuring 10-15mm 
(7.2  vs  8.8),  total  number  of  follicles  aspirated  (15  vs  18),  total  number  of 
oocytes collected (14 vs 17), total number of oocytes used for fertilisation (13 vs 
17),  number  of  2-PN  embryos  created  (9.9  vs  12.7),  number  of  embryos 
transferred  (1.79  vs  1.29),  number  of  embryos  cryopreserved  (8.2  vs  9.9), 
number of embryos cryopreserved after cell division (5.4 vs 6.9), and number of 
embryos implanted per fresh cycle initiated (0.3 vs 0.1).
For women in the DRRC group the length of the menstrual cycle was  1.5 days 
longer than for women in the NC group (28.5 vs 30 days; p: <0.05).  There was 
no  difference  between  the  NC  and  DRRC  groups  for female  age  (34  vs  33 
years), duration of subfertility (49 vs 59 months), past obstetric history, and BMI 
(Table  7.47CD).  In  both the  NC and  DRRC groups, the distribution of primary 
and  secondary  male  and  female  subfertility was  similar,  but there were  more 
couples with secondary subfertility in the NC group (p:0.01).  No difference was 
noted  between  the  NC  and  DRRC  groups for aetiology of subfertility.  Female 
life-style,  in  terms  of  smoking  and  alcohol  consumption  was  similar  in  both 
groups.
209Type of fertilization (IVF or ICSI) used in the fresh IVF cycles was similar in both 
groups. The distribution of divided and pronuclear stage embryos was equal  in 
the  NC  and  DRRC  groups  (Table  7.48-7.58CD).  The  majority of the fresh  ET 
procedures  were  graded  ‘easy’,  but the women  in the  NC  group  appeared to 
have easier fresh  ETs than women in the DRRC group (p: 0.04).  In the DRRC 
group  10.2% of women experienced a difficult FTER and  in the  NC group this 
was  1.8% (p: 0.17) (Table 7.59,  7.60CD). There was no difference in the grade 
of the embryos transferred in the fresh cycle (Table 7.47CD).
Although,  differences  between  the  NC  and  DRRC  groups  in  the  outcome  of 
their primary fresh  IVF treatment cycles were not statistically significant, it may 
be of particular interest to  review the absolute values.  From the  primary fresh 
IVF  treatment  cycle  72%  of  women  with  ongoing  pregnancy  subsequently 
underwent a NC and 27.8% DRRC. Where conception was not achieved in the 
primary fresh  IVF treatment cycle, 47.9% of the women were in the NC group 
and 52.1% in the DRRC group (Table 7.5).  When we reviewed the outcome of 
the  related  non-study  FTER  cycles  using  embryos from  the  cohort created  in 
the  fresh  IVF  cycle,  but  not  transferred  in  the  index  study  FTER  cycle,  no 
difference was observed in the pregnancy rates of the two groups (Table 7.6).
Table 7.6: Outcome of the Other Related FTER for NC vs DRRC Groups
i
I_______________ Type OF FTER  | _..  P
Natural Cycle  |  DRRC  1
Pregnancy with ________________ 2 j________6 j  NS
other FTER cycles |  Not Pregnant 19  |  15  !
In the NC and DRRC groups, pregnancy and ongoing pregnancy rates of FTER 
were  similar  (Table  7.7)  as  was  the  quality  of transferred  embryos  in  FTER 
(Table 7.77CD).
Table 7.7: Outcome of the Study FTER for NC vs DRRC Cycles
Natural Cycle DRRC P
Pregnant
Yes 14  | 14
NS
No 42  | 35
Ongoing Pregnancy
Yes 11  | 11
NS
No 45  | 38
210Ten women in the NC group and  13 in the DRRC group were randomised and 
the  remaining  women  allocated  to  either group  according  to their preference. 
Couples who were randomized or allocated to their treatment cycles based on 
personal  preference  were  compared,  to  assess  whether  there  were  any 
differences  which  may  affect  the  homogeneity  of  the  study  groups  and  so 
confound the comparative statistics (Table 7.61CD).
Only duration of menstrual cycle differed between the randomized and allocated 
groups  respectively  (28  vs  29  days;  p:<0.01).  Although  the  difference  was 
statistically significant,  the variation of one day in  a  range of 26 to 36 days is 
less likely to  be clinically relevant.  Female age and  BMI,  early follicular phase 
FSH level, duration of subfertility, past obstetric history, sperm parameters, and 
clinical and embryological parameters of ovarian stimulation were similar in both 
groups (Table 7.61 CD).
There  was  no  difference  between  the  randomised  and  allocated  groups  in 
distribution  of  female,  male  and  couple  subfertility,  aetiology  of  subfertility, 
female smoking and alcohol consumption, use of the day 2 or day 21  protocol, 
type of GnRHa down-regulation in the primary fresh IVF treatment cycle, type of 
gonadotrophin  used  for  ovarian  stimulation,  number  of divided  or  pronuclear 
stage embryos,  difficulty of ET in fresh and  FTER cycles,  type of FTER cycle 
(NO  or  DRRC)  or  outcome  of the fresh  ET  and  FTER  cycle  (Table  7.8,  7.9, 
Table 7.62-7.76CD).
Table  7.8:  Association  between  the  State  of  Randomization  and  the  Outcome  of the  FTER 
Cycles
Allocation .....P.| 1 Randomized Non-randomized |
Outcome
Pregnant
Yes_
No
-   _   _
18
23
59
NS
of FTER
Ongoing Pregnancy
Yes 5 17
NS  |
No 18 65
211Table 7.9: Randomization for the Type of FTER Groups
Allocation P
Randomized Non-randomized
NS Natural Cycle 10 46
DRRC 13 36
7.6  Factors Linked to Embryo Survival Rate
In the NC group the embryo survival rate (ESR) did not correlate with any of the 
patient characteristics, clinical and embryological variables of the primary fresh 
IVF treatment and  subsequent FTER cycles,  including the number of embryos 
implanted  after FTER,  serum VEGF and VEGFR levels on the day of ET,  and 
grade of embryos selected for fresh ET (Table 7.78-7.83,  7.110CD).
In the  DRRC group, the embryo survival  rate did  not correlate with any of the 
clinical and embryological parameters, with the exception of positive correlation 
with the  number of developing  follicles  at  16-17mm  (p:  0.01),  total  number of 
follicles aspirated  (p:  0.01),  number of oocytes collected  (p: <0.05),  number of 
oocytes used for fertilisation (p: <0.05) and number of 3-PN embryos (p: <0.01) 
and  negative  correlation  with  the  number  of  embryos  transferred  during  the 
fresh IVF cycle (p: 0.01) (Table 7.78-7.83CD).
In  both  the  NC  and  DRRC  groups,  there was  an  association  between  higher 
ESR  and  a  diagnosis  of  secondary  female  subfertility  but  this  approached 
statistical  significance  only  in  the  DRRC  group  (p:  0.05).  Male  and  couple 
subfertility and type of subfertility did  not correlate with  ESR.  Female smoking 
and alcohol consumption did not affect ESR. A day 2 or day 21  start for down- 
regulation and type of fertilisation (IVF or ICSI) did  not affect ESR (Table  7.84- 
7.103CD).
The  outcome  of  the  fresh  IVF  cycle  did  not  affect  the  survival  rate  of 
cryopreserved  embryos  in  a  subsequent  study  FTER  cycle  (Table  7.104, 
7.105CD); and  in  both the NC and  DRRC groups, the embryo survival  rate did 
not  affect  the  pregnancy  and  ongoing  pregnancy  rates  of  the  FTER  cycles 
(Table 7.106-7.109CD). Although quality of the embryos transferred in the fresh
212IVF cycle did not affect the ESR in either NCs or DRRCs, ESR was associated 
with  the  quality  of the  best  embryo  transferred  in  both  FTER  groups  (Table 
7.110CD).
In  the  DRRC  group,  ESR  was  significantly  higher  if  embryos  were 
cryopreserved  at the  pronuclear stage rather than  after cell  division  (p:  <0.05) 
(Table 7.10, 7.11).
Table 7.10: Association between  Embryo Survival Rate and Stage of Embryo Development in 
NC and DRRC
Embryo Survival Rate (%) N Mean ± SD P
Divided 38 0.7 ± 0.2
Natural Cycle Pro Nuclear 4 0.9 ±0.1 NS
Divided and Pro Nuclear 10 0.7 ±0.3
Divided 28 0.7 ± 0.2
DRRC Pro Nuclear 5 1.0 ±0.0 0.01
Divided and Pro Nuclear 16 0.9 ±0.1
Percentages represented as decimal of 1.0 ± SD
Table 7.11: Association  between  Embryo Survival  Rate and Stage of Embryo Development in 
DRRC (Bonferroni Multiple Comparisons)
P  I
Divided vs
Pro Nuclear <0.05  |
DRRC Embryo Survival Rate
Divided and Pro Nuclear <0.05  |
Pro Nuclear vs
Divided <0.05  |
Divided and Pro Nuclear NS  |
7.7  Cleavage  Stage  vs  Pro-nuclear Stage  Embryo  at the time  of Cryo- 
preservation
Embryos  cryopreserved  at the  pronuclear stage were compared with embryos 
cryopreserved  after cleavage stage.  In the  DRRC  group the survival  rate was 
significantly higher for pronuclear-stage embryos (100% vs 72%) and this trend 
was  evident  in  the  NC  group  but  not  at  a  significant  level  (93%  vs  78%). 
Although differences in clinical pregnancy rates were not statistically significant 
(pronuclear  stage  44.4%  >  cleavage  stage  19.7%),  ongoing  pregnancy  rates 
(pronuclear  stage  33.3%  >  cleavage  stage13.6%;  p:0.05)  and  number  of 
embryos  implanted  (pronuclear  stage  0.55  >  cleavage  stage  0.18  p:<0.05) 
showed a clear distinction. This effect was probably due to the survival ability of
213the embryos, as there was no difference in the embryo quality between PN and 
cleavage stage (Table 7.111-7.113CD). When we separately evaluated the NC 
and DRRC groups, there was an evident trend of embryos cryopreserved at the 
pronuclear  stage  having  higher  survival  and  pregnancy  outcome  rates  than 
embryos divided at the time of cryopreservation. Because, the number of cycles 
was  reduced  in this  subgroup analysis,  statistical  significance appeared to  be 
lower (Table 7.114-7.119CD).
7.8  VEGF,  VEGFR,  VEGF:VEGFR in  Predicting the Treatment Outcome 
in the Whole Study Population
VEGF  and  VEGFR  concentrations  were  measured  in  61  serum  samples 
obtained  on  the  day  of  FTER  (Table  7.12).  In  pregnant  and  non-pregnant 
women,  on  the  day  of  FTER  the  difference  in  serum  VEGF  and  VEGFR 
concentrations was not statistically significant. This was also the case in women 
with ongoing pregnancy and those with no-ongoing pregnancy (Table 7.13).
Despite  not  reaching  statistical  significance,  higher VEGF  and  lower VEGFR 
levels  were  evident  in  women  who  achieved  pregnancy  after  FTER  and  this 
distinction became more marked in those with ongoing pregnancy (Table 7.13).
Table 7.12: VEGF, VEGFR Levels
N  | Mean ± SD
VEGF (pg/ml) 61  | 306.5 ± 196.0  I
VEGFR (pg/ml) 61  I 37.6 ± 18.7  |
Table  7.13:  VEGF,  VEGFR  levels  for  Clinical  and  Ongoing  Pregnancy  in  the  Whole  Study 
Population
Clinical Pregnancy N Mean ± SD P
VEGF (pg/ml)
Yes 16 331.3 ±231.0
NS
No 45 297.7 ± 184.0
VEGFR (pg/ml)
Yes 16 34.3 ± 11.2
NS
No 45 38.7 ± 20.7
Ongoing Pregnancy  |
VEGF (pg/ml)
Yes 13 346.2 ± 248.3
NS
No 48 295.7 ± 180.9
VEGFR (pg/ml)
Yes 13 34.7 ±12.5
NS
No 48 38.3 ±20.1
214Differences  in  serum  VEGF  and  VEGFR  levels  did  not  reach  statistical 
significance  in  women  with  primary or secondary subfertility,  women  who  are 
smokers or non-smokers and women who do or do not consume alcohol (Table 
7.120-7.122CD).
VEGF  levels did  not differ in different aetiologies of subfertility,  unlike VEGFR 
levels.  Levels  of  VEGFR  in  unexplained  subfertility  (25.3  pg/ml)  were 
significantly lower than in tubal factor subfertility (43.7 pg/ml) (p: <0.05).  Lower 
levels of VEGFR in endometriosis (29.2 pg/ml) and higher levels in male factor 
subfertility (39.2 pg/ml) were not significantly different (Table 7.123,  7.124CD).
The ratio of VEGF to its receptor did not improve the discriminative power of the 
individual  parameters in the prediction of pregnancy following  FTER.  However, 
a higher ratio was evident in pregnant cycles (Table 7.14, 7.15).
Table 7.14: VEGF:VEGFR Ratio
N Mean ± SD  |
VEGF:  VEGFR  |  61  | ..................................10.3 ± 8.9  |
Table 7.15: VEGF:VEGFR Ratio for Clinical Pregnancy
N Mean ± SD  |  p  |
Pregnant  |  16  |  11.1  ±9.7]
Not Pregnant  |  45  |  10.0±8.6|  [
7.8.1  VEGF,  VEGFR,  VEGF:VEGFR  in  Predicting the Treatment Outcome  in 
the NC vs DRRC Groups
Serum VEGF, VEGFR, and VEGF:VEGFR levels were not significantly different 
between pregnant and non-pregnant women in both the NC and DRRC groups. 
However,  the  NC  group  had  lower  VEGF  and  VEGFR  levels  in  pregnancy 
cycles than  in non-pregnancy cycles (NS). The DRRC group had higher VEGF 
and  lower  VEGFR  levels  in  pregnancy  cycles  than  in  non-pregnancy  cycles 
(NS). (Table 7.17, 7.18).
VEGFR  levels  were  significantly  lower  in  DRRCs  when  compared  with  NCs 
(Table 7.16). This difference between NCs and DRRCs was mainly observed in
215the  pregnant women,  as VEGFR  in  non-pregnant women  was  similar in  NCs 
and DRRCs (Table 7.19-7.21).
VEGF  levels  were  similar  in  both  NCs  and  DRRCs.  However,  the  absolute 
VEGF  levels  were  higher  in  the  DRRC  group  than  in  the  NC  group  with 
pregnancy, but the reverse was true if pregnancy was not achieved (NS) (Table 
7.19-7.21).
In  both  the  NC  and  DRRC  groups,  the  diagnosis  of subfertility did  not  affect 
VEGF levels at a statistically significant level. In the NC group the differences in 
VEGFR  levels  were  statistically  significant  (p:0.01)  and  the  levels  in 
unexplained  subfertility were  significantly lower than  in  tubal  factor subfertility 
(Table 7.128CD).
Table 7.16: VEGF and VEGFR levels for NC vs DRRC
N Mean ± SD P  I
VEGF Natural Cycle 35 301.1 ± 176.5
NS  I (pg/ml) DRRC 26 313.7 ±223.0
VEGFR Natural Cycle 35 40.5 ±18.6
<0.05  | (pg/ml) DRRC 26 33.6 ±18.5
Table 7.17: VEGF, VEGFR, VEGF:VEGFR for Clinical Pregnancy in NC and DRRC
Natural Cycle
Pregnant N Mean ± SD P
VEGF: VEGFR
Yes 10 7.5 ±4.1
NS
No 25 9.4 ± 7.4
VEGF (pg/ml)
Yes 10 287.4 ± 162.3
NS
No 25 306.7 ± 184.8
VEGFR (pg/ml)
Yes 10 39.2 ±10.7
NS
No 25 41.0 ±21.2
DRRC
Pregnant N Mean ± SD P
VEGF: VEGFR
Yes 6 17.1  ±13.6
NS
No 20 10.6 ± 10.1
VEGF (pg/ml)
Yes 6 404.6 ± 320.0
NS
No 20 286.4 ± 187.2
VEGFR (pg/ml)
Yes 6 26.1  ±6.7
NS
................ No 20 35.9 ± 20.3
216Table 7.18: VEGF, VEGFR for Ongoing Pregnancy in NC and DRRC
Natural Cycle
Ongoing Pregnancy N  |  Mean ± SD  |  p
VEGF (pg/ml)
Yes 8 289.8 ± 165.5 I
NS  [
5 No 27 304.5 ±182.5
VEGFR (pg/ml)
Yes__________________ ]___8 j_________ 40.9 ± 11.4  [  Ng  I
No  I  27  |  40.3 ± 20.5  |  |
DRRC
Ongoing Pregnancy N  |  Mean ± SD  |  p
VEGF (pg/ml)
Yes 5  |  436.5 ± 347.0
NS
No 21  |  284.4 ±182.7
VEGFR (pg/ml)
Yes 5  |  24.8 ± 6.7
NS
No 21 35.7 ±19.8
Table 7.19: VEGF, VEGFR, VEGF:VEGFR Levels in the Pregnant Group of NC vs DRRC
Pregnant Women  |
N Mean ± SD P  I
VEGF: VEGFR
Natural Cycle 10 7.5 ±4.1 I
0.05
DRRC 6 17.1  ± 13.6
VEGF (pg/ml)
Natural Cycle 10 287.4 ± 162.3 !
NS
DRRC 6 404.6 ± 320.0
VEGFR (pg/ml)
Natural Cycle 10 39.2 ± 10.7
<0.05
DRRC 6 26.1 ±6.7
Table 7.20: VEGF, VEGFR, VEGF:VEGFR Levels in the Non-pregnant Group of NC vs DRRC
Non-pregnant Women
I  N Mean ± SD P
VEGF: VEGFR
Natural Cycle 25 9.4 ± 7.4
NS
DRRC 20 10.6 ± 10.1
VEGF (pg/ml)
Natural Cycle 25 306.7 ±184.8
NS
DRRC 20 286.4 ± 187.2
VEGFR (pg/ml)
Natural Cycle 25 41.0 ± 21.2
NS
DRRC 20 35.9 ± 20.3
Table 7.21  : Summary of Associations between VEGF-VEGFR and Treatment Outcome
Whole Population DRRC NC
VEGF Higher in pregnant
Higher in pregnant 
Higher than NC in pregnant 
Lower than NC in non-pregnant
Lower in pregnant
VEGFR Lower in pregnant
Lower in pregnant
Lower than NC in pregnant (p<0.05)
Lower than NC in non-pregnant
Lower in pregnant
2177.9  Endometrial Echo-pattern of FTER Cycles
Three  different  endometrial  patterns  were  recognised  on  the  day  of  FTER: 
w,  w-b-w  and  w-b-ml-b-w,  in  which  ‘w’  represents  the  hyperechogenic  zone, 
‘b’ the hypoechogenic zone, and ‘ml’ the midline echo.
In  the whole  study  population,  female  age,  height,  weight or BMI,  duration  of 
subfertility,  gravidity,  parity,  duration  of  menstrual  cycle,  and  early  follicular 
phase  FSH  did  not differ significantly  between the  endometrial  patterns  of w, 
w-b-w and w-b-ml-b-w (Table 7.139CD).
In  the  NC  FTER  group,  the  endometrial  patterns  w,  w-b-w,  and  w-b-ml-b-w 
presented different levels of receptivity, as assessed by the average number of 
embryos  implanted  per  cycle  (p:0.05),  parity  (p:0.08),  and  mid-luteal  P4  
concentrations (p:0.09) (Table 7.22, Table 7.140CD).
In the DRRC group, the endometrial patterns w, w-b-w, and w-b-ml-b-w did not 
differ in association with any of these parameters.
In  the  NC  FTER  group,  the  w-b-w  pattern  was  associated  with  the  highest 
implantation  rate  per  cycle  (p:0.05),  and  a  trend  for  the  highest  number  of 
previous  pregnancies  beyond  viability,  the  highest  serum  VEGF  and  lowest 
VEGFR  level  on  the  day  of assessment,  the  highest  LH  level  on  the  day  of 
surge,  the  highest  maximum  LH  level  during  the  surge,  and  the  highest  mid- 
luteal  P4  (NS).  In  these  associations  the  w  pattern  appeared  to  be  placed 
between the w-b-w and w-b-ml-b-w patterns. This trend was not evident in the 
DRRC group (Table 7.22,  Table 7.140CD).
The  endometrial  pattern  did  not  differ  with  the  type  of  female  subfertility, 
diagnosis of subfertility, smoking, or alcohol consumption and this was valid for 
the NC and  DRRC groups (Table  7.141-7.144CD). The endometrial pattern did 
not differ between pregnant and non-pregnant women (Table 7.23).
218Table 7.22: Clinical and Embryological Variables for Different Endometrial Echo-patterns
Natural Cycle
1   Endometrial 
1   Pattern
N Mean ± SD
P
w.b.ml.b.w 12 278.4 ± 117.9 |
VEGF (pg/ml) w.b.w 6 336.8 ±212.8 NS
w 17 296.3 ±211.5
w.b.ml.b.w 12 41.5 ± 11.5
VEGF Receptor (pg/ml) w.b.w 6 36.2 ±13.9 NS
w 17 40.5 ± 24.6
w.b.ml.b.w 21 0.1  ±0.4
Number of Implanted Embryos FTER w.b.w 11 0.7 ±0.9 0.05
w 19 0.2 ± 0.5
w.b.ml.b.w 21 35.4 ± 23.5
LH Level on the Day of LH Surge (IU/I) w.b.w 11 38.3 ± 23.3 NS
w 20 34.7 ± 18.9
w.b.ml.b.w 21 45.1  ±20.3
Maximum LH Level (IU/I) w.b.w 11 56.8 ± 30.9 NS
w 20 39.8 ± 19.8
w.b.ml.b.w 14 38.9 ± 15.7
Luteal P4  Level (nmol/l) w.b.w 10 54.5 ± 15.0 NS
w 20 44.9 ±18.6
w.b.ml.b.w 21 0.1 ±0.4
Parity w.b.w 11 0.7 ± 0.9 NS
w 20 0.4 ± 0.6
Table 7.23: Associations between Endometrial Echo-pattern and Treatment Outcome in FTER
Endometrial Pattern P
w-b-ml-b-w w-b-w w
Pregnancy
No
______________ 10J
35  |
________ 6
9
_____§L
26
NS
Ongoing Pregnancy
Yes 8  I 5 5
NS
No 37  | 10 27
2197.10  Endometrial Thickness of FTER Cycles
In the FTER group, regardless of type of endometrial preparation, on the day of 
ET the mean endometrial thickness was 9.5mm (3.7-15mm) (Table 7.24, 7.25).
Table 7.24: Endometrial Thickness in the Whole Study Population
Endometrial Thickness  I
Mean ± SD 9.5 ± 2.7 mm
Minimum 3.7 mm
Maximum 15.0 mm
Table 7.25: Frequency Distribution of Endometrial Thickness in the Whole Study Population
Endometrial Thickness Cumulative Percent
5 mm and less 4.3  |
5 to 6.9 mm 20.7  |
7 to 8.9 mm .............................39.1..]
9 to 10.9 mm 77.2
11 to 15 mm 100.0  |
In the NC and  DRRC groups the mean endometrial thickness was 9.5 mm and
9.6  mm  respectively.  Although  the  mean  values  were  almost  the  same,  the 
distribution around this mean differed in both groups. In the NC group 7.7% had 
an endometrial thickness of < 5 mm and in the DRRC group this was only 2.5%. 
Similarly, in the NC group 23% had an endometrial thickness of < 7 mm and in 
the  DRRC  group  this  was  only  17%.  From  this  measurement  of  thickness 
upwards the distribution between the two groups is similar. This indicates that in 
the  DRRC  group,  HRT  could  possibly correct the  thin  endometrium  of some 
women who would otherwise have developed a thinner endometrium if they had 
had an NC (Table 7.26, 7.27).
Table 7.26: Endometrial Thickness for NC and DRRC
I  N Mean Min Max P  I
Natural Cycle 52 9.5 ± 2.8 mm 3.7 mm 15.0 mm
NS  |
DRRC 40 9.6 ± 2.5 mm 5.3 mm 15.0 mm
220Table 7.27:  Frequency Distribution of Endometrial Thickness in the NC and DRRC
Endometrial Thickness Cumulative Percent  i
5 mm and less 7.7  |
5 to 6.9 mm 23.1  I
Natural Cycle 7 to 8.9 mm 44.2  i
9 to 10.9 mm 76.9  I
11 to 15 mm 100.0  |
5 mm and less 2.5  !
5 to 6.9 mm 17.5  |
DRRC 7 to 8.9 mm |  40.0  I
9 to 10.9 mm I  77.5  |
11  to 15 mm |  100.0  |
In the whole study  population,  endometrial thickness  positively correlated with 
the duration  of subfertility (p:  0.03), weight (p:  0.02),  and  BMI  (p:  0.08) of the 
patient.  No  correlation  was  observed  with  female  age,  past  obstetric  history, 
duration of menstrual cycle and bleeding, and early follicular phase FSH levels 
(Table 7.145,  7.146CD).
In the NC group, endometrial thickness correlated negatively with the day of LH 
surge (p: 0.03), with the LH level on the day of LH surge (p: 0.08), and with the 
maximum LH level during the surge (p: 0.01); and positively with the E2 level on 
the  day  of  LH  surge  (p:  0.03).  In  the  DRRC  group,  endometrial  thickness 
correlated  negatively  with  VEGFR  levels  (p:  0.01),  and  positively  with  the 
duration of subfertility (p: 0.04) and with parity (p: 0.04) (Table 7.147-7.150CD). 
In  both  the  NC  and  DRRC  groups,  no  correlation  was  observed  between 
endometrial thickness and the average number of embryos implanted per cycle 
(Table  151CD). The endometrial thickness did not differ with the type of female 
subfertility, diagnosis of subfertility, smoking, or alcohol consumption. This was 
valid for the NC and DRRC groups (Table 7.152-7.155CD)
7.10.1  Endometrial Thickness in Different Echo-patterns
Endometrial  thickness  did  not  differ  significantly  with  different  endometrial 
patterns and  mean values of endometrial thickness were >9mm in all  patterns. 
This  observation  was  also  valid  for  NCs  and  DRRCs  separately  (Table  7.28, 
Table 7.156CD).
221In  the  last  two  analyses  ‘VEGFR’,  ‘female  weight’,  ‘day  of  LH  surge’  and 
‘maximum  LH  level  during  the  surge’  were  used  to  build  the  model  by linear 
regression  analysis  using  the  forced  entry  method  to  assess  the  overall 
performance of all four variables and then the forward conditional entry method 
to  assess the  performance of the  best  predictor.  Both  revealed  the  maximum 
LH  level  as  the  only  independent  predictor with  statistical  significance  at  5%. 
The final model with maximum LH level has the p value of 0.002 and explained 
22% of the variation (Table 7.164,  7.165CD).
7.10.3  Prognostic Significance of Endometrial Thickness for Pregnancy in 
NCs and DRRCs
In  both  the  NC  and  DRRC  FTER  groups,  the  mean  value  of  endometrial 
thickness did  not differ between the pregnant and  non-pregnant groups (Table 
7.166,  7.167CD). While the thinnest endometrium for pregnancy was 3.8 mm in 
NC,  this  figure  was  7  mm  in  DRRC.  Half of the  clinical  pregnancies  in  each 
group occurred in endometrial thickness of  >9.6mm (Table 7.29).
In the NC group the thinnest endometrium for ongoing  pregnancy was 4.8 mm 
and  in  the  DRC  group  7mm.  In  both  groups,  half of the ongoing  pregnancies 
were achieved with endometrial thickness of 10 mm to 15 mm (Table 7.168CD).
223Table 7.29: Frequency Distribution of Endometrial Thickness for Clinical Pregnancy in NC and DRRC
Endometrial Thickness (mm)
1   Pregnant 3.70  !   3.80 4.80  I   5.30 5.40  I   5.50 5.90  !   6.10  I   6.20 6.60 6.80 7.00
Natural Cycle  |  Yes !   1   I   1   I ______ L ______ ....................... 2 1
1   No 1   I   I   I   I 1 1   I   1   | 2 1
DRRC  |   Yes  |  |  | I |   |   | 2
1   No 1 1   |   I   i   2  I   1
Endometrial Thickness (mm)
i   Pregnant 7.20  I   7.30  I  7.40  I   7.50  I   8.40  I   8.50 8.70  |   8.80  I   8.90  j  9.10  |   9.30  |   9.40
Natural Cycle  |  Yes  |   |   j  |   !   1 |   |   j  j   1   |
I   No 2  I I   1 !   5  I  1   I  i  1 |   1
DRRC  |   Yes 1   I j   )   i
.............................|  ..................1   i
I   No  |   I   1   j  2  I I I   I:  i   1   I   1 2  l:   |   2  i
Endometrial Thickness (mm)  I
j  Pregnant 9.50  j  9.60  |   9.70  i   9.80  )   9.90  |  10.00  j  10.50  |   11.00  |   12.00 13.00 14.00 15.00  |
Natural Cycle  i   Yes I  I I I   1   I   1   !   i   3  |   1 : _ _ _ _ _ _ i...... ... J
I   No  I   1   I   !   1   I   1   I   3 1   j 3  I  4  I  1 2  |  3  |
DRRC  |  Yes  I  I  1   I I  1  i  |  1   |  I  1 ...........  I:  ...................   I
I  No  (  I   1   |  1   I   1 1   I  3  |  |  2  I  3  I  2 1   I  2  I
The number of pregnant and non-pregnant women at different values of their endometrial thickness is given.
2248  Frozen-Thawed Embryo Replacement Cycles: Discussion
A total of 105 women were recruited for the study. Of these, 23 women (21.9%) 
were randomised to either the NC or DRRC groups. The remaining 82 women 
(78.1%)  were  allocated  to  the  treatment  group  for  which  they  expressed  a 
strong preference. Overall, randomisation was 18% in the NC group (n:  10) and 
26.5%  in the  DRRC group (n:  13).  Of all the FTER cycles,  53%  had  NCs and 
47% had  DRRCs. All the couples recruited for the study completed their FTER 
cycles,  with  no  cancellations  arising  from  cycle  monitoring  or  frozen-thawed 
embryo failure to survive.
The  available  data  from  published  studies  suffer  from  the  methodological 
problem  of comparing  the  response of two  unidentical  groups to two different 
therapeutic  regimens,  when  women  with  proven  ovulation  and  regular cycles 
are  primarily  given  natural  cycles  and  women  with  anovulation  or  irregular 
cycles  are  given  hormone  replacement  cycles.  In  the  current  study,  these 
methodological  problems  were  minimised  and,  unlike  any  of  the  published 
literature,  the  importance  of tissue  perfusion  in terms  of VEGF-VEGFR  levels 
was considered and discussed. The main limitation of the current study was its 
limited  power to fulfil  the  requirements of the power calculation.  Because the 
majority of couples expressed a strong preference for either an NC or a DRRC, 
a  preference  arm  was  included  in  the  study  to  maximise  data  collection. 
However,  a  post-hoc analysis revealed that the measured  prognostic variables 
were similar for the randomised and allocated couples.
The discussion section begins by evaluating the predictive role of the fresh IVF 
cycles for the outcome of subsequent FTER cycles. The prognostic importance 
of the variables of the FTER cycles will be appraised and compared against the 
background  of  the  primary  fresh  IVF  treatment  cycles.  The  second  section 
evaluates  the factors  that  may affect embryo  survival  during  cryopreservation 
and  thawing,  and  this  will  be  followed  by  a  brief overview  of the  prognostic 
significance of cleavage stage and pronuclear stage embryos. The final section 
presents an argument on VEGF-VEGFR interaction in FTER cycles followed by 
the evaluation of the endometrial echo-pattern and thickness.
2258.1.1  Predictive Role of the Variables of the Fresh IVF Treatment Cycles
for the Outcome of Subsequent FTER Cycles
To  predict the  pregnancy outcome of the subsequent  FTER  cycle, the clinical 
and  embryological  variables  of the  primary  fresh  IVF  treatment  cycles  were 
evaluated.
Demographic  features  of the female  partners  did  not  affect  the  probability of 
ongoing  pregnancy  after  FTER  cycles.  These  included  age,  duration  of 
subfertility,  previous  obstetric  history,  type  and  aetiology  of  subfertility,  BMI, 
FSH  levels, and lifestyle in terms of smoking and alcohol  consumption. Sperm 
parameters and the technical difficulty in ET during the primary fresh IVF cycles 
were  not prognostic for the  FTER cycles  (Table  7.25-7.36CD).  These findings 
did not agree with those of Karlstrom et. al.549 and Wang et. al.484 who analysed 
3570 FTER cycles in  1438 couples, to evaluate the clinical  circumstances that 
influence the potential for embryo implantation, and report that female age <40 
years  and  non-tubal  factor  subfertility  are  associated  with  a  more  favourable 
implantation rate.
The  clinical  and  embryological  parameters  of  a  better  ovarian  response  to 
stimulation during the fresh  IVF cycle were associated with a higher probability 
of ongoing  pregnancy  in the subsequent  FTER cycles.  This  association  could 
be  explained  by  the  availability  of  a  greater  number  of  embryos  for  the 
subsequent FTER cycles increasing the probability of selection of better quality 
embryos  for transfer,  but  it  could  also  be due to  an  inherently  better embryo 
cohort.
In the primary fresh  IVF treatment cycle, the quality of the embryos transferred 
did  not  affect  the  outcome  of  the  subsequent  related  FTER  cycles  (Table 
7.25CD).  This  finding  may  provide  evidence  against  the  argument  that  the 
success  rate  of the  FTER  cycles was  compromised  because the  best  quality 
embryos were already selected for transfer in the  primary fresh  IVF treatment 
cycle.
226The  outcome  of  the  primary  fresh  IVF  treatment  cycle  in  terms  of  ongoing 
pregnancy,  miscarriage,  biochemical  pregnancy  or  no  pregnancy  did  not 
influence the outcome of the related FTER cycle (Table 7.4). This finding was in 
contrast  to  those  published  by  Karlstrom  et.  al.549  and  Wang  et.  al.484,  who 
report a more favourable implantation rate in FTER cycles if the previous fresh 
ET cycle was successful. However, it is of note that in the current study cohort, 
none of the women with a biochemical pregnancy or miscarriage in the fresh ET 
cycle achieved ongoing pregnancy in the subsequent FTER cycle. Furthermore, 
as  only  one  FTER  cycle  was  evaluated  from  a  possible  series  using  the 
embryos created in the primary fresh IVF treatment cycle, the apparent absence 
of association between the outcome of two treatment modalities may be due to 
under-representation of the FTER cycles.
To  reconsolidate  the  findings  that  only  the  better  ovarian  response  in  the 
primary fresh IVF treatment cycle (but not its surrogate demographic variables, 
or quality of the  transferred  embryos,  or the  actual  outcome)  can  predict the 
outcome of the subsequent FTER cycle, the argument is presented that it is the 
quality of the embryo cohort as a whole that determines the eventual success of 
the treatment, whether this is achieved at fresh  ET or subsequent FTER.  The 
probability of random  events dictates equal  and  independent probability of the 
outcome,  and this  may  be the simple reason why the observation that  neither 
the quality of the two selected embryos nor the outcome of their implantation in 
the fresh  IVF  treatment can  reliably predict the  implantation  potential  of other 
embryos  in  the  subsequent  FTER  cycles.  However,  the  two  treatment 
modalities  are  hardly independent from  each  other.  The  link  between them  is 
the  mutual  embryo  source  (despite  one  being  fresh  and  the  other  frozen- 
thawed)  and  the  attempted  implantation  in  the  same  endometrium  (probably 
with different levels of receptivity), with one being exposed to the high hormonal 
milieu  of ovarian  stimulation  and the other to  natural  or hormone  replacement 
levels.
No difference was observed  in the outcome of the primary fresh  IVF treatment 
cycle  between  couples  randomised  or  allocated  to  the  NC  or  DRRC  groups 
(Table 7.5).
2278.1.2  Clinical and Embryological Variables of the FTER Cycles
No correlation was found between the day of LH surge and the level of LH, or 
E2 on the day of surge, or P4 in the mid-luteal phase.  Furthermore, E2 levels on 
the  day  of  surge  did  not  correlate  with  P4  levels  in  the  mid-luteal  phase. 
Therefore,  it  is  the  trend  in,  and  not  the  absolute  values  of,  E2  or  LH 
concentrations  that  should  be  considered  during  cycle  monitoring  for  the 
prospective  timing  of  ovulation  and  subsequent  ET.  Similarly,  the  absolute 
values of these two hormones had no association with the post-ovulatory P4 rise 
and so could  not be  used to  predict the likelihood of ovulation or the need for 
luteal support (Table 7.22-7.24CD).
The E2 level on the day of LH surge correlated positively with the quality of the 
transferred  embryos.  This  association  could  reflect  the  link  between  the 
competency  of  folliculogenesis  measured  by  the  surrogate  marker  of  E2 
concentration, and the quality of oocyte maturation.  Despite the embryos being 
created  in a different ovulatory cycle than that during which the E2 levels were 
measured,  the  presence  of  a  competent  folliculogenesis  reflected  by  high 
hormonal  response  can  be traced  back to the  quality of the  embryos/oocytes 
and hence the presence of a better ovarian reserve (Table 7.22-7.24 CD).
As  expected,  the  number  of  embryos  thawed  correlated  positively  with  the 
number  of  surviving  embryos,  but  also  with  the  number  and  grade  of  the 
embryos transferred. This association indicated the clinical intention for a better 
selection opportunity for ET where higher quality embryos might be transferred 
if  they  can  be  selected  from  a  larger  cohort.  Furthermore,  the  number  of 
embryos  remaining  after the  index  FTER  cycle  correlated  negatively with  the 
grade of the best embryo and, despite not reaching the level of significance, this 
trend indicated a positive link between the quantitative and qualitative elements 
of  the  ovarian  response,  where  higher  numbers  usually  equated  with  better 
quality and outcome.
No link was found between the number of embryos transferred and their quality. 
This was  not  only  because  of the  Unit  policy advising  against the transfer of
228extra embryos if the quality is less than  ideal  but also because the  majority of 
embryos transferred were of good grade.
8.1.3  Predictive Role of the Clinical and  Embryological Variables of the
NC for the Treatment Outcome
When  the  clinical  and  embryological  parameters  of  the  NC  group  were 
evaluated for pregnancy rates, only the number of embryos remaining and mid- 
luteal  P4  levels  were  significantly different  between  outcome  groups.  Women 
with a higher number of embryos remaining or exhibiting higher luteal phase P4 
levels tended to have higher pregnancy rates (Table 7.39-7.42 CD).
The first association  reflects the wider picture of a greater number of embryos 
being associated with better treatment outcome. Higher embryo availability may 
also  equate  with  better  survival  rates  and  so  better  embryo  quality  and 
treatment outcome.  However, having more embryos remaining for future cycles 
also indicated that successful index treatment was less likely to be preceded by 
multiple previous replacement cycles.
Although  the  association  is  not always  acknowledged,  higher luteal  phase  P4 
levels may reflect a more competent corpus luteal function, which is structurally 
and  functionally dependent  upon  a  more competent folliculogenesis.  Although 
the embryos were generated in a previous stimulated cycle, the finding of ‘good’ 
follicular  development  fits  a  general  model  of  higher  ovarian  reserve,  which 
should have been even better at a younger female age of the primary fresh IVF 
treatment  cycle.  Furthermore,  considering  that  endometrial  receptivity  is  a 
function of adequate decidualisaton under the effect of P4, this association finds 
its  biological  plausibility  both  in  endometrial  and  embryological  development. 
Garcia  et.  al.550  point  out  the  same  contention  from  a  different  perspective, 
stating  that  inadequate  induction  of the  progesterone  receptors  as  a  result of 
suboptimal folliculogenesis can lead to defective secretory differentiation.
In  NC,  ET is usually scheduled with reference to the LH surge, determined  by 
serial  urinary or serum tests with or without E2 measurements;  confirmation of 
ovulation  by  ultrasonography  could  be  added  to  this  protocol.  There  are  no
229studies comparing the different cycle  monitoring  protocols with  regard to their 
efficiency in  optimising the timing of ET.  In the  current study serial  serum  LH 
and E2 measurements were used to detect the onset of LH surge.
It is of note that neither the day of LH surge nor the level of LH  and E2 on the 
day of LH surge or at its peak differed between the pregnant and non-pregnant 
cycles,  indicating that none of these variables  has  any prognostic significance 
on  outcome.  Therefore,  no  assumption  of  outcome  and  treatment  alteration 
should be based on these follicular phase findings.
With  respect  to  the  onset  of  LH  surge,  the  day  of  ET  had  no  effect  on  the 
probability of  pregnancy.  Therefore,  within  the  range of 3 to  6  days  after the 
onset of LH surge,  no deterioration of the endometrial receptivity was detected. 
In natural cycles, the endometrium reaches a state of readiness for implantation 
approximately  7  days  after the  LH  peak,  or  5.5  days  after  ovulation367.  This 
maximum endometrial receptivity extends to post-ovulatory day 10, defining the 
‘window  of  implantation’  between  days  19  and  24  of  the  NC372.  Pinopode 
expression  linked  to  the  ‘implantation  window’,  has  been  observed  at  around 
day 20 of the NC. The entire lifespan of pinopods is a maximum 48 hours, albeit 
with variation of up to 3 days between  individual women373,374,375.  The current 
study confirmed that endometrial maturity did not negatively affect the outcome 
within  the  range  of  LH+3  to  6  days.  Considering  that  LH+3-endometrium 
corresponds to day 1   embryonic growth and LH+6 to day 4, and the transferred 
embryos are  at day 2  of maturity,  requiring  a further 3 days of maturity in the 
uterus  before implantation, the endometrium would  be at LH+6 to 9, within the 
proposed window of implantation ‘LH+6.5 to 11.5’.
The  quality  of  the  transferred  frozen-thawed  embryos  was  superior  in  the 
pregnant  women  but  this  did  not  reach  significance  in  the  whole  study 
population;  this  was  also  valid  when  ongoing  pregnancy  rather  than  clinical 
pregnancy  was  used  as  the  outcome  measure.  It  has  been  reported  that 
morphologically evaluated embryo quality is the most important clinical factor for 
successful implantation in FTER406,483.
230It appeared that embryo quality was the key element and this was linked directly 
to  the  quality  and  quantity  of the  ovarian  response  in  the  primary fresh  IVF 
treatment  cycle.  In  this  context,  the  optimum  hormonal  milieu  required  for 
endometrial development and a successful outcome also linked to the ovarian 
performance with a good margin of flexibility for the ‘window of implantation’.
8.1.4  Predictive Role of the Clinical and  Embryological Variables of the 
DRRC for the Treatment Outcome
In  the  DRRC  group,  embryo  quality  was  significantly  better  in  the  pregnant 
group but was short of significance in the NC group.  Embryo quality evaluated 
morphologically is shown to be the most important clinical factor for successful 
implantation  of  FTER  cycles483.  With  ongoing  pregnancy  as  the  outcome 
measure,  the  difference  in  embryo  quality  between  the  pregnant  and  non­
pregnant groups  lost significance  but the trend was  maintained.  This  provided 
further  supporting  evidence  that  embryo  quality  was  the  critical  prognostic 
variable,  and  circumstantial  evidence  that  embryo  quality  assessed 
anatomically,  despite  maintaining  its  deterministic  influence  over  the  initial 
implantation,  did  not  differentiate  subsequent  miscarriages  in  FTER  cycles 
(Table 7.43-7.46CD).
8.1.5  Comparison  of  the  Clinical  and  Embryological  Variables  in  the
Primary Fresh IVF Treatment Cycles of the NC and DRRC Groups
Clinical and embryological parameters of the primary fresh IVF treatment cycles 
were compared, to assess whether they differed  between couples having  NCs 
or DRRC FTERs (Table 7.47CD).
There  were  no  differences  between  the  NC  and  DRRC  groups  in  terms  of 
female  age,  duration  and  aetiology  of subfertility,  past  obstetric  history,  BMI, 
smoking  and  alcohol  use,  sperm  parameters,  type  of fertilization  in  the fresh 
cycle (conventional  IVF or ICSI),  grade of embryos selected for transfer in the 
fresh treatment cycle, and distribution of divided and pronuclear stage embryos 
and the quality of embryos transferred in the FTER cycle.
231The duration  of the  menstrual  cycle was  1.5  days  longer in  the  DRRC  group 
than  the  NC  group  respectively  (28.5 vs  30  days)  and  although  this  reached 
statistical  significance  it  is  unlikely to  have  any  clinical  relevance  in  terms  of 
ovulatory potential in either group.
Women  in  the  DRRC  group  presented  with  better ovarian  reserve  and  better 
ovarian  response to  milder ovarian  stimulation  in their fresh  IVF  cycles.  Early 
follicular FSH values and the total gonadotrophin dose used during stimulation 
was lower in the DRRC group, and E2 level on the day of hCG injection, number 
of developing  follicles  particularly those  measuring  10-15mm,  total  number of 
follicles  aspirated,  number  of  oocytes  collected  and  oocytes  used  for 
fertilisation,  number  of  2-PN  embryos  created  and  number  of  embryos 
cryopreserved,  were  all  higher  in  the  DRRC  group.  Because  these  fresh 
treatment cycle variables are those that affect FTER cycle outcome,  as would 
be expected the pregnancy rate was higher in the DRRC group (28.6%) than in 
the NC group (25%) but the difference did not reach statistical significance.
It was of note that in the fresh treatment cycle of the NC group, the number of 
embryos implanted was higher (p: 0.03) and the ongoing  pregnancy rate twice 
that of the DRRC group (p: 0.2) (Table 7.1, 7.2, 7.5,  Table 7.47CD). However, it 
was already noted that the outcome of the fresh treatment cycle did  not affect 
the outcome of subsequent FTER cycles.
The majority of the fresh ET procedures were graded as easy, but women in the 
NC group had their fresh ET procedures more easily than women in the DRRC 
group.  This  may explain  why the fresh  IVF treatment cycles  of the  NC  group 
achieved  higher  pregnancy  rates  despite  having  poorer  ovarian  response. 
Nevertheless,  it was  already shown that the grade of difficulty of the fresh  ET 
procedure  did  not  present  as  a  statistically  significant  confounding  factor  in 
analysis of FTER cycles (Table 7.73-7.75CD).
Couples  randomized  or  allocated  to  their  treatment  cycles  on  personal 
preference  did  not  differ  in  the  demographic  variables  or  the  clinical  and 
embryological  parameters  of the  primary fresh  IVF  treatment  cycles.  Hence,
232although the majority of the participating couples were not randomised, all of the 
relevant  prognostic factors found  to  affect the  outcome  had  equal  distribution 
between  the  randomised  and  allocated  subjects  (Table  7.61-7.72CD). 
Therefore, in statistical terms, an apparent disadvantage to the study design did 
not introduce a prognostic bias.  Despite the domination of good responders in 
the  primary  fresh  IVF  treatment  of the  DRRC  group  over  the  NC  group  did 
introduce  a  potential  heterogeneity,  the  quality  of  the  transferred  embryos 
during FTER in the NC and DRRC groups was similar (Table 7.77CD).
In  the  DRRC  group,  variations  in  embryo  quality  significantly  affected  the 
treatment outcome,  but  not  in the  NC group.  As the quality of the transferred 
embryos was similar in  both the NC and  DRRC groups, this may indicate that 
other aspects of implantation  might have assumed  a compensatory role in the 
NC  group  to  offset  the  variation  in  embryo  quality.  Hence,  endometrial 
receptivity might  be  less compensating  in the  DRRC group.  However,  despite 
this  probable  vulnerability  in  the  DRRC  group their  pregnancy  rates  in  FTER 
were insignificantly higher. This may have been due to the inherent high fertility 
potential  of  the  embryos  in  the  DRRC  group,  evidenced  by  higher  ovarian 
response  parameters  in  the  fresh  treatment  cycle  but  not  detectable  by  the 
current anatomical grading of the embryos.
Some  authors  report  higher  pregnancy  rates  in  hormonally  controlled  cycles 
than in natural cycles, but mostly in small studies440,445, while others using larger 
semi-randomized or retrospective studies report a similar outcome in both types 
of  cycles409,454,478,479,482.  On  the  contrary,  Loh  and  Leong485  report  a  natural 
cycle  pregnancy  rate  almost  twice  that  of  the  hormone  replacement  cycles. 
With ET on days 14 to 16 of a natural cycle, the pregnancy rate reaches 33%.
The available data from these studies suffers from the methodological  problem 
of  comparing  two  unidentical  groups  in  their  response  to  two  different 
therapeutic  regimens.  Women  with  proven  ovulation  and  regular  cycles  were 
mostly included  in the natural cycles and women with anovulation and irregular 
cycles  in the hormone  replacement cycles.  Furthermore, variables of the fresh
233IVF  cycles were  rarely taken  into consideration  limiting the chances of like-to- 
like comparison. The current study minimised these methodological problems.
8.2  Factors Linked to Embryo Cryo-survival Rate in FTER
In the NC FTER group, the embryo survival rate did not correlate with any of the 
demographical,  clinical,  and  embryological  variables  of the  primary fresh  IVF 
treatment cycle,  or with the serum VEGF and VEGFR levels on the day of ET 
and number of embryos implanted in FTER cycles (Table 7.78-7.110CD).  Konc 
et.  al.5 5 1   report that female BMI  but not age affects the embryo survival  rates. 
PN stage-embryo survival  is shown to be negatively affected  by ICS I,  possibly 
caused  by disruption of the zona pellucida and vitelline membrane552; while no 
effect on the implanting capacity of the surviving embryos is observed553.
However,  in the DRRC group,  embryo survival was higher in cycles where the 
fresh  IVF  treatment  was  characterised  by  better  ovarian  response  to 
stimulation. A greater number of developing follicles measuring  16-17mm, and 
total  number  of  follicles  aspirated,  oocytes  collected,  and  oocytes  used  for 
fertilisation,  provided a favourable background for embryos likely to survive the 
cryopreservation and thawing processes.
This observation  gave  credit to the  contention that  better ovarian  response to 
stimulation  indicated  an  inherently better quality embryo, and that this not only 
affected the treatment outcome of the FTER but also the survival capacity of the 
embryos  during  the  cryopreservation  and  thawing  processes.  As  the  embryo 
survival rate was independent of the absolute number of embryos, it was not the 
high  number  of  embryos  that  was  associated  with  a  higher  probability  of 
survival.  Furthermore,  higher quality embryos were available from the embryo 
cohorts with higher survival rates and this was valid for both the NC and DRRC 
groups;  yet  again  the  association  was  more  significant  in  the  DRRC  group 
(Table  7.110CD).  High  quality  embryos  are  known  to  sustain  less  cryoinjury 
during  cryopreservation,  when  compared  with  those  of  moderate  and  poor 
quality549.  Interestingly, the survival  rates themselves did  not directly associate 
with the treatment outcome of the FTER cycles or that of the primary fresh IVF 
treatment cycle (Table 7.104-7.109CD).
234Whilst these  observations were  more  significant  in  the  DRRC  group,  logically 
they cannot be due to the differences in the treatment protocols as the embryos 
of both  groups were cryopreserved  and thawed  in  accordance with the  same 
protocol, regardless of the way the endometrium was prepared. Furthermore, in 
both groups the embryo survival rate was the same at 80%.
In the NC and  DRRC groups, embryo survival was higher in secondary female 
subfertility but this approached statistical significance only in the DRRC group. 
Female smoking and alcohol consumption, stimulation protocol, type of GnRHa 
and type of fertilisation (IVF or ICSI) did not affect the embryo survival rate.
8.3  Comparison of the Cleavage Stage and Pro-nuclear Stage Embryo
The  survival  rate  was  significantly  higher in  pronuclear stage  embryos  in  the 
DRRC group and although this trend was also evident in the NC group it did not 
reach  a  level  of  significance.  Ongoing  pregnancy  rates  and  the  number  of 
implanted  embryos  were  significantly  higher  with  pronuclear  stage  embryos. 
This  effect  must  partly  have  been  due  to  the  higher  survival  ability  of  the 
embryos cryopreserved  at the pronuclear stage.  However,  a  likely explanation 
was the higher quality of the transferred embryos, which were cryopreserved at 
pronuclear  stage.  Nonetheless,  this  trend  failed  to  reach  a  level  of statistical 
significance  (Table  7.111-7.119CD).  Salumets  et.  al.554  have  shown  that 
developmental  stage  of  embryos  at  freezing  has  a  profound  effect  on  cryo- 
survival,  but  has  little  effect  on  rates  of  implantation  and  ongoing  pregnancy 
rates. The poor survival and elevated miscarriage rates are both high for day 3 
when compared with PN embryos.
8.4  Predictive  Role  of the VEGF,  VEGFR,  VEGF:VEGFR  Levels  for the 
Treatment Outcome
Differences in VEGF and VEGFR concentrations in serum on the day of FTER 
did  not  reach  a  level  of  statistical  significance  between  pregnant  and  non­
pregnant  women  and  women  with  ongoing  pregnancy  and  no  ongoing 
pregnancy  (Table  7.13).  No  published  literature was  available for comparison 
on this topic.
235Despite  not reaching  a level of statistical  significance,  higher VEGF and  lower 
VEGFR levels were evident in women who subsequently achieved  pregnancy 
and this distinction became even more evident in those whose pregnancy was 
ongoing.
Higher VEGF  levels  indicate  a  state  of activated  angiogenetic  response  and 
concomitantly  lower  VEGFR  concentrations  ensure  the  maximisation  of  the 
biologically  active  free  VEGF  molecules  for  end  organ  stimulation.  Hence,  it 
may  be  deduced  that  the  treatment  cycles  with  a  higher  angiogenetic  milieu 
through  provision  of  better  tissue  oxygenation,  were  more  likely  to  achieve 
higher  implantation  and  pregnancy  rates.  Supporting  this  observation,  a  high 
ratio of VEGF to  its  receptor was also evident in  conception  cycles,  reflecting 
the  availability  of  more  free  VEGF  molecules  for  its  biological  action  (Table 
7.15).
Despite  not  reaching  a  level  of statistical  significance,  ET cycles  destined  for 
ongoing  pregnancies  had  higher  VEGF  concentrations  when  compared  with 
those with early miscarriages,  reflecting a  possible dose response relationship 
between  the  intensity  of  facilitating  factors  and  the  successive  stages  of 
implantation (Table 7.13). If angiogenetic support to implantation is optimum the 
process  is  likely  to  reach  completion  and  the  outcome  would  be  ongoing 
pregnancy.  Alternatively,  if  the  angiogenetic  support  is  suboptimum  the 
implantation  process  is  likely to arrest prematurely and the outcome would  be 
early miscarriage.
8.4.1  VEGF-VEGFR Levels in the NC and DRRC Groups
When  compared  with  NC,  VEGF  levels were  higher and  VEGFR  levels were 
lower in  DRRC.  However, only the latter reached a level of significance. VEGF 
response  also  differed  between  the  NC  and  DRRC  groups  in  relation  to  the 
treatment outcome,  but at a statistically insignificant level.  In the NC group both 
VEGF  and  VEGFR  levels  were  lower  in  the  pregnant  cycles.  In  the  DRRC 
group,  high  VEGF  and  low VEGFR  levels  characterised  the  pregnant  cycles. 
When NCs and DRRCs were compared, VEGF levels were higher in the DRRC 
if there was pregnancy but lower if there was no pregnancy. These differences
236did  not  reach  a  level  significance  (Table  7.16-7.20).  When  NCs  and  DRRCs 
were  compared,  VEGFR  levels  were  lower  in  the  DRRC.  These  differences 
reached a level of significance if there was pregnancy.
In  the  DRRC  group  the  high  VEGF  levels  might  have  been  induced  by  the 
transient  local  hypoxic  state  generated  by  GnRH  analogue  down-regulation, 
associated  with  low  oestrogen  levels  and  decreased  tissue  perfusion. 
Subsequent  exogenous  oestrogen  supplementation  may  have  further 
stimulated  VEGF  levels  in  the  DRRC  group,  above  that  achievable  by  the 
endogenous oestrogen concentrations of the NC group.  Physiological levels of 
oestrogen  are  shown  to  stimulate  VEGF  production  by  human  epithelial  and 
stromal  cell  cultures through  both  oestrogen  receptor a  and  p555-556.  However, 
oxygen  tension  appears  to  be  more  important  in  regulating  VEGF  synthesis 
than proposed hormonal effects. Sharkey et. al.545 show that hypoxic regulation 
of VEGF expression is a potent feature of endometrial VEGF regulation.
Cycles achieving higher VEGF levels and thus perhaps with better oxygenation 
potential, appeared to have a higher probability of pregnancy in DRRC. On the 
contrary,  in  non-conception  cycles  of  the  DRRC  group,  VEGF  levels  were 
particularly low, further reflecting that hypoxia might be the underlying problem. 
Also  in  the  literature,  a  high  proportion  of women  (37%)  are  found  to  have 
impaired uterine perfusion in  HRT cycles for FTER228.  In the DRRC group, low 
VEGF  levels  appeared  to  be  more detrimental  than  in  the  NC  group  and  this 
was  possibly  because  low VEGF  levels  indicated  a  core  subgroup of women 
with  a  more  fundamentally  seated  hypo-responsiveness  in  angiogenesis, 
despite having an exogenous stimulant (E2) in DRRC. Low VEGF levels in NCs 
may reflect a state of optimum oxygenation or unsuppressed intact mechanisms 
may  have  provided  alternative  means  to  support  angiogenesis  so  that 
pregnancy can still occur with low VEGF levels.
When compared with NC, an insignificantly higher VEGF and significantly lower 
VEGFR  levels  in  the  DRRC,  may  be  the  indicative  of  a  more  active 
angiogenetic  state.  Higher  pregnancy  rates  in  the  DRRC  group  have  already 
been  pointed out and  although this did  not reach significance,  it supported our
237initial  contention that  better oxygenation  potential  is  linked  to  better functional 
capacity and treatment outcome. A possible vulnerability of the DRRC outcome 
to  embryo  quality  was  hypothesised  to  be  due  to  a  probable  loss  of 
compensatory mechanisms for low embryo quality at the endometrial level; this 
may  be  the  inability  of  DRRC  to  maintain  optimum  angiogenetic  stimuli  and 
hence, oxygenation in a subgroup of women with low VEGF levels.
8.5  Endometrial Echo-pattern of FTER Cycles
Before the  ET  procedure,  an  ultrasonographic assessment of the  endometrial 
echo-pattern  and  thickness  was  performed  using  a  transvaginal  probe.  The 
endometrial  echo-pattern  was  classified  according  to  the  appearance  of the 
hyper-  (w)  and  hypo-  (b)  echogenic zones  of the  endometrium  relative to the 
myometrium,  and  the  presence  or  absence  of  a  distinct  midline  echo  (ml). 
Three  distinct  patterns  were  recognised.  The  first  was  dominated  by  a 
homogeneously hyperechogenic endometrium with no distinct midline echo ‘w’. 
The second  had  a  homogeneous hyper-echogenic endometrium with a central 
hypo-echogenic zone but no midline echo ‘w-b-w’.  The third was characterised 
by a triple layer of peripheral  hyper-echogenic zone at the myometrial junction, 
separated by inner hypo-echogenic zones and a midline echo ‘w-b-ml-b-w’. The 
central  echogenic  line  ‘ml’  represents  the  uterine  cavity  and  the  outer  hyper 
echogenic zones  ‘w’  represent the  basal  layer of the  endometrium.  Between 
the  two  outer  zones  and  the  central  line,  the  hypo-echogenic  regions  ‘b’ 
represents the functional layer of the endometrium384.
The  endometrial  patterns  described  as  ‘w’,  ‘w-b-w’  and  ‘w-b-ml-b-w’  did  not 
differ significantly among the different demographic and clinical variables of the 
female partner and FTER cycles (Table 7.139,  7.140CD). These include female 
age,  height,  weight,  or  BMI,  duration  of  subfertility,  type  and  aetiology  of 
subfertility,  past  obstetric  history,  duration  of  menstrual  cycle,  smoking  or 
alcohol  consumption,  early follicular phase  FSH,  day of LH  surge,  LH  and  E2 
level on the day of LH surge, ET day, mid-luteal  P4 in NC, E2 and  P4 level after 
down-regulation in DRRC, and VEGF and VEGFR concentrations on the day of 
ET.  These observations were valid for the whole  study population  as well  as 
separately  for  the  NC  and  DRRC  groups.  Bustillo  et.  al.277  also  report  no
238correlation  between  the  cumulative  dose  of  oestrogen  intake  or  serum 
oestradiol concentration prior to progesterone administration, and the echogenic 
pattern of the endometrium.
In the  NC  FTER group, the ‘w-b-w’  pattern, which  associated with the  highest 
implantation  rate  per  cycle  (p:  0.05)  and  number of previous  pregnancies  (p: 
0.09),  also  associated  with  the  highest  LH  level  on  the  day of the  surge,  the 
highest  maximum-LH  level  during  the  surge  and  the  highest  mid-luteal  P4 
concentrations albeit at a statistically insignificant level.
The  favourable  echo-pattern  ‘w-b-w’  also  associated  with  the  highest  serum 
VEGF  and  lowest  VEGFR  level,  but  although  numerical  differences  were 
obvious,  these  did  not  reach  significance.  This  VEGF-VEGFR  pattern  may 
signify the maximum availability of angiogenetic stimuli to the target organs. The 
pattern  ‘w-b-ml-b-w’,  which  associated  with  the  lowest  number  of  implanted 
embryos, also associated with the VEGF-VEGFR pattern possibly indicating the 
lowest availability of angiogenetic stimuli (low VEGF and high VEGFR). In these 
associations the significance of the ‘w’  pattern appeared to fall between the ‘w- 
b-w’, and ‘w-b-ml-b-w’ patterns (Table 7.140CD).
Association  between  high  LH  and  high  VEGF  concentrations  arises  from  LH 
stimulation of the VEGF activity557,558, which is vital in the neovascularisation of 
the  corpus  luteum  formation  and  the  adequacy  of corpus  luteum  function.  In 
turn,  corpus  luteum  function  links to endometrial  maturity and  function,  which 
requires  adequate  progesterone  and  possibly VEGF  from  the  corpus  luteum. 
Nevertheless,  human endometrial cells are known to produce VEGF under the 
stimulatory  effect  of  oestrogen555,556  and  probably  also  by  progesterone, 
although there are conflicting reports on the latter545,559,560 561,562.
Therefore,  the  association  between VEGF  levels and  endometrial  growth  may 
be indirect through ovarian function orchestrated by steroid hormones and/or by 
ovarian  angiogenetic  stimuli;  or  direct  through  local  endometrial  VEGF 
production and neovascularisation.
239In the DRRC group, these trends were not evident and this is probably due to 
the  loss  of  natural  homeostatic  dynamics  by  down-regulation  not  being 
effectively replaced with the hormone replacement.  Nevertheless, this apparent 
deficiency  at  the  endometrial  level  did  not  seem  to  alter  the  probability  of 
pregnancy in the DRRC group and this, yet again,  may be due to a presumed 
superiority of the embryo cohort in this group.
Endometrial thickness did  not differ significantly between  different endometrial 
patterns with mean values of endometrial thickness >9mm in all patterns.  As a 
proxy measure of endometrial  growth,  endometrial thickness  is  reported to  be 
unrelated to endometrial pattern on the day of HCG injection378,389,390,395.
In summary, with the  limitation  of a significant chance factor in  mind,  superior 
progesterone  and  angiogenetic  stimuli  appeared  to  be  associated  with  better 
endometrial  receptivity and this was linked to higher LH  stimuli  and  presumed 
superior corpus  luteal function.  This combination was  best represented  by the 
‘w-b-w’ endometrial echo-pattern and least by the ‘w-b-ml-b-w’ pattern. Although 
an  association  between  the  endometrial  echo-pattern  and  the  number  of 
implanted  embryos  was  demonstrated,  no  significant  differences  between 
conception  and  non-conception  cycles  were  found.  In  their  ultrasonographic 
evaluation of the endometrium in women undergoing natural cycle IVF, Ueno et. 
al.404 report that endometrial  pattern A (homogeneous,  hyperechogenic ‘w’) on 
the  day  prior to  oocyte  collection  had  a  predictive  value  of  100%  for  a  non­
conception cycle but pattern B (mixed, with an outer hyperechogenic and inner 
hypoechogenic layer ‘w-b-w’) correlated with a significantly greater proportion of 
conception than non-conception cycles.
With findings similar to those of the current study, Al Shawaf et. al.409 report that 
the methodology of endometrial  preparation  had  no influence on the observed 
endometrial  echo-pattern,  because  no  significant  differences  were  noted 
between  NCs and  DRRCs and conception and  non-conception cycles.  Check 
et.  al.417  and  Alam  et.  al.4 1 1   also  report  no  significant  variations  in  the 
endometrial  echo-pattern  of conception  and  non-conception  cycles  after  HRT 
treatment cycles.  However,  Bustillo et.  al.277, Coulam et.  al.256, and  Shapiro et.
240al.412 noted significant differences, with a triple line pattern, the most commonly 
distinguished in conception cycles, but this is not a consistent observation.
The  ‘w-b-ml-b-w’  pattern  indicates  a  more  advanced  stage  of  endometrial 
development  and  the  negative  prognostic  effect  is  likely  to  be  the  result  of 
significant  asynchrony  between  embryo  and  endometrial  maturity.  If embryos 
are transferred  into a less advanced endometrium the chances of implantation 
would  be  higher  because  advanced  embryonic  growth  allows  embryos  to 
implant  as  soon  as  the  less  advanced  endometrium  gets  receptive. 
Endometrium  may  quickly  become  post-mature  and  closes  the  implantation 
window,  so  less  mature  embryos  may lose the chance  of implantation  by the 
time  they  are  ready.  Likewise,  a  lower  pregnancy  rate  is  reported  if  the 
endometrium pattern is more advanced397.
8.6  Endometrial Thickness of FTER Cycles
In the NC and DRRC groups, mean endometrial thickness was 9.5 and 9.6 mm 
respectively  (Table  7.166-7.168CD).  Although  mean  values  were  similar,  the 
distribution  around  this  mean  differed. While 7.7% of women  in the  NC group 
had an endometrial thickness of 5 mm or less, in the DRRC group this was only 
2.5%.  Similarly,  in the  NC group 23% of women  had  an endometrial thickness 
of 7 mm or less and in the DRRC group this was only 17%. However, from 7mm 
upwards towards the thicker endometrium, the distribution in both groups is of a 
similar  pattern.  Therefore,  for  women  who  would  have  had  a  thinner 
endometrium  if in the NC group,  exogenous hormone replacement might have 
corrected  this to  some  extent and  a  core subgroup  of 5%  of the study cohort 
could  have  benefited  from  this  effect.  We  argued  that  there  is  a  threshold 
stimulatory level  of endometrial growth,  above which the dose  response curve 
between hormone stimulation and endometrial thickness flattens.
A threshold  value for endometrial  thickness  varying  between  5mm  and  8mm, 
below which implantation is exceptional, is common in the literature391,409. In the 
NC group,  a  larger proportion of women were below this threshold than  in the 
DRRC group, and the expectation would be for lower pregnancy rates in the NC
241group.  This  was,  what  we  observed,  but  not  at  a  level  of  significance,  as 
discussed in the previous section.
In  the  current  study,  there  was  only  one  pregnancy  when  the  endometrium 
measured  <6.6mm  (4.8mm)  compared  with  17  pregnancies  when  the 
endometrium measured £6.6 mm.
Furthermore,  once  the  minimum  endometrial  thickness  was  achieved,  there 
seemed  to  be  no  additional  benefit with  a thicker endometrium.  Hence,  when 
the  whole  spectrum  of  endometrial  values  from  thinnest  to  thickest  was 
evaluated, no correlation was observed between endometrial thickness and the 
average  number of embryos  implanted  in  either the  NC  or  DRRC  group  and 
mean values of endometrial  thickness at the time of ET in  pregnant and  non­
pregnant women, were not statistically different. This was also valid for ongoing 
pregnancies. Therefore,  mean endometrial thickness was not a determinant for 
the probability of implantation or early miscarriage.
The  evidence  from  the  literature  is  conflicting.  While  Al  Shawaf  et.  al.409, 
Friedler  et.  al.410,  Coulam  et.  al.256  and  Bustillo  et.  al.277  find  no  significant 
differences  between  conception  and  non-conception  HRT  cycles,  Check  et. 
al.417'539, Alam et. al.411, Abdalla et. al.391, Schwartz et. al 406 and Banz et. al.563, 
report  significant  differences,  but  even  these  amount  to  only  a  1   to  1.5  mm 
variation.
Hence,  the  clinical  role  of  physical  assessment  of  endometrial  growth  as  a 
surrogate  marker for  endometrial  receptivity  must  be,  at  best  marginal,  when 
only the extremes of poor growth are seen288,393,403,405,564.  However, employing 
a  minimal  threshold  for  endometrial  thickness  is  more  promising  with  the 
assumption that such a crude physical variable only allows a gross ‘all or none’ 
assessment,  and  its  sensitivity  does  not  allow  fine-tuning  of  the  receptivity 
evaluation.
2428.6.1  Endometrial Thickness and Clinical Variables
Endometrial  thickness  correlated  positively with the  E2  level  on the day of LH 
surge  and  the  stimulatory  role  of oestrogens  on  endometrial  proliferation  and 
growth is well known394,540.  A negative correlation observed with the day of LH 
surge and LH level may be an indirect one, arising from its positive associations 
with oestrogen. While high oestrogen levels led to a thicker endometrium they 
may also  induce an  earlier LH  surge.  In this contention  it is assumed that the 
relatively  early  termination  of the  follicular  phase  and  oestrogen  stimulation, 
before the  availability of progesterone with  its anti-oestrogenic  properties,  had 
less effect on the final  endometrial thickness.  This  assumption was supported 
by the finding of no correlation  between endometrial thickness and the level of 
luteal phase P4 in the NC group (Table 7.145-7.151 CD).
A negative correlation with VEGFR levels reflected the role of angiogenesis  in 
endometrial development.  Higher VEGFR levels work to lower the biologically 
active free VEGF molecules and the subsequent angiogenetic stimuli that seem 
to  lead  to thinner endometrium  on  the  day of transfer.  A  positive  correlation 
was  observed  between  female weight  and  endometrial  thickness  and  so  any 
future  comparative  analysis  of endometrial  thickness  should  be  corrected  for 
female  weight.  No  correlation  was  observed  with  endometrial  thickness  and 
VEGF levels, indicating that the endometrium may have higher sensitivity to the 
level  of suppression  but less to the level of stimulation.  Endometrial thickness 
did not differ with the type or aetiology of subfertility, or with the female smoking 
or alcohol consumption.
The current study included a series of linear regression analyses to assess the 
association  between  endometrial  thickness  and  different  clinical  variables.  As 
independent predictors, VEGFR and female weight explained only 4% and 3% 
respectively  of the  variation  in  the  endometrial  thickness  and  addition  of the 
VEGF  levels  did  not  improve the  statistical  significance  of the  equation  or its 
predictive  power.  In  the  NC  group,  a  further linear  regression  analysis,  using 
VEGFR, female weight, day of LH surge and maximum LH level as independent 
variables,  revealed  the  maximum  LH  level  as the  only  independent  predictor.
243The final  model with  maximum LH  level  had a p value of 0.002 and  explained 
23%  of the  variation.  This  indicated  the  primacy  of the  LH  stimulation  in  the 
successive  events  of  angiogenesis  and  steroid  production  leading  to 
endometrial growth.
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